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Slow and deep breathing (SDB) is a promising intervention that has provided reductions 
in blood pressure (BP) in primary hypertension when practised daily and has potential 
as an intervention to treat women who develop hypertension during pregnancy. Before 
SDB can be introduced in a clinical setting during pregnancy, it is important to understand 
whether normal cardiovascular changes that accompany pregnancy influence the acute 
responses to SDB. Additionally, known structural and mechanical differences in the 
respiratory systems of men and women may also influence cardiovascular responses to 
SDB. As most published studies include only male participants this has not been fully 
investigated. 
 
In preparation for a clinical study of SDB with women who develop pregnancy-induced 
hypertension, this thesis characterised the acute cardiovascular responses to a range of 
different SDB protocols in three distinct population groups (men, women and pregnant 
women). Novel analysis techniques were applied to delve deeper into the acute 
cardiovascular responses, by analysing the inter- and intra-breath phase cardiovascular 
fluctuations induced by breathing. The results highlight the limitation of using averages 
to understand the cardiovascular changes induced by SDB. Analysis of within-breath 
(peak-valley) haemodynamics revealed an increase in the amplitude of oscillations 
during SDB, whilst the average was unchanged. Respiratory sinus arrythmia tripled 
during SDB compared with rates during normal breathing across all participant groups. 
The observed increase of the amplitude of BP oscillations provides clues to potential 
error signal(s) linking daily practise of SDB to chronic BP reductions. This thesis makes 
an original contribution to existing knowledge by furthering our understanding of the 
acute cardiovascular responses to SDB and the need to look more closely at peak-valley 
haemodynamic oscillations. It provides evidence to support the development of an 
evidence-based SDB intervention to be used with pregnant women, supporting women-
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4Ffr - Fixed breathing frequency of 4 breaths.min-1. 
6Ffr - Fixed breathing frequency of 6 breaths.min-1. 




Acute response - Immediate, short-term response to a single session of slow and deep 
breathing. 
Antenatal - Period of pregnancy before the birth. 
Aorta - The large, elastic artery that carries blood away from the left ventricle and into 
the systemic circuit. 
Aortic (central) pulse pressure (AoPP) - Pressure difference between central systolic 
and diastolic blood pressure. 
Aortic (central) systolic blood pressure (AoSBP) - Pressure in the aorta.  
Arterial blood pressure (ABP) - Pressure in the arteries (see blood pressure). 
Augmentation Index (AIx) - Ratio of augmentation pressure and pulse pressure; 
indirect measure of arterial stiffness. Equation: AIx = (augmentation pressure ÷ aortic 
pulse pressure) x 100. 
AIx@HR75 - Augmentation index adjusted for heart rate at 75 beats.min-1. 
Augmentation Pressure (AP) - The increase in systolic pressure due to the early return 
of the reflective wave. Represents pressure at the heart from the reflective wave. 
Autonomic nervous system - Centres, nuclei, tracts, ganglia and nerves involved in 
the unconscious regulation of visceral functions; includes components of the central 
nervous system and the peripheral nervous system. 
Autoregulation - Changes in activity that maintain homeostasis in direct response to 




Baroreceptor reflex/ Baroreflex - A reflexive change in cardiac activity in response to 
changes in blood pressure. 
Baroreceptors - The receptors responsible for detecting changes in pressure.  
Baroreflex sensitivity (BRS) - Measure of the autonomic effector response to a given 
change in arterial pressure, often measured as the relationship between heart rate 
18 
fluctuations and blood pressure fluctuations. A measure of autonomic control of the 
cardiovascular system. 
Baseline breathing (B) - Baseline normal (spontaneous) breathing. 
Blood pressure (BP) - A force exerted against vessel walls by the blood in the vessels, 
due to the push exerted by cardiac contraction and the elasticity of the vessel walls. 
Equation: BP = Cardiac output x total peripheral resistance. 
Blood pressure fluctuations/ oscillations - Acute changes in blood pressure in 
response to a change in internal environment such as breathing frequency or external 
stressor. 
Blood pressure variability - Differences in blood pressure taking over a set period of 
time. 
Brachial artery - Main artery in the arm. 
Breathing condition - Protocol for slow and deep breathing exercises. 
Breathing frequency - Number of breaths take per minute. 
Breath - Full cycle of breathing phases (inspiration and expiration). 
Breath phase - Inspiration or expiration phase of breathing. 




Cardiac output (Q̇) - The volume of blood ejected by the left ventricle each minute. 
Equation: Cardiac output = heart rate x stroke volume. 
 Q̇e      Cardiac output during expiration. 
 Q̇i     Cardiac output during inspiration. 
 Q̇Δ     Inter-breath phase cardiac output variation (Q̇i- Q̇e). 
 Q̇Δe     Peak-valley cardiac output during expiration (Q̇e max – Q̇e min). 
 Q̇Δi     Peak-valley cardiac output during inspiration (Q̇i max – Q̇i min). 
 Q̇ΔPV      Peak-valley cardiac output (Q̇i max – Q̇e min or Q̇i min – Q̇e max). 
Q̇ΔPVInd Peak-valley breath independent pulse wave velocity (Q̇ max – Q̇ min). 
Cardiovascular - Pertaining to the heart, blood and blood vessels.  
Carotid artery - The principal artery of the neck; one branch the internal carotid provides 
a major blood supply to the brain. 
Carotid body - A group of receptors, adjacent to the carotid sinus, that are sensitive to 
changes to the carbon dioxide levels, pH, and oxygen concentrations of arterial blood. 
Carotid sinus - A dilated segment at the base of the internal carotid artery whose walls 
contain baroreceptors sensitive to changes in blood pressure. 
Central nervous system - The brain and spinal cord. 
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Chronic adaptations  - Habitual or long-term physiological adaptations following 
repeated sessions of slow and deep breathing. 
Chronic heart failure (CHF) - The failure to maintain adequate cardiac output due to 
cardiovascular problems or myocardial damage. 
Chronic hypertension - Hypertension that is present at a women’s first antenatal visit 
during pregnancy, or before 20 weeks, or the women is already taking antihypertensive 





Detraining - Changes in physiological function in response to a reduction or cessation 
of regular physical training.  
Device-guided breathing (DGB) - Slow and deep breathing delivered using an external 
device. 
Diaphragm - The respiratory muscle that separates the thoracic cavity from the 
abdominopelvic cavity.  
Diastolic blood pressure (DBP) - Pressure measured in the walls of an artery when the 
left ventricle is in diastole. The lowest pressure when the heart is at rest. 
 DBPe        Diastolic blood pressure during expiration. 
 DBPi        Diastolic blood pressure during inspiration. 
 DBPΔ        Inter-breath phase diastolic blood pressure variation (DBPi - DBPe). 
 DBPΔe       Peak-valley DBP during expiration (DBPe max – DBPe min). 
 DBPΔi        Peak-valley DBP during inspiration (DBPi max – DBPi min). 
 DBPΔPV      Peak-valley DBP (DBPi max – DBPe min or DBPi min – DBPe max). 
 DBPΔPVInd Peak-valley breath independent DBP (DBP max – DBP min). 
Duty cycle (T I/TTOT) - Ratio of inspiration duration to total breath cycle duration. 
Dynamic breathing condition (Dfr) - Dynamic breathing frequency using optimisation 
algorithm. 
Dyspnoea - Laboured or difficult breathing.  
 
E   
 
Electro-cardiogram (ECG) - A graphic record of the electrical activities of the heart, as 
monitored at specific locations on the body surface. 
Epoch – A specific period of time that is a subdivision of a period. 
Error signal - A signal that represents the difference between the set point value and 
the actual value of the regulated variable. For example, the resting value of blood 
20 
pressure compared with the dynamic value of blood pressure caused by blood pressure 
fluctuations.  




fc - See heart rate. 
Fetus - An unborn baby from 8 weeks after fertilisation until the time of birth. 
Ffr - Fixed breathing frequency; in the present thesis study relating to either 4 (4Ffr), 6 
(6Ffr) or 8 (8Ffr) breaths.min-1. 
Frank-Starling mechanism - The mechanism by which an increased amount of blood 





Gestation - The period of the fetus developing inside the womb between conception and 
birth. 




Haemodynamics - Relating to the flow of blood within the organs and tissues of the 
body. 
Heart rate (fc) - The frequency the heart pumps per minute. 
 fce    Heart rate during expiration. 
 fci     Heart rate during inspiration.  
 fcΔ    Inter-breath phase heart rate variation (fci - fce). 
 fcΔe     Peak-valley heart rate during expiration (fce max – fce min). 
 fcΔi     Peak-valley heart rate during inspiration (fci max – fci min). 
 fcPV     Peak-valley heart rate (fci max – fce min or fci min – fce max). 
 fcΔPVInd Peak-valley breath independent heart rate (fc max – fc min). 
Heart rate variability (HRV) - Variation in the time interval between consecutive 
heartbeats.  
Homeostasis - The maintenance of a relatively constant internal environment.  
Hypertension - Abnormally high blood pressure. Normally defined as a systolic pressure 
of 140 mmHg or higher and/or a diastolic pressure of 90 mmHg or higher. 
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Hypercapnia - An abnormally high plasma PCO2 commonly as a result of 
hypoventilation. 
Hypertension - A condition in which the blood vessels have persistently raised pressure. 
Also known as high blood pressure. 
Hyperventilation - A rate of respiration sufficient to reduce plasma PCO2 to levels below 
normal. 
Hypocapnia - An abnormally low plasma PCO2 commonly as a result of hyperventilation. 





Inspiration (i) - Inhalation, breathing in. 
Inspiratory resistance (IR) - Breathing condition using an added inspiratory resistance 




Mean arterial pressure (MAP) - The average pressure exerted by the blood in the 
arteries. Estimated using equation: MAP = diastolic blood pressure + (0.333 x pulse 
pressure) 
 MAPe        Mean arterial pressure during expiration. 
 MAPi        Mean arterial pressure during inspiration. 
 MAPΔ        Inter-breath phase mean arterial pressure variation (MAPi - MAPe). 
 MAPΔe      Peak-valley MAP during expiration (MAPe max – MAPe min). 
 MAPΔi       Peak-valley MAP during inspiration (MAPi max – MAPi min). 
 MAPΔPV    Peak-valley MAP (MAPi max – MAPe min or MAPi min – MAPe max). 
 MAPΔPVInd Peak-valley breath independent MAP (MAP max – MAP min). 
Multipara (Multip) - A woman who has given birth at least once before >24 weeks 
gestation. 




Nadir - The lowest point. 
National Health Service (NHS) - Publicly-funded healthcare system of the United 
Kingdom.  
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Normotensive - Normal levels of blood pressure. 




Parasympathetic - One of the two divisions of the autonomic nervous system, generally 
responsible for activities that conserve energy and lower the metabolic rate. 
Peak-valley (PV) - Difference between maximum and minimum values. 
Perturbation - A disturbance or change in a structure or function, as a result of an 
external influence. 
Postnatal/ postpartum - The period after birth. 
Pregnancy-induced hypertension (PIH) - New high blood pressure (hypertension) 
presenting after 20 weeks of pregnancy without significant proteinuria. 
Pre-eclampsia - New onset of high blood pressure (hypertension) after 20 weeks of 
pregnancy with significant proteinuria. 
Preterm/ premature - A baby born before 37 weeks of pregnancy. 
Primary hypertension - High blood pressure (hypertension) that doesn’t have a 
secondary cause. 
Primigravida - A woman who is pregnant for the first time. 
Primipara - A woman who is giving birth for the first time. 
Proteinuria - Increased levels of protein in the urine. 
Pulse pressure (PP) - The difference between systolic and diastolic blood pressures. 
Equation: PP = systolic blood pressure minus diastolic blood pressure 
 PPe   Pulse pressure during expiration. 
 PPi   Pulse pressure during inspiration. 
 PPΔ   Inter-breath phase pulse pressure variation (PPi - PPe). 
 PPΔe   Peak-valley pulse pressure during expiration (PPe max – PPe min). 
 PPΔi   Peak-valley pulse pressure during inspiration (PPi max – PPi min). 
 PPΔPV   Peak-valley pulse pressure (PPi max – PPe min or PPi min – PPe max). 
 PPΔPVInd Peak-valley breath independent pulse pressure (PP max – PP min). 
Pulse transit time (PTT) - Time taken for the pulse wave to travel between two sites. 
 PTTe    Pulse transit time during expiration. 
 PTTi    Pulse transit time during inspiration. 
 PTTΔ    Inter-breath phase pulse transit time variation (PTTi - PTTe). 
 PTTΔe   Peak-valley pulse transit time during expiration (PTTe max – PTTe min). 
 PTTΔi    Peak-valley pulse transit time during inspiration (PTTi max – PTTi min). 
 PTTΔPV  Peak-valley PTT (PTTi max – PTTe min or PTTi min – PTTe max). 
 PTTΔPVInd Peak-valley breath independent PTT (PTT max – PTT min). 
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Pulse wave analysis (PWA) - Innovative method to measure central blood pressure 
measures using the analysis of pressure wave reflection characteristics.  
Pulse wave velocity (PWV) - The rate at which pressure waves move down a vessel.  
 PWVe      Pulse wave velocity during expiration. 
 PWVi      Pulse wave velocity during inspiration. 
 PWVΔ      Inter-breath phase pulse wave velocity variation (PWVi - PWVe). 
 PWVΔe    Peak-valley PWV during expiration (PWVe max – PWVe min). 
 PWVΔi     Peak-valley PWV during inspiration (PWVi max – PWVi min). 
 PWVΔPV  Peak-valley PWV (PWVi max – PWVe min or PWVi min – PWVe max). 








Randomised control trial (RCT) - A study in which a number of similar people are 
randomly assigned to two or more groups to test a specific drug, treatment or other 
intervention. One group (the experimental group) has the intervention being tested, the 
other (the control group) has an alternative treatment, a dummy intervention (placebo) 
or no intervention at all. 
Renal resistive index (RRI) - Ratio of peak systolic and end diastolic velocity. Normal 
= 0.6 and the upper healthy limit is <0.7. Equation: RRI = (Peak systolic velocity minus 
end diastolic velocity) ÷ peak systolic velocity. 
Respiration - The exchange of gases between cells and the environment; includes 
pulmonary ventilation, external respiration, internal respiration, and cellular respiration.  
Respiratory condition - Disease or condition related to the respiratory system such as 
asthma. 
Respiratory pump - A mechanism by which changes in the intrapleural pressures during 
the respiratory cycle assist the venous return to the heart. 
Respiratory sinus arrhythmia (RSA) - Within breath fluctuations in heart rate. 
Difference between the maximum RR interval during expiration minus minimum RR 
interval during inspiration. 
Rest period (R) - Period of normal breathing between two breathing conditions to allow 
cardiovascular variables to return to normal levels. 





Singleton pregnancy - A pregnancy with one fetus. 
Slow and deep breathing (SDB) - Breathing at a frequency lower than 10 breaths.min-1. 
Spontaneous breathing condition (Sfr) - Spontaneous breathing frequency 
(uncontrolled normal breathing). 
Stroke volume (SV) - The amount of blood ejected from the left ventricle during each 
contraction. 
 SVe       Stroke volume during expiration. 
 SVi       Stroke volume during inspiration.  
 SVΔ      Inter-breath phase stroke volume variation (SVi - SVe). 
 SVΔe       Peak-valley stroke volume during expiration (SVe max – SVe min). 
 SVΔi      Peak-valley stroke volume during inspiration (SVi max – SVi min). 
 SVΔPV     Peak-valley stroke volume (SVi max – SVe min or SVi min – SVe max). 
 SVΔPVInd Peak-valley breath independent stroke volume (SV max – SV min). 
Sympathetic - One of the two divisions of the autonomic nervous system, primarily 
concerned with the elevation of metabolic rate and increased alertness.  
Systolic blood pressure (SBP) - Pressure measured in the walls of an artery when the 
left ventricle is in systole. The peak pressure when the heart beats. 
 SBPe          Systolic blood pressure during expiration. 
 SBPi          Systolic blood pressure during inspiration. 
 SBPΔ          Inter-breath phase systolic blood pressure variation (SBPi - SBPe). 
 SBPΔe         Peak-valley SBP during expiration (SBPe max – SBPe min). 
 SBPΔi          Peak-valley SBP during inspiration (SBPi max – SBPi min). 
 SBPΔPV       Peak-valley SBP (SBPi max – SBPe min or SBPi min – SBPe max). 




T I/TTOT - See duty cycle. 
Tidal volume (VT) - The volume of air inspired or expired during a normal breathing 
cycle. 
Term (full term) - Considered to be 40 weeks of pregnancy from the first day of the 
woman’s last menstrual period. Normal duration of pregnancy is 37-42 weeks gestation. 
Total peripheral resistance (TPR) - The resistance to blood flow, primarily caused by 
friction with the vascular walls. Equation: TPR = mean arterial pressure ÷ cardiac output. 
TPRe        Total peripheral resistance during expiration. 
 TPRi        Total peripheral resistance during inspiration. 
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 TPRΔ        Inter-breath phase total peripheral resistance variation (TPRi- TPRe). 
 TPRΔe       Peak-valley TPR during expiration (TPRe max – TPRe min). 
 TPRΔi        Peak-valley TPR during inspiration (TPRi max – TPRi min). 
 TPRΔP       Peak-valley TPR (TPRi max – TPRe min or TPRi min – TPRe max). 
 TPRΔPVInd  Peak-valley breath independent TPR (TPR max – TPR min). 
Trimester - A time span of 3 months during pregnancy, each marked by different phases 
of fetal development. First trimester (first 12 weeks), second trimester (13-27 weeks) and 




VT – See tidal volume. 
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Chapter 1. Introduction 
 
1.1 Hypertensive disorders of pregnancy  
 
Hypertension is the most common medical disorder during pregnancy (Moser et al. 
2012), and hypertensive disorders of pregnancy are the second highest direct cause of 
maternal deaths worldwide, accounting for 14% of direct deaths (Say et al. 2014). 
Although frequently referred to as “hypertension in pregnancy” (NICE: National Institute 
for Health and Care Excellence 2019b; Royal College of Obstetricians and 
Gynaecologists 2019), caution must be taken when interpreting research and statistics 
due to the different conditions that are often grouped together, and not always analysed 
independently, despite the differences between conditions in both aetiology and 
outcomes. The Report of the National High Blood Pressure Education Program Working 
Group on High Blood Pressure in Pregnancy (2000) groups women with high blood 
pressure into 4 classification groups; 1) chronic hypertension, 2) pre-eclampsia/ 
eclampsia, 3) Pre-eclampsia super imposed on chronic hypertension and 4) gestational 
hypertension (transient hypertension of pregnancy if no pre-eclampsia present and blood 
pressure (BP) returns to normal by 12 weeks post-partum, or chronic hypertension if BP 
does not return to normal post-partum). 
 
Chronic hypertension is hypertension that was observed prior to pregnancy or before the 
20th week of gestation. Pregnancy-induced hypertension (PIH), or gestational 
hypertension, is a specific hypertensive condition that presents with high BP that was 
not present before pregnancy and BP that returns to normal following giving birth. The 
National Institute for Health and Care Excellent (NICE) define PIH as new high blood 
pressure (≥140 / ≥90 mmHg) presenting after 20 weeks of pregnancy, which was not 
present before conception, without significant proteinuria (NICE: National Institute for 
Health and Care Excellence 2019b).  
 
Pre-eclampsia, is a more serious hypertensive disorder of pregnancy, which is 
characterised by PIH onset with proteinuria (NICE: National Institute for Health and Care 
Excellence 2019b) and 25% of women with PIH progress to develop pre-eclampsia 
(Tranquilli et al. 2014). Due to the separate aetiology and differences in physiological 
changes/outcomes between the conditions, the present thesis will focus on the study of 
women with PIH, allowing a specific focus of the hypertension element of the condition. 
It is possible that the findings within this thesis could be applicable to women who have 
pre-eclampsia, however as pre-eclampsia involves multisystem dysfunction (Karthiga et 
al. 2019) there are likely to be other factors that interventions targeting a reduction in BP 
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may not be able to treat. Additionally, control of BP alone does not treat pre-eclampsia 
(Abbas et al. 2005). Further research would be needed to apply any findings to pre-
eclampsia, hence the focus on women who have PIH. Where possible, references are 
used that studied PIH specifically, and did not group hypertensive disorders of pregnancy 
together. If these references are not available then it is made clear that the reference 
includes other types of hypertensive disorders of pregnancy and is not specific to PIH. 
 
In the United Kingdom (UK), PIH affects around 8-10% of all pregnant women and can 
cause maternal morbidity, stillbirths and neonatal deaths, and perinatal morbidity (NICE: 
National Institute for Health and Care Excellence 2019b). Additionally, women who 
experience PIH during pregnancy are at an increased risk of developing cardiovascular 
disease later in life including stroke, coronary artery disease, cardiac arrhythmias, 
chronic kidney disease and multimorbidity (Garovic et al. 2020). There may also be an 
increased risk of developing mental health disorders such as anxiety, postpartum 
depression and post-traumatic stress disorder (Roberts et al. 2019). 
 
It seems possible that PIH may become an increasing problem, as trends in ‘normal’ BP 
during pregnancy have shown a significant rise in diastolic BP (DBP) of 0.26 mmHg 
every year between 1969 and 2017 and a non-significant increase of 0.12 mmHg every 
year for systolic BP (SBP) (Loerup et al. 2019). Therefore, although rates of PIH are 
currently falling, rising BP is a problem for the general pregnant population, which may 
lead to higher rates of PIH in the future. Predictive modules using risk factors of  PIH to 
calculate rates of hypertension, such as increasing maternal age and obesity, reveal a 
predicted increase in rates of PIH (Roberts et al. 2015). Additionally, with the 
reclassification of hypertension by the American Heart Association at levels of 
≥130mmHg SBP and ≥80mmHg DBP (Whelton et al. 2018), levels of BP that were once 
considered normotensive may have greater negative consequences than previously 
known, which may be applicable during pregnancy, although this has yet to be reviewed. 
 
There is evidence of an increasing trend of early delivery in women with PIH. In data 
collected between 2001 and 2012, Roberts et al. (2015) observed increasing early 
delivery before 38 weeks in women who had experienced PIH, compared with trends in 
normotensive women who showed an increasing percentage of births after 39 weeks. 
Although the study was undertaken in Australia, the authors suggest findings are 
generalisable to other high-income countries (Roberts et al. 2015). Preterm birth 
complications are the leading cause of death among children under 5 years of age (Liu 
et al. 2016) and the WHO’s antenatal care guidelines include strategies to help prevent 
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preterm birth (World Health Organization 2016). Currently the only cure for PIH is to give 
birth, with recommended treatments normally involving pharmaceuticals.  
 
The current NICE recommended pharmaceutical treatments for hypertension during 
pregnancy (chronic, gestational and pre-eclampsia) recommend using labetalol as a first 
choice (NICE: National Institute for Health and Care Excellence 2019b; Royal College of 
Obstetricians and Gynaecologists 2019). Alternatively, if labetalol is not suitable then 
nifedipine or subsequently methyldopa should be considered. Pharmaceutical 
treatments for PIH should be chosen based on pre-existing treatments, side-effect 
profiles, risks (including fetal effects) and the women’s preference (NICE, 2019). 
However, there is a paucity of data available for most of the new antihypertensive drugs 
over the last 20 years due to pharmaceutical companies being reluctant to test 
medication with pregnant women (Cifkova 2011). As a result of this, despite the general 
(non-pregnant) use of medications such as methyldopa declining since its introduction 
more than 50 years ago, it is still one of the preferred choices during pregnancy (Okur et 
al. 2017). Consequently, treatments that can be trialled specifically in pregnant women 
are important in widening options for treatment of hypertension during pregnancy. 
 
An alternative treatment for PIH is to give birth early (pre-term), however there are 
associated risks. The 2017 Cochrane Review (Cluver et al. 2017) compared planned 
early delivery versus expectant management for hypertensive disorders from 34 weeks 
gestation to term. The review concluded that early delivery reduced the risk of maternal 
complications but there was not enough information to draw conclusions on the effects 
on infant mortality or morbidity. However, planned early delivery was associated with 
higher levels of admission to neonatal intensive care unit. Although, the authors also 
noted that evidence was limited and more research is needed to specifically examine the 
any potential differences between types of hypertensive conditions. For PIH specifically, 
the optimal time for delivery is argued to be between 38-39 weeks based on the balance 
of lowest maternal and neonatal morbidity and mortality (Cruz et al. 2012). Neonatal 
complications from pre-term births can also have long-term consequences, with 
evidence suggesting significant adverse performance across a range of  cognitive and 
educational measures compared with children born at term (Chan et al. 2016). 
 
In terms of healthcare costs, pre-term births are associated with higher mean cost per 
infant over the child’s first three years of life and these costs decreased with increasing 
gestational age at birth (Clements et al. 2007). Children born between 32 to 36 weeks 
gestation had more than double the associated costs compared with children born at 
term, and children born between 24 to 31 weeks gestation had associated costs over 7 
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times higher (Clements et al. 2007). Therefore, interventions are needed that can prolong 
the gestation period by controlling BP, consequently not requiring planned pre-term 
delivery, and benefiting the development of the baby and its ongoing health during early 
childhood. 
 
Furthermore, a diagnosis of PIH changes the experience of pregnancy for women and  
following a diagnosis of hypertension pregnant women feel a lack of control (Roberts et 
al. 2017) and may experience psychological trauma caused by a lack of information and 
control (Cowan et al. 2017). This feeling of lacking control could be reduced by providing 
a treatment method, such as non-pharmacological interventions including slow and deep 
breathing (SDB), which gives the women back an element of control over their condition. 
Additionally, improving women’s involvement in the management of their disease, fits 
into the ‘women-centred’ model that underpins midwifery practice (Royal College of 
Midwives 2014) by actively involving the women in their care (Lavallee et al. 2018).  
 
Research utilising interventions that include SDB (e.g. yoga, meditation) have shown 
encouraging reductions in BP that warrant further examination using a more robust 
intervention than those applied to date (Curtis et al. 2012; Cullins et al. 2013; 
Rampalliwar et al. 2013; Aalami et al. 2016). Specifically, yoga, which emphasises slow 
breath control, has been shown to improve pregnancy and fetal outcomes, including the 
incidence of PIH (Rakhshani et al. 2012). A full review of studies utilising interventions 
that include SDB during pregnancy will be provided in section 2.2. 
 
Overall, women who have PIH are a promising group in which to examine the potential 
benefits of SDB. The aetiology of PIH has been linked to dysfunctional breathing (Jerath 
et al. 2009), in particular, high breathing frequencies (Fischer and Voss 2014). Pregnant 
women are also normally otherwise healthy, and therefore less likely to be taking certain 
medications that may impact the effectiveness of SDB. Finally, most pregnant women 
have an aversion to medication (Twigg et al. 2016) and therefore they have high levels 
of engagement and are highly motivated to comply with non-pharmacological 
interventions (Adams et al. 2009). SDB may be an important component of behavioural 
interventions aimed at reducing BP (Sica 2011) and therefore given pregnant women’s 
potential acceptability of such an intervention there is a need to conduct this potentially 
beneficial research. However, Band and colleagues note that few trials using digital 
interventions aimed at pregnant women have conducted in-depth acceptability testing 
(Band et al. 2019), which is important to evaluate the feasibility of such interventions, 
and is the reason this thesis is important. Using SDB as an independent intervention has 
recently gained popularity, but the origins of SDB are found within more integrative 
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exercises, and these are outlined below to provide perspective on the intervention in 
question. 
 
1.2 Background to the therapeutic use of slow and deep breathing 
 
Yoga, Qigong and meditation have been practiced for thousands of years, with the 
original purpose of spiritual enlightenment and correcting supposed imbalances of mind, 
body and spirit. The common element between these exercises is the regulated 
breathing and it is theorised that the associated benefits are due to this element of 
controlled breathing (Gerritsen and Band 2018). Since the 1960s, the benefits have first 
been researched in yoga (Miles 1964), meditation (Benson et al. 1974) and qigong (Koh 
1982). A search of Web of Science showed the number of published clinical trials on 
meditation, mindfulness, yoga, tai chi or qi gong increased from approximately 20 in 2000 
to 250 in 2014, with citations also increasing from 20 in 2000 to 7,112 in 2014 (Gerritsen 
and Band 2018). Integrated treatments, which include both the general practise of the 
above exercises and integrated breathing techniques, have subsequently formed part of 
interventions aiming to improve health. Research studies date back to the 1970s with 
the first recorded published articles on PubMed using integrated treatments to reduce 
anxiety (Dillbeck 1977), weight (Madhavi et al. 1985), blood pressure (Silverberg 1990), 
and low back pain (Cramer et al. 2013). 
 
When comparing different types of exercise, yoga has proved to be the most beneficial 
for a range of health outcomes (Ross and Thomas 2010), leading to the suggestion that 
the breathing exercises within yoga provide an additional benefit that is separate from 
the benefits of exercise alone. The health benefits of breathing techniques, which include 
changing breathing patterns and breath control, became popular in the 1970s and 80s. 
Breathing techniques such as Lamaze breathing (Hughey et al. 1978), and Leboyer’s 
‘Art of breathing’ (Leboyer 1985) became particularly popular during childbirth. Using 
breathing exercises as a treatment for respiratory conditions such as asthma are also 
common place and have been subject to the scrutiny of a recent Cochrane systematic 
review (Santino et al. 2020), which concluded breathing exercises may increase quality 
of life and lung function, and decrease hyperventilation symptoms. Breathing exercises 
used by physiotherapists include breathing retraining, pranayama, Papworth method 
(breathing with the nose and diaphragm), deep diaphragmatic breathing, thoracic 
expansion exercises, pursed lip breathing exercises and glossopharyngeal exercises, 
which often include an element of reducing breathing frequency (Santino et al. 2020). 
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Pranayama breathing techniques, originating within yoga practice, are nowadays 
practiced independently from yoga. There are multiple types of pranayama techniques, 
but most involve reducing breathing frequency and this has developed into a technique 
known in the research context as “slow and deep breathing” (SDB). In the past 30 years 
SDB has gained prominence as a standalone intervention, with new delivery methods 
eliminating the need for technique training and/or a yoga/meditation teacher to be 
present. Standalone implementation of SDB has produced beneficial health outcomes 
for a variety of conditions, including hypertension (Grossman et al. 2001), stress and 
anxiety (Clark and Hirschman 1990), depression (Chung et al. 2010), post-traumatic 
stress disorder (PTSD; (Descilo et al. 2010), pain threshold and tolerance (Chalaye et 
al. 2009), chronic pain (Busch et al. 2012) and conflict monitoring (Cheng et al. 2017). 
However, conditions like menopausal hot flushes (Huang et al. 2015) and overactive 
bladder syndrome (Huang et al. 2019) did not show improvement after SDB, compared 
with control groups.  
 
Typical SDB interventions involve reducing breathing frequency to less than 10 
breaths.min-1 for at least 5 minutes, on at least 3 days per week and a recent meta-
analysis found device guided breathing can reduce SBP by 5.3 mmHg and DBP by 2.7 
mmHg (Chaddha et al. 2019). Device guided breathing involves using an external pacing 
device to guide breathing in a more robust way (Rosenthal et al. 2000; Parati and 
Cerretta 2007), ensuring consistency and accuracy between sessions. When using a 
device to guide breathing, breath synchronisation, time spent in SDB and average 
reduction in breathing frequency are not correlated with number of sessions completed 
(Gavish 2010), showing that experience is not a requirement to achieve successful SDB 
when using a device to guide breathing. On the other hand, undertaking non-device 
guided SDB, such as yoga exercises or meditative breathing, requires training and 
practice to learn how to independently control breathing (Patel 1975). 
 
The most frequently used device guided breathing system is the RESPeRATE product, 
which was cleared by the Food and Drug Administration (FDA) in the U.S.A. in 2002 and 
added to the National Health Service (NHS) Drug Tariff List in 2012 in the UK. 
RESPeRATE provides pacing via headphones, which play a fluctuating musical tone to 
lower the user’s breathing rate to what the makers claim to be the ‘therapeutic breathing 
zone’ (≤10 breaths.min-1). Users breathe in time with the musical tones and breathing 
frequency is monitored using a belt worn around either the chest or upper abdomen. It 
is recommended to attain 40 minutes or more of SDB per week (40 minutes in therapeutic 
breathing zone). A full description of how RESPeRATE works can be found in Gavish 
(2010) and Cernes & Zimlichman (2017). Evaluation of the related clinical trials are 
32 
discussed in the Literature Review chapter of this thesis, only an overview is provided in 
this chapter. 
 
RESPeRATE is recommended by the American Heart Association as an effective 
treatment for hypertension (Brook et al. 2013). However, there is much debate around 
this recommendation due to the evidence on which the recommendation was based, 
specifically there are concerns regarding the influence of manufacturer-sponsored 
studies and methodological weaknesses (Landman et al. 2014; van Hateren et al. 2015; 
Zimlichman 2017). Additionally, despite RESPeRATE being included in the UK NHS 
Drug Tariff List, many localised NHS Clinical Commissioning Groups (CCG) do not 
support its prescription, citing limited evidence of the long-term effects and the lack of 
recommendation by NICE, or other national hypertension guidelines. In fact the British 
Hypertension Society (2012) released a statement that current research has only shown 
small effects over short durations, which they believe is insufficient evidence to 
recommend the device for routine use. This scepticism was also reflected in the advice 
in other countries such as Australia and New Zealand (National Horizon Scanning Unit 
2004). 
 
Despite the widespread promotion and the focus of research articles on RESPeRATE, 
there are a number of disadvantages to the product, and limitations of the evidential 
support for its marketing claims. Firstly, there are a high number of industry sponsored 
RESPeRATE studies, which when removed from meta-analyses reduce the magnitude 
of its effectiveness (Mahtani et al. 2012). Additionally, as RESPeRATE costs ~£250 at 
the time of writing, it is not an easily accessible or affordable treatment method, 
especially in the UK where the NHS CCG will currently not cover the cost. It is also a 
fairly bulky (12.4 x 11.7 x 6.6cm), albeit lightweight (360g), device to carry around for 
everyday use. Increasing the ease with which users can undertake SDB, such as being 
able to practice anywhere, would support greater adherence and therefore increase the 
potential associated benefits. Harnessing the capabilities of portable devices that are 
more easily integrated into modern busy life is critical to moving the SDB research 
forward. 
 
Thus, although there are data supporting the antihypertensive effects of SDB, the current 
evidence is inconsistent; indeed, a recent mainstream media article in The Observer 
newspaper attested that the ‘jury is still out’ until better quality, well-controlled human 
studies are conducted (Fleming 2020). Although SDB has the potential to reduce BP, 
the current evidence is preliminary, and more consistent support is needed before 
recommending its use as a behavioural therapy to reduce BP (Sica 2011). Importantly, 
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the mechanisms by which SDB reduces BP are not fully understood (Gerritsen and Band 
2018) and further research is needed to investigate both the short-term (acute) 
responses to, and long-term effects of, SDB. In order to improve SDB interventions and 
provide the sufficient evidence required by national governance organisations, a 
mechanistic understanding of SDB is needed. Once this is achieved, interventions can 
be designed around the physiological systems that SDB targets, thereby enhancing the 
potential benefits and/or reducing the ‘investment’ from users. By using SDB 
interventions that are tailored to the population in question, this could lead to more 
consistent outcomes by targeting the physiological pathways that lead to BP reductions. 
 
Finally, feasibility trials for integrating SDB interventions into the healthcare system are 
lacking for SDB interventions, despite the recommendation that the evaluation and 
establishment of nonpharmacological treatments for hypertension is a public health 
priority (Adler et al. 2019). This is especially important with different population groups 
such as pre-hypertensive individuals and pregnant women with high BP. As outlined in 
section 1.1, SDB has the potential to be an important nonpharmacological treatment 
method for PIH, but this has not been trialled. It is vital that researchers investigate how 
best to deliver SDB, as a therapy, so that users find it both accepted and engaging. 
 
Existing studies of SDB have focussed on populations with primary hypertension, but 
using SDB as a non-pharmacological intervention to reduce BP in pregnant women could 
be a significant step forward in saving mothers’ lives and/or reducing risk in women who 
develop PIH. The benefits of drug treatment for mild to moderate high BP (hypertension) 
during pregnancy (≤160/≤110 mmHg) are uncertain (European Society of Hypertension 
and European Society of Cardiology 2013) and the American Heart Association suggest 
alternative approaches are becoming increasingly important in the management of all 
forms of hypertension (Brook et al. 2013). Therefore, there is a strong argument to 
support exploring alternative non-pharmacological interventions to reduce BP in 
pregnant women with hypertension, such as SDB. 
 
In summary, SDB has shown promising reductions in BP following daily use in primary 
hypertension. Using a device to guide breathing requires less training and monitoring 
than traditional delivery of breathing exercises (yoga and meditation). The most popular 
method to deliver SDB (RESPeRATE) has limitations both in the device design itself and 
the existing evidence to support its use. A SDB intervention has the potential to offer a 
non-pharmacological treatment method for PIH, but must be tested in this population 
group, with a full understanding of the changes which SDB produces in pregnant women.  
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1.3 Outline of the thesis 
 
This thesis combines the need for non-pharmacological treatments for PIH with a novel 
SDB intervention. The first study compared the acute (short-term) cardiovascular 
responses to an existing device (RESPeRATE) with those to a new device designed at 
Bournemouth University. The responses to both devices were compared in men and 
women, to allow a comparison of possible sex-related differences in the acute 
cardiovascular responses to SDB (Chapter 4). To understand the mechanisms by which 
SDB may reduce BP in women who have PIH, normative data in normotensive non-
pregnant (Chapter 5) and normotensive pregnant women (Chapter 6) was needed for 
comparison. Due to the cardiovascular changes caused by pregnancy it is important to 
understand any potential differences in the acute responses to SDB of healthy pregnant 
and healthy non-pregnant women, which may influence any long-term adaptations 
following a SDB intervention (Chapter 7). This study design also allowed the optimal SDB 
frequency, specific to pregnant women, to be used in a planned, future long-term 
intervention to explore the feasibility of using SDB with pregnant women who develop 
PIH (Chapter 8). The planned protocol has been published in Hypertension in Pregnancy 
in 2021 (Felton et al. 2021). 
 
1.4 Impact of the coronavirus pandemic on the research 
 
In 2020, the coronavirus pandemic caused worldwide disruption to both life and research. 
At this time, the final study of this thesis (investigating the feasibility of using SDB as a 
treatment method with women who develop PIH), was recruiting from the local NHS 
maternity unit, but no women had been enrolled into the study. Pregnant women are 
classed as high risk for COVID-19 infection, especially when combined with existing 
medical conditions such as hypertension. All NHS research studies not linked to 
coronavirus were paused, and specifically in our local maternity unit, only 2/11 studies 
were still open for recruitment by the end of March 2020. Therefore, the decision was 
made to stop the study and to include only the planned protocol as part of this thesis. 
 
To supplement the data already collected from the laboratory-based studies 
(investigating acute cardiovascular responses to SDB, presented in Chapters 5 and 6), 
an additional study was included in the thesis. The data presented in Chapter 4 was 
collected as part of a linked research study, in which the author (MF) was involved. For 
narrative reasons, these data have been presented first in the thesis, although the 
timeframe of data collection was simultaneous with the Chapter 5 data set. The data in 
Chapter 4 provides a comparison of the cardiovascular responses to different methods 
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of SDB delivery; an existing device, a new biofeedback device, and a fixed SDB 
frequency.  
  
The result is a thesis that explores the acute cardiovascular responses to SDB and 
reports the development and validation of a novel intervention, which is based on 
scientific data, as well as women’s user feedback. To investigate the complex topic of 
SDB, an interdisciplinary approach is taken, combining physiology and maternal health 
perspectives. As such, the thesis will be examined by a multi-disciplinary team of 
examiners and therefore certain terminology may be used that is unfamiliar to one or 
other examiner. A glossary, including abbreviations, is included on page 17 and where 





Chapter 2. Literature Review 
 
This chapter will provide an overview of the relevant literature related to slow and deep 
breathing (SDB) and its potential as a treatment method for hypertension that develops 
during pregnancy. The chapter will start by outlining the respiratory and cardiovascular 
changes associated with normal pregnancies, comparing these normal adaptations with 
the different changes observed in hypertensive pregnancies (Section 2.1). Section 2.2 
will provide an overview of interventions, which include or have similarities with SDB, 
and have already been used as interventions during pregnancy. Next, an overview of the 
evidence of using SDB interventions to reduce blood pressure (BP) in primary 
hypertension will be presented (Section 2.3), followed by an exploration of the short-term 
(acute) responses to SDB, which may provide mechanistic explanations for any long-
term (chronic) reduction in BP (Section 2.4). The chapter will finish with a summary of 
the literature and the overall aims for this thesis (Section 2.5).  
 
2.1 Respiratory and cardiovascular changes during pregnancy 
 
A woman’s body experiences dramatic changes during pregnancy, with maternal 
adaptations supporting the development and growth of the fetus (Weissgerber and Wolfe 
2006). During pregnancy, the body undergoes intense haemodynamic modifications, 
such as an increase in blood volume of 30-40% (Heidemann and McClure 2003), but at 
the same time, hemodynamic stability needs to be maintained to preserve the health of 
the mother and growing fetus (da Silva Correa et al. 2019). 
 
The most profound physiological changes are those that occur in the cardiovascular 
system (Carlin and Alfirevic 2008). However, the mechanisms which control adaptations 
to autonomic cardiovascular modulation during pregnancy are not fully understood (da 
Silva Correa et al. 2019), especially in relation to hypertensive disorders of pregnancy. 
Although the aetiology of pregnancy-induced hypertension (PIH) remains unknown, 
there are known physiological differences in women with PIH compared with 
normotensive pregnancies (Dudenhausen and Travis 2014). These differences will be 
outlined below in relation to the physiological changes experienced during a healthy 
pregnancy.  
 
2.1.1 Respiratory  
 
During pregnancy, the growing fetus expands the uterus upwards changing the shape of 
the chest (Carlin and Alfirevic 2008). The organ where this process is most felt by women 
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is the lungs, as their natural resting position is changed throughout pregnancy. The 
diaphragm ascends up to 5cm (Elkus and Popovich Jr 1992) and to maintain adequate 
lung volumes and capacity (which are unchanged or undergo minimal decreases during 
pregnancy), the angle of the ribcage and the circumference of the lower ribcage both 
increase during pregnancy (Hegewald and Crapo 2011). This anatomic change peaks at 
37 weeks gestation (Hegewald and Crapo 2011) and is primarily caused by hormonal 
changes causing the ligaments of the ribcage to relax (McCormack and Wise 2009). 
 
Despite the changes in diaphragm position, there are no significant changes in 
respiratory muscle strength (LoMauro and Aliverti 2015) and diaphragm range of 
movement is increased by 2cm, which is explained by an increased area of the 
diaphragm next to the ribcage resulting in improved coupling (McCormack and Wise 
2009; Hegewald and Crapo 2011). After ~15 weeks of gestation, respiratory rate 
(breathing frequency) remains steady throughout the remaining pregnancy (Heidemann 
and McClure 2003), although a recent meta-analysis could not find sufficient data on 
breathing frequencies during pregnancy to produce normative values (Loerup et al. 
2019). 
 
During pregnancy, an increase in minute ventilation and tidal volume is observed 
(Norwitz et al. 2005; Hegewald and Crapo 2011). The amount of air breathed in (minute 
ventilation) increases significantly during pregnancy compared with non-pregnant 
women, peaking during the third trimester and showing a slight dip during the second 
trimester (McAuliffe et al. 2002). Minute ventilation can increase by up to 30% and is 
associated with feelings of an increased drive to breathe  (McCormack and Wise 2009). 
Interestingly, this has not been found to increase any further with twin pregnancies 
(McAuliffe et al. 2002). 
 
Tidal volume increases by ~200 ml due to a reduced functional residual capacity (the 
amount of gas left in the lungs after normal expiration) (Carlin and Alfirevic 2008). As a 
result of increases in minute ventilation and tidal volume, the majority of women (70%) 
experience dyspnoea (shortness of breath) by 30 weeks gestation (LoMauro and Aliverti 
2015). However, spirometry testing during pregnancy reveals no significant differences  
in forced vital capacity, compared with non-pregnant women, suggesting no difference 
in expiratory airflow resistance during pregnancy (Hegewald and Crapo 2011). A higher 
than average minute ventilation can be a sign of pre-eclampsia (da Silva et al. 2010) and 
further decreases in functional residual capacity, oxygenation and changes in airway size 
occur in the supine position (Hegewald and Crapo 2011). The increase in ventilation also 
causes an increase in PCO2 (Weissgerber and Wolfe 2006). 
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Overall, disorders of breathing may be a mechanism in the development of pre-
eclampsia (Jerath et al. 2009) and pregnancy is also linked with a higher incidence of 
respiratory dysfunctions, such as snoring. There is also an association between snoring 
and sleep apnoea, alongside higher levels of hypertension, as well as increased 
incidence of infants born small for gestational age (Franklin et al. 2000; Facco et al. 
2017). Consequently, the cardiorespiratory relationship is clearly important in 
hypertensive pregnancies and should be explored to investigate treatments which can 
normalise disorders of breathing, and establish if they in turn can affect the associated 
high blood pressure of hypertension. 
 
2.1.2 Blood pressure 
 
Normative values for blood pressure (BP) during pregnancy are based on general 
population guidelines, with a lack of separate, pregnant-specific ranges to diagnose high 
BP. Indeed, NICE Hypertension in Pregnancy guidelines (NICE: National Institute for 
Health and Care Excellence 2019b) are based predominately on adult guidance (NICE: 
National Institute for Health and Care Excellence 2019a) in addition to one pregnancy-
specific study (CHIPS: Control of Hypertension in Pregnancy Study). This is due to “very 
little evidence on treatment initiation thresholds for hypertension during pregnancy” 
(NICE: National Institute for Health and Care Excellence 2019b; page 43). Moreover, the 
CHIPS Study specifically investigated the treatment thresholds for hypertension, rather 
than the threshold for hypertension per se (Magee et al. 2015; Pels et al. 2018). 
Guidance values recommended during pregnancy are often based on insufficient 
evidence, referencing outdated data from textbooks (Loerup et al. 2019). Nonetheless, 
BP during pregnancy is traditionally described as decreasing during the first trimester 
before returning to normal in the third trimester (Sanghavi and Rutherford 2014). It has 
therefore been suggested that normative BP guidelines during pregnancy should be 
related to gestational age, but this idea has not been widely accepted (Higgins and de 
Swiet 2001). 
 
Women who experience hypertensive disorders of pregnancy, exhibit BP that rather than 
returning to normal in the second and third trimesters, continues to rise to hypertensive 
levels as defined by the NICE guidelines (NICE: National Institute for Health and Care 
Excellence 2019b). Although, it has been observed that pregnant women who later 
develop PIH may also exhibit higher than average BP earlier in pregnancy compared 
with normotensive women (Higgins and de Swiet 2001). However, due to the lack of 
gestational age specific data these comparisons are difficult to make, and impossible to 
use at this time for clinical decision making.  
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BP may decrease by 5 – 10 mmHg during the first trimester of pregnancy and the 
greatest changes are observed in diastolic blood pressure (DBP) compared with 
changes in systolic blood pressure (SBP) (Moser et al. 2012). A recent meta-analysis 
found SBP during pregnancy fluctuates from between 110 mmHg at 10 weeks gestation 
to 116 mmHg at 40 weeks gestation, a difference of 5.6 mmHg (Loerup et al. 2019). DBP 
fluctuated from 67 mmHg at 10 weeks gestation to 73 mmHg at 40 weeks gestation, with 
a nadir at 21 weeks of 66 mmHg (a change of 7.6 mmHg during pregnancy). The 
reduction in systemic vascular resistance, caused by vasodilation, is offset by an 
increase in cardiac output, which subsequently reduces DBP more than SBP (Moser et 
al. 2012). The changes in cardiac output and systemic vascular resistance are outlined 
below (Section 2.1.3 and 2.1.5).  
 
The most important short-term (acute) mechanism to control arterial BP oscillations 
during pregnancy is the baroreceptor system, the sensitivity of which is increased during 
pregnancy (Leduc et al. 1991). In both normotensive and preeclamptic pregnancies 
arterial blood pressure (ABP) variability is preserved at rest  (Eneroth-Grimfors et al. 
1994) and there is no difference in SBP response to orthostatic tests between pregnant 
and non-pregnant women (Ekholm et al. 1993). Consequently, although baseline resting 
BP differs between normotensive and hypertensive pregnancies, the ability of the 
cardiovascular system to fluctuate and respond to stressors is maintained during 
pregnancy and during hypertensive pregnancies.  
 
2.1.3 Hemodynamics: Blood volume, heart rate, stroke volume and cardiac 
output 
 
Pregnancy is characterised as a high volume, low-resistance cardiovascular state 
(Abbas et al. 2005). Blood volume increases by 30-40% throughout pregnancy, due to 
an increase in plasma volume, which reaches a peak between 20-32 weeks before 
maintaining a steady level during the third trimester (Soma-Pillay et al. 2016; da Silva 
Correa et al. 2019). Higher blood volumes are also seen in twin pregnancies (Norwitz et 
al. 2005). The increase in blood volume for singleton pregnancies can be as much as 
1.2-1.6 L (Soma-Pillay et al. 2016). The expansion of blood volume increases pre-load 
and end-diastolic volume, leading to increased stroke volume during pregnancy 
(Sanghavi and Rutherford 2014), by as much as 25% (Heidemann and McClure 2003). 
 
There is also an increase in ventricular wall thickness, which contributes to and is caused 
by the higher stroke volume and heart rate during pregnancy (Soma-Pillay et al. 2016; 
Ngene and Moodley 2017). Left ventricular wall thickness can increase by 28% and wall 
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mass by 52% (Sanghavi and Rutherford 2014). A recent meta-analysis found heart rate 
increased from 79 beats.min-1 at 10 weeks gestation to 87 beats.min-1 at 40 weeks 
(Loerup et al. 2019), with heart rate starting to increase as early as 5 weeks and peaking 
at 32 weeks gestation with a ~20% increase (Norwitz et al. 2005). The increase in heart 
rate is likely a result of counterbalance measures to maintain BP due to the decrease in 
systemic vascular resistance, as part of the contribution of heart rate to cardiac output 
(Norwitz et al. 2005). An outline of the cardiovascular variables which contribute to BP is 
presented in Figure 2-1. Arterial BP is maintained by total peripheral resistance and 
cardiac output, which in turn is controlled by heart rate and stroke volume. Consequently, 
any changes ‘downstream’ to heart rate and stroke volume can affect arterial BP through 







Heart rate (fc) Stroke volume (SV)
 
Figure 2-1 Cardiovascular variables contributing to arterial blood pressure 
 
Cardiac output increases during pregnancy between 30-50%, with a peak between 20 
and 28 weeks gestation when cardiac output plateaus until delivery (Del Bene et al. 2001; 
Hegewald and Crapo 2011). Cardiac output is influenced by stroke volume and heart 
rate (Figure 2-1), and during pregnancy stroke volume is the major determinant of 
cardiac output, until the second trimester when heart rate takes over (Ngene and 
Moodley 2017). Twin pregnancies exhibit an increase in cardiac output of up to 20% 
compared with singleton pregnancies, supported by increases in stroke volume of 15% 
and heart rate of 3.5% (Kametas et al. 2003). 
 
Comparisons between pregnant and non-pregnant women reveal that the responses to 
exercise are significantly different; cardiac output is higher for a given exercise intensity 
during pregnancy, primarily due to an increased stroke volume (Hegewald and Crapo 
2011). This shows that baseline levels of cardiac output, stroke volume, and by its nature 
heart rate, affect maternal responses to external stimuli, such as exercise.  
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When supine, pregnant women in later gestational ages experience a reduction in 
venous return due to the pressure of the gravid uterus on the inferior vena cava, leading 
to a decrease in stroke volume, and consequently cardiac output (Heidemann and 
McClure 2003). Cardiac output can fall by as much as 25%, compared with a lateral body 
position (Soma-Pillay et al. 2016). It is therefore important that cardiovascular and 
respiratory measurements are not measured in the supine positioning, due to the 
associated haemodynamic changes (Hegewald and Crapo 2011). 
 
2.1.4 Respiratory sinus arrythmia and other cardiovascular oscillations 
 
Respiratory sinus arrythmia (RSA) is reduced during pregnancy and has been shown to 
exhibit an attenuated response to relaxation compared with non-pregnant women 
(DiPietro et al. 2012). RSA during pregnancy can be 65% lower than non-pregnant 
women (Miyazato and Matsukawa 2010) and depressed RSA has been suggested to be 
a biophysical marker of pre-eclampsia (Lakhno 2016). 
 
As well as RSA, there are other cardiovascular variability measures that are observed in 
non-pregnant women including BP oscillations at ~0.1 Hz called Mayer waves (outlined 
in more detail in section 2.4.2). However, although Mayer waves have been found to 
change during different phases of the menstrual cycle (Lutsenko and Kovalenko 2017) 
the author is not aware of any studies reporting Mayer waves during pregnancy. 
Although, high frequency oscillations of SBP increased in women with PIH compared 
with healthy normotensive pregnant women (Ekholm et al. 1997). 
 
2.1.5 Systemic vascular resistance 
 
Systemic vascular resistance decreases by up to 40% during pregnancy until the middle 
of the second trimester (Sanghavi and Rutherford 2014) and starts to fall as early as 
week 6 of gestation (Soma-Pillay et al. 2016). The initial decrease in BP, traditionally 
observed in pregnancy, is a result of this immediate drop in vascular resistance, which 
cannot be fully compensated by the accompanying increase in cardiac output (Ngene 
and Moodley 2017) (see TPR in Figure 2-1). The decrease in systemic vascular 
resistance is caused by widespread vasodilation (Ngene and Moodley 2017), a result of 





2.1.6 Autonomic nervous system 
 
Pregnancy is associated with reduced baroreflex sensitivity (BRS) and lower 
parasympathetic modulation (Blake et al. 2000; Voss et al. 2000; Brooks et al. 2010; 
Kolovetsiou-Kreiner et al. 2018). There is a move towards more sympathetically 
mediated changes during normotensive pregnancies, including reduced vagal 
modulation of the heart caused by increased BP stretching the sinoatrial node (da Silva 
Correa et al. 2019). This is manifested in increased muscle sympathetic nervous activity 
(MSNA) by 6 weeks gestation, compared with pre-pregnancy values (Spradley 2018). 
 
Primary hypertension can be caused by sympathetic overactivity and parasympathetic 
withdrawal (Joseph et al. 2005). In hypertension that develops during pregnancy there 
is an exaggerated sympathetic nervous system activation prior to the development of 
hypertension (Spradley 2018). Normal pregnancies show a decrease in parasympathetic 
cardiovascular control (Ekholm et al. 1993) and an increase in sympathetic activity early 
in pregnancy (Sanghavi and Rutherford 2014). When this increase in sympathetic activity 
becomes excessive, hypertensive disorders develop during pregnancy (Sanghavi and 
Rutherford 2014). 
 
In summary, pregnancy is characterised by substantial changes to both the respiratory 
and cardiovascular system. Cardiorespiratory interactions may be important in the 
development of hypertensive disorders of pregnancy, which are associated with 
increased sympathetic activity. In both normotensive and hypertensive pregnancies, 
systemic vascular resistance decreases, placing greater importance on cardiac output 
(and consequently heart rate and stroke volume) to maintain adequate BP during 
pregnancy.   
 
2.2 Effect of interventions including an element of breath control  
upon blood pressure during pregnancy  
 
One of the most common ways in which pregnant women practice breathing exercises 
is during yoga. A 2012 systematic review found that yoga reduces stress, and increases 
quality of life, autonomic nervous system functioning and labour parameters such as 
comfort, pain and duration (Curtis et al. 2012). Using the Jadad scale and Delphi List the 
review only found 6 studies of high quality to include, showing the scarcity of high quality 
non-pharmacological trials in maternity research. Two hundred and twenty-two studies 
were excluded because they were cross-sectional studies, qualitative studies, case 
reports, commentary’s or non-academic articles. Overall, yoga has been found to be 
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beneficial for pregnant women and specifically, practising yoga during pregnancy can 
increase birth weight with significantly more babies born >2500g, and reduce the 
incidence of preterm labour (Narendran et al. 2005). Practicing yoga throughout 
pregnancy also reduces the incidence of PIH compared with walking twice a day, which 
is the current routine obstetric advice (Narendran et al. 2005; Rakhshani et al. 2012). 
 
One of the first studies to examine the impact of relaxation, and by association controlled 
breathing, on BP during pregnancy was Little et al. (1984). Following 6 weeks of 
relaxation therapy, they observed a reduction in hospital admissions and a significant 
reduction in BP compared with a control group. Relaxation remains popular with women 
during pregnancy, and pregnant women who develop PIH have benefited from both 
muscle relaxation (Jacobson method) and deep breathing, compared with a control 
group (Aalami et al. 2016). After 4 weeks of undertaking slow and deep breathing (SDB; 
5-min daily) at 6-10 breaths.min-1, SBP decreased by 10.6 mmHg compared with only 
1.5 mmHg in the control group; DBP decreased by 3.6 mmHg and 0.4 mmHg 
respectively (Aalami et al. 2016). The significant reduction in SBP was observed 
following just 1 week of SDB, whereas DBP only exhibited a significant reduction after 
three weeks of practice. This suggests although SDB can produce fast reductions in BP, 
decreases in DBP take longer to occur.  
 
In a comparison of a SDB intervention, breathing at 4.5 - 7 breaths.min-1, compared with 
bed rest for women with PIH (Cullins et al. 2013), no difference was found in BP between 
groups following intervention. However, women in the SDB group had a 35% greater 
birth weight and gave birth at a gestational age which was 10% greater than the women 
in the bed rest group. Thus, even if SDB does not reduce BP it has the potential to 
produce better birth outcomes. Qualitative data from this study also revealed that women 
felt the SDB helped them fall asleep, calm down and to relax. Therefore, using SDB as 
an intervention during pregnancy produces additional benefits beyond direct BP 
reductions, which could reduce stress and produce better birth outcomes for women and 
their babies.  
 
Mindfulness and meditation exercises, which in their essence involve reducing breathing 
frequency, have also generated health benefits for pregnant women. Compared with 
usual care, mindfulness meditation decreases perceived stress scores and increases 
heart rate variability (Muthukrishnan et al. 2016). Although their study only included 
normotensive women, the authors suggest that meditation has the potential to modulate 
sympathetic nervous system activity. Therefore, as PIH is characterised as a disorder 
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involving sympathetic overactivity, SDB could be beneficial to modulate nervous system 
activity during pregnancies effected by hypertensive disorders. 
 
2.3 Chronic cardiovascular adaptations following daily intervention 
of slow and deep breathing 
 
Despite the cardiovascular abnormalities associated with hypertension, a functional 
component remains operative. This means that acute cardiovascular regulation is still 
possible and the system can be operated to ‘normal’ capacity (i.e. at normotensive 
levels) when it is stimulated appropriately (Calcaterra et al. 2013). Conditions that exhibit 
a health benefit following SDB are those that are often characterised by sympathetic 
overactivity and/or stress such as hypertension (Gerritsen and Band 2018). Therefore, if 
SDB is able to provide the appropriate stimulation to provoke a change in cardiovascular 
regulation, stimulating a move to functioning at ‘normal’ capacity, SDB could potentially 
combat the sympathetic overactivity associated with hypertension by eliciting 
parasympathetic activity (Calcaterra et al. 2013). The long-term outcomes of SDB 
interventions are discussed below in the context of the potential mechanistic error 
signal(s)1 that might underpin reduction in long-term blood pressure (BP). 
 
Research has progressed from studies examining breathing exercises that are 
integrated within other modes of exercise such as yoga, to isolating the breathing 
element and using slow and deep breathing (SDB) as a distinct intervention. SDB has 
been investigated as a treatment method for a variety of health conditions, but primarily 
to treat hypertension and the focus of this section will be on the chronic (long-term) 
cardiovascular adaptations produced by SDB in hypertensive individuals.  
 
SDB used as a distinct intervention is often externally guided, known as device-guided 
breathing. SDB guided by a device ensures consistency and is easy to master, with 
user’s reduction in breathing frequency, time spent in SDB and breath synchronisation 
not being correlated with experience and number of sessions already completed (Gavish 
2010). The most cited device in the literature is RESPeRATE, but other biofeedback 
devices exist and have been discussed in more detail by Gavish (2010). 
 
 
1 An error signal is a signal that represents the dif ference between the set point value and the 
actual value of  the regulated variable. For example, the resting value of  blood pressure compared 
with the dynamic value of  blood pressure caused by blood pressure f luctuations. 
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2.3.1 Reductions in blood pressure following daily practice of slow and deep 
breathing 
 
The most recent meta-analysis of SDB as a treatment for hypertension found an overall 
reduction in SBP of 5.62 mmHg and 2.97 mmHg for DBP, following daily practice of SDB 
(Chaddha et al. 2019). However, the overall efficacy of SDB has also been questioned 
by others (Parati and Cerretta 2007). The impact on 24-hour ambulatory BP has also 
been inconsistent. However, studies that did not find a reduction in BP were typically 
short in duration (only 4 weeks) and the authors suggest that reductions in BP may have 
been seen following a longer intervention (Anderson et al. 2010). This suggestion was 
supported by a significant reduction in 24-hour SBP following an 8 weeks of SDB (Bazzini 
et al. 2011). 
 
Additionally, there have been mixed effects on the reduction of BP during pregnancy with 
some studies finding no significant reductions in BP compared with control groups 
(listening to music). For example, Altena and colleagues (2009) observed a non-
significant reduction of 4.2 mmHg in systolic BP (SBP) compared with a 2.6 mmHg 
reduction in the control group. Notwithstanding, a reduction of this magnitude could 
potentially have a clinically meaningful effect. It is also worth noting that mean breathing 
frequency at the end of the SDB exercise was 8.4 (±3.9) breaths.min-1, i.e. relatively high 
for SDB (see below), and that 33% of participants did not reach the target breathing 
frequency of <10 breaths.min-1 (Altena et al. 2009). Accordingly, SDB was unlikely to 
reduce BP in 33% of participants, as they did not achieve the criterion for SDB. A 
breathing frequency of 8 breaths.min-1 may also not be a low enough frequency, 
compared with the often cited optimal of 6 breaths.min-1, to reduce BP chronically. 
Grossman et al. (2001) also observed that 23% of participants did not reach the threshold 
of 10 breaths.min-1 and therefore many of the inconsistencies of BP findings may relate 
to the breathing frequency that was achieved by participants rather than the SDB 
intervention itself.    
 
Individuals who are experienced in techniques that involve SDB have slower 
spontaneous breathing frequencies (Spicuzza et al. 2000) and therefore repeated SDB 
training may reduce long-term spontaneous breathing frequencies  (Bernardi et al. 2001), 
even after only 4 weeks of SDB training (Anderson et al. 2009). Subsequently, when 
considering the hypothesised link between PIH and dysfunctional breathing (Jerath et al. 
2009), if SDB is able to reduce spontaneous breathing frequency and then SDB may 
specifically target the aetiology of PIH. Additionally, SDB has also produced significant 
reductions in BP in patients who have both hypertension and obstructive sleep apnea 
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(Bertisch et al. 2011), which when linked with the higher rates of obstructive sleep apnea 
in women with PIH outlined earlier in section 2.1.1, provides evidence to support a 
potential beneficial effect of SDB during pregnancy. 
 
2.3.2 Potential mechanisms for long-term reduction in blood pressure following 
daily practice of slow and deep breathing 
 
The long-term reduction in BP, following daily practice of SDB, is attributed to changes 
in mechanical and neural pathways, including in baroreflex sensitivity, heart rate 
variability, microvascular flow and venous return (Zhang et al. 2009). SDB increases 
heart rate variability (HRV) and consequently increases baroreflex sensitivity (BRS), 
which might contribute to BP reduction, accompanied by a chronic decrease in 
sympathetic nervous system activity when practiced daily (Anderson et al. 2009). 
  
The kidneys regulate BP automatically and chronic hypertension is only maintained when 
there is sustained impairment of the ability of the kidneys to regulate BP (Anderson et al. 
2009). Following 8 weeks of SDB, renal resistive index (RRI) significantly decreased 
(Bazzini et al. 2011), with significant reductions, compared with control group, observed 
as early as 1 week (Modesti et al. 2015). The combination of improvements in BRS, 
reduction of RRI and changes in autonomic nervous system are suggested as key 
mechanisms in the antihypertensive effects of repeated SDB (Modesti et al. 2015). In 
normotensive pregnancies renal blood flow increases (Lote 2012), but in hypertensive 
pregnancies indices of renal venous impedance are significantly higher (Bateman et al. 
2004). Consequently, reductions in RRI may also benefit women who develop PIH. 
 
SDB also enhances cardio-respiratory coupling, but in order to have a therapeutic effect, 
and for long-term health benefits there must be a lasting affect (Dick et al. 2014). Acute 
responses to SDB do not persist post-intervention, when breathing frequency returns to 
pre-SDB levels, as shown for HRV (Cheng et al. 2019) and BP (Anderson et al. 2009). 
SDB is likely to require constant engagement with the exercises to maintain the health 
benefits, in a similar way to the physiological effects of physical activity and exercise, 
which are reversable following a period of sedentary behaviour, known as detraining 
(Mujika and Padilla 2000). Consequently, the acute cardiovascular responses to SDB 
are central to understanding the mechanisms on which BP is reduced chronically. The 
acute responses must lead to a re-setting of the cardiovascular system, in one way or 
another, through repeated exposure to the internal environment created by SDB, and 
thus by understanding the acute responses to SDB, the error signal(s) which results in 
chronic BP reduction can be investigated.  
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2.4 Acute cardiovascular responses to slow and deep breathing 
 
This section will explore the short-term immediate (acute) responses to SDB. During a 
long-term intervention, SDB acts as an acutely perturbing physiological stimulus, with 
the adaptations occurring as a result of repeated stimulation (Keerthi et al. 2013). To 
understand the chronic adaptations induced by SDB it is important to understand the 
acute response to the repeated stimulus of SDB. The cardiovascular responses to SDB 
are short-lived post-SDB, returning to baseline levels within 20 minutes (Dick et al. 2014), 
but the changes within the period of SDB appear sufficient to generate a long-term 
adaptation.  
 
The cardiovascular system is designed to be adaptable and has inbuilt variability, which 
in most cases is reflective of a healthy system. Multiple processes, driven by receptors 
in the heart, lungs and vascular beds, respond to external and internal changes with the 
aim of maintaining homeostasis and/or responding to the needs placed on the body in 
different situations. SDB produces a response across the cardiovascular system and 
these responses are outlined below. Restoration of this healthy cardiovascular variability 
has been suggested to offer a potential treatment to prolong life (Elstad et al. 2018). 
 
At rest, breathing represents a normal mechanism associated with cardiovascular control 
via respiratory modulation (Convertino 2019) and it is well established that 
cardiovascular variables fluctuate with breath phase. For example, during normal 
inspiration, heart rate increases and BP decreases while the opposite is true during 
expiration (Chang et al. 2013). The most well-known fluctuation is respiratory sinus 
arrythmia (RSA), which is the change in heart rate caused by respiratory breath phase. 
Although this cardiorespiratory coupling is well established, the physiological purpose for 
the interaction is not fully understood or accepted (Dick et al. 2014). It is not within the 
scope of this thesis to fully explore RSA’s purpose; however, some theories will be 
discussed in relation to the changes in RSA induced by SDB.  
 
It has been suggested that the long-term BP reductions could be due to the relaxation 
process itself, rather than the SDB. However, although mental relaxation has been 
shown to exhibit a reduction in systolic blood pressure (SBP), diastolic blood pressure 
(DBP) and heart rate, the reduction was significantly larger in all variables following SDB 
(Kaushik et al. 2006). Additionally, simply controlling breathing frequency, without 
reducing it, does not seem to elicit the same cardiovascular response as SDB, since 
controlled, faster breathing does not produce the same physiological changes as SDB, 
despite providing the same regularisation of breathing (Bernardi et al. 2002; Pinna et al. 
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2006; Guzik et al. 2007). By reducing breathing frequency during controlled breathing, 
breath phase duration is increased, which is not the case for controlled breathing at 
higher frequencies. Due to the longer duration for each breath phase it is plausible to 
suggest that heart rate and BP have more time to fluctuate during each prolonged breath 
phase and therefore greater cardiovascular changes would be produced during SDB 
compared with controlled higher frequency breathing. Given the interlinked variables 
within the cardiovascular system, it is also logical to suggest that changes in heart rate 
and BP would cause, or be caused by, responses in other variables such as stroke 
volume, cardiac output and total peripheral resistance (Figure 2-1). 
 
There has also been debate regarding the effect of the conscious control of breathing, 
i.e. that the mental effort required to reduce breathing frequency may alter the 
physiological response to breathing (Cooke et al. 1998). However, SDB techniques have 
been modified over the past 20 years and, rather than the traditional techniques which 
require a concerted effort to count and concentrate on breathing, device-guided 
breathing techniques require less mental effort. In fact, multiple studies have 
encountered problems with participants feeling too relaxed and falling asleep (Gavish 
2010; Cullins et al. 2013; Adler et al. 2019), which shows that the mental concentration 
required to follow device guided breathing is not taxing and therefore should not alter the 




Increases in tidal volume compensate for the lower breathing frequency during SDB 
(Anderson et al. 2009). Increased tidal volume activates the Hering-Breuer reflex causing 
a reduction in chemoreflex sensitivity and possible enhancement of baroreflex (Bernardi 
et al. 2002). The increased tidal volume also activates lung stretch receptors, which 
increase inhibitory neural impulses, both in frequency and duration or neural impulses 
(Keerthi et al. 2013). This has an additional effect of reducing BP and sympathetic activity 
through baroreflex activation as similar control mechanisms are shared by both the 
respiratory and cardiovascular systems (Joseph et al. 2005). 
 
Respiratory-induced cardiovascular variability can originate from mechanical, neural and 
metabolic pathways, which arise from volume alternations, cardiopulmonary and arterial 
baroreceptors, and chemoreceptors (Parati et al. 2008). These pathways can all be 
altered by modulating breathing. PCO2 has a role in cardiovascular homeostasis via 
chemoreceptor reflexes (Anderson et al. 2009) and PCO2 is decreased by 15% during 
SDB, which contributes to the decrease in mean arterial pressure (MAP) (Dick et al. 
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2014). Additionally, the efficiency for oxygen transport at the lungs is increased during 
SDB, as shown by an increase in SpO2 at both high and normal altitudes (Bilo et al. 2012; 
Esposito et al. 2016). 
 
2.4.2 Blood pressure 
 
Despite long-term reductions in BP following long-term practice of SDB, the acute 
response of BP to SDB is heterogeneous. While normotensive individuals experienced 
no significant differences in heart rate, SBP or DBP during SDB, hypertensive 
participants experienced a 8.3 mmHg decrease in SBP at 6 breaths.min-1 (Joseph et al. 
2005). Other studies observed an acute reduction in SBP of between 2.9 – 9 mmHg for 
SBP and 2 – 4.9 mmHg in DBP (Bernardi et al. 2002; Anderson et al. 2009; Esposito et 
al. 2016; Fonkoue et al. 2018; Jette et al. 2019).  
 
The heterogeneity of acute changes in BP during SDB are suggestive of an individual 
response, which is reflected in the differences between SBP and DBP changes. 
Opposing responses can be compared between Esposito et al. (2016), who observed a 
significant reduction in DBP but not in SBP, with DBP reductions of 2.9 mmHg in diabetic 
participants and 1.7 mmHg in healthy participants; whilst Anderson et al. (2009) found a 
6.4 mmHg reduction in SBP, but no change in DBP. Fluctuations in BP are primarily 
caused by respiratory-induced fluctuations in stroke volume (SV) causing changes in 
cardiac output (Toska and Eriksen 1993). The SDB responses of SV and cardiac output 
are outlined below in section 2.4.6. 
 
Some studies have shown that BP regulation is different between the sexes (Wallin et 
al. 2010). Specifically, women have significantly lower SBP, DBP, MAP, cardiac output 
and SV and significantly higher heart rate than men (Wallin et al. 2010). There is also a 
lack of agreement in the literature regarding whether acute reductions of BP during SDB 
are similar between men and women (Adler et al. 2019), or whether reductions are only 
exhibited by males (Nili et al. 2017). As men and women use different physiological 
mechanisms to maintain normal BP (Hart et al. 2009), this may influence their acute 
response to the internal stimuli generated by SDB. Differences in maintenance of normal 
BP were observed in the differences in correlations for sympathetic activity and total 
peripheral resistance and cardiac output between men and women (Hart et al. 2009). 
Muscle sympathetic nerve activity had no relationship to either total peripheral resistance 
or cardiac output in women, but exhibited positive relationships in men. Consequently, 
the cardiovascular responses created by SDB may therefore produce different chronic 
adaptations in men and women, depending which cardiovascular variables are affected. 
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The breath phase relationships of BP also change during SDB. Although during normal 
breathing BP falls during inspiration, when breathing at SDB frequencies, BP tends to 
increase during inspiration (Parati et al. 2008). Due to the longer duration of breath phase 
at reduced breathing frequencies, the natural fluctuations of BP peak during different 
stages of the breath phase cycle, thereby changing the phase relationship of BP during 
SDB. The amplitude of BP oscillations is inversely proportional to breathing frequency 
<6 breaths.min-1  (Parati et al. 2008) and therefore BP fluctuations could be amplified at 
breathing frequencies lower than the traditionally utilised 6 breaths.min-1. Acute BP 
variability is linked to Mayer waves, which are spontaneously occurring oscillations of BP 
at a frequency of 0.1 Hz (equivalent to 6 breaths.min-1). This frequency of 0.1 Hz is 
suggested to be one reason that 6 breaths.min-1 may be the optimal SDB frequency due 
to the matching of Mayer waves with breathing frequency at resonance frequencies. 
Arterial BP oscillations are buffered by heart rate oscillations (Julien 2006) and therefore 
link with respiratory sinus arrythmia (RSA; outlined below in section 2.4.3). 
 
Under normal conditions, acute intrinsic increases in BP are caused by vasoconstriction, 
and increased cardiac output, via the sympathetic nervous system (Sharma et al. 2011). 
An increase in BP inhibits sympathetic activation and activates parasympathetic nerves 
through arterial baroreceptors (Elstad et al. 2018). If SDB creates an increase in the 
amplitude of BP oscillations, it is likely the arterial baroreceptors will be activated to a 
greater extent during SDB. Consequently, acute responses to SDB could reflect 
activation of the parasympathetic nervous systems.  
 
2.4.3 Heart rate and respiratory sinus arrhythmia (RSA) 
 
Respiratory sinus arrythmia (RSA) is the difference between maximum heart rate during 
inspiration and minimum heart rate during expiration (or the equivalent for RR interval). 
Although, average heart rate remains stable during SDB when a small inspiratory 
resistance is added, the extra effort needed to inhale results in augmentation of 
sympathetic activity and slight tachycardia (Nuckowska et al. 2019). Synchronisation of 
heart rate with respiration occurs at 6 breaths.min-1 (Parati et al. 2008). During 
pregnancy, when breathing at 6 breaths.min-1, heart rate is significantly lower, compared 
with non-pregnant women (Ekholm et al. 1993). There is no difference in nulliparous 
compared with multiparous women (Ekholm et al. 1993). 
 
During SDB the amplitude of RR internal fluctuations increases at the rate of respiration 
at 6 breaths.min-1 and this in turn increases the amplitude of fluctuations and therefore 
RSA (Joseph et al. 2005). RSA is a measure of parasympathetic neural control of the 
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heart (Zhang et al. 2009) and therefore increasing RSA during SDB also switches the 
dominance to parasympathetic activity, supported by BRS. As RSA can be seen as a 
reflection of vagal tone (Gerritsen and Band 2018), it could be argued that an increase 
in RSA is caused by an increase of vagal nerve activity resulting from the SDB. However, 
there is also debate regarding the specific relationship between RSA and autonomic 
control and therefore these ‘cause and effect’ associations should be made with caution 
(Parati et al. 2006; Eckberg 2009; Karemaker 2009a). 
 
RSA is suggested to maintain cardiac output by opposing the respiration-induced 
fluctuation in SV. An inverse relationship exists whereby when SV decreases during 
inspiration heart rate increases and vice-versa during expiration (Elstad 2012). 
Consequently, by maintaining cardiac output, RSA buffers oscillations in MAP, but may 
increase variations in SBP (Elstad et al. 2001). This could suggest that while RSA can 
maintain average BP (MAP) it is unable to fully buffer variations in the peak of BP (SBP). 
While the arterial baroreceptors impact on RSA, their response is slow, and therefore 
impulses from arterial baroreceptors are not the only cause of RSA due to the speed in 
which changes in heart rate occur (Elstad et al. 2001). Consequently, while RSA is 
increased during SDB, this is not due solely, or even predominantly, to an increase in 
baroreceptor sensitivity. 
 
Heart rate variability (HRV), of which RSA is one index, is attenuated in people with 
hypertension (Singh et al. 1998; Terathongkum and Pickler 2004). This reduction in 
variability associated with hypertension leads to the argument that there would be health 
benefits from restoring variability which could be produced via device-based approaches 
(Elstad et al. 2018). SDB has been found to acutely increase HRV accompanying the 
increase in heart rate (Guzik et al. 2007). Overall, reduced RSA may be a sign of 
hypertension, but SDB produces an acute increase in RSA, which  may be linked with 
its relationship with both stroke volume, cardiac output and BP. 
 
2.4.4 Baroreflex sensitivity and the autonomic nerve system 
 
Breathing is one of the most powerful modulators of the arterial baroreflex (Sharma et 
al. 2011); given the important role of the arterial baroreflex in maintaining acute BP, this 
suggests that respiration can have a large impact on BP. Sympathetic nervous system 
activity increases during inspiration and decreases during expiration. During SDB 
baroreflex sensitivity (BRS) varies depending on the respiratory phase and is enhanced 
during expiration (Parati et al. 2008). SDB is associated with a change in autonomic 
balance shown by an increase in BRS (Joseph et al. 2005) and a decrease in 
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sympathetic nerve activity (de Barros et al. 2014). Accompanying small decreases in 
heart rate, SBP and DBP could enable the increase in BRS to occur due to a relative 
increase in vagal activity and reduction in sympathetic activity (Bernardi et al. 2002). 
 
BRS is attenuated in people with hypertension, and resets to regulate around a higher 
pressure range (Sharma et al. 2011). In other patient groups who also exhibit elevated 
sympathetic nervous activity, such as posttraumatic stress disorder, SDB has been 
shown to have positive effect by reducing SBP, DBP and MSNA (Fonkoue et al. 2018). 
Sympathetic tone is reduced and parasympathetic tone is increased during SDB 
(Wallbach and Koziolek 2018) showing an autonomic shift occurs, from sympathetic to 
parasympathetic dominance. The baroreceptor reflex is a suggested mechanism for 
stimulation of the vagal nerve (Gerritsen and Band 2018). This increase in vagal activity 
could also result in a resetting of the baroreflex to the normotensive ranges, thereby 
responding to lower, more ‘normal’ levels of BP. Acute resetting of the cardiac baroreflex 
is present when an inspiratory resistance is applied to breathing, similar to the effect 
seen during exercise (Convertino 2019) and the threshold for triggering the baroreflex is 
lowered when breathing at 6 breaths.min-1 (Gerritsen and Band 2018). This resetting 
allows an elevated cardiac output to be maintained, despite an elevated ABP, which 
would normally result in a reduction in heart rate and cardiac output. 
 
Evidence to support the activation of the parasympathetic nervous system leading to 
acute BP changes comes from Pramanik et al. (2009) who found acute BP reductions 
only occurred in the group without a parasympathetic nervous system blockade, 
suggesting that it is, at least in part, the vagal activity that produces BP reductions. SDB 
is a potential method for vagal nerve stimulation (Gerritsen and Band 2018). 
 
Despite, chronic reductions in renal resistive index (RRI) following repeated SDB practice 
(Bazzini et al. 2011; Modesti et al. 2015), to the best of the author’s knowledge, there 
are no studies which investigate acute responses to SDB. In summary, baroreflex 
sensitivity is increased during SDB, which may be a sign of increased parasympathetic 
activity during SDB. 
 
2.4.5 Muscle sympathetic nerve activity 
 
Muscle sympathetic nerve activity (MSNA) reflects tonic sympathetic nervous system 
activity and acute adjustments of the cardiovascular system in response to perturbation. 
MSNA increases during expiration and is at its lowest at the end of inspiration/start of 
expiration (Seals et al. 1993). Differences in the responses to SDB between males and 
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females have been found; Wallin et al. (2010) observed lower MSNA in women (although 
not significantly) but detected no correlation between breathing frequency and MSNA in 
women despite this being observed in men. On the other hand, Adler et al. (2019) 
observed a reduction in MSNA for both males and females during SDB (Adler et al. 
2019). The difference may be explained in the different breathing frequencies utilised in 
each study; spontaneous breathing (~14 breaths.min-1) in Wallin et al. (2010) and <10 
breaths.min-1 in Adler et al. (2019). Although MSNA baseline values may differ between 
men and women, the response to SDB is similar.  
 
MSNA decreases acutely in participants with post-traumatic stress disorder (PTSD) 
following SDB and also decreases to a greater extent in those with more severe 
symptoms (Vemulapalli et al. 2019). This may mean that people who have higher levels 
of sympathetic overactivity experience greater benefits from SDB.  
 
2.4.6 Stroke volume and cardiac output 
 
During inspiration, intra-abdominal pressure increases and intrathoracic pressure 
decreases, which increases blood flow to the right atrium (venous return) and right 
ventricle, thereby increasing right ventricular stroke volume (Elstad et al. 2018). This 
increase in right ventricular stroke volume has an opposing influence on left ventricular 
stroke volume (SV), which decreases (Harrison et al. 1963). Changes in right- and left- 
ventricular SV are of equal amplitude (Elstad 2012), suggesting a degree of 
interdependence. 
 
However, the effects of SDB upon SV have yet to be fully explored in a peer reviewed 
study. An unpublished PhD thesis (Vargas 2017) found that SDB increased SV, which 
was attributed to within-breath changes in venous return. At frequencies of ≤6 
breaths.min-1, SV during expiration was higher than SV during inspiration, suggesting 
that the augmented venous return generated during inhalation had time to transit the 
pulmonary system, bolstering SV during the subsequent expiration. This effect of 
pulmonary transit time most likely explains individual differences in optimal breathing 
frequencies and in responses to SDB. 
 
Cardiac output (Q) displays a significant inverse correlation with breathing frequency in 
men, but not women (Wallin et al. 2010). However, alternative studies observed no 
difference in cardiac output response to SDB in males and females (Adler et al. 2019). 
As mentioned above, this difference could also be due to the breathing frequencies 
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utilised in both studies. Additionally, the inverse relation of heart rate (RSA) with SV 
reduces respiratory variations in cardiac output (Elstad 2012). 
 
Stroke volume variability was observed to increase when tidal volume was increased 
from 0.5 L to 0.8 L (Roeth et al. 2014), however it should be noted that breathing 
frequency was not maintained during tidal volume changes and therefore this would not 
be classed as a SDB condition. However, as SDB does produce an increase in tidal 
volume then it would be reasonable to suggest SV variability may increase during SDB. 
 
2.4.7 Different breathing frequencies used for slow and deep breathing 
 
The most common device-guided SDB method is the RESPeRATE system, which 
produces a dynamically driven breathing frequency < 10 breaths.min-1. The most 
common fixed breathing frequency explored in the literature is 6 breaths.min-1 and this is 
often touted as the optimal breathing frequency for SDB (Vaschillo et al. 2006). However, 
there is a paucity of research directly examining the cardiovascular responses to different 
SDB frequencies. The known studies examining the acute cardiovascular response to 





Table 2-1 Literature overview of short-term studies examining multiple breathing frequencies 
Author Number of 
participants 
Health condition Breathing frequency Duration Summary outcomes 
Anderson et al. (2010) 22 
(12 hypertensive. 12 
control) 
Hypertension & control Average 8.7 breaths .min-1 
(<10 breaths.min-1 f rom 
min 2-15) 
15 min (split into 1 min 
sections for analysis) 
Decreasing SBP with 
decreasing frequency 
Bernardi et al. (2014) 102 
(81 chronic heart failure. 
21 control) 
Chronic heart failure 
(CHF) & control 
6, 15 breaths.min-1 and 
Spontaneous 
4 min (5 min 
Spontaneous) 
BRS enhanced at 6 
breaths.min-1 CHF and 
control 
Calcaterra et al. (2013) 133 obese 
168 healthy 
Children – Obese and 
healthy 
6, 15 breaths.min-1 and 
Spontaneous 
Not stated BRS enhanced SDB for 
those with higher BMI 
and insulin resistance 




>2min SDB increases pain 
threshold and tolerance 
Chang et al. (2013) 
 
53 Healthy 8, 12 and 16 breaths .min-1 Not stated Respiratory peak shifts 
to LF range in HRV at 8 
breaths.min-1 
Cooke et al. (1998) 10 Healthy Stepwise 3, 6, 9, 12, 15, 
18 breaths.min-1 and Spon 




2 min at each stepwise 
stage 
5 min Spon 
No dif ference with and 
without tidal volume 
control 
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Author (cont.) Number of 
participants 
Health condition Breathing frequency Duration Summary outcomes 
Guzik et al. (2007) 15 Healthy 6, 9, 12, 15 breaths .min-1 5 min Increased heart rate, 
HRV and BRS only at 6 
breaths.min-1 
Joseph et al. (2005) 46 
(20 hypertension, 26 
control) 
Hypertensive & control 6, 15 breaths.min-1 and 
Spontaneous 
2 min (5min Spontaneous) Decrease BP only in 
hypertensive group at 6 
breaths.min-1. BRS 
increased to values 
similar to control. 
Nuckowska et al. (2019) 
 
20 Healthy 6, 12, 18 breaths.min-1, 
spontaneous and 
resistance at 6 
breaths.min-1 
Protocol 1: 10 min 
Protocol 2: 5 min 
Reduction DBP and 
MAP during SDB and 
Oneda et al. (2010) 27 (14 completed SDB, 
13 placebo) 
Hypertensive Average 6.8 breaths.min-1 
(<10 breaths.min-1 
average for all 5 min 
sections) 
15 min (split into 3 x 5 min 
for analysis) 
BP decreased both 
SDB and placebo, 
MSNA reduced SDB. 
Zhang et al. (2009) 
 
13 Healthy 7, 8, 9.5, 11, 12.5, 14 
breaths.min-1 
Gradual decrease. Total 
time 15 min (2-3 min per 
f requency) 
PTT and RR interval 
increased with 
decreasing frequency 
Baroreflex sensitivity (BRS), blood pressure (BP), chronic heart failure (CHF), diastolic blood pressure (DBP), muscle sympathetic nerve activity (MSNA),  




Most of the reviewed literature examined breathing frequencies of 6 breaths.min-1 or a 
variable rate <10 breaths.min-1. Research to date has therefore failed to investigate the 
differences that alternative SDB frequencies may have on cardiovascular responses, 
and to fully understand the differences between normal to SDB frequencies. 
Furthermore, relatively few studies have examined multiple breathing frequencies (Table 
2-1). As SDB is considered to be breathing at a frequency less than10 breaths.min-1, then 
most studies examine only one breathing frequency that would be considered to be SDB 
(Bernardi et al. 2002; Joseph et al. 2005; Chalaye et al. 2009; Calcaterra et al. 2013; 
Chang et al. 2013; Nuckowska et al. 2019). Although RESPeRATE creates a dynamic 
breathing frequency that results in different breathing frequencies over time, only 2 
studies report results at different time points during the intervention rather than averaging 
an epoch of the whole intervention (Anderson et al. 2009; Oneda et al. 2010). These 
studies examine variables relative to time and cannot therefore link cardiovascular 
responses to specific breathing frequencies due to the individual nature of the 
RESPeRATE breathing frequency implementation. Only 2 studies have examined 
multiple fixed breathing frequencies but this was also within a protocol with a gradually 
declining breathing frequency, resulting in short periods at each individual frequency 
(Zhang et al. 2009), or  breathing conditions that used breathing frequencies of 9 
breaths.min-1 and above (Guzik et al. 2007). This overview highlights the large gap in the 
current understanding of the cardiovascular responses to different fixed breathing 
frequencies. In particular, the steady state responses, where sufficient time is allowed 
(at least 5 minutes) for acute responses to mature fully. By understanding how steady-
state cardiovascular responses change across a range of  fixed breathing frequencies 
this will provide a better understanding of the mechanisms that may lead to the long-term 




Overall, there is a heterogenous pattern within the literature describing the acute 
cardiovascular responses to SDB; for example, both increases and decreases in BP 
have been found during SDB. Understanding the acute responses is important in order 
to develop an understanding of the mechanisms that result in any chronic reduction in 
BP following daily practice of SDB. The above literature review revealed that the 
understanding of the acute responses to SDB is currently limited, with variables often 
investigated independently, with no acknowledgement of their interaction within the 
cardiovascular system. Since BP is influenced by the ensemble of changes in total 
peripheral resistance, cardiac output, SV and heart rate, it is therefore important to 
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understand the complex interactions of all variables simultaneously to complete the 
picture of acute cardiovascular responses during SDB. 
 
The baseline cardiovascular differences between both males and females and during 
pregnancy have been outlined in the literature review above. These differences may 
influence how the body responds to SDB and therefore warrant further investigation of 
whether differences between populations changes the acute cardiovascular response to 
SDB. 
 
2.6 Aims, objectives, and hypothesis 
 
The overall aims of this thesis are to characterise and compare the acute cardiovascular 
responses to SDB of pregnant women and design a specific slow and deep breathing 
intervention for women who develop pregnancy-induced hypertension. A series of 
research questions, objectives and hypotheses were set and were answered 
systematically in each chapter. 
 
In summary, the objectives for the thesis were to: 
 
1. Identify the acute response in blood pressure and amplitude of blood pressure 
oscillations during SDB for healthy young men, healthy non-pregnant women and 
healthy pregnant women. 
2. Characterise and compare the response of mechanism-related parameters (e.g. 
respiratory sinus arrythmia, stroke volume, cardiac output) to SDB for healthy 
young men, healthy non-pregnant women and healthy pregnant women. 
3. Evaluate differences in acute cardiovascular responses to a range of SDB 
frequencies for healthy non-pregnant women and healthy pregnant women. 
4. Design an evidence based SDB intervention for women with PIH. 
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Chapter 3. General Methods 
3.1 Introduction 
 
This chapter outlines a detailed explanation of the general methods (slow and deep 
breathing delivery, pre-test procedures & physiological equipment and procedures) that 
are common between the studies that form this thesis. Unique methods that are specific 
to individual studies are described in the relevant chapters, such as ultrasound 
measurements of renal resistive index (RRI), central blood pressure measures, and the 
proposed long-term intervention. The thesis includes three experimental lab-based 
studies (Chapters 5, 6 & 7) and a proposed clinical study which was postponed due to 
COVID-19. The first three studies aim to investigate the immediate (acute) responses to 
slow and deep breathing (SDB) to understand the potential mechanisms by which SDB 
may lower long-term blood pressure (BP) when practiced daily. They are conducted in 
normotensive participants in order to understand the different responses to SDB of males 
and females (Chapter 4), normotensive non-pregnant women (Chapter 5), and 
normotensive pregnant women (Chapter 6). The final proposed study (Felton et al. 2021) 
presented in Chapter 8) was planned to include hypertensive pregnant women who 
would complete the acute SDB responses protocol, in addition to moving the research 
to a clinical setting using a SDB long-term intervention. The final study would have 
provided the next step between the theoretical lab-based study in a controlled 
environment to a real-life pragmatic study, where the greatest impact can be found. 
Unfortunately, due to COVID-19 it was not possible to complete this experimental study 
but the proposed protocol is presented in this thesis. 
 
An overview of the thesis structure and chapters is shown in Figure 3-1. Chapter 7 
provides a comparison of the data collected in the studies presented in Chapter 5 and 6 
(healthy pregnant and healthy non-pregnant women), therefore as it does not have a 
separate methodology it is not presented in Figure 3-1. The greyed sections of Figure 
3-1 show common methods between studies and chapters and it is these sections that 
are outlined in this General Methods chapter to avoid repetition in subsequent chapters.  
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Figure 3-1 Overview of studies comprising this thesis 
Blood Pressure (BP); Electrocardiogram (ECG); Renal Resistive Index (RRI). 
Chapter 7 contains an integrated paper comparing the results of data collected from Chapters 5 
and 6. 
 
3.1.1 Ethics approval 
The experimental protocols in Chapters 5, 6 & 7 were approved by Bournemouth 
University’s Research Ethics Committee (Appendix VI) and all experiments conformed 
to the Declaration of Helsinki. The protocol for the final study (Felton et al. 2021) 
presented in Chapter 8) was approved by the Hampshire B Research Ethics Committee 
and Health Research Authority, but due to COVID-19 the study was not completed as 
part of this thesis. It is included as a protocol paper to show the work completed to date. 
 
3.2 Slow and deep breathing delivery 
 
Participants completed a range of breathing conditions2 during each study including a 
spontaneous ‘normal’ breathing condition. A different set of breathing frequencies and 
conditions were used in each study and these are justified and outlined separately in 
each chapter. Figure 3-1 provides an overview of the breathing conditions used in each 
study. Breathing conditions were ten minutes in duration in Chapter 4 and five minutes 
 
2 In the context of  this thesis breathing conditions means the dif ferent breathing exercise protocols 
that the participants undertook. 
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in Chapter 5 and Chapter 6. A SDB session of 10-min is commonly used in literature for 
long-term SDB interventions to reduce BP (Chaddha et al. 2019). The results from 
Chapter 4 revealed no significant differences in the acute cardiovascular differences 
between the first and final 5-min for all conditions except RESPeRATE and therefore 
subsequent studies used 5-min duration to reduce time burden on the participants. An 
equal period of rest to the breathing protocol length (either ten or five minutes) was 
undertaken prior to each measurement with participants instructed to breathe normally. 
An equal rest to breathing ratio is sufficient to allow cardiovascular and respiratory 
variables to return to baseline levels (Vargas 2017). Controlling tidal volume during SDB 
has no effect on cardiovascular rhythms and normal end-tidal CO2 levels are maintained 
without direct control (Cooke et al. 1998). Additionally, there is no advantage of 
simultaneously controlling breathing frequency and tidal volume (Vargas 2017) and 
therefore only breathing frequency was controlled.  
 
For the spontaneous breathing condition, participants were instructed to breathe 
normally, and no visual feedback was provided to control breathing. The spontaneous 
breathing condition provided the baseline comparison for the SDB frequencies. 
Participants also completed a dynamic breathing frequency condition using an 
optimisation algorithm (McConnell et al. 2017). The optimisation algorithm guides 
breathing frequency dynamically to a personalised optimum frequency. Further details 
of the optimisation algorithm are outlined below (3.2.2). As the optimal SDB frequency is 
widely regarded in the literature to be 6 breaths.min-1 to maximise hemodynamic changes 
(Vaschillo et al. 2006; Russo et al. 2017) this was used as the comparison condition to 
the dynamic breathing frequencies in all studies. In Chapter 5 and Chapter 6 fixed 
breathing frequencies of 4 and 8 breaths.min-1 were chosen to span the optimal 
frequency to provide a linear range of frequencies to understand any potential graduated 
response to SDB and discover differences in lower and higher breathing frequencies 
based on results from Chapter 4.   
 
3.2.1 Brythm app 
All SDB conditions were delivered in the laboratory by Bournemouth University’s (BU) 
Brythm app using an iPad (iPad Pro, 12.9in, 1st Gen). Brythm provides visual feedback 
to guide the user’s breathing frequency, whereby the user inhales when the dome 
graphic rises and exhales when the dome falls (Figure 3-2 Screenshots of Brythm 
graphic). The speed of the graphic can be changed to manipulate the user’s breathing 
frequency to a fixed respiratory rate. The set graphic speed is adjusted prior to starting 
each breathing condition and is consistent throughout each condition. Inspiration and 
expiration phases were matched to create an equal duty cycle (~0.5). Although the 
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RESPeRATE research reflects a benefit of prolonged expiration, acute responses to 





Figure 3-2 Screenshots of Brythm graphic 
N.B: Arrows do not appear on app but are shown here to display the direction of graphic  
movement. 
 
3.2.2 Brythm optimisation algorithm 
The Brythm app also has an inbuilt optimisation algorithm (McConnell et al. 2017) which 
dynamically changes breathing frequency based on the user’s physiological response to 
the breathing. The app responds to data measured from a finger sensor 
(photoplethysmography; Figure 3-3), which tracks the user’s instantaneous physiological 
responses to their breathing. The optimisation algorithm creates a dynamically driven 
breathing frequency, which strives to maximise cardiovascular perturbation, using the 
amplitude of RSA as the controlled variable. The finger sensor is connected via the 




Figure 3-3 Brythm app finger sensor 
 
For the clinical study (Felton et al. 2021) presented in Chapter 8) it was proposed that 
the SDB protocol would be delivered using a video graphic instead of the Brythm app, 
as described below. 
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3.2.3 Alternative slow and deep breathing delivery method: Video graphic 
In accordance with the EU Medical Device Regulations 2017/745 (European Union 2017) 
and the MHRA guidance regarding medical device stand-alone software including apps 
(Medicines and Healthcare products Regulatory Agency 2018), Brythm is classed as a 
medical device due to the intention to treat hypertension. Any research investigating 
medical devices outside of the legal entity that developed it (in this case BU), is required 
to notify the relevant national regulatory body. In the UK the regulatory body is the MHRA 
and submission of a clinical investigation of a medical device requires completion of a 
large application including in-depth technical documentation and a large processing fee. 
Additionally, when research is undertaken with the NHS the associated university is 
required to oversee the management of the project by accepting sponsorship 
responsibilities for the study. At the time of planning for the final study of this thesis, 
which required collaboration with the NHS for recruitment of participants, BU was unable 
to accept sponsorship of studies requiring MHRA notification.  
 
Due to the financial and technical limits restricting PhD research, the challenges outlined 
above meant that using Brythm to deliver the SDB in the final study of this thesis was 
unfeasible (Chapter 8). Consequently, to deliver the SDB with pregnant women who 
would be recruited from the NHS, an alternative method of delivery was needed. Due to 
the results of the three studies outlined in Chapters 4, 5 and 6 it was concluded there 
was no difference in the physiological response between the optimisation algorithm and 
the fixed breathing condition of 6 breaths.min-1. Therefore, there would not be any extra 
benefit from using the optimisation algorithm compared with fixed breathing at 6 
breaths.min-1 for the long-term intervention. This decision negated the need for the finger 
sensor, which tracks the user’s physiological response and is needed to run the 
algorithm. It was therefore possible to use a video of the graphic designed for the app 
(Figure 3-2) which was set at a fixed breathing frequency of 6 breaths.min-1. Video aids 
are not classed as a medical device and therefore a video delivering SDB can be used 
within an NHS study without requiring MHRA notification. A full description of how this 
video was shared with participants is provided in Chapter 8 (Felton et al. 2021). 
 
3.3 Pre-test procedures 
 
3.3.1 Randomisation procedures 
To remove potential order effects breathing conditions in all studies were randomised 
using a random number generator (www.randomizer.org). The randomised numbers are 
generated by means of a complex algorithm using the computer’s clock. Order was not 
weighted to have the same condition performed at each order point the same number of 
64 
times. An example of the randomisation from Chapter 6 is outlined in Table 3-1, to show 
the frequency in which breathing conditions were performed in each position order (1st – 
5th). 
 
Table 3-1 Example randomisation order: number of times each breathing 












1st  6 6 2 3 1 
2nd  5 5 4 3 1 
3rd  2 2 5 3 6 
4th  3 2 4 3 6 
5th  2 3 3 6 4 
 
The randomised breathing condition order was set prior to the start of data collection and 
no changes were possible after this point. The randomised order was linked to a 
participant number (P01, P02, P03 etc) and each new participant received the next 
condition order in the list. Participants recruited were booked in at the next available time 
and the order of conditions was not looked at during the booking process. The 
investigator (MF) generated the randomised order using the website but after this only 
accessed the order of breathing conditions on the day of data collection and therefore 
was not able to make any changes to the order or select people as certain participants. 
Participants were informed of the order prior to data collection but could not choose or 
change the order of the breathing conditions. No information was given to participants 
on the expectation of any effects for the breathing conditions, such as whether a larger 
response was expected to a specific condition.  
 
3.3.2 Participants, recruitment and pre-test procedures 
Participants taking part in studies including short-term protocols (Figure 3-1) were asked 
to refrain from eating for 2 hours and from caffeine, strenuous exercise and alcohol for 
12 hours prior to attending the session at the Cardiorespiratory Research Laboratory at 
Bournemouth University. 
 
Following consumption of food there is an ingestion related increase in blood flow to the 
splenic organs which leads to an increase in cardiac output (Q̇) to meet the additional 
demand (Waaler and Eriksen 1992). An increase in stroke volume (SV) contributes to 
the rise in Q̇, with total peripheral resistance (TPR) decreasing to maintain mean arterial 
pressure (MAP) (Sidery and Macdonald 1994). These cardiovascular responses have 
been shown to last up to 2 hours (Waaler et al. 1991). Participants could consume water 
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during the 2 hours prior to data collection as no cardiovascular responses are associated 
with water consumption (Waaler and Eriksen 1992). Central blood pressure measures 
are also more reliable when measured in a fasted state (Young et al. 2015) and the 
waveform measured by finger plethysmography can be altered following consumption of 
food (Tanaka et al. 2015). 
 
Immediately after consuming alcohol, respiratory sinus arrythmia (RSA) and heart rate 
(fc) are decreased, which may suggest that cardiac vagal tone is reduced (Reed et al. 
1999). Additionally SV, Q̇ and brachial artery diameter are effected immediately after 
alcohol consumption (Spaak et al. 2008). Systolic (SBP) and diastolic blood pressure 
(DBP) experience a biphasic effect of alcohol consumption, which can last until the next 
day (>12 hours) (Bau et al. 2005). Additionally, it is well known that caffeine immediately 
increases BP (Smits et al. 1985) and the acute response of BP remains even in people 
who are regular consumers (Lovallo et al. 2004). This is true whether the caffeine is 
consumed in tea or coffee (Quinlan et al. 1997). 
 
Participants received a participant information sheet (Appendix II) at least 24 hours prior 
to participating in the study. Written informed consent was obtained from all participants 
prior to taking part (Appendix III). A health questionnaire was also completed by 
participants to ensure that they met the inclusion and exclusion criteria for each study 
(Appendix IV). Inclusion and exclusion criteria are outlined individually in each chapter. 
All participants were free from any current cardiovascular or respiratory disease such as 
asthma, Chronic Obstructive Pulmonary Disease (COPD) or hypertension, and were all 
non-smokers. The exception is that participants outlined in the planned Chapter 8 
protocol (Felton et al. 2021) would have been diagnosed with pregnancy-induced 
hypertension (PIH).  
 
3.4 Equipment and procedures 
 
This section outlines the equipment used to collect the cardiovascular and respiratory 
data in the short-term responses protocols. Where equipment was used in one study 
only this is outlined in the relevant chapter. Participants were seated in an upright 
position, at an approximate angle of 60o for the duration of the data collection. Full 





Figure 3-4 Full equipment set up with participant 
Note: Photo as example set up only; in all studies blood pressure was measured on the lef t side 
of the body. 
 
3.4.1 Anthropometry 
Prior to all short-term responses protocols stretch stature was measured using a 
stadiometer (SECA 213, Germany) and participants were asked to stand barefoot with 
their feet together, and heels, buttocks and upper part of back touching the stadiometer 
(International Society for the Advancement in Kinanthropometry 2011).  Stature was 
measured to the vertex of the head while the participant’s head was in the Frankford 
horizontal plane. Body mass was recorded in minimal clothing using calibrated electronic 
scales (SECA 804, Germany). 
 
3.4.2 Respiratory measures 
Respiratory airflow was monitored continuously throughout each breathing condition. 
Participants wore an oronasal mask that covered both mouth and nose (Oro Nasal 7450 
V2 Mask, Hans Rudolph Inc., Kansas, USA) and respired flow rate was measured 
continuously using a heated pneumotachograph (Model 3700, Hans Rudolph Inc., 
Kansas, USA) connected to a flow measurement system (RSS 100-HR, Hans Rudolph 
Inc., Kansas, USA). The respiratory equipment set up can be seen above in Figure 3-4. 
The flow measurement system was zeroed prior to the start of each breathing condition. 
 
3.4.3 Cardiovascular measures 
Heart rate (fc) was monitored continuously using a 3-lead ECG and non-invasive beat-
to-beat arterial blood pressure (ABP) was estimated using a Finometer (Finapres NOVA, 
Finapres Medical Systems, The Netherlands). The Finometer uses an inflatable finger 
cuff (Figure 3-5) with inbuilt photo-electric plethysmography to detect finger pulse 
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pressure waveforms, using the volume-clamp method (Peňáz 1973). The diameter of the 
artery in the finger pulsates when the heart beats, which causes pulsation in the light 
detector signal as the blood absorbs the infrared light from the plethysmograph (Finapres 
2012). Using the volume-clamp method the diameter of the finger artery is kept constant 
(clamped) by the cuff rapidly increasing pressure when diameter changes are detected, 
which prevents the diameter change (Bogert and van Lieshout 2005). Finger cuff 
pressure therefore equals intra-arterial pressure, however other factors can influence the 
unloaded diameter requiring regular verification throughout continuous measurements 
(Bogert and van Lieshout 2005). The Finapres has an inbuilt autocalibration algorithm 
(Physiocal) which calibrates the finger cuff pressure. Physiocal interrupts the 
measurement for one heart beat and keeps cuff pressure constant at a level halfway 
between SBP and DBP to determine the cuff pressure set point to maintain an unloaded 
diameter (Langewouters et al. 1998). As the calibration interrupts the data collected, due 
to the maintained pressure intervals, Physiocal was turned off during each breathing 
condition to maintain uninterrupted data collection but was turned on during each rest 
period to allow calibration of the finger cuff and ensure accurate measurement. 
 
 
Figure 3-5 Finapres inflatable finger cuff 
 
The Finapres uses brachial arterial reconstruction technology to correct for the 
distortions in the pressure waveform as it travels from the brachial artery to the finger. 
Distortion is caused by increased arterial stiffness at the peripheral arteries, faster 
transmission of the higher pressure components and wave reflections (Levick 2013) with 
a difference of 8-10 mmHg between brachial and finger arterial blood pressures for DBP 
and MAP (Bogert and van Lieshout 2005). The Finapres restores the waveform to the 
brachial level and allows for differences and changes in height between the finger and 
heart level by using a height correction unit to correct hydrostatic BP changes (Carlson 
et al. 2019). 
 
To ensure accurate BP readings from the finger cuff the Finapres uses an upper arm 
calibration whereby an arm cuff is used on the same arm as the finger cuff (Figure 3-5). 
The arm cuff uses return to flow calibration whereby when the first pulsation is sensed in 
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the finger (after cuff inflation) the corresponding arm cuff pressure is recorded. The 
reconstructed brachial pressure is defined by this recorded measurement and SBP and 
DBP are both calibrated in this way. The brachial calibration was performed prior to the 
first breathing condition and halfway through each session; following 3 breathing 
conditions in the studies outlined in Chapter 5 and Chapter 6, and following 2 conditions 
in the Chapter 4 and proposed Chapter 8 study. When used with the brachial calibration, 
the Finapres passes the AAMI ISO81060-2 measurement standards which evaluates 
performance validation of BP measurement equipment. Additionally, the Finapres BP 
measures have found to correlate with auscultatory BP measurements in normotensive 
participants (Carlson et al. 2019). The Finapres (finger and arm cuff) were both set up 
on the left side of the body in all studies. 
 
The Finapres estimated stroke volume (SV) using the Modelflow method, which 
computes aortic flow over time using a three-element model (Wesseling et al. 1993). The 
Finapres uses age, sex, height and weight, which are inputted prior to data collection, to 
determine pressure-volume, pressure-compliance, and pressure-characteristic 
impedance relationships (Jansen et al. 2001). This approach produces measurements 
that show excellent agreement with SV measured by Doppler ultrasound (Van Lieshout 
et al. 2003) and when blood is withdrawn by phlebotomy (Leonetti et al. 2004).  
 
The Finapres NOVA (or its predecessors the Finapres and Portpres) has limited data on 
validity of cardiovascular measures during pregnancy. The Portapres overestimated 
SBP by 5mmHg and underestimated DBP by 3mmHg compared with standard 
sphygmomanometry in healthy pregnant women (Hehenkamp et al. 2002).  In women 
with pre-eclampsia, SBP was overestimated by 3mmHg and DBP underestimated by 
8mmHg. However, it was found to meet the Association for the Advancement of Medical 
Instrumentation (AAMI) criteria and compares favourably with other non-invasive 
automated BP monitors (Hehenkamp et al. 2002).  Using the Finometer, SBP was also 
overestimated compared to the Dinamap (an automated oscillometric BP measurement 
device) (Grindheim et al. 2012). As the majority of BP analysis in this thesis will be within 
participants, examining responses to SDB compared with normal breathing, 
overestimations should be consistent across all conditions, and have minimal effect on 
results. However, reliability data during pregnancy is not available for the Finapres 
NOVA. 
 
3.4.4 Data acquisition 
Analogue outputs from the Finapres NOVA (reconstructed brachial pressure waveform, 
ECG waveform, SV, SBP, DBP) and the flow meter were sampled continuously at 250Hz 
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via an analogue to digital converter (NI USB-6218 BNC, National Instruments Inc.) and 
captured using bespoke acquisition and analysis software (LabView 2015, National 
Instruments, Inc.). The LabView software corrected for the 4 second delay between the 
Finapres NOVA output and the respiratory output. A raw data file was created after each 
condition and summary data files were produced using the LabView software. The 
summary data files contain beat-by-beat, breath-by-breath and epoch summary data.  
LabView uses both built-in and bespoke coded sub-routines that calculate mean (Figure 
3-6 calculation 1), peak, nadir, and amplitude variations for all cardiovascular and 
respiratory variables. These calculations were performed for whole breath and within 
respiratory phases (inspiration & expiration; Figure 3-6 calculations 2 and 3 respectively). 
Mean data for all variables were calculated in one-minute epochs during each five- or 
ten-minute condition, for the whole five- or ten-minute epoch and for the 10-min 
conditions (Chapter 4) into first and final 5-min epochs. Section 3.4.5 provides more 
detail on the amplitude variation calculations. 
 
The following calculations were applied in LabView, or in subsequent analysis, to 
calculate the variables used throughout this thesis. Total peripheral resistance (TPR; 
Equation C) is derived from the measured variables of BP and cardiac output as there is 
no method available to provide a direct measurement of TPR (Elstad et al. 2011). 
 
Equation A: Cardiac output (Q̇) = fc x SV 
Where fc is heart rate and SV is stroke volume. 
Note cardiac output is presented as ml.min-1 in this thesis. 
 
Equation B: Mean arterial pressure (MAP) = DBP + (0.333 x PP) 
Where DBP is diastolic blood pressure and PP is pulse pressure. 
 
Equation C: Total peripheral resistance (TPR) = MAP / Q̇ 
Where MAP is mean arterial pressure and Q̇ is cardiac output. 
 
Equation D: Pulse transit time (PTT) = time peak pulse pressure (finger cuff) –
time peak R wave (ECG). 
Time difference between pulse detected at heart (from ECG) and detected at the 
finger (pulse pressure at left index finger). 
 
Equation E: Pulse Wave Velocity (PWV) = path length (m) / PTT (s) 
Where path length was measured from sternal notch to the left index finger and 
PTT is pulse transit time. 
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Path length for PWV was measured in accordance with Hansen (2010) using the 
distance measured from sternal notch to the acromiale, added to the distance from the 
acromiale to the middle of the Finapres finger cuff  (left index finger).  
 
3.4.5 ‘Peak-valley’ calculation methods applied to cardiovascular data 
 
Respiratory sinus arrhythmia (RSA) is a variable calculated to determine the amplitude 
of fc rhythms using the ‘peak-valley’ method. In this thesis RSA was calculated using two 
methods 1) the difference between the average heart rate (fc) during inhalation (fci) and 
exhalation (fce) (fcΔ; Equation F); 2) the difference in maximum and minimum beat-to-
beat intervals (RR) during inhalation and exhalation respectively (RSA; Equation G).   
 
 Equation F: fcΔ = fci - fce 
Where fci is average heart rate during inspiration and fce is average heart rate 
during expiration. 
 
 Equation G: Respiratory sinus arrythmia (RSA) = RRi max – RRe min 
Where RRi max is maximum beat-to-beat intervals during inhalation and RRe min 
is minimum beat-to-beat intervals during exhalation.   
  
In addition to RSA, other cardiovascular variables were also analysed using the ‘peak-
valley’ method, to determine breath related variations induced by SDB. Cardiovascular 
responses will be grouped into intra- and inter- breath phase responses in the results 
sections of each chapter (Table 3-2). 
 
Table 3-2 Breath phase analysis calculation 
i = Average inspiration. e = Average expiration. Δi = Max I – Min I. Δe = Max E – Min E. Δ = i – e 
(average inspiration – average expiration). ΔPV = Max I – Min E or Min I – Max (whichever 
calculation gives largest difference). Mean = mean full breath cycle. ΔPV_Ind = Max – Min 
(irrespective of breath phase; max value during full breath cycle, min value during full breath 
cycle). 
Breath phase analysis Mean values Peak-valley analysis 
Intra-breath phase 
response 
Within breath phase 
i, e Δi, Δe 
Inter-breath phase 
response 
Between breath phase 
Δ 
(Difference in mean values) 
ΔPV 
Full breath cycle response 






Inter-breath phase indices (Δ) were quantified as the difference between mean 
inspiration (i) and mean expiration (e) values (Figure 3-6 calculation 4). Peak-valley (PV) 
indices were calculated as maximum minus minimum values during inspiration (Δi: 
Figure 3-6 calculation 6) and expiration (Δe: Figure 3-6 calculation 5). Within-breath 
phase PV indices (ΔPV) were calculated using maximum inspiration minus minimum 
expiration, or minimum inspiration minus maximum expiration, depending which 
calculation gave the largest difference. Figure 3-6 calculation 7 shows an example using 



































Figure 3-6 Calculations for example cardiovascular variable plot 
1) Ave = average of whole breath. 2) i = Average inspiration. 3) e = Average expiration. 4) Δ = i – 
e (average inspiration – average expiration). 5) Δe = Max E – Min E. 6) Δi = Max I – Min I. 7) ΔPV 
= Max I – Min E (Note ΔPV calculation varies and can be Min I – Max E depending on which 
calculation provides largest difference). 
Note: Example cardiovascular plot shows arbitrary values, not based on real data, to demonstrate 
simplified calculations. The point of breath phase change occurs at different points on the sine 
wave for different variables and during different breathing conditions.  
 
‘Breath phase independent’ peak-valley calculations (ΔPVInd) were also performed with 
the maximum and minimum values measured irrespective of the breath phase in which 
they occurred. Blood pressure fluctuations were calculated as maximum – minimum 
divided by mean during each breath phase. This method has been used for other 
cardiovascular variables to calculate respiratory variability (Elstad and Walløe 2015). 
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In summary, this chapter has described the common elements between methods for the 
following chapters. A short overview of the methodology is provided in the methods 
section of each chapter and this chapter can be referred to for more detailed information. 
Any methods unique to a chapter are outlined fully within the chapter’s method section.  
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Chapter 4. Short-term cardiovascular responses to slow 




The main section of this chapter (4.2) has been prepared as a manuscript as it is intended 
for publication in European Journal of Applied Physiology. It is presented in the next 
section as part of the integrated thesis format submission and the supplementary 
information for the publication is included in section 4.3. Full methodology, including 
reliability and validity of equipment, procedures and analysis can be found in Chapter 3. 
 
The research questions, objectives and hypothesis for this chapter are outlined below: 
 
Research question 
1. Are there differences in the acute cardiovascular responses to an existing SDB 
device (RESPeRATE) compared with alternative SDB delivery methods? 
 
Objectives 
1. Identify whether mechanism-related parameters (e.g. respiratory sinus arrythmia, 
stroke volume, cardiac output, blood pressures) respond similarly during SDB 
delivered using an existing device (RESPeRATE) compared with alternative SDB 
delivery methods. 
2. Test a novel method of analysis, which uses peak-valley methods to investigate 
changes in the amplitude of cardiovascular oscillations.  
 
Hypothesis 
1. Alternative SDB delivery methods will produce the same acute cardiovascular 
responses as RESPeRATE. 
2. Peak-valley analysis of cardiovascular oscillations will reveal larger amplitude 




4.2 Integrated paper: Acute cardiovascular responses to slow 




Daily practice of slow and deep breathing (SDB; ≤10 breaths.min-1) has been 
recommended by the American Heart Association as an effective treatment for 
hypertension (Brook et al. 2013). Specifically, the RESPeRATE device, which reduces 
breathing frequency using auditory tones, has been researched extensively as a long-
term intervention to reduce blood pressure (BP) in hypertensive individuals (Viskoper et 
al. 2003; Landman et al. 2013). A recent meta-analysis (Chaddha et al. 2019) found SDB 
interventions induced a significant reduction of -5.62 mmHg and -2.97 mmHg in systolic 
BP (SBP) ad diastolic BP (DBP) respectively.  
 
Despite the apparent health benefits associated with SDB, there is a lack of information 
relating to the mechanism(s) underlying its antihypertensive effect (Gerritsen and Band 
2018). Accordingly, these mechanisms remain poorly understood and there is a limited 
understanding of acute cardiovascular interactions during SDB, including any potential 
error signal(s) that might underpin its anti-hypertensive effect.   
 
Additionally, those studies that have investigated the mechanistic role of SDB in reducing 
BP have either excluded women or have not compared the responses of men and 
women. For example, Yepryntseva and Shekh (2019) included only male participants, 
whereas Anderson et al. (2009) studied a mixed participant group of men and women 
(men = 18, women = 26), but used total group analysis for the results, failing to compare 
results in men and women. In a subsequent paper, Anderson and colleagues (2010) did 
examine sex differences but in chronic BP changes following SDB, finding reductions in 
24-hour BP in women, but not in men. 
 
There are differences between the size, structure and mechanics of the ribcage and 
lungs of men and women (Sheel et al. 2016), which may influence cardiorespiratory 
interactions during SDB. For instance, during normal spontaneous breathing women 
predominantly breathe with their ribcage rather than their diaphragm (LoMauro and 
Aliverti 2018). It has been suggested that the health benefits associated with SDB are 
related to diaphragmatic breathing (Gerritsen and Band 2018), which may be promoted 
during SDB. Thus, men may be more likely to benefit from SDB, due to their propensity 
to breathe diaphragmatically.  
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Furthermore, although spontaneous breathing frequencies are similar between men and 
women, there are differences in BP regulation between the sexes. Specifically, breathing 
frequency is correlated with cardiac output, heart rate and total peripheral resistance in 
men, but not correlated in women (Wallin et al. 2010).  Additionally, the autonomic 
response to SDB is different between the sexes (Nili et al. 2017) and different 
physiological mechanisms are used to maintain normal BP in men and women (Hart et 
al. 2009). For example, total peripheral resistance and cardiac output were not related 
to sympathetic activity in women, but had a significant relationship in men, suggesting 
differences in BP regulation from modulation of sympathetic activity. It is therefore 
conceivable that sex differences in the interrelationship of the respiratory and 
cardiovascular systems, as well as sex differences in the physiological mechanisms 
controlling BP regulation, might result in women responding differently to SDB than men 
(Anderson et al. 2010). 
 
Recent debate about the appropriate analysis of cardiovascular variability suggests that 
multi-parametric approaches to analysing multiple variables are needed to provide a 
more complete picture of the dynamics of cardiovascular variability (Castiglioni and 
Parati 2011). Previous research has taken a singular approach to the cardiovascular 
responses during SDB, such as Calcaterra and colleagues who have investigated the 
acute effects of baroreflex sensitivity and arterial function (pulse wave velocity and 
augmentation index) following SDB but in separate research studies (Calcaterra et al. 
2013; Calcaterra et al. 2014). Since breathing-related fluctuations in variables such as 
stroke volume and BP are pre-requisites to the generation of any error signal that 
underpins anti-hypertensive effects of SDB, the present study measured the 
instantaneous, multi-parameter haemodynamic responses to SDB using RESPeRATE. 
In addition, responses to RESPeRATE were compared with those of two other SDB 
conditions, 1) a fixed frequency of 6 breaths.min-1, 2) a dynamic algorithm that maximised 
respiratory sinus arrhythmia (RSA). 
 
The aim of the present study was to characterise the acute cardiovascular responses to 
SDB using a number of variables and applying a multi-parametric approach. The 
responses were compared across different SDB conditions (RESPeRATE, fixed 









The experimental protocol was approved by Bournemouth University’s Research Ethics 
Committee and all experiments conformed to the Declaration of Helsinki. Written 
informed consent was obtained from all participants prior to participating in the study. 
 
Participants 
Twelve participants took part in the study (6 males & 6 females). All participants were 
non-smokers with no current diagnosis of cardiovascular or respiratory disease. No 
participants were pregnant at the time of taking part. Participants refrained from eating 
for 2 hours and from caffeine, strenuous exercise and alcohol for 12 hours prior to data 
collection.  
 
Slow and Deep Breathing Protocol 
Participants completed three controlled breathing conditions and one spontaneous 
breathing condition in a randomised order. All breathing conditions were 10 minutes in 
duration with a 10-minute period of normal breathing prior to each measurement. A 10-
minute intervention has been used in previous studies of daily SDB using RESPeRATE 
(Chaddha et al. 2019). Participants rested at baseline for 5 minutes prior to starting the 
first breathing condition to ensure cardiovascular variables were in a resting state. During 
the spontaneous breathing condition (Sfr), participants were instructed to breathe 
normally and no visual feedback was provided to control breathing. The three SDB 
conditions were 1) RESPeRATE (Rfr), 2) a dynamic algorithm driven by RSA (Dfr) and 
3) a fixed breathing frequency of 6 breaths.min-1 (6Ffr). 
 
The RESPeRATE device gradually lowers breathing frequency as users breathe in time 
with a fluctuating musical tone. Breathing frequency is reduced to ≤10 breaths.min-1 and 
is measured using a belt worn around either the chest or upper abdomen. A full 
description of RESPeRATE can be found in Gavish (2010) and Cernes & Zimlichman 
(2017). Participants completed the dynamic breathing frequency condition (Dfr) using a 
novel, bespoke algorithm that guided breathing dynamically to a personalised frequency. 
The algorithm created a dynamically driven breathing frequency, which strived to 
maximise cardiovascular perturbation, using the amplitude of RSA as the controlled 
variable. The algorithm used data measured from a finger sensor 
(photoplethysmography), which tracked the user’s instantaneous physiological 
responses to their breathing. The finger sensor was connected via the headphone socket 
of an iPad.  
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As the optimal SDB frequency is widely regarded in the literature to be 6 breaths.min-1 
(Cullins et al. 2013; Russo et al. 2017); accordingly, a final condition of 6 breaths.min-1 
(6Ffr) was included. Both the dynamic algorithm and 6 breaths.min-1 conditions were 
delivered by Bournemouth University’s Brythm app. Brythm provides visual feedback, 
displayed on an iPad screen, to guide the user’s breathing frequency, whereby the user 
inhales when the dome graphic rises and exhales when the dome falls (Figure 4-1). 
 
 
Figure 4-1 Screenshots of Brythm graphic 
N.B: Arrows do not appear on app but are shown here to display the direction of graphic  
movement. 
 
Data Acquisition   
Participants were seated in an upright position, at an approximate angle of 60o for the 
duration of the data collection. Respiratory airflow was monitored continuously 
throughout each breathing condition. Participants wore an oronasal mask that covered 
both mouth and nose (Oro Nasal 7450 V2 Mask, Hans Rudolph Inc., Kansas, USA) and 
respired flow rate was measured continuously using a heated pneumotachograph 
(Model 3700, Hans Rudolph Inc., Kansas, USA) connected to a flow measurement 
system (RSS 100-HR, Hans Rudolph Inc., Kansas, USA). 
 
Heart rate (fc) was monitored continuously using a 3-lead ECG and non-invasive beat-
to-beat arterial BP was estimated using a Finometer (Finapres NOVA, Finapres Medical 
Systems, The Netherlands). The finger cuff derived BP was calibrated using an arm cuff 
prior to and halfway through data collection. Stroke volume (SV) was calculated by the 
Finometer using the Modelflow method. Total peripheral resistance (TPR) was 
calculated as mean arterial pressure divided by cardiac output (Q̇). Peripheral pulse 
transit time (PTT) was calculated from the time delay between the peak of the R wave of 
the ECG and the peak of the pressure pulse recorded at the finger. End-tidal CO2 was 
recorded at the end of each minute using an iWorx CO2/O2 Gas Analyzer (GA-200, New 
Hampshire, USA). 
 
Analogue outputs from the Finapres NOVA (reconstructed brachial pressure waveform, 
ECG waveform, SV, SBP, DBP) and the respiratory flow meter were sampled 
continuously at 250Hz via an analogue to digital converter (NI USB-6218 BNC, National 
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Instruments Inc.) and captured using bespoke acquisition and analysis software 
(LabView 2015, National Instruments, Inc.). The LabView software corrected for the 4 
second delay between the Finapres NOVA output and the respiratory output. Data were 
recorded during the baseline period (5 minutes), and during each breathing condition (10 
minutes; Sfr, Rfr, 6Ffr, Dfr). 
 
Data Analysis  
Within the bespoke LabView software, cardiovascular and respiratory parameters were 
derived breath-by-breath, and minimum, maximum and mean values were calculated for 
every inhalation and exhalation. Data were calculated in epochs of one-minute, first 5- 
and final 5-min and the full 10-min for each condition. Data were compared for the three 
SDB conditions (Rfr, 6Ffr, Dfr) and spontaneous breathing (Sfr). 
 
Respiratory sinus arrhythmia (RSA) was calculated using two methods 1) the difference 
between the average heart rate (fc) during inhalation (fci) and exhalation (fce) (fcΔ); 2) the 
difference in maximum and minimum beat-to-beat intervals (RR) during inhalation and 
exhalation respectively (RSA). RSA is a variable calculated to determine the amplitude 
of heart rate rhythms using the ‘peak-valley’ method and in this study the peak-valley 
method was used to analyse all variables including BP.  
 
Calculated parameters and their derivation are displayed schematically using a sinewave 
in Figure 4-2 (with corresponding calculation numbers). Inter-breath phase indices (Δ) 
were quantified as the difference between mean inspiration (i) and mean expiration (e) 
values for all variables (calculation 4). Peak-valley (PV) indices were calculated as 
maximum minus minimum values during inspiration (Δi: calculation 6) and expiration (Δe: 
calculation 5). Inter-breath phase PV indices (ΔPV) were calculated using maximum 
inspiration minus minimum expiration, or minimum inspiration minus maximum 
expiration, dependent on which calculation gave the largest difference. Calculation 7 
shows an example using the calculation maximum inspiration minus minimum expiration. 
PV indices irrespective of breath phase, known as peak-valley breath phase independent 
calculations (ΔPV_Ind), were calculated as the difference between the maximum and 
minimum values, irrespective of the breath phase in which they occurred (not shown in 



































Figure 4-2 Calculations for example cardiovascular variable plot 
1) Ave = average of whole breath. 2) i = Average inspiration. 3) e = Average expiration. 4) Δ = i 
minus e (average inspiration minus average expiration). 5) Δe = Max E minus Min E. 6) Δi = Max 
I minus Min I. 7) ΔPV = Max I minus Min E (Note ΔPV calculation varies and can be Min I minus 
Max E depending on which calculation provides largest difference). 
 
Each condition was 10 minutes in duration but the final 5-minute epochs of each SDB 
condition (Rfr, 6Ffr, Dfr) were used for analysis to ensure steady state values were 
analysed. For spontaneous breathing (Sfr), the first 5-minute epoch was used, as 
participants were already in a steady state. Dynamic breathing frequencies were also 
compared across the full 10-minute condition and between the first- and final-5 minutes.  
 
Values are expressed as means ± SD unless stated otherwise. Statistical analysis was 
undertaken using SPSS Statistics 24 (IBM Corp.). After normality was confirmed for 
cardiovascular variables, repeated measures ANOVA with planned pairwise 
comparisons using Bonferroni corrections were used. Independent samples t-test were 
used to test for baseline sex differences. Reported p values are those following 
adjustment for repeated comparisons. For all analyses, P was set at 0.05. Due to the 
large amount of data, additional results (not focused on in this paper) can be viewed in 
the online supplementary information (calculations 1-4 in Figure 4-2). Where significant 
differences are stated between breathing conditions, these are calculated using 




Data were collected from 12 participants, but 1 participant was excluded due to failure to 
adhere to the prescribed breathing conditions. Data for five males and six females were 
analysed and full descriptive statistics can be seen in Table 4-1. Due to missing data 
from the Sfr condition for 2 participants, data from baseline spontaneous measurements 
were used in place of Sfr data for these 2 participants, to ensure adequate power was 
maintained. Before doing so, data integrity checks were performed to ensure the 
substitution did not affect the study results. Furthermore, for all other participants (n=9), 
it was confirmed that breathing frequency was not significantly different between baseline 
and the first 5-min Sfr condition. There were no significant differences between the 
baseline data and the first 5-min Sfr condition for mechanistically meaningful variables. 
 
Table 4-1 Participant characteristics 
 Female Male P value 
 n = 6 n = 5  
Age (years) 42.0 ± 10.1 40.4 ± 15.9 0.844 
Stature (m) 1.66 ± 0.06 1.76 ± 0.04   0.013* 
Mass (kg) 71.5 ± 10.9 75.4 ± 9.3 0.546 
BMI (kg/m2) 26.2 ± 5.5 24.4 ± 2.3 0.500 
Baseline SBP (mmHg) 118.3 ± 11.4 118.0 ± 8.6 0.958 
Baseline DBP (mmHg) 72.2 ± 11.4 69.8 ± 7.0 0.696 
Baseline fr (breaths.min-1) 12.5 ± 2.8 12.0 ± 2.8 0.750 
Baseline Tidal Volume (L) 0.5 ± 0.2 0.6 ± 0.1 0.472 
Body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), breathing 
frequency (fr); *significant difference between groups. 
 
Respiratory variables 
Table 4-2 provides an overview of the respiratory parameters for each condition. There 
were no significant differences between males and females for any respiratory variables.  
Breathing frequency during Sfr was significantly different from all SDB conditions but 
frequency during SDB conditions were not significantly different from each other. The 
dynamic algorithm (Dfr) computed the optimal breathing frequency to be 5.5 ± 1.3 
breaths.min-1 and maintained a steady SDB frequency throughout the 10 minutes with 
no difference in breathing frequency between first 5- and final 5-min. Whereas 
RESPeRATE (Rfr) averaged 6.4 ± 1.9 breaths.min-1 during the final 5 minutes, but 
produced a significantly higher frequency during the first 5 minutes (Figure 4-3; 8.1 
breaths.min-1; p=0.02). There was no significant difference in end-tidal CO2 between any 
conditions (Table 4-2). 
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Table 4-2 Respiratory parameters 
  








Female 12.2 ± 4.7 6.0 ± 1.2 6.0 ± 0.1 5.8 ± 1.7 
<0.001 0.735 
Male 12.3 ± 2.5 7.0 ± 2.5 6.0 ± 0.0 5.2 ± 0.4 
All 12.3 ± 3.7¥†¤ 6.4 ± 1.9* 6.0 ± 0.0* 5.5 ± 1.3* 
VT 
Female 0.6 ± 0.2 1.2 ± 0.4 0.9 ± 0.5 1.1 ± 0.5 
<0.001 0.621 
Male 0.6 ± 0.1 1.0 ± 0.4 0.9 ± 0.2 1.1 ± 0.4 
All 0.6 ± 0.2¥†¤ 1.1 ± 0.4* 0.9 ± 0.3* 1.1 ± 0.4* 
TI / 
TTOT 
Female 0.4 ± 0.0 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
0.129 0.569 
Male 0.4 ± 0.0 0.5 ± 0.1 0.6 ± 0.4 0.5 ± 0.0 




Female 4.7 ± 0.6 4.4 ± 0.7 4.7 ± 0.7 4.7 ± 0.8 
0.535 0.167 
Male 5.3 ± 0.5 5.1 ± 0.5 5.2 ± 0.5 5.3 ± 0.6 
All 5.0 ± 0.6 4.8 ± 0.7 5.0 ± 0.6 5.0 ± 0.7 
Data represent mean ± SD (female n = 6, male n = 5); Spontaneous breathing (Sf r), RESPeRATE 
(Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic breathing frequency (Dfr);  
Breathing frequency (fr; in breaths.min-1), tidal volume (VT; L), duty cycle (TI /TTOT), end-tidal CO2 
(%); Significantly different from Sfr (*); Rfr (¥), 6Ffr (†), Dfr (¤); P<0.05. 
 
 
Figure 4-3 Breathing frequency during RESPeRATE (Rfr) and dynamic breathing 
frequency (Dfr) conditions 
Solid line RESPeRATE (Rfr), dashed line dynamic algorithm (Df r); Circle data points - male; 
Triangle data points - female; Data points represent the average value for the preceding minute 
(1 min epoch) i.e. data point at 5 min represents average breathing frequency between 4-5min. 
  
Arterial blood pressures 
There were no significant differences between males and females for any BP variables. 
When combining male and female data there were no significant differences for average 








































however peak-valley amplitude was significant different between Sfr and all SDB 
conditions (Table 4-3). All SDB conditions were significantly different from Sfr for SBPΔi 
and SBPΔe and between Sfr and Dfr and 6Ffr for SBPΔPV. This was reflected in the 
equivalent DBP values. Peak-valley breath phase independent values (ΔPV _Ind) 
revealed larger changes for SBP and DBP than peak-valley values (ΔPV).  
 
Table 4-3 Peak-valley differences (±SD) for blood pressure variables (mmHg) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); systolic blood pressure (SBP; mmHg), diastolic blood pressure (DBP; 
mmHg); within inspiration difference (∆i), within expiration difference (∆e), inter-breath phase 
peak-valley difference (∆PV), breath phase independent peak -valley difference (∆PV_Ind);  
Significantly different from Sfr (*); Rfr (¥), 6Ffr (†), Dfr (¤); P<0.05. 
 
  








F 3.6 ± 2.6 11.7 ± 3.5 10.5 ± 2.5 11.7 ± 4.5 
<0.001 0.979 
M 3.0 ± 1.6 10.0 ± 5.6 9.5 ± 5.0 11.1 ± 3.6 
All 3.4 ± 2.1¥†¤ 10.9 ± 4.4* 10.0 ± 3.7* 11.4 ± 3.9* 
SBPΔe 
F 4.7 ± 2.6 10.0 ± 2.4 10.6 ± 2.1 10.9 ± 4.3 
<0.001 0.611 
M 3.5 ± 2.3 7.0 ± 6.1 6.6 ± 3.2 9.0 ± 5.7 
All 4.2 ± 2.4¥†¤ 8.6 ± 4.5* 8.8 ± 3.3* 10.0 ± 4.8* 
SBPΔPV 
F -9.2 ± 4.1 -6.8 ± 16.0 -5.4 ± 15.8 -11.5 ± 11.8 
0.267 0.251 
M -6.6 ± 3.5 -14.3 ± 8.6 -16.1 ± 6.7 17.9 ± 8.3 
All -8.0 ± 3.9 -10.2 ± 13.1 -10.3 ± 13.2 -14.4 ± 10.4 
SBPΔPV 
_Ind 
F 13.4 ± 3.3 15.9 ± 3.3 17.2 ± 3.9 15.7 ± 5.2 
0.001 0.150 
M 12.4 ± 3.6 16.2 ± 6.9 17.3 ± 5.1 19.5 ± 7.8 
All 12.9 ± 3.3†¤ 16.0 ± 4.9 17.3 ± 4.3* 17.4 ± 6.5* 
DBPΔi 
F 1.9 ± 1.0 7.1 ± 2.9 7.2 ± 2.4 7.6 ± 2.8 
<0.001 0.635 
M 1.0 ± 0.4 5.0 ± 2.8 4.1 ± 1.3 5.3 ± 1.5 
All 1.5 ± 0.9¥†¤ 6.1 ± 2.9* 5.8 ± 2.5* 6.6 ± 2.5* 
DBPΔe 
F 2.9 ± 1.1 6.1 ± 2.8 7.2 ± 2.7 6.4 ± 2.1 
0.001 0.463 
M 1.7 ± 0.8 3.8 ± 2.1 3.5 ± 1.8 4.3 ± 2.3 
All 2.4 ± 1.1†¤ 5.1 ± 2.7 5.5 ± 2.9* 5.4 ± 2.3* 
DBPΔPV 
F -4.2 ± 1.7 -1.4 ± 10.8 1.2 ± 10.3 -4.8 ± 8.3 
0.292 0.096 
M -1.2 ± 1.8 -6.5 ± 3.6 -6.7 ± 2.5 -8.0 ± 3.3 
All -2.8 ± 2.3 -3.7 ± 8.4 -2.4 ± 8.5 -6.2 ± 6.4 
DBPΔPV 
_Ind 
F 7.7 ± 1.4 9.9 ± 3.1 10.6 ± 1.9 9.4 ± 1.3 
0.007 0.288 
M 6.2 ± 0.2 7.8 ± 2.0 7.7 ± 1.6 9.2 ± 2.6 
All 7.0 ± 1.3¤ 9.0 ± 2.7 9.3 ± 2.3* 9.3 ± 1.9* 
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There were high correlations (>0.8) between SBPΔi and SBP and between SBPΔe and 
SBP and the DBP equivalents across all breathing conditions. Therefore, percentage 
change BP oscillations were calculated during inspiration and expiration, producing 
relative intra-breath phase peak-valley differences (relative Δi and Δe). There were 
significant differences for all percentage BP oscillations during all SDB variables 
compared with Sfr. There were also significant differences for SBP%Δi, SBP%Δe and 
DBP%Δi between first 5- and final 5-min for Rfr, but only for SBP%Δi during the Dfr 




Figure 4-4 Blood pressure oscillations: Relative change of ΔI and ΔE for systolic 
blood pressure (A) and diastolic blood pressure (B) 
Systolic blood pressure (SBP), diastolic blood pressure (DBP); within inspiration difference (∆i),  
within expiration difference (∆e); Spontaneous breathing (Sfr), RESPeRATE (Rfr), 6 
breaths.minute-1 (6Ffr), optimisation algorithm dynamic breathing frequency (Df r). Variable 
calculated as SBP∆i as a percentage of average SBP during inspiration, or equivalent during 
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Heart rate and respiratory sinus arrythmia 
Average heart rate was significantly higher during 6Ffr and Dfr, compared with Sfr, but not 
during Rfr (Sfr 58.6 ± 8.5; Rfr 60.6 ± 8.5; 6Ffr 62.4 ± 9.0; Dfr 62.3 ± 9.4 beats.min-1). 
Whereas, Rfr and 6Ffr were significantly different from Sfr for fcΔi. Additionally, the 
amplitude of RSA was significantly different from Sfr for Rfr (p=0.05) and Dfr (p=0.018), 
but not for 6Ffr (p=0.130; Figure 4-5).  
 
Table 4-4 Mean (±SD) peak-valley differences for heart rate (fc) and respiratory 
sinus arrythmia (RSA) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); heart rate (fc; beats.min-1), respiratory sinus arrythmia (RSA; s); within 
inspiration difference (∆i), within expiration difference (∆e), inter-breath phase peak-valley  














F 4.3 ± 2.5 10.9 ± 5.0 13.4 ± 7.5 13.6 ± 10.3 
0.004 0.741 
M 2.6 ± 2.9 7.2 ± 4.8 9.3 ± 5.9 9.4 ± 5.3 
All 3.5 ± 2.7¥† 9.2 ± 5.1* 11.5 ± 6.8* 11.7 ± 8.3 
fcΔe 
F 6.5 ± 3.9 7.6 ± 4.3 11.6 ± 5.5 9.6 ± 3.7 
<0.001 0.477 
M 3.2 ± 2.2 6.4 ± 3.2 10.3 ± 6.3 10.4 ± 6.5 
All 5.0 ± 3.5† 7.1 ± 3.7† 11.0 ± 5.6*¥ 10.0 ± 4.9 
fcΔPV 
F -2.1 ± 7.7 11.5 ± 10.6 8.2 ± 17.1 14.2 ± 13.3 
0.021 0.963 
M -1.1 ± 6.8 9.2 ± 7.4 10.6 ± 11.3 13.2 ± 8.1 
All -1.7 ± 7.0 10.4 ± 8.9 9.3 ± 14.1 13.7 ± 10.7 
RSA 
(s) 
F 0.09 ± 0.04 0.16 ± 0.05 0.14 ± 0.08 0.15 ± 0.04 
0.001 0.284 
M 0.13 ± 0.13 0.22 ± 0.15 0.26 ± 0.19 0.27 ± 0.17 
All 0.11 ± 0.09¥¤ 0.18 ± 0.10* 0.20 ± 0.14 0.21 ± 0.13* 
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Figure 4-5 Respiratory sinus arrythmia (RSA) response to slow and deep 
breathing 
Data represent mean ± SD (n=11); Spontaneous breathing (Sf r), RESPeRATE (Rfr), 6 
breaths.minute-1 (6Ffr), optimisation algorithm dynamic breathing frequency (Dfr); respiratory  
sinus arrythmia (RSA; s). 
 
Stroke volume and cardiac output 
There was a significant effect of condition upon SV∆i and SV∆e, but paired comparisons 
revealed no significant differences between breathing conditions (Table 4-5). Intra-
breath phase cardiac output (Q̇) increased during SDB significantly and was significantly 



































Table 4-5 Mean (±SD) peak-valley differences for stroke volume (SV) and cardiac 
output (Q̇) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); stroke volume (SV; ml), cardiac output (Q̇; ml.min-1); within inspiration 
difference (∆i), within expiration difference (∆e), inter-breath phase peak-valley difference (∆PV), 
breath phase independent peak-valley difference (∆PV_Ind); Significantly different from Sfr (*);  
Rfr (¥), 6Ffr (†), Dfr (¤); P<0.05. 
 
Total peripheral resistance and pulse transit time 
 
In keeping with the pattern of hemodynamic responses, intra-breath phase total 
peripheral resistance (TPR) and peripheral transit time (PTT) increased during both 
phases of respiration (Table 4-6). 
 
  








F 5.3 ± 2.5 8.5 ± 3.8 9.5 ± 5.4 10.3 ± 6.2 
0.006 0.895 
M 5.2 ± 1.0 9.8 ± 8.7 11.2 ± 6.1 10.1 ± 5.6 
All 5.3 ± 1.9 9.1 ± 6.1 10.3 ± 5.5 10.2 ± 5.6 
SVΔe 
F 6.7 ± 3.0 9.9 ± 3.9 9.3 ± 1.1 11.1 ± 5.0 
0.025 0.816 
M 5.7 ± 2.0 7.7 ± 4.3 8.0 ± 4.2 8.2 ± 5.5 
All 6.3 ± 2.5 8.9 ± 4.0 8.7 ± 2.8 9.8 ± 5.2 
SVΔPV 
F -10.4 ± 3.3 -13.7 ± 3.3 -8.5 ± 12.4 -14.2 ± 4.5 
0.384 0.248 
M -10.5 ± 4.0 -14.9 ± 10.6 -17.9 ± 9.9 -14.9 ± 9.1 
All -10.4 ± 3.5 -14.2 ± 7.1 -12.8 ± 11.9 -14.5 ± 6.6 
SVΔPV 
_Ind 
F 11.2 ± 2.7 11.1 ± 2.6 12.1 ± 3.3 13.0 ± 4.8 
0.440 0.527 
M 14.8 ± 3.4 14.4 ± 8.2 17.2 ± 9.6 14.3 ± 7.0 
All 12.8 ± 3.4 12.6 ± 5.8 14.4 ± 7.1 13.6 ± 5.6 
Q̇Δi 
F 363.0 ± 301.2 878.2 ± 463.5 943.6 ± 474.3 1042.4 ± 694.5 
<0.001 0.820 
M 304.2 ± 134.2 937.0 ± 760.7 1186.5 ± 764.9 1119.4 ± 734.7 
All 336.3 ± 231.3†¤ 904.9 ± 583.0 1054.0 ± 602.1* 1077.4 ± 677.3* 
Q̇Δe 
F 517.8 ± 452.7 821.2 ± 485.3 860.1 ± 363.3 760.8 ± 449.2 
<0.001 0.209 
M 415.9 ± 113.7 686.7 ± 275.4 1020.5 ± 447.2 967.8 ± 535.2 
All 471.5 ± 332.3† 760.0 ± 391.2 933.1 ± 391.2* 854.9 ± 476.6 
Q̇ΔPV 
F -751.2 ± 337.6 719.2 ± 1015.5 281.3 ± 1187.0 486.6 ± 1200.3 
0.083 0.506 
M -496.7 ± 754.3 -62.8 ± 1259.1 -105.1 ± 1727.6 27.1 ± 1508.6 
All -635.6 ± 549.8 363.8 ± 1147.4 105.7 ± 1392.5 277.8 ± 1299.4 
Q̇ΔPV 
_Ind 
F 842.6 ± 344.6 1034.6 ± 560.9 1086.2 ± 474.4 941.9 ± 584.6 
0.037 0.246 
M 1010.5 ± 196.8 1112.9 ± 514.1 1485.6 ± 699.5 1368.3 ± 746.6 
All 918.9 ± 287.3 1070.2 ± 514.5 1267.7 ± 593.2 1135.7 ± 665.9 
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Table 4-6 Mean (±SD) peak-valley differences for total peripheral resistance (TPR) 
and pulse transit time (PTT) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); total peripheral resistance (TPR; mmHg⋅min⋅L-1); pulse transit time 
(PTT; ms); within inspiration difference (∆i), within expiration difference (∆e), inter-breath phase 
peak-valley difference (∆PV), breath phase independent peak-valley difference (∆PV_Ind);  
Significantly different from Sfr (*); Rfr (¥), 6Ffr (†), Dfr (¤); P<0.05. 
 
Peak-valley (ΔPV) and peak-valley breath phase independent (ΔPV_Ind) 
 
Comparison of peak-valley values (ΔPV; highest difference between min/max inspiration 
and expiration; Calculation 7 Figure 4-2) and peak-valley breath phase independent 
values (ΔPV_Ind; highest difference across breath irrespective of breath phase) reveals 
  








F 1.4 ± 1.2 2.3 ± 1.0 2.3 ± 1.2 2.7 ± 1.8 
0.001 0.176 
M 1.5 ± 0.6 3.1 ± 1.8 4.3 ± 2.2 3.9 ± 1.9 
All 1.4 ± 1.0† 2.7 ± 1.4 3.2 ± 1.9* 3.2 ± 1.8 
TPRΔe 
F 1.9 ± 1.7 2.7 ± 1.5 2.7 ± 1.1 2.3 ± 1.4 
0.004 0.058 
M 2.0 ± 0.6 3.2 ± 1.8 4.5 ± 2.4 4.7 ± 2.8 
All 2.0 ± 1.2 3.0 ± 1.6 3.5 ± 1.9 3.4 ± 2.4 
TPRΔPV 
F -0.1 ± 2.8 -1.7 ± 3.5 -1.4 ± 3.4 -1.8 ± 3.7 
0.037 0.284 
M 2.3 ± 3.6 -2.0 ± 4.6 -1.3 ± 6.4 -5.7 ± 2.9 
All 1.0 ± 3.3¤ -1.8 ± 3.9 -1.4 ± 4.7 -3.6 ± 3.7* 
TPRΔPV 
_Ind 
F 3.1 ± 1.6 3.2 ± 1.5 3.5 ± 1.7 2.9 ± 1.8 
0.190 0.180 
M 4.9 ± 1.1 4.7 ± 1.0 5.5 ± 2.1 5.6 ± 2.1 
All 3.9 ± 1.6 3.9 ± 1.0 4.4 ± 2.1 4.2 ± 2.3 
PTTΔi 
F 11 ± 8 14 ± 4 17 ± 7 16 ± 8 
<0.001 0.104 
M 9 ± 4 19 ± 10 22 ± 10 27 ± 17 
All 10 ± 6† 16 ± 7 19 ± 9* 21 ± 13 
PTTΔe 
F 12 ± 8 15 ± 9 18 ± 7 16 ± 5 
0.001 0.043 
M 10 ± 3 23 ± 11 28 ± 15 33 ± 23 
All 11 ± 6¥† 19 ± 10* 23 ± 12* 23 ± 17 
PTTΔPV 
F 16 ± 10.0 9 ± 18 10 ± 25.0 21 ± 6 
0.750 0.251 
M 16 ± 6.0 25 ± 10 34 ± 14.3 10 ± 45 
All 16 ± 8.0 16 ± 17 21 ± 23.3 16 ± 29 
PTTΔPV 
_Ind 
F 17 ± 9 16 ± 8 21 ± 8 17 ± 6 
0.076 0.480 
M 24 ± 9 24 ± 7 32 ± 12 32 ± 18 
All 80 ± 9 19 ± 8 26 ± 11 24 ± 14 
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a clear difference in magnitude for some variables, such as SBP. Figure 4-6 shows the 
last minute of the 6Ffr condition for 1 female participant; there was synchronisation 
between respiratory flow and heart rate (A), but asynchrony between inspiratory flow and 
BP (B). As such, when peak-valley calculations are analysed larger differences are seen 




Figure 4-6 Respiratory synchronisation of heart rate (fc) (A) and systolic blood 
pressure (SBP) (B) 
Heart rate (fc; beats.min-1), systolic blood pressure (SBP; mmHg), inspiratory flow (L: 1 second 














































































A small subset analysis was performed analysing differences in the acute cardiovascular 
responses to SDB by sex. No significant differences were found in the responses of men 
and women and therefore data were pooled for most analyses. Additionally, with small 
sample sizes for both groups (female n=6 & male n=5) any comparisons are limited in 
their statistical power. The results reveal that hemodynamic responses to SDB are 
similar between males and females, supporting the results of Adler et al. (2019), who 
found no sex differences in muscle sympathetic nerve activity and vascular sympathetic 
baroreflex sensitivity when comparing cardiovascular responses to RESPeRATE and 
spontaneous breathing. The amplitude of cardiovascular oscillations observed in the 
present study increased during SDB in both male and female participants, with pairwise 
comparisons revealing no sex differences across any variables. The lack of observed 
differences in the cardiovascular response to SDB, could be explained by the absence 
of significant differences between men and women in baseline cardiovascular variables 
during the spontaneous breathing condition (Sfr). As baseline values were similar, the 
variables consequently responded to SDB in the same way regardless of sex. Due to the 
lack of observed differences between sexes, the following discussion will focus on 
combined data of males and females. 
 
The main aim of the study was to characterise and compare the multi-parametric 
response to SDB using RESPeRATE, a fixed breathing frequency of 6 breaths.min-1 and 
a dynamic algorithm driven by RSA. This is the first study to provide a comprehensive 
characterisation of the acute cardiovascular responses to SDB, including consideration 
of the inter- and intra- breath perturbations created by breathing, as well as providing a 
comparison of responses by sex. 
 
The novel analysis presented in this paper highlights the importance of measuring more 
than simple average values, as only average heart rate showed a significant increase 
between spontaneous and SDB. Previous research has been limited as it only compared 
average values, which as our data indicate, overlook the more complex cardiovascular 
oscillations created by SDB. The novel analysis provides evidence that differences 
between SDB and spontaneous breathing are only revealed by the peak-valley (Δi, Δe, 
ΔPV) and peak-valley breath phase independent (ΔPV_Ind) analyses. Therefore, 
analysis of inter- and intra- breath oscillations is needed to reveal the true cardiovascular 
perturbation induced by SDB. 
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These perturbations are markedly observed within BP oscillations and their response to 
SDB. The SBP oscillations within breath phases increased during SDB by up to 10.2% 
(11.4 mmHg) during inspiration (SBPΔi) and up to 8.4% (10 mmHg) during expiration 
(SBPΔe). In comparison, during spontaneous breathing (Sfr) oscillations were just 2.9% 
(3.4 mmHg) and 3.4% (4.2 mmHg), respectively. For DBP, oscillations increased during 
SDB by up to 9.6% (6.6 mmHg) during inspiration and 7.7% (5.5 mmHg) during 
expiration, compared with fluctuations during Sfr of 3.4% (1.5 mmHg) and 3.3% (2.4 
mmHg), respectively. Thus, SDB generates an increase in the amplitude of BP 
oscillations during SDB. Interestingly, the largest oscillations were found in the SDB 
condition with the lowest average breathing frequency (Dfr). The amplitude of BP 
oscillations increased as breathing frequency was reduced and could perhaps be 
amplified further at breathing frequencies lower than those assessed in the present 
study. Extending breath phase duration, allows more time for BP to fluctuate within-
breath and provides a possible explanation for the largest fluctuations occurring during 
the slowest breathing frequency. Fluctuations in BP have been found previously and are 
potentially linked to cardiorespiratory coupling of respiration, BP and heart rate (Chang 
et al. 2013; Russo et al. 2017; Nuckowska et al. 2019). This is supported by the RSA 
data in the present study, which also increased as breathing frequency decreased 
reaching a peak during Dfr, the lowest breathing frequency. It may also be possible to 
further increase RSA, using frequencies lower than those used in the present study. 
 
Additionally, during the SDB conditions the largest percentage within-breath BP changes 
were observed during inspiration, but during spontaneous breathing the largest 
percentage change was during expiration. This was the same for both sexes. This 
reflects the known respiratory interactions where BP increases during inspiration when 
undertaking SDB, but decreases during inspiration during spontaneous breathing, so-
called pulsus paradoxus (Parati et al. 2008). The largest oscillations therefore occur in 
the breath phase in which BP is rising. During inspiration, venous return is increased, 
which may be amplified by SDB due to a larger amplitude change of intra-thoracic 
pressure (Russo et al. 2017). The increased BP oscillations during inspiration may 
therefore be a reflection of the cardiovascular responses to the change in intra-thoracic 
pressure and subsequent increased venous return during SDB. 
 
A key finding from this study is the higher amplitude of ‘breath phase independent’ 
cardiovascular fluctuations, as well as those of the peak-valley intra-breath phase 
fluctuations. Figure 4-6 shows the mismatch of synchronisation between inspiratory flow 
and heart rate, and SBP. For heart rate, the peak-valley value (RSA) matches closely 
the peak-valley breath phase independent values, due to the synchronisation of heart 
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rate and breathing phase. However, the oscillations of other variables, such as SBP, are 
misrepresented by inter-breath phase peak-valley values; in Figure 4-6B the minimum 
and maximum SBP values occur during the same breath phase, which reflects the 
influence of differing kinetics of the effect of breathing upon heart rate and 
haemodynamics. If one only considers the instantaneous haemodynamic responses 
during a given breath phase, then the true amplitude of the perturbations created by SDB 
are obscured. This is reflected in our statistical analyses, as only ΔPV_Ind values, and 
not ΔPV, were significantly different between conditions for Q̇, SBP and DBP. Therefore, 
it is important to evaluate breath phase independent values of cardiovascular 
oscillations, due the nature of acute changes caused by SDB, in order to evaluate the 
true cardiovascular perturbations. Coherence analysis could further the understanding 
of this phenomenon, but was beyond the scope of this study. 
 
When comparing between SDB conditions there were no significant differences between 
the SDB breathing frequencies in the final 5 minutes, which may explain why all three 
SDB conditions seemed to elicit the same cardiovascular responses compared to 
spontaneous breathing. This suggests that the 6Ffr and Dfr conditions induced similar 
amplitudes of cardiovascular perturbation as RESPeRATE, a device already shown to 
reduce BP when practiced daily. It seems that the important feature of SDB is that 
breathing frequency is ~6 breaths.min-1, but not necessarily how this frequency is 
achieved. Additionally, for ΔPV_Ind values only 6Ffr and Dfr were significantly different 
from Sfr for SBPΔPV_Ind and DBPΔPV_Ind suggesting they may generate slightly 
superior cardiovascular perturbations to RESPeRATE. Since 6Ffr and Dfr produce the 
same error signal(s) as RESPeRATE, it is reasonable to suggest they may produce the 
same long-term health benefits. Our data indicate that, at the very least, 6Ffr and Dfr 
provide alternative methods to implement SDB as an intervention to reduce BP. Indeed, 
6Ffr and Dfr may prove superior to RESPeRATE, since the reduced breathing frequency 
is experienced for a longer duration, as the conditions either reduce breathing frequency 
faster (dynamic algorithm) or maintain the same reduced frequency throughout (6 
breaths.min-1). For example, RESPeRATE produced an average frequency of 8.1 
breaths.min-1 during the first 5 min compared with 6.4 breaths.min-1 in last 5 min, whilst 
the dynamic algorithm produced a frequency of 5.8 breaths.min-1 (first 5) and 5.5 
breaths.min-1 (last 5), respectively. Further research is required to determine whether the 
hemodynamic responses at ~8 breaths.min-1 and ~6 breaths.min-1 differ, and whether 
any acute differences reflect changes in the anti-hypertensive effect of SDB. However, 
there were significantly higher BP oscillations during the final 5-min of RESPeRATE than 
the first 5-min, showing the potential for different acute cardiovascular responses at 
higher SDB frequencies.  
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A final practical consideration is whether the increased ‘exposure time’ to the optimal 
SDB frequencies delivered by the 6Ffr and Dfr conditions could shorten the length of the 
daily SDB intervention. It is reasonable to suggest if the stimulus (optimal SDB 
frequency) is applied for a longer duration in these new potential conditions compared 
with the RESPeRATE condition, then the overall duration of the SDB session could be 
reduced. The ‘active SDB time’ would still be the same in the new conditions as during 
the normal RESPeRATE session, but the overall length of the session could be reduced 
to remove the time spent above optimal SDB frequencies during RESPeRATE sessions. 
Further research examining the long-term benefits of these alternative conditions is 
needed to test this theory. 
 
Limitations 
This study did not control for or measure menstrual phase and/or contraceptive phase in 
the female participants. It has previously been recommended that when testing 
autonomic function, females should be tested during the early follicular phase of the 
menstrual cycle or placebo phase of oral contraceptive use (Wallin et al. 2010). However, 
a previous study found no influence of menstrual cycle or oral contraceptive on the 
cardiovascular responses to SDB (Nili et al. 2017). Future studies should explore 
whether menstrual cycle phase influences the cardiovascular response to SDB, 




In conclusion, all three SDB conditions elicit similar cardiovascular responses to each 
other, when compared with normal breathing. Thus, both the new dynamic algorithm (Dfr) 
or a fixed frequency of 6 breaths.min-1 (6Ffr) could potentially be used in future studies 
using a SDB intervention to reduce BP. Future research should examine a range of 
breathing frequencies to examine if BP oscillations can be maximised at breathing 
frequencies <6 breaths.min-1 and whether SDB at higher frequencies of 8 breaths.min-1 
(replicating the first 5 min of RESPeRATE) produce the same cardiovascular responses 
as found in the present study. All future studies should note the importance of looking 
beyond average responses to examine inter- and intra-breath phase cardiovascular 
oscillations, especially for BP and RSA, to reflect the true cardiovascular responses to 
SDB. In this respect, analysis of breath phase independent peak-valley fluctuations of 




4.3 Supplementary material 
 
The following results tables will be included as supplementary information for the 
publication in European Journal of Applied Physiology. 
 
Table S4-7 Mean values (±SD) for blood pressure variables (mmHg) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); systolic blood pressure (SBP; mmHg), diastolic blood pressure (DBP; 












F 117.5 ± 16.8 115.9 ± 14.4 116.0 ± 15.5 115.0 ± 10.5 
0.358 0.857 
M 123.0 ± 5.8 118.7 ± 7.3 118.3 ± 7.9 116.1 ± 10.4 
All 120.0 ± 12.8 117.2 ± 11.2 117.1 ± 12.1 115.5 ± 9.9 
SBPi 
F 114.8 ± 16.9 114.2 ± 14.7 114.3 ± 15.4 112.6 ± 11.5 
0.157 0.445 
M 121.3 ± 5.0 115.3 ± 8.2 113.7 ± 8.2 111.3 ± 11.6 
All 117.7 ± 12.8 114.7 ± 11.6 114.0 ± 12.1 112.0 ± 11.0 
SBPe 
F 120.3 ± 16.8 117.6 ± 14.7 117.8 ± 16.2 117.5 ± 9.7 
0.659 0.992 
M 124.8 ± 6.7 122.1 ± 7.0 122.9 ± 8.2 121.0 ± 9.7 
All 122.3 ± 12.8 119.7 ± 11.5 120.1 ± 12.8 119.1 ± 9.4 
SBPΔ 
F -5.5 ± 2.3 -3.4 ± 6.3 -3.5 ± 6.2 -4.9 ± 3.4 
0.158 0.026 
M -3.5 ± 2.1 -6.9 ± 4.5 -9.2 ± 4.6 -9.6 ± 5.1 
All -4.6 ± 2.3 -5.0 ± 5.6 -6.1 ± 6.0 -7.0 ± 4.7 
DBP 
F 70.5 ± 10.3 70.0 ± 7.4 70.8 ± 10.5 70.4 ± 9.4 
0.412 0.592 
M 72.6 ± 7.7 67.6 ± 8.8 70.7 ± 8.9 69.3 ± 9.8 
All 71.4 ± 8.8 68.9 ± 7.7 70.7 ± 9.3 69.9 ± 9.1 
DBPi 
F 69.5 ± 10.2 70.0 ± 8.8 70.5 ± 11.6 69.8 ± 10.0 
0.326 0.232 
M 72.4 ± 7.6 66.3 ± 8.8 68.9 ± 8.5 67.2 ± 9.8 
All 70.8 ± 8.8 68.3 ± 8.6 69.8 ± 9.9 68.6 ± 9.5 
DBPe 
F 71.5 ± 10.5 70.0 ± 6.3 71.0 ± 9.6 71.0 ± 9.0 
0.482 0.886 
M 72.8 ± 7.7 68.9 ± 8.9 72.4 ± 9.4 71.3 ± 9.8 
All 72.1 ± 8.9 69.5 ± 7.2 71.7 ± 9.0 71.2 ± 8.9 
DBPΔ 
F -1.9 ± 1.1 -0.1 ± 4.1 -0.5 ± 3.2 -1.2 ± 2.0 
0.288 0.031 
M -0.4 ± 0.6 -2.6 ± 2.0 -3.5 ± 1.8 -4.1 ± 2.4 
All -1.2 ± 1.2 -1.2 ± 3.4 -1.9 ± 3.0 -2.5 ± 2.5 
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Table S4-8 Mean values (±SD) for heart rate (fc) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); heart rate (fc; beats.min-1); mean inspiration (i), mean expiration (e),  














F 63.6 ± 7.6 65.7 ± 8.0 67.6 ± 7.9 67.3 ± 8.8 
<0.001 0.999 
M 52.5 ± 4.8 54.5 ± 3.8 56.3 ± 6.1 56.2 ± 6.2 
All 58.6 ± 8.5†¤ 60.0 ± 8.5 62.4 ± 9.0* 62.3 ± 9.4* 
fci 
F 63.6 ± 6.9 68.0 ± 8.7 69.3 ± 9.2 69.4 ± 9.0 
<0.001 0.960 
M 52.0 ± 4.1 56.8 ± 3.4 58.5 ± 5.7 59.0 ± 6.2 
All 58.4 ± 8.2¥†¤ 62.9 ± 8.8* 64.4 ± 9.3* 64.7 ± 9.2* 
fce 
F 63.8 ± 8.5 63.4 ± 7.6 66.0 ± 7.4 65.2 ± 8.7 
0.125 0.921 
M 52.9 ± 5.7 52.2 ± 4.9 54.0 ± 7.6 53.3 ± 6.9 
All 58.8 ± 9.0 58.3 ± 8.5 60.5 ± 9.5 59.8 ± 9.8 
fcΔ 
F -0.1 ± 2.3 4.6 ± 3.1 3.3 ± 5.2 4.1 ± 2.4 
0.005 0.865 
M -0.9 ± 3.1 4.5 ± 3.6 4.5 ± 5.7 5.7 ± 4.2 
All -0.5 ± 2.6¥† 4.6 ± 3.2* 3.8 ± 5.2 4.9 ± 3.3* 
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Table S4-9 Mean values (±SD) for stroke volume (SV) and cardiac output (Q̇) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); stroke volume (SV; ml), cardiac output (Q̇; ml.min-1); mean inspiration 
(i), mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr 


















F 77.5 ± 14.7 74.8 ± 15.5 74.0 ± 13.8 75.1 ± 13.3 
0.027 0.205 
M 82.0 ± 13.8 79.1 ± 15.4 79.6 ± 13.6 74.5 ± 14.0 
All 79.6 ± 13.8 76.7 ± 14.8 76.6 ± 13.3 74.8 ± 12.9 
SVi 
F 75.3 ± 14.9 72.8 ±15.4 72.4 ± 12.7 72.8 ± 13.0 
0.013 0.232 
M 79.4 ± 14.3 76.4 ± 14.5 75.6 ± 13.3 71.4 ± 13.9 
All 77.1 ± 14.0 74.4 ± 14.4 73.9 ± 12.4 72.2 ± 12.8 
SVe 
F 79.7 ± 14.7 76.9 ± 15.6 75.7 ± 14.9 77.4 ± 13.7 
0.070 0.173 
M 84.6 ± 13.4 81.7 ± 16.6 83.6 ± 14.6 77.5 ± 14.4 
All 82.0 ± 13.6 79.0 ± 15.4 79.3 ± 14.6 77.4 ± 13.3 
SVΔ 
F -4.4 ± 1.5 -4.1 ± 1.2 -3.2 ± 3.1 -4.6 ± 2.4 
0.668 0.097 
M -5.3 ± 3.2 -5.2 ± 4.4 -8.0 ± 5.9 -6.1 ± 4.4 
All -4.8 ± 2.3 -4.6 ± 3.0 -5.4 ± 5.0 -5.3 ± 3.4 
Q̇ 
F 4985 ± 1311 4949 ± 1329 5007 ± 1190 5047 ± 1138 
0.454 0.271 
M 4274 ± 626 4274 ± 740 4436 ± 646 4135 ± 647 
All 4662 ± 1074 4642 ± 1107 4748 ± 982 4633 ± 1021 
Q̇i 
F 4845 ± 1266 4994 ± 1419 5047 ± 1288 5046 ± 1123 
0.122 0.746 
M 4093 ± 605 4325 ± 782 4397 ± 647 4187 ± 705 
All 4503 ± 1050 4690 ± 1172 4752 ± 1054 4656 ± 1015 
Q̇e 
F 5134 ± 1359 4893 ± 1253 4975 ± 1095 5052 ± 1156 
0.078 0.122 
M 4452 ± 701 4225 ± 728 4473 ± 779 4084 ± 636 
All 4824 ± 1116 4589 ± 1058 4747 ± 995 4612 ± 1042 
Q̇Δ 
F -289 ± 129 101 ± 329 72 ± 260 -6 ± 95 
0.001 0.642 
M -359 ± 388 99 ± 306 -75 ± 621 103 ± 355 
All -321 ± 265¥† 100 ± 303* 5 ± 441 44 ± 241* 
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Table S4-10 Mean values (±SD) for total peripheral resistance (TPR) and pulse 
transit time (PTT) 
Data represent mean ± SD (female n = 6, male n = 5); Female (F), Male (M); Spontaneous 
breathing (Sfr), RESPeRATE (Rfr), 6 breaths.minute-1 (6Ffr), optimisation algorithm dynamic 
breathing frequency (Dfr); total peripheral resistance (TPR; mmHg⋅min⋅L-1); pulse transit time 
(PTT; ms); mean inspiration (i), mean expiration (e), inter-breath phase difference (∆; i minus e); 












F 17.8 ± 3.9 17.9 ± 4.4 17.5 ± 3.1 17.3 ± 3.7 
0.612 0.643 
M 21.2 ± 4.3 20.3 ± 5.2 19.7 ± 2.8 20.9 ± 4.1 
All 19.3 ± 4.2 19.0 ± 4.7 18.5 ± 3.0 18.9 ± 4.1 
TPRi 
F 18.0 ± 4.0 17.7 ± 4.3 17.2 ± 3.0 17.1 ± 3.5 
0.098 0.473 
M 21.9 ± 4.9 19.6 ± 5.2 19.2 ± 2.9 19.9 ± 4.1 
All 19.8 ± 4.7 18.5 ± 4.6 18.1 ± 3.0 18.4 ± 3.9 
TPRe 
F 17.6 ± 3.9 18.3 ± 4.5 17.7 ± 3.2 17.6 ± 3.8 
0.554 0.526 
M 20.4 ± 3.8 21.0 ± 5.4 20.2 ± 3.1 21.8 ± 4.2 
All 18.9 ± 3.9 19.5 ± 4.9 18.8 ± 3.2 19.5 ± 4.4 
TPRΔ 
F 0.4 ± 0.7 -0.6 ± 0.8 -0.5 ± 1.1 -0.5 ± 0.6 
<0.001 0.051 
M 1.5 ± 1.9 -1.4 ± 1.4 -0.9 ± 2.0 -1.9 ± 1.5 
All 0.9 ± 1.4 -0.9 ± 1.2* -0.7 ± 1.5 -1.1 ± 1.3* 
PTT 
F 180 ± 23 183 ± 21 180 ± 21 183 ± 24 
0.445 0.269 
M 210 ± 27 212 ± 24 215 ± 27 210 ± 22 
All 193 ± 28 196 ± 26 196 ± 29 195 ± 26 
PTTi 
F 182 ± 24 185 ± 22 184 ± 23 183 ± 21 
0.499 0.695 
M 213 ± 29 215 ± 23 215 ± 23 217 ± 24 
All 196 ± 30 199 ± 26 198 ± 27 198 ± 27 
PTTe 
F 177 ± 22 180 ± 21 181 ± 24 177 ± 21 
0.646 0.167 
M 207 ± 26 209 ± 24 205 ± 22 211 ± 29 
All 191 ± 27 194 ± 26 192 ± 25 192 ± 30 
PTTΔ 
F 5.1 ± 2.7 4.7 ± 2.8 2.7 ± 6.8 6.4 ± 2.4 
0.827 0.208 
M 6.4 ± 3.5 5.3 ± 2.5 10.4 ± 4.6 5.5 ± 8.0 




This chapter has used novel methods of analysis for the first time that reveal the inter- 
and intra-breath phase responses to SDB. Previous research has focused on average 
changes during SDB and found mixed responses. However, cardio-respiratory 
interactions are complex and therefore require a deeper investigation of the full set of 
cardiovascular responses to SDB. Using this analysis, SDB was observed to cause an 
increase in the amplitude of BP oscillations. Both the amplitude of BP oscillations relative 
to mean BP, and RSA increased as breathing frequency decreased, to a maximum at 
the lowest breathing frequency. The lowest breathing frequency in this study was 6 
breaths.min-1 and future research should investigate if the amplitude of fluctuations could 
be increased further at lower breathing frequencies than those undertaken in the present 
study.  
 
The three SDB frequencies (RESPeRATE, dynamic algorithm and 6 breaths.min-1) 
produced similar cardiovascular responses, suggesting that alternative delivery methods 
of SDB could be used to reduce BP with daily SDB practice, using a cheaper alternative 
to RESPeRATE. There is also potential for the alternative methods to produce a further 
benefit due to the increased stimulus and duration the user experiences SDB 
frequencies, without waiting for breathing frequencies to reach the optimal of 6 
breaths.min-1. The higher breathing frequency during the first 5 min of the RESPeRATE 
trial (~ 8 breaths.min-1) may not elicit the full cardiovascular responses of SDB and 
therefore further investigation of the potential for differing responses to a range of 
different breathing frequencies is needed. Future studies should investigate a range of 
frequencies to track the cardiovascular responses from spontaneous normal breathing 
to different levels/frequencies of SDB. This will allow an evaluation of the optimal 
breathing frequency for cardiovascular responses based on maximising cardiovascular 
perturbations, including BP oscillations and RSA.  
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Chapter 5. Short-term cardiovascular responses to slow 




Regular practice of slow and deep breathing (SDB) can lower blood pressure in 
individuals with hypertension (Chaddha et al. 2019). Although significant reductions in 
blood pressures (BP) have been found (Zou et al. 2017) the mechanisms underpinning 
the anti-hypertensive effects of SDB remain poorly understood. To date, a limited number 
of studies have examined the acute cardiovascular responses to SDB, and there is a 
limited understanding of the cardiorespiratory interactions that might underpin the anti-
hypertensive effect of SDB. In particular, the systematic characterisation of the acute 
responses to a range of SDB frequencies is lacking; no published studies have examined 
discrete SDB frequencies, with the exception of an unpublished thesis (Vargas 2017). 
The studies that have compared acute responses to SDB at a range of frequencies have 
done so using a progressively decreasing SDB protocol, with only short durations at each 
individual SDB frequency (Anderson et al. 2009; Zhang et al. 2009). Although Guzik et 
al. (2007) did examine heart rate variability (HRV) and baroreflex sensitivity (BRS) during 
5 minute protocols of different SDB frequencies (6 and 9 breaths.min-1) by their own 
admission the authors did not focus on the physiological meaning of their findings. 
 
Whilst the extant literature suggests SDB at frequencies of ≤6 breaths.min-1 generates 
the greatest perturbation3 to the cardiovascular system, preliminary research suggests 
that the optimal perturbing frequency exhibits individual variation (Vargas 2017). Thus, 
implementing SDB at a personalised breathing frequency, which perturbs each 
individual’s cardiovascular system maximally, could elicit larger anti-hypertensive effects 
compared with a ‘one frequency fits all’ SDB model (Vargas 2017).  
 
Characterising the cardiovascular responses to a range of breathing frequencies, 
including a personalised frequency, may shed light on potential ‘error signals’ that are 
responsible for reducing BP following the daily practice of SDB. Chapter 4 also 
suggested the potential for BP oscillations to be further increased at levels <6 
breaths.min-1. As the increase in amplitude of BP during SDB was a novel finding, it has 
not previously been investigated at different SDB frequencies. Additionally, the data 
presented in Chapter 4 revealed differences in the cardiovascular response during the 
 
3 Perturbation means a disturbance or change in a structure or function, as a result of an external 
influence.  
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RESPeRATE condition between the first 5- and last 5-min, accompanied by a difference 
in breathing frequency of ~8 breaths.min-1 (first 5-min) and ~6 breaths.min-1 (last 5-min). 
However, whether the acute cardiovascular responses are different at higher SDB 
frequencies (between 6-10 breaths.min-1) has also not been investigated. 
 
Although the link between acute breathing-related cardiovascular perturbations and BP 
regulation remains unknown, the kidneys are known to be central to regulating BP 
(Levick 2013). Eight weeks of daily SDB has been shown to reduce renal resistive index 
(RRI; (Modesti et al. 2015), but it is not known whether there is an immediate change in 
RRI as a response to SDB. In addition to lowering breathing frequency, adding an 
inspiratory resistance to SDB has been shown to reduce BP to a greater extent than SDB 
alone in numerous studies (Jones et al. 2010; Vranish and Bailey 2015; DeLucia et al. 
2018; Ubolsakka‐Jones et al. 2019). 
 
In summary, the mechanisms by which SDB might reduce BP remain unknown. An 
essential first step towards addressing this deficit is gaining an understanding of the 
acute cardiovascular responses to SDB. The purpose of this study was therefore to 
characterise the acute cardiovascular responses to a variety of SDB conditions, including 
at a range of breathing frequencies and with added inspiratory resistance. The research 
questions, objectives and hypothesis for this study are outlined below: 
 
Research questions 
1. Using a novel peak-valley analysis method, what are the complex cardiovascular 
responses to SDB of healthy young women? 
2. Are there differences in the acute cardiovascular responses at a range of SDB 
frequencies for healthy young women? 
3. Does adding an inspiratory resistance to SDB amplify cardiovascular responses 
to SDB for healthy young women? 
4. Does SDB elicit acute changes in renal resistive index and/or indices of central 
blood pressure for healthy young women? 
 
Objectives 
1. Characterise the response of mechanism-related parameters (e.g. respiratory 
sinus arrythmia, stroke volume, cardiac output, blood pressures) during SDB for 
healthy young women. 
2. Characterise acute cardiovascular responses to a range of SDB frequencies in 
healthy young women. 
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3. Assess the acute responses of pulse wave velocity, central blood pressure 
parameters and renal resistive index to SDB for healthy young women. 
 
Hypothesis 
1. Peak-valley measures of cardiovascular parameters (respiratory sinus arrythmia, 
stroke volume and cardiac output) and the amplitude of blood pressure 
oscillations will increase during SDB for healthy young women. 
2. The amplitude of peak-valley fluctuations will increase as SDB frequency 
decreases for healthy young women. 
3. An inspiratory resistance will amplify the amplitude of cardiovascular fluctuations 
during SDB for healthy young women. 
4. Renal resistive index and central blood pressure measures will decrease in 
response to SDB for healthy young women. 
 
5.2 Specific Methods 
 
5.2.1 Participants 
Twenty-three female participants took part in the study from forty one participants who 
were assessed for eligibility (Figure 5-3). Participants were all of reproductive age as 
defined by the World Health Organization (2006) in order to match the age range of 
participants from Chapter 6 who were pregnant women. None of the participants in this 
chapter were known to be pregnant at the time of participating. As oral contraceptives 
and the phase of the menstrual cycle may influence BP responses to SDB (Fonkoue et 
al. 2018), these were tracked in our participants and analysed for significance.  
 
5.2.2 General Design 
Participants attended one session at the Cardiorespiratory Research Laboratory at 
Bournemouth University. Lab conditions were recorded for each session and averages 
for the study were 24.1 ± 2.9 oC (range 20.1–31.9 oC), 991.2 ± 7.3 hPa (975-1000 hPa), 
42.8 ± 11.4% (26-68%). Using a within-subject design, participants undertook the 
breathing conditions in a randomised order. Participants were asked to complete six 
breathing conditions; spontaneous breathing (Sfr), 4 (4Ffr), 6 (6Ffr), and 8 (8Ffr) 
breaths.min-1, optimisation algorithm (Dfr), and 6 breaths.min-1 with an added inspiratory 
resistance (IR). All breathing conditions were five-minutes in duration with a five-minute 
period of normal breathing prior to each measurement. The reduction in condition length 
to 5-minutes from the 10-minutes used in Chapter 4 was chosen partly to minimise the 
burden on participants by reducing the duration of the data collection session, due to the 
increase of adding 2 additional conditions compared with Chapter 4. This protocol 
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change was supported by the results of the RESPeRATE study (Chapter 4) which 
showed a steady state of breathing frequency and key BP variables before 5 minutes of 
SDB for all but the RESPeRATE condition which was not replicated in this study. As the 
study aims to explore the immediate responses to SDB, 10-minutes would have shown 
no additional responses and therefore would have been an unnecessary burden on 
participants. Additionally shorter durations of 5 minutes (compared with durations of 7 
and 9 min) produced the largest increase in HRV during SDB (Cheng et al. 2019).  Figure 
5-1 shows a schematic of the protocol.  
4FfrSfr 6Ffr 8Ffr Dfr IRRB R R RR
60 minutes





























































Figure 5-1 Schematic of protocol 
All breathing condition and recovery periods were 5-minutes in duration; spontaneous baseline 
breathing (B), rest periods (R), uncontrolled spontaneous breathing (Sf r), optimisation algorithm 
dynamic breathing frequency (Dfr), fixed breathing frequency of 4 breaths .minute-1(4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), inspiratory resistance (IR).  
 
An added inspiratory resistance of 9cm H2O (IR) was added to the optimal SDB 
frequency of 6 breaths.min-1 using a POWERbreathe Medic Plus (POWERbreathe 







Figure 5-2 Inspiratory resistance set-up (POWERbreathe Medic Plus) 
 
5.2.3 Equipment and procedures 
Respiratory airflow, ECG and arterial blood pressure (ABP) were monitored continuously 
throughout each breathing condition. Participants wore an oronasal mask (Oro Nasal 
7450 V2 Mask, Hans Rudolph Inc., Kansas, USA) and respired flow rate was measured 
continuously using a heated pneumotachograph (Model 3700, Hans Rudolph Inc., 
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Kansas, USA) connected to a flow measurement system (RSS 100-HR, Hans Rudolph 
Inc., Kansas, USA). End-tidal CO2 was not measured in this study as the results in 
Chapter 4 revealed no significant differences between SDB and spontaneous breathing 
conditions. 
 
Heart rate was monitored using a 3-lead ECG and non-invasive beat-to-beat ABP was 
obtained using finger photoplethysmography (Finapres NOVA, Finapres Medical 
Systems, The Netherlands). Finapres derived ABP was calibrated using a brachial cuff 
prior to and halfway through data collection. Analogue outputs from the Finapres NOVA 
and the flow meter were sampled continuously at 250Hz via an analogue to digital 
converter (NI USB-6218 BNC, National Instruments Inc.) and captured using bespoke 
acquisition and analysis software (LabView 2015, National Instruments, Inc.). For more 
detailed explanation of the data acquisition system see section 3.4. 
 
Additional measures of ABP, including pulse wave analysis (PWA) and pulse wave 
velocity (PWV), were recorded pre- and post- each breathing condition using a Vicorder 
(Vascular Complete Model, SMT Medical, Germany). PWA was measured using a 
brachial cuff and PWV using a neck and femoral cuff. The neck cuff was a 30mm pad 
that was placed at the level of the left carotid artery, and the femoral cuff a larger 
oscillometric cuff (100mm) that was placed around the uppermost section of the right 
thigh. PWV was calculated using the path length of sternal notch to the middle of the 
femoral cuff. 
 
Renal ultrasound was also performed pre- and post- each condition on a subsection of 
participants (n=10) to measure renal resistive index (RRI). Due to time constraints of the 
rest period between conditions, PWV was not measured for participants when ultrasound 
measures were recorded. Therefore, participants either had ultrasound or PWV 
measurements recorded, but PWA was recorded for all. To maintain consistency the 
renal ultrasound measures were always recorded following PWA measurements which 
were always measured first. The renal ultrasound measurements were undertaken by a 
trained sonographer. Doppler measurements of kidney blood flow were performed using 
a Terason t3200 (uSmart 3200T, Terason, Massachusetts, USA) with a curvilinear 
transducer (5C2, Terason, Massachusetts, USA). Three measurements were recorded 
for the right kidney during a breath hold and were averaged during analysis.  
 
5.2.4 Statistical analysis 
Values are expressed as means ± SD unless stated otherwise. Statistical analysis was 
undertaken using SPSS Statistics 24 (IBM Corp.). After normality was confirmed 
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(Shapiro Wilk) repeated measures ANOVA with planned pairwise comparisons using 
Bonferroni corrections were used. Pairwise comparisons were only viewed when the 
ANOVA reached significance. If the Mauchly’s sphericity condition was violated the 
Greenhouse-Geisser correction was applied. Reported p values are those following 
adjustment for repeated comparisons. For all analyses, P was set at 0.05. 
 
The Vicorder blood pressure measurements were calculated as follows for pulse wave 
analysis (PWA) and pulse wave velocity (PWV): 
 
Equation H: Augmentation Index (AIx) = (AP / AoPP) x 100 
Where AP is augmentation pressure and AoPP is aortic pulse pressure. 
 
Equation I: Heart rate adjusted Augmentation Index (AIx75) = (-0.48 x (75 – fc)) 
+ AIx 
Where fc is heart rate and AIx is Augmentation Index. 
 
Equation J: Pulse Wave Velocity (PWV) = path length / transit time 
Where path length was measured from sternal notch to mid femoral cuff.  
 
Renal resistive index (RRI) was calculated by the inbuilt Terason software using the 
following equation: 
 
Equation K: Renal resistive index (RRI) = (PS - ED) / PS 




Data were collected from 23 participants and 56% of women assessed for eligibility took 
part (Figure 5-3). Five participants were excluded from the analysis; three due to 
technical errors in the measurement of respiratory airflow, one due to a failure of the 
acquisition system to save the signal data, and one because the participant failed to 
adhere to the prescribed breathing condition. In addition, due to practical problems with 
implementing the added inspiratory resistance (IR), it was not possible to acquire an 
accurate respiratory airflow signal for 4 participants. Data from the 14 participants with a 
full data set revealed no significant difference between the IR and 6Ffr conditions for any 
variables, when examining pairwise comparisons following repeated measures ANOVA. 
Therefore, it was decided to exclude this condition (IR) from the data presented and 






Excluded (n = 18)
Chose not to take part (n = 12)
Not of reproductive age (n = 1)
Smoker/vaper (n = 4)
Hypertension (n = 1)
Excluded from analysis (n = 5)
Technical error respiratory 
airflow (n = 3)
Acquisition system failure (n = 1)
Noncompliance with breathing 




Figure 5-3 Flow chart for number of women who were assessed for eligibility and 
took part in the study 
*Due to problems with respiratory airflow signal for 4 participants, data from the inspiratory  
resistance (IR) condition was excluded from analysis and the n = 18 data analysed. 
 
Eighteen participants were included in data analysis (age 30.1 ± 8.8 years; stature 1.66 
± 0.5 m; mass 65.6 ± 10.3kg; BMI 23.9 ± 3.3kg/m2; systolic BP 113.9 ± 9.1 mmHg; 
diastolic BP 68.9 ± 8.0 mmHg). Seven participants were taking oral contraception and 
the average menstrual stage was 16.1 ± 10.1 days. Eight women were in the follicular 
phase of menstruation and nine in the luteal phase. There were no significant differences 
found between menstruation cycle phase or contraceptive use for respiratory sinus 
arrythmia (RSA) and for all SBP and DBP variables (p>0.05). 
 
5.3.1 Respiratory variables 
Table 5-1 provides an overview of the respiratory parameters for each condition. Duty 
cycle remained consistent throughout conditions. The optimisation algorithm (Dfr) 
computed the optimal breathing frequency to be 6.3 ± 1.1 breaths.min-1, which was not 
significantly different from 6Ffr (p>0.05). All other breathing conditions were significantly 
different from each for breathing frequency (p<0.001). 
 
Table 5-1 Respiratory parameters  
 Sfr 8Ffr Dfr 6Ffr 4Ffr 
fr  13.3 ± 2.1¥¤†§ 8.0 ± 0.0*¤†§ 6.3 ± 1.1*¥§ 6.0 ± 0.0*¥§ 4.0 ± 0.0*¥¤† 
VT 0.4 ± 0.2¥¤†§ 0.9 ± 0.4*†§ 1.0 ± 0.4* 1.1 ± 0.4*¥ 1.3 ± 0.4*¥ 
TI / TTOT 0.42 ± 0.0¥¤†§ 0.48 ± 0.0* 0.48 ± 0.0* 0.50 ± 0.1* 0.48 ± 0.0* 
Data represent mean ± SD (n = 18). Spontaneous breathing (Sfr), fixed breathing frequency of 4 
breaths.minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm 
dynamic breathing frequency (Dfr). Breathing frequency (fr) in breaths.min-1, tidal volume (VT) in 
L, duty cycle (TI /TTOT); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
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In accordance with the analysis groups outlined in Section 3.4.5 (Table 3-2) all results 
for each variable are grouped into mean and intra-breath phase responses (mean, mean 
i, mean e), inter-breath phase responses (Δ), peak-valley intra-breath phase (Δi, Δe), 
peak-valley inter-breath phase (ΔPV), and peak-valley breath phase independent 
(ΔPV_Ind). Unless stated otherwise, all data are mean values for the full 5-minute epoch. 
A reminder that a visual representation of these calculations can be found in section 
3.4.5 (Figure 3-6 page 71).  
 
5.3.2 Arterial blood pressures 
 
Mean and intra-breath phase responses 
There were no significant differences in mean SBP, DBP, pulse pressure (PP) or mean 
arterial pressure (MAP) between any of the breathing conditions (p>0.05; Table 5-2). 
There were also no significant difference for mean BP variables during inspiration 
(calculation 2, Figure 3-6) or mean BP variables during expiration (calculation 3 (Figure 
3-6) between breathing conditions (p>0.05). 
 
Inter-breath phase responses 
Inter-breath phase responses (i.e., difference between mean value during inspiration vs. 
mean value during expiration, calculation 4, Figure 3-6) were significantly different 
between breathing conditions for SBPΔ (p<0.001), DBPΔ (p<0.001), PPΔ (p=0.02) and 
MAPΔ (p<0.001; Table 5-2). At 4Ffr, SBPΔ, DBPΔ and MAPΔ were significantly different 
from all other conditions (p<0.01), and MAPΔ during 8Ffr was also significantly different 
















Table 5-2 Mean values (±SD) and inter-breath phase differences (Δ) for blood 
pressure variables (mmHg) 
Data represent mean ± SD (mmHg; n = 18). Spontaneous breathing (Sfr; average 13.3 
breaths.min-1), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 
breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing frequency (Dfr; average 6.3 
breaths.min-1); systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure 
(PP), mean arterial blood pressure (MAP); mean inspiration (i), mean expiration (e), inter-breath 
phase difference (∆; i minus e); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§);  
P<0.05. 
 
Peak-valley intra-breath phase responses 
Intra-breath phase fluctuations in SBPΔi, DBPΔi, and MAPΔi, as well as SBPΔe, DBPΔe, 
and MAPΔe, were significantly different between the Sfr and 8Ffr conditions and the 4Ffr, 
6Ffr and Dfr conditions (p<0.05; Table 5-3 & Figure 5-4). Following on from the analysis 
in Chapter 4, relative peak-valley intra-breath phase variables were calculated for Δi and 
Δe as a percentage of mean i and e for SBP and DBP (Figure 5-4). BP oscillations 
(relative Δi and Δe for both SBP and DBP) were significantly greater for the 4Ffr, 6Ffr and 
Dfr SDB conditions from both spontaneous (Sfr) and 8Ffr conditions, but not significantly 
different from each other. However, 8Ffr was also significantly greater than Sfr. 
 
Sfr 
13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr p value 
SBP 121.3 ± 17.6 118.0 ± 9.6 115.3 ± 19.9 119.8 ± 13.8 116.2 ± 10.5 0.481 
SBPi 118.9 ± 17.4 114.3 ± 9.8 112.3 ± 20.2 117.1 ± 14.7 116.5 ± 10.4 0.475 
SBPe 123.8 ± 17.8 121.8 ± 9.6 118.4 ± 20.0 122.7 ± 13.3 115.8 ± 11.1 0.200 
SBPΔ –4.9 ± 2.1§ –7.5 ± 3.4§ –6.0 ± 5.0§ –5.6 ± 5.2§ 0.7 ± 5.0*¥¤† <0.001 
 
DBP 74.7 ± 17.1 73.1 ± 7.3 67.5 ± 14.7 74.1 ± 11.4 69.8 ± 8.7 0.166 
DBPi 73.9 ± 17.3 71.8 ± 7.3 67.1 ± 15.4 73.6 ± 11.9 71.9 ± 9.0 0.286 
DBPe 75.5 ± 17.0 74.3 ± 7.3 68.0 ± 14.2 74.6 ± 11.1 67.7 ± 8.6 0.064 
DBPΔ –1.5 ± 1.0§ –2.5 ± 1.5§ –0.9 ± 3.4§ –1.0 ± 3.4§ 4.2 ± 3.3*¥¤† <0.001 
 
PP 46.6 ± 7.9 45.0 ± 7.9 47.8 ± 9.6 45.8 ± 7.3 46.4 ± 8.3 0.414 
PPi 45.0 ± 7.4 42.4 ± 7.5 45.3 ± 8.8 43.5 ± 7.2 44.6 ± 7.5 0.286 
PPe 48.2 ± 8.5 47.5 ± 8.3 50.4 ± 10.6 48.1 ± 7.7 48.1 ± 9.3 0.447 
PPΔ –3.4 ± 2.0 –5.1 ± 2.6 –5.1 ± 3.2§ –4.6 ± 2.8 –3.5 ± 2.9¤ 0.002 
 
MAP 88.7 ± 16.9 86.6 ± 7.2 81.9 ± 15.9 87.8 ± 11.7 83.7 ± 8.4 0.238 
MAPi 87.4 ± 17.0 84.6 ± 7.4 80.7 ± 16.5 86.7 ± 12.4 85.3 ± 8.8 0.346 
MAPe 90.0 ± 16.8 88.5 ± 7.1 83.1 ± 15.4 89.0 ± 11.2 82.1 ± 8.4 0.064 
MAPΔ –2.5 ± 1.1¥§ –4.0 ± 1.9*§ –2.5 ± 3.7§ –2.4 ± 3.8§ 3.2 ± 3.6*¥¤† <0.001 
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Figure 5-4 Blood pressure oscillations: Relative change of ΔI and ΔE for systolic 
blood pressure (A) and diastolic blood pressure (B) 
Systolic blood pressure (SBP), diastolic blood pressure (DBP); within inspiration difference (∆i),  
within expiration difference (∆e); Fixed breathing frequency (Ffr), Spontaneous breathing (Sfr), 
optimisation algorithm dynamic breathing frequency (Df r). Variable calculated as SBP∆i as a 
percentage of average SBP during inspiration, or equivalent during expiration and for DBP.  
 
Peak-valley inter-breath phase responses 
The within-breath peak-valley fluctuations of SBPΔPV, DBPΔPV, and MAPΔPV were 
significantly different between 4Ffr and all other conditions, except for SBPΔPV between 
Sfr and 4Ffr  (p<0.05; Table 5-3). There were no pairwise significant differences for peak-































FfR Δi FfR Δe
SfR Δi SfR Δe






























Table 5-3 Peak-valley differences (±SD) for blood pressure variables (mmHg) 
 
Sfr 
13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr p value 
SBPΔi 3.6 ± 1.7¥¤†§ 8.2 ± 2.9*¤†§ 12.8 ± 5.4*¥ 13.5 ± 4.6*¥ 15.5 ± 6.1*¥ <0.001 
SBPΔe 4.5 ± 2.5¥¤†§ 6.9 ± 2.7*¤†§ 10.2 ± 4.6*¥ 10.5 ± 4.6*¥ 12.1 ± 6.6*¥ <0.001 
SBPΔPV -8.6 ± 3.6 -13.1 ± 7.0§ -11.5 ± 13.6§ -15.3 ± 9.5§ 2.3 ± 18.4¥¤† 0.001 
SBPΔPV_Ind 15.0 ± 6.1 17.5 ± 5.6 19.1 ± 6.3 19.0 ± 5.1 17.4 ± 6.9 0.014 
 
DBPΔi 2.5 ± 1.2¥¤†§ 5.2 ± 1.8*¤†§ 8.8 ± 2.9*¥ 9.3 ± 3.1*¥ 10.0 ± 3.0*¥ <0.001 
DBPΔe 3.2 ± 1.6¥¤†§ 5.6 ± 2.1*¤†§ 7.6 ± 3.1*¥ 8.2 ± 3.2*¥ 8.8 ± 3.1*¥ <0.001 
DBPΔPV –4.0 ± 2.2¥§ –7.6 ± 2.0*§ –1.9 ± 11.2§ –3.4 ± 11.1§ 11.6 ± 7.3*¥¤† <0.001 
DBPΔPV_Ind 9.9 ± 4.4 10.6 ± 2.9 12.1 ± 3.3 12.1 ± 2.5 12.7 ± 3.3 0.014 
 
PPΔi 3.5 ± 1.6¥¤†§ 4.8 ± 2.3*†§ 6.0 ± 3.1*§ 6.3 ± 2.6*¥§ 9.2 ± 4.4*¥¤† <0.001 
PPΔe 4.0 ± 2.3†§ 5.8 ± 2.8§ 6.9 ± 4.3 7.0 ± 3.7* 8.8 ± 5.0*¥ <0.001 
PPΔPV –6.7 ± 4.2 –9.5 ± 5.9 –10.6 ± 7.0 –10.1 ± 6.7 –10.5 ± 7.4 0.034 
 
MAPΔi 2.3 ± 1.3¥¤†§ 5.8 ± 2.0*¤†§ 9.8 ± 3.5*¥ 10.3 ± 3.4*¥ 11.2 ± 3.7*¥ <0.001 
MAPΔe 3.1 ± 1.7¥¤†§ 5.5 ± 1.8*¤†§ 7.9 ± 3.0*¥ 8.4 ± 3.3*¥ 9.1 ± 3.9*¥ <0.001 
MAPΔPV –5.1 ± 1.9¥§ –9.1 ± 2.4*§ –4.8 ± 11.3§ -6.8 ± 10.8§ 7.8 ± 11.8*¥¤† <0.001 
Data represent mean ± SD (mmHg; n = 18). Spontaneous (Sfr; average 13.3 breaths .min-1), fixed 
breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr),  
optimisation algorithm dynamic breathing frequency (Df r; average 6.3 breaths .min-1); systolic 
blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), mean arterial blood 
pressure (MAP); within inspiration difference (∆i), within expiration difference (∆e), inter-breath 
phase peak-valley difference (∆PV), breath phase independent peak-valley difference (∆PV_Ind);  
Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
5.3.3 Heart rate and respiratory sinus arrhythmia 
 
Mean and intra-breath phase responses 
Mean heart rate (fc) did not differ significantly between conditions (Table 5-4 & Figure 
5-6A; p>0.05). Mean values for heart rate during inspiration (fci) during 4Ffr, 6Ffr and Dfr 
were significantly different from Sfr (p<0.01), and significantly different between 6Ffr and 
8Ffr (p<0.05). During expiration fce was significantly different between 8Ffr, and both 4Ffr 
and 6Ffr (p<0.01), and between 4Ffr and Sfr (p<0.01). 
 
Inter-breath phase responses 
fcΔ was significantly different between both Sfr and 8Ffr, and all other conditions (Table 
5-4; p<0.001).  
 
Peak-valley intra-breath phase responses 
All SDB conditions were significantly different from Sfr for fcΔi and fcΔe except for fcΔe 
between 4Ffr and Sfr. 
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Peak-valley inter-breath phase responses 
For the maximal within-breath fluctuation of fc (fcΔPV), Sfr was significantly different from 
all SDB conditions (p<0.01), and fcΔPV significantly different between 8Ffr and both 6Ffr 
and Dfr (Table 5-5; p<0.05). 
 
Respiratory sinus arrythmia (peak-valley inter-breath phase) 
Respiratory sinus arrythmia (RSA, i.e., the maximal amplitude of fc fluctuations) was 
significantly higher in all SDB conditions compared with Sfr (P<0.001; Table 5-5). In 
addition, RSA was significantly different between 8Ffr and both 6Ffr (p<0.001) and Dfr 
(p=0.019). RSA amplitude increased with decreasing frequency, reaching a zenith at ~6 
breaths.minute-1 (Figure 5-5). Although group mean RSA is similar for 4Ffr, 6Ffr and Dfr, 
the frequency at which peak RSA occurred differed between individuals, occurring during 
4Ffr for 9 participants, during Dfr for 6 participants and during 6Ffr for 3 participants. 
 
 
Figure 5-5 Respiratory sinus arrythmia (RSA) response to slow and deep 
breathing 
Values are mean ± SD; Spontaneous breathing (blue ◼; Sfr), fixed breathing conditions (black ⚫; 





























Table 5-4 Mean values (±SD) and inter-breath phase differences (Δ) for heart rate 
(fc), stroke volume (SV) and cardiac output (Q̇) variables 
Data represent mean ± SD (n = 18). Spontaneous breathing (Sfr; average 13.3 breaths .min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 6.3 breaths .min-1); heart  
rate (fc; beats.min-1), stroke volume (SV; ml), cardiac output (Q̇; ml.min-1); mean inspiration (i), 
mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr 
(*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
5.3.4 Stroke volume 
 
Mean and intra-breath phase responses 
The SV, SVi, SVe, and SVΔ did not differ between conditions (p>0.05; Table 5-5 & Figure 
5-6B). 
 
Peak-valley intra-breath phase responses 
However, peak-valley values for SVΔPV, SVΔi and SVΔe exhibited significant 
differences between conditions (p<0.001; Table 5-5). In particular, SVΔi was significantly 











6.3 breaths .min-1 
6Ffr 4Ffr p value 
fc 67.6 ± 10.9 70.7 ± 11.6 70.0 ± 11.0 70.0 ± 10.5 69.5 ± 10.3 0.091 
fci 67.0 ± 11.3¤†§ 72.5 ± 12.1† 74.4 ± 12.5* 74.4 ± 12.0*¥ 74.5 ± 11.0* <0.001 
fce 68.3 ± 10.6§ 68.5 ± 10.8†§ 65.8 ± 10.3 65.6 ± 9.2¥ 64.6 ± 10.1*¥ 0.002 
fcΔ –1.4 ± 1.4¥¤†§ 4.0 ± 2.9*¤†§ 8.6 ± 5.4*¥ 8.9 ± 4.9*¥ 9.9 ± 4.8*¥ <0.001 
 
SV 67.4 ± 19.8 66.7 ± 21.1 68.3 ± 21.3 66.2 ± 22.0 68.5 ± 18.4 0.539 
SVi 65.2 ± 19.7 63.5 ± 20.4 64.9 ± 20.4 63.1 ± 20.7 65.1 ± 18.1 0.366 
SVe 69.6 ± 20.0 69.9 ± 21.9 71.6 ± 22.4 69.3 ± 23.3 71.9 ± 18.9 0.490 
SVΔ –4.4 ± 2.9 –6.4 ± 3.6 –6.7 ± 4.6 –6.2 ± 4.4 –6.8 ± 3.5 0.188 
 
Q̇ 4441 ± 1047 4564 ± 1144 4633 ± 1097 4482 ± 1220 4632 ± 1017 0.530 
Q̇i 4247 ± 1018¤ 4476 ± 1181 4707 ± 1184* 4562 ± 1266 4737 ± 1096 0.026 
Q̇e 4639 ± 1083 4639 ± 1117 4566 ± 1034 4406 ± 1197 4527 ± 952 0.435 
Q̇Δ –392 ± 155¥¤†§ –163 ± 250*¤†§ 141 ± 307*¥ 156 ± 278*¥ 210 ± 264*¥ <0.001 
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Table 5-5 Peak-valley differences (±SD) for heart rate (fc), stroke volume (SV) and 
cardiac output (Q̇) variables 
Data represent mean ± SD (n = 18). Spontaneous breathing (Sfr; average 13.3 breaths .min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 6.3 breaths .min-1); heart  
rate (fc; beats.min-1), respiratory sinus arrhythmia peak/valley amplitude (RSA; s), stroke volume 
(SV; ml), cardiac output (Q̇; ml.min-1); within inspiration difference (∆i), within expiration difference 
(∆e), inter-breath phase peak-valley difference (∆PV), breath phase independent peak-valley  
difference (∆PV_Ind); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
5.3.5 Cardiac output 
 
Mean and intra-breath phase responses 
Lower breathing frequencies were associated with an inversion of the within-breath 
pattern of Q̇ (Figure 5-6C); at a breathing frequency of ~6 breaths.min-1 and lower (4Ffr, 
6Ffr & Dfr), Q̇i was higher than Q̇e. 
 
Inter-breath phase responses 
This produced significant differences for QΔ between all SDB conditions compared with 
Sfr, as well as between 8Ffr and all other conditions (p<0.05; Table 5-4). 
 
Sfr 
13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr p value 
fcΔi 5.4 ± 2.2¥¤†§ 14.4 ± 6.9* 15.5 ± 6.2* 15.5 ± 5.9* 15.9 ± 7.1* <0.001 
fcΔe 7.3 ± 3.2¥¤† 14.3 ± 6.0* 14.1 ± 8.4* 13.4 ± 6.7* 10.3 ± 8.3 <0.001 
fcΔPV –6.6 ± 5.1¥¤†§ 16.1 ± 8.9*¤† 20.7 ± 8.5*¥ 20.6 ± 7.5*¥ 21.1 ± 9.5* <0.001 
RSA 0.12 ± 0.05¥¤†§ 0.21 ± 0.07*¤† 0.25 ± 0.09*¥ 0.25 ± 0.08*¥ 0.25 ± 0.10* <0.001 
 
SVΔi 5.1 ± 2.0¤†§ 7.3 ± 3.9§ 7.1 ± 3.5*§ 7.7 ± 4.0*§ 11.8 ± 4.9*¥¤† <0.001 
SVΔe 5.6 ± 2.0¥¤†§ 8.2 ± 3.1*§ 8.9 ± 4.0*§ 9.2 ± 3.9* 13.5 ± 6.3*¥¤ <0.001 
SVΔPV –8.9 ± 4.2§ –13.1 ± 5.9§ –13.8 ± 6.4 –14.6 ± 6.4 –18.6 ± 6.4*¥ 0.001 
SVΔPV_Ind 11.9 ± 4.2§ 13.7 ± 5.9 13.6 ± 6.4 13.4 ± 6.4 16.2 ± 6.4* 0.027 
 
Q̇Δi 292 ± 119¥¤†§ 1092 ± 646* 1107 ± 561* 1129 ± 607* 1073 ± 474* <0.001 
Q̇Δe 414 ± 184¥¤†§ 831 ± 359* 840 ± 469* 787 ± 424* 747 ± 413* <0.001 
Q̇ΔPV –738 ± 203¤†§ –638 ± 1153¤†§ 402 ± 1268*¥ 493 ± 1208*¥ 903 ± 923*¥ <0.001 




Figure 5-6 Mean intra-breath phase heart rate (fc), stroke volume (SV) and 
cardiac output (Q̇) variables response to slow and deep breathing 
Data represent mean ± SD. Inspiratory (i: solid blue shapes), expiratory (e: open red shapes);  
uncontrolled spontaneous breathing (Sf r; ◼), fixed breathing frequencies (4Ffr, 6Ffr, 8Ffr; ⚫), 
optimisation algorithm dynamic breathing frequency (Df r; ⧫); A. heart rate (fc), B. stroke volume 
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5.3.6 Pulse transit time and pulse wave velocity 
 
Mean responses 
There were no significant differences between conditions for mean pulse transit time 
(PTT) or pulse wave velocity (PWV, p>0.05; Table 5-6). 
 
Inter-breath phase responses 
PTTΔ at 4Ffr was significantly different to during 6Ffr and 8Ffr (p<0.001), and significantly 
different between Dfr and 8Ffr (p<0.01; Table 5-6). PWV followed the same pattern 
(p<0.05) except there was no significant difference between 6Ffr and 8Ffr (p>0.05; Table 
5-6). 
 
Table 5-6 Mean values (±SD) and inter-breath phase differences (Δ) for pulse 
transit time (PTT) and pulse wave velocity (PWV) variables 
 
Sfr 
13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr p 
value 
PTT 187.2 ± 16.2 188.3 ± 19.3 185.6 ± 16.1 184.5 ± 16.8 184.3 ± 16.8 0.173 
PTTi 190.5 ± 16.2 192.8 ± 18.9§ 188.8 ± 16.8 188.3 ± 17.3 185.4 ± 17.6¥ 0.005 
PTTe 184.4 ± 16.3 184.0 ± 19.8 182.4 ± 15.5 180.7 ± 16.5 183.4 ± 16.2 0.440 
PTTΔ 6.2 ± 1.6§ 8.8 ± 3.9§ 6.4 ± 3.2§ 7.5 ± 3.7§ 2.0 ± 4.3*¥¤† <0.001 
 
PWV 4.6 ± 0.4 4.6 ± 0.4 4.7 ± 0.4 4.7 ± 0.4 4.7 ± 0.4 0.143 
PWVi 4.6 ± 0.4 4.5 ± 0.4§ 4.6 ± 0.4 4.6 ± 0.4 4.7 ± 0.4¥ 0.002 
PWVe 4.7 ± 0.4 4.7 ± 0.4 4.8 ± 0.4 4.8 ± 0.4 4.8 ± 0.4 0.472 
PWVΔ  –0.2 ± 0.1 –0.2 ± 0.1 –0.1 ± 0.1 –0.2 ± 0.1 –0.1 ± 0.2 0.030 
Data represent mean ± SD (n = 18). Spontaneous breathing (Sfr; average 13.3 breaths .min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 6.3 breaths .min-1); pulse 
transit time (PTT) in ms, pulse wave velocity (PWV) in m.s-1; mean inspiration (i), mean expiration 
(e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤),  
6Ffr (†), 4Ffr (§); P<0.05. 
 
Peak-valley intra-breath phase responses 
PWVΔI was significantly different during Sfr to all SDB conditions except 8Ffr (p0.05; 
Table 5-7). 
 
Peak-valley inter-breath phase responses 
The maximal inter-breath phase fluctuation of PWV (PWVΔPV) was significantly different 




Table 5-7 Peak-valley differences (±SD) for pulse transit time (PTT) and pulse 
wave velocity (PWV) variables 
Data represent mean ± SD (n = 18). Spontaneous breathing (Sfr; average 13.3 breaths .min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 6.3 breaths .min-1); pulse 
transit time (PTT) in ms, pulse wave velocity (PWV) in m.s-1; within inspiration difference (∆i), 
within expiration difference (∆e), inter-breath phase peak-valley difference (∆PV), breath phase 
independent peak-valley difference (∆PV_Ind); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤),  
6Ffr (†), 4Ffr (§); P<0.05. 
 
5.3.7 Total peripheral resistance 
 
There was no significantly difference in total peripheral resistance (TPR) between 
breathing conditions for any mean variables (TPR, TPRi, TPRe). For TPRΔPV, 6Ffr 
and Dfr were significantly different from spontaneous breathing (Sfr). 
 
Table 5-8 Mean values (±SD), inter-breath phase differences (Δ) and peak-valley 
differences for total peripheral resistance (TPR) 
Data represent mean ± SD (n = 18). Spontaneous breathing (Sfr; average 13.3 breaths .min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Dfr; average 6.3 breaths .min-1); total 
peripheral resistance (TPR) in mmHg⋅min⋅L-1; mean inspiration (i), mean expiration (e), inter-
breath phase difference (∆; i minus e), within inspiration difference (∆i), within expiration difference 
(∆e), inter-breath phase peak-valley difference (∆PV), breath phase independent peak-valley  




13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr p value 
PTTΔi 8.2 ± 2.5¤†§ 15.7 ± 10.3 18.1 ± 7.1* 19.0 ± 10.5* 17.0 ± 5.7* <0.001 
PTTΔe 11.0 ± 4.1¥¤† 17.2 ± 9.5* 16.8 ± 7.3* 17.1 ± 7.8* 15.0 ± 9.1 0.003 
PTTΔPV 13.1 ± 8.4¥¤† 24.5 ± 9.4* 23.0 ± 8.6* 25.3 ± 11.6* 11.2 ± 18.0 0.003 
  
PWVΔi 0.2 ± 0.1¥¤†§ 0.4 ± 0.2* 0.5 ± 0.2* 0.5 ± 0.2* 0.4 ± 0.1* <0.001 
PWVΔe 0.3 ± 0.1¥¤† 0.4 ± 0.2* 0.5 ± 0.2* 0.4 ± 0.2* 0.4 ± 0.2 0.001 
PWVΔPV  0.4 ± 0.1¥¤†§ –0.7 ± 0.5*† –0.6 ± 0.3*† 0.6 ± 0.3*¥§ –0.3 ± 0.5*† <0.001 
 
Sfr 
13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr p value 
TPR 21.5 ± 8.3 20.0 ± 3.7 18.3 ± 3.5 20.9 ± 5.4 18.8 ± 3.5 0.171 
TPRi 22.2 ± 8.6 20.0 ± 3.9 17.8 ± 3.6 20.2 ± 5.1 18.9 ± 3.8 0.084 
TPRe 20.8 ± 7.9 20.0 ± 3.5 18.8 ± 3.6 21.6 ± 5.7 18.8 ± 3.4 0.233 
TPRΔ 1.3 ± 1.1¥¤† 0.0 ± 1.1*¤† -1.0 ± 0.9*¥ -1.4 ± 1.3*¥ 0.0 ± 1.6 <0.001 
  
TPRΔi 1.8 ± 2.2¥†§ 4.0 ± 1.9* 3.0 ± 1.2 4.3 ± 2.4* 3.5 ± 1.7* <0.001 
TPRΔe 2.1 ± 2.0† 3.1 ± 1.4 2.8 ± 1.5 3.7 ± 2.3* 3.2 ± 1.3 0.020 
TPRΔPV  2.3 ± 3.8¤† 0.8 ± 4.7 -3.3 ± 2.7* -3.3 ± 5.1* 0.3 ± 4.8 <0.001 
TPRΔPV_Ind 6.0 ± 6.3 5.2 ± 2.1 4.4 ± 1.9 5.4 ± 2.7 4.1 ± 1.7 0.192 
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5.3.8 Central blood pressure 
Pre- vs. post- condition changes in blood pressures were extremely small and showed 
no significant differences between conditions for any measured parameter (p>0.05; 
Table 5-9). 
 
Table 5-9 Pre- vs. post- breathing condition differences in blood pressures and 
renal resistive index (RRI) 
 n Sfr 
13.3 breaths .min-1 
8Ffr Dfr 
6.3 breaths .min-1 
6Ffr 4Ffr 
SBP 18 -2.9 ± 8.7 4.8 ± 18.5 0.1 ± 6.7 -2.9 ± 7.9 -1.0 ± 9.0 
DBP 18 -1.9 ± 8.4 0.4 ± 12.5 -4.1 ± 5.9 -2.3 ± 10.8 0.3 ± 6.5 
PP 18 -1.0 ± 9.7 4.3 ± 13.4 4.2 ± 8.1 -0.6 ± 10.2 -1.3 ± 9.0 
AoSBP 18 -2.6 ± 9.5 3.5 ± 18.1 -0.7± 6.4 -2.8 ± 8.1 -1.0 ± 8.6 
AIx 17* 0.7 ± 4.1 0.5 ± 9.3 -3.5 ± 8.1 -0.3 ± 3.7 -0.7 ± 3.5 
AIx75 17* 1.5 ± 4.2 -0.1 ± 10.7 -3.8 ± 8.4 -0.9 ± 3.8 -0.4 ± 2.8 
PWV 9* -0.3 ± 0.8 -0.2 ± 0.4 -0.4 ± 0.6 -0.3 ± 0.4 -0.4 ± 0.7 
RRI 8 -0.03 ± 0.04 0.00 ± 0.03 0.00 ± 0.03 0.01 ± 0.02 -0.01 ± 0.04 
Data represent mean ± SD. Spontaneous breathing (Sfr; average 13.3 breaths .min-1), fixed 
breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr),  
optimisation algorithm dynamic breathing frequency (Dfr; average 6.3 breaths .min-1); Systolic 
blood pressure (SBP; mmHg), diastolic blood pressure (DBP; mmHg), aortic central systolic blood 
pressure (AoSBP; mmHg), pulse pressure (PP; mmHg), augmentation index (AIx; mmHg), pulse 
wave velocity (PWV; (m.s-1), renal resistive index (RRI). *1 participant’s data not recorded due to 
technical error. 
 
5.3.9 Renal resistive index 
 
Renal resistive index (RRI) showed no difference pre- and post- breathing conditions 
between any of the conditions (p>0.05; Table 5-9).  
 
Figure 5-7 displays mean heart rate (red line) calculated from the mean during a full 
breath phase (calculation 1, Figure 3-6), with beat-by-beat heart rate values (green line), 
to show the fluctuations of heart rate around mean breath values. 
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Figure 5-7 Example participant data: beat by beat and mean heart rate (fc) during 
spontaneous breathing (A) and fixed breathing frequency of 6 breaths.min-1 (B) 
Beat by beat heart rate (fc; green ⚫ ) and mean full breath cycle heart rate (red ◼) for A.) 
uncontrolled spontaneous breathing (Sfr), and B.) fixed breathing frequency at 6 
breaths.min-1 (6Ffr) during the third minute of data collection (120-180 seconds) for one 




The main finding of the study was that the influence of SDB is only revealed by a within-
breath analysis, using peak-valley analysis. The true magnitude of perturbations created 
by SDB are obscured when mean values for the entire breath are examined. This is 
demonstrated by the response of heart rate, which shows no significant effect of 
breathing frequency upon mean heart rate, but a marked effect of SDB for fcΔ, fcΔPV and 
RSA. Figure 5-7 illustrates this hidden response by presenting mean fc during Sfr and 











































rate is considered (red series) then the true fc response is obscured and averaged out of 
existence. In accordance with Nili et al. (2017) no influence of contraceptive pill or 
menstrual cycle phase was observed for the cardiovascular responses to SDB, 
supporting the use of the full data set for analysis, without separate analysis groups. 
 
In accordance with previous studies (Anderson et al. 2009; Zhang et al. 2009) the 
amplitude of RSA increased as breathing frequency declined. This was due to changes 
both in fci and fce, but without a significant change in mean heart rate (fc). Interestingly, 
although RSA plateaued at ~6 breaths.min-1, for 50% of participants maximum RSA 
occurred during 4Ffr. This supports the notion that individual differences exist in 
responsiveness to SDB and indeed Vargas (2017) found individual variation in the 
breathing frequency which produced the largest cardiovascular perturbations. Despite 
this, the individualised breathing condition used in this study (Dfr) did not produce 
significantly larger RSA values, or produce larger cardiovascular perturbations than the 
fixed breathing frequency of 6 breaths.min-1. An explanation may be that because the 
average frequency for Dfr was 6.3 breaths.min-1, and therefore was not significantly 
different from the fixed frequency of 6 breaths.min-1, Dfr could not produce a larger 
cardiovascular response as RSA was already maximised at this level. Dfr uses RSA to 
drive breathing frequency and therefore as the data shows that RSA maximises at ~6 
breaths.min-1 there was nothing to drive the algorithm to reduce breathing frequency 
further. Consequently, building on the results from Chapter 4, RSA was not further 
amplified at lower breathing frequencies and ~6 breaths.min-1 may the lowest breathing 
frequency to maximise perturbations, beyond which further increase in amplitude are not 
possible. The Dfr in Chapter 4 did produced peak RSA (0.21s) at 5.5 breaths.min-1, 
however peak RSA in Chapter 4 was lower than the peak RSA produced in the present 
study (0.25s), supporting the theory that peak RSA is produced ~6 breaths.min-1. 
 
The finding that mean BP values do not change during SDB is in agreement with results 
found previously in normotensive participants (Joseph et al. 2005), and supports the 
need for researchers to look beyond mean values, as BP oscillations exhibited significant 
increases during SDB. As mean ABP measured during SDB were not significantly 
different it is unsurprisingly that PWA and PWV measures were also found not to be 
significantly affected by SDB. The cardiovascular system seems to be able to maintain 
mean ABP during SDB, including at a central level (AoSBP), through the peripheral 
vasculature. AIx and AIx75 were found to decrease following SDB in children, with no 
change in PWV, however it should be noted that these values both increase with age 
(Calcaterra et al. 2014) and therefore direct comparisons are limited due to differing 
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baseline values. Higher baseline levels may influence the response to SDB and explain 
the lack of response observed in this study. 
 
No response of BP to SDB is discernible when mean values are examined, which 
accords with previous studies of normotensive individuals (Bernardi et al. 2002). 
However, the novel analytical approach used in this study revealed oscillations in ABP 
that were not apparent within the mean data in all variables. The intra-breath phase 
analyses undertaken in this study revealed fluctuations of SBP during inspiration (SBPΔi) 
of up to 13.3% (15.5 mmHg) and up to 10.4% (12.1 mmHg) during expiration (SBPΔe). 
During Sfr fluctuations in SBPΔi were only 3% (3.6 mmHg) and 3.6% (4.5 mmHg) in 
SBPΔe. This is mirrored in the response of DBP, with maximum changes of up to 13.9% 
(10 mmHg) during inspiration (DBPΔi) and up to 12.9% (8.8 mmHg) during expiration 
(DBPΔe). In comparison fluctuations in DBPΔi were 3.3% (2.5 mmHg) and 4.3% (3.2 
mmHg) in DBPΔe during Sfr. The largest amplitude of BP oscillations occurred during 
4Ffr showing that BP oscillations increase as breathing frequency reduces. Following the 
future research suggestions from Chapter 4, where the lowest breathing at 5.5 
breaths.min-1 produced the largest BP oscillations, this present study revealed that 
further reductions in breathing frequency to 4 breaths.min-1 are able to increase 
amplitude of BP oscillations further, unlike RSA. 
 
The SDB-induced amplification of fluctuations in both SBP & DBP, within inspiration and 
expiration, suggest that fluctuations in ABP are adequately minimised during normal 
breathing and to a certain extent at higher frequencies of SDB (8Ffr). However, at 
frequencies ≤6 breaths.min-1 BP fluctuations can no longer be managed by 
countermeasures and changes in other cardiovascular variables that stabilise ABP. In 
normal breathing conditions it is suggested the synchronisation of SV with heart rate 
stabilises ABP across breath phases (Elstad et al. 2018), as cardiac output is maintained 
across breath phases due to respiratory-induced changes in heart rate (RSA) 
counteracting the decrease in SV which occurs during inspiration (Elstad 2012). Within 
the SV/RSA synchronisation it is believed RSA is the main mechanism stabilising ABP, 
as MAP fluctuations are increased when RSA is removed using a parasympathetic 
blockade (Toska and Eriksen 1993). Through RSA’s relationship with cardiac output, 
RSA can influence oscillations in MAP (Elstad et al. 2011). The results in the present 
study show mean heart rate and RSA plateau ≤ 6 breaths.min-1 and therefore have 
potentially reached their maximum amplitude, meaning they can no longer contribute to 
system regulation and assist in maintaining cardiac output and therefore BP. Without 
being able to call on heart rate to buffer breathing-induced fluctuations in cardiac output, 
there are no control measures to prevent the larger fluctuations in BP caused by SDB as 
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seen in this study. Although mean BP is maintained, the fluctuations during breath 
phases (inspiration and expiration) are not controlled during SDB, and consequently the 
amplitude of BP oscillations increases.  
 
Research into resistant hypertension has utilised baroreceptor activation therapy, 
providing repeated stimulation of the baroreceptors, as a treatment method for high blood 
pressure (Cracchiolo et al. 2021). Baroreflex sensitivity has been observed to increase 
acutely during SDB (Guzik et al. 2007) and consequently SDB could use the same 
mechanisms for chronic BP reduction as baroreceptor activation therapy. The 
aforementioned increase in amplitude of BP oscillations could provide the stimulation of 
baroreceptors which is produced by electrical stimulation during baroreceptor activation 
therapy. Consequently, one mechanism contributing to the anti-hypertensive effect of 
SDB could be the acute intra-breath phase fluctuations in BP. In addition to the acute 
hemodynamic changes SDB extends the duration of both breath phases such that 
fluctuations with a fixed time constant are afforded longer to reach their peak, which 
would inevitably increases their amplitude, assuming the system has not yet reached its 
saturation point. For example, whilst breathing at 6Ffr, SBPi fluctuates from 110.8 to 
124.3mmHg and SBPe from 116.9 to 127.4mmHg. Oscillations in the cardiorespiratory 
system are lost in many diseases and therefore it is logical, but currently unproven, that 
re-establishing these fluctuations may be beneficial to numerous clinical conditions 
including hypertension (Elstad et al. 2018). In hypertension, following chronic adaptation, 
the body’s control circuits are adjusted to a higher set point (Wallbach and Koziolek 
2018). It is possible BP oscillations of the amplitude found in this study could be sufficient 
to create an ‘error signal’ that resets these circuits to a lower, more normal set point, 
reducing BP chronically. 
 
No significant differences in RRI were found, which also supports this study’s findings 
that responses to SDB are only visible in the inter- and intra-breath phase analysis, with 
mean values not reflecting the full cardiovascular response. This may be amplified by 
the technique needed to measure RRI (recorded during a breath hold), which negates 
any possible inter- and intra- breath responses to SDB. It seems that measuring 
variables during a breath hold, or as a full breath cycle mean, will be unlikely to reveal 
any cardiovascular responses to SDB. 
 
Previous research has suggested that breathing through an inspiratory resistance can 
increase cardiovascular perturbations (Vargas 2017). However, the present study found 
no significant differences for any cardiovascular variables between 6Ffr and the same 
frequency with an added IR. The lack of amplification of cardiovascular response with an 
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added resistance has been reported previously, with no added benefits of inspiratory 
resistance observed compared with breathing at the same SDB frequency (Nuckowska 
et al. 2019). Previous studies using IR to reduce BP following daily practice have 
included a control condition where participants are instructed to just breathe deeply 
without breathing frequency being measured to ensure compliance (Ubolsakka-Jones et 
al. 2017; Ubolsakka-Jones et al. 2018). Therefore, there is a question on whether the 
deep breathing control condition is fully optimising cardiovascular perturbations at an 
optimal SDB breathing frequency, without the inspiratory load, and therefore whether the 
inspiratory load is simply creating the optimal conditions to increase perturbations, in lieu 
of the optimal breathing frequency. This suggests that if breathing frequency is truly 
optimised at ~6 breaths.min-1 the cardiovascular perturbations are already maximised 
and that adding an inspiratory resistance produces no extra benefit, except in conditions 
where the breathing frequency has not reached optimal levels. 
 
Finally, when examining the differences between breathing at 8 breaths.min-1 and lower 
breathing frequencies, observations revealed significant differences between 8Ffr and 
other SDB conditions (4Ffr, 6Ffr, Dfr) for variables such as RSA and both absolute and 
relative BP oscillations. Nevertheless, 8Ffr was significantly different from Sfr, for most 
variables which showed a response to SDB conditions, revealing there was an 
attenuated response to SDB. However, cardiovascular fluctuations during 8Ffr were 
lessened compared with lower SDB breathing frequencies, suggesting that although 
there is a cardiovascular response to breathing at 8 breaths.min-1, it does not produce 
optimal conditions to produce maximum cardiovascular perturbations. This has a 
potential impact on the effectiveness of the RESPeRATE device, as within Chapter 4 it 
produced an average breathing frequency of ~8 breaths.min-1 in the first 5-min. The data 
from the present study therefore suggests that the first 5-min of RESPeRATE may not 
maximise cardiovascular perturbations and consequently alternative SDB conditions 
such as 6Ffr and Dfr could produce enhanced health benefits, as a result of  larger 




The data suggest that personalising breathing frequency during SDB using a method 
driven by RSA amplitude may not always maximise cardiovascular perturbations. 
However, the data confirm that SDB of ≤6 breaths.min-1 is needed to maximise the BP 
fluctuations that may provide the error signal underpinning the antihypertensive effects 
of regular practice of SDB. SDB frequencies ~8 breaths.min-1 produce attenuated 
responses to SDB and therefore interventions which utilise SDB at these levels may not 
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produce optimal results for health benefits compared with lower breathing frequencies. 
Analysis of the inter- and intra-breath phase fluctuations are vital to gaining an 
understanding of the true nature and magnitude of cardiovascular perturbations created 
by SDB. 
 
This study addressed the need to understand the cardiovascular responses in healthy 
young women and should be replicated in other populations who have clinically 
diagnosed hypertension. It will be important to investigate whether the responses to SDB 
are different in people who have higher resting BP. Specifically, a condition exists which 
is unique to pregnancy whereby high BP develops in previously healthy women; so-
called pregnancy-induced hypertension (PIH). These women often have no other 
confounding health variables that affects the researcher’s ability to pinpoint potential 
mechanisms of change, and therefore PIH is a logical next step to understanding the 
cardiovascular responses to SDB. However, given the physiological changes that 
pregnancy itself brings, it is important to understand how pregnancy per se influences 
the cardiovascular responses to SDB. Therefore, an understanding of how the 
physiological changes during pregnancy affect women’s cardiovascular responses to 
SDB in a normotensive population is needed, so that data is available to act as a baseline 




A full understanding of the complex cardiovascular responses of healthy non-pregnant 
women to SDB has now been completed. Due to the physiological differences and 
adaptations associated with pregnancy, as outlined in section 2.1 it is important to 
explore whether these adaptations influence the responses of pregnant women to SDB. 
Pregnancy increases heart rate, stroke volume, cardiac output, and these higher 
baseline levels may affect the ability of the body to respond acutely to the stimuli 
generated by SDB.  
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Chapter 6. Short-term cardiovascular responses to slow 




Breathing exercises are an integral part of most antenatal classes undertaken during 
pregnancy, where relaxation and deep breathing to support labour and manage 
contractions is taught. Additionally, practices that incorporate controlled breathing such 
as yoga and meditation are popular during pregnancy and produce health benefits 
associated with reducing stress levels, autonomic nervous system functioning and labour 
parameters (Curtis et al. 2012; Muthukrishnan et al. 2016). Initial evidence suggests 
yoga is well suited to pregnancy (Satyapriya et al. 2009), however robust randomised 
controlled trials (RCTs) are lacking in this area (Curtis et al. 2012) and it is not known 
which elements of yoga (exercise or breathing) cause the physiological adaptations that 
result in measurable health benefits. 
 
Slow and deep breathing (SDB), using biofeedback pacing is a new type of breathing 
exercise that has been used in the general population to reduce blood pressure (BP) 
when practiced daily (Chaddha et al. 2019; see Chapter 2.3). During pregnancy a 
specific type of hypertension can develop called pregnancy-induced hypertension (PIH). 
NICE (NICE: National Institute for Health and Care Excellence 2019b) define PIH as 
“new hypertension presenting after 20 weeks of pregnancy without significant 
proteinuria” and the only known cure for PIH is to give birth. Specific controlled SDB has 
not yet been evaluated as a treatment method for women who develop PIH, however a 
number of related studies indicate the potential for benefit. For example, muscle 
relaxation techniques (Jacobson method) and SDB to a non-specific range of 6-10 
breaths.min-1 performed daily for 4 weeks reduced both systolic BP and diastolic BP for 
pregnant women with PIH (Aalami et al. 2016). Although some studies found no direct 
change in BP following breathing exercise interventions, variables related to delivery 
(childbirth) were improved, including a 35% higher birth weight and 10% greater 
gestational age at delivery compared with the control group (Cullins et al. 2013). The 
greater gestational age at delivery is likely linked to the higher birth weight in the 
intervention group but this correlation was not examined or taken into consideration. It 
should also be noted that this study was not a randomised control trial. Consequently, 
confounding factors were unlikely to be evenly disrupted across groups and therefore it 
is not known whether participant characteristics in this group would be associated with a 
higher risk of pre-term birth or low birth weight. Other interventions, such as those 
including yoga, which includes elements of SDB, also reduce stress levels, improve 
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quality of life, autonomic nervous system functioning and labour parameters such as 
comfort, pain and delivery duration in pregnant women (Curtis et al. 2012). 
 
The mechanisms that lead to any anti-hypertensive effects of SDB in the general 
population are not fully understood, but preliminary research to understand the acute 
cardiovascular response to SDB was presented in Chapters 4 and 5. Understanding the 
immediate cardiovascular responses to SDB can provide an indication to the potential 
error signal(s) that could elicit BP reductions. The acute cardiovascular responses to 
SDB have been characterised in healthy women in Chapter 5, using novel inter- and 
intra-breath phase analyses. Among other variables, respiratory sinus arrythmia (RSA) 
was shown to be amplified significantly during SDB, as were the amplitude of BP 
oscillations. Increases in the amplitude of BP oscillations during SDB were only revealed 
by using within- and between-breath analyses. These revealed SDB induces BP 
oscillations across the respiratory cycle in the region of 5-10% for both SBP and DBP. 
Due to the known cardiovascular and respiratory changes that women experience during 
pregnancy (see section 2.1) the cardiovascular response to SDB may differ in pregnant 
women. 
 
It is not known whether differing haemodynamics and breathing mechanics between 
healthy non-pregnant and healthy pregnant women influence the response to SDB. It is 
important to understand the acute response of healthy pregnant women to SDB, before 
exploring the acute and chronic effects of SDB with women who develop PIH. The 
present study aims to characterise the acute cardiovascular response to SDB in healthy 
pregnant women, using a similar experimental design and novel inter- and intra-breath 
phase analysis used in Chapters 4 and 5 with healthy non-pregnant women. The 
research questions, objectives and hypothesis for this study are outlined below: 
 
Research questions 
1. Using a novel peak-valley analysis method, what are the complex cardiovascular 
responses to SDB of healthy pregnant women? 
2. Are there differences in the acute cardiovascular responses at a range of SDB 
frequencies for healthy pregnant women? 
 
Objectives 
1. Characterise the response of mechanism-related parameters (e.g. respiratory 
sinus arrythmia, stroke volume, cardiac output, blood pressures) during SDB for 
healthy pregnant women. 
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2. Characterise acute cardiovascular responses to a range of SDB frequencies in 
healthy pregnant women. 
 
Hypothesis 
1. Peak-valley measures of cardiovascular parameters (respiratory sinus arrythmia, 
stroke volume and cardiac output) and amplitude of blood pressure oscillations 
will increase during SDB for healthy pregnant women. 
2. The amplitude of peak-valley fluctuations will increase as SDB frequency 
decreases for healthy pregnant women. 
 
6.2 Specific Methods 
 
6.2.1 Participants 
Eighteen pregnant women participated in the study. Participants were recruited from 
local antenatal groups, Facebook groups, and events such as expectant parent 
evenings, ‘bump to baby’ shows and specialised markets selling second-hand baby and 
maternity related items. Specifically, the NCT (National Childbirth Trust) and other local 
antenatal groups promoted the study on social media and during their local antenatal 
classes. 
 
Participants were pregnant women at >20 weeks gestation at the time of data collection. 
This eligibility criterion was chosen to match the gestation in weeks of participants who 
are diagnosed with pregnancy-induced hypertension (planned participants for Chapter 
8).   All participants were also carrying singleton pregnancies due to the physiological 
differences associated with multiple pregnancies such as increased blood volume 
(Norwitz et al. 2005), heart rate, stroke volume, and increases in BP prominent after 20 
weeks gestation (Kametas et al. 2003), which may change the cardiovascular response 
to SDB. Multiple pregnancies may also require an increase in the use of the accessory 
muscles of respiration, which may affect the ability to perform SDB or change the 
respiratory-cardiovascular interactions (Norwitz et al. 2005). All women were nulliparous 
(never given birth to a live baby). For full inclusion and exclusion criteria see the general 
methods chapter (section 3.3.2). 
 
6.2.2 General Design 
Participants attended one session at the Cardiorespiratory Research Laboratory at 
Bournemouth University. Laboratory conditions were recorded for each session; 24.0 ± 
3.6 oC (range 19.1 – 28.6 oC), 994.3 ± 18.9 hPa (959 – 1050 hPa), 42.4 ± 9.7% (25 – 
61%). Using a within-subject design, participants performed the breathing conditions in 
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a randomised order. Participants completed five breathing conditions; spontaneous 
breathing, 4, 6 and 8 breaths.min-1 and a dynamic frequency controlled by an optimisation 
algorithm. All breathing conditions were five-minutes in duration with a five-minute period 
of normal breathing prior to each measurement. Participants performed the five breathing 
conditions in a randomised order (see Figure 6-1 for a schematic of the protocol). 
4FfrSfr 6Ffr 8Ffr DfrB R R RR
50 minutes














































Figure 6-1 Schematic of protocol 
All breathing condition and recovery periods were 5-minutes in duration; spontaneous baseline 
breathing (B), recovery periods (R), uncontrolled spontaneous breathing (Sf r), fixed breathing 
frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr),  
optimisation algorithm dynamic breathing frequency (Df r). 
 
Using a fetal monitor was considered to monitor the fetus during the study protocol but 
currently available equipment such as the Novii Wireless Patch System and Meridian 
M110 Fetal Monitor are only approved for monitoring fetus >36 weeks gestation. Study 
participants were recruited from 20 weeks gestation and therefore the majority of 
participants could not have been monitored under the equipment’s approved usage. 
Research during clinical trials has successfully monitored a fetus at 26 weeks, but given 
the investigator’s lack of clinical experience in midwifery and fetal monitoring it was 
decided that this could cause concern if monitoring of the fetus was not successful at 
these lower gestational ages. 
 
The intervention (SDB) was not considered to be a risk to the fetus. Controlled breathing 
is commonly taught during pregnancy, and breathing techniques such as Lamaze 
breathing specifically recommend slow breathing (Hughey et al. 1978). Yoga, which 
involves breathing are a controlled and slow rate, does not significantly change fetal 
heart rate compared with either rest or meditation (Gavin et al. 2020). Although breathing 
at a frequency of 7.5 breaths.min-1 for 10 minutes produced a decrease in fetal heart rate 
of 4.5 beats.min1 (Vasundhara et al. 2018), fetal heart rate did not reach levels of 
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bradycardia <110 beats.min1 which would be considered a sign of fetal distress. 
Additionally, feto-placental circulation and fetal cardiac function are not significantly 
affected by breathing conditions such as obstructive sleep apnoea (Robertson et al. 
2020).  
 
After completing the protocol, participants were asked which breathing condition they 
preferred. The question was framed in the context of choosing the breathing condition 
they would prefer to use if they were asked to perform the SDB daily at home until they 
gave birth. Following the data collection session participants submitted their antenatal 
appointment BP measurements up until they gave birth to ensure that no participants 
subsequently developed hypertension. The submitted BP measurements were recorded 
by their midwife during their routine antenatal appointments. The measurements were 
submitted via an online form (Online Surveys) or via e-mail. 
 
6.2.3 Equipment and procedures 
Respiratory airflow, ECG and arterial blood pressure (ABP) were monitored continuously 
throughout each breathing condition. Participants wore an oronasal mask (Oro Nasal 
7450 V2 Mask, Hans Rudolph Inc., Kansas, USA) and respired flow rate was measured 
continuously using a heated pneumotachograph (Model 3700, Hans Rudolph Inc., 
Kansas, USA), connected to a flow measurement system (RSS 100-HR, Hans Rudolph 
Inc., Kansas, USA).  
 
Heart rate was monitored using a 3-lead ECG and non-invasive beat-to-beat ABP was 
obtained using finger photoplethysmography (Finapres NOVA, Finapres Medical 
Systems, The Netherlands). Finapres derived ABP was calibrated using a brachial cuff 
prior to and halfway through data collection. Analogue outputs from the Finapres NOVA 
and the flow meter were sampled continuously at 250Hz via an analogue to digital 
converter (NI USB-6218 BNC, National Instruments Inc.) and captured using bespoke 
acquisition and analysis software (LabView 2015, National Instruments, Inc.). For more 
detailed explanation of the data acquisition refer to Chapter 3.4. 
 
6.2.4 Statistical analysis  
Values are expressed as means ± SD unless stated otherwise. Statistical analysis was 
undertaken using SPSS Statistics 25 (IBM Corp.). After normality (Shapiro Wilk) was 
confirmed repeated measures ANOVA with planned pairwise comparisons using 
Bonferroni corrections were used. Reported p values are those following adjustment for 





Data were collected from 18 participants. One participant was excluded as she failed to 
adhere to the prescribed breathing condition and therefore data are presented for 17 
participants (age 32.0 ± 5.4 years; stature 1.67 ± 0.8 m; mass 84.1 ± 13.4kg: systolic BP 
118.2 ± 7.7 mmHg; diastolic BP 71.9 ± 7.9 mmHg; gestational age 31.4 ± 5.2 weeks). 
Figure 6-2 presents a flow chart of the number of women who were excluded, withdrew 
and participated in the study, with 36% of women taking part after being assessed for 
eligibility. The 8 women who actively chose not to take part contacted the investigator to 
remove themselves from the list of potential participants. Half of these women did not 
give a reason for not taking part, 3 women chose not take part due to time constraints 






Excluded (n = 11)
Not first pregnancy (n = 5)
Gave birth/induced  (n = 2)
Cardiovascular problem (n = 2)
<20 weeks gestational age (n = 1)
Multiple pregnancy  (n = 1)
Excluded from analysis (n = 1)
Noncompliance with breathing 




Chose not to take part (n = 21)
Actively chose not to take part (n = 8)
No further contact after receiving 
Participant Information Sheet (n = 13)
 
Figure 6-2 Flow chart of pregnant women who participated, were excluded, and 
withdrew  
Note: One women is duplicated in the above numbers, she was excluded for not being above 20 
weeks gestation at first contact, she subsequently suffered a miscarriage and participated in the 
study during a subsequent pregnancy. 
 
6.3.1 Recruitment 
The majority of the women were made aware of the study through Facebook (Figure 
6-3). However, the investigator (MF) conducted a number of public engagement events 
such as the Dorset Bump 2 Baby Show and attended antenatal workshops in person. 
128 
 
Figure 6-3 Source of participant recruitment 
n = 18. National Childbirth Trust (NCT), Antenatal workshop is a local series of workshops for 
expectant mothers and their partners. Other includes women where the source of recruitment  
was unknown, i.e. unknown leaflet and through word of mouth with unknown origin. 
  
Despite high engagement with the Facebook groups, only 43% of women who made 
contact following a Facebook promotional post took part in the study. Additionally, only 
20% of women who provided their contact details at the Dorset Bump 2 Baby Show took 
part in the study, with 60% not engaging in any further contact after the event.  
 
6.3.2 Normative respiratory and cardiovascular data during pregnancy 
 
Due to the lack of normative respiratory and cardiovascular data during pregnancy, Table 
6-1 presents average cardiovascular data for 17 pregnant participants during the 5-min 
spontaneous breathing condition (Sfr). 
 
Table 6-1 Normative respiratory and cardiovascular data in pregnancy 
Cardiovascular variable Average 
Breathing f requency (breaths.minute-1) 14.2 ± 2.7 
Tidal volume (L) 0.8 ± 0.5 
Systolic blood pressure (mmHg) 122.1 ± 12.5 
Diastolic blood pressure (mmHg) 74.5 ± 10.2 
Pulse pressure (mmHg) 47.6 ± 6.0 
Mean arterial pressure (mmHg) 88.8 ± 10.6 
Heart rate (beats.min-1) 80.7 ± 10.1 
Stroke volume (ml) 82.3 ± 9.8 
Cardiac output (l.min-1) 6.6 ± 0.9 
Pulse wave velocity (m.s-1) 5.1 ± 0.5 
Normative respiratory and cardiovascular data from spontaneous breathing condition (Sfr; 5-min 












6.3.3 Respiratory variables 
Seventeen participants were included in the data analysis. Table 6-2 provides an 
overview of the respiratory parameters for each condition. Duty cycle (TI / TTOT) remained 
consistent throughout conditions. The optimisation algorithm (Dfr) produced a 
significantly different breathing frequency from all other breathing conditions (p<0.001) 
with the optimum (maximal RSA) occurring at a breathing frequency of 7.0 ± 1.1 
breaths.min-1. All other breathing conditions were significantly different from each other. 
 
Table 6-2 Respiratory parameters  
 Sfr 8Ffr Dfr 6Ffr 4Ffr 
fr 14.2 ± 2.7¥¤†§ 8.0 ± 0.1*¤†§ 7.0 ± 1.1*¥†§ 6.0 ± 0.0*¥¤§ 4.0 ± 0.0*¥¤† 
VT 0.8 ± 0.5¤†§ 1.1 ± 0.3§ 1.1 ± 0.3*§ 1.5 ± 0.7* 1.6 ± 0.6*¥¤ 
TI / TTOT 0.54 ± 0.4 0.52 ± 0.2 0.48 ± 0.1 0.47 ± 0.0 0.56 ± 0.3 
Data represent mean ± SD (n = 17). Spontaneous breathing (Sfr), fixed breathing frequency of 4 
breaths.minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm 
dynamic breathing frequency (Dfr). Breathing frequency (fr; breaths.min-1), tidal volume (VT; L), 
duty cycle (TI /TTOT); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
Breathing frequency during the Sfr condition was not correlated with gestational age 
(R2=0.14) and neither was the average optimal breathing frequency based on RSA 
maximisation (Dfr; R2=0.11). 
 
6.3.4 Arterial blood pressures 
 
Mean and intra-breath phase responses 
 
There were no significant differences in mean systolic blood pressure (SBP), diastolic 
blood pressure (DBP), pulse pressure (PP) or mean arterial pressure (MAP) between 
any of the breathing conditions (p>0.05; Table 6-3). However, for Dfr and 6Ffr, mean DBP 
and MAP during expiration were significantly lower than Sfr (p=0.021).  
 
Inter-breath phase responses 
 
Inter-breath phase responses (i.e., difference between mean value during inspiration vs. 
mean value during expiration, calculation 4, Figure 3-6) were significantly different 
between breathing conditions for SBPΔ (p<0.001), DBPΔ (p<0.001) and MAPΔ 
(p<0.001). All SDB breathing conditions less than 8 breaths.min-1 were significantly 




Table 6-3 Mean values (±SD) and inter-breath phase differences (Δ) for blood 
pressure variables (mmHg) 
Data represent mean ± SD (mmHg; n = 17). Spontaneous breathing (Sfr; average 14.2 
breaths.min-1), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 
breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing frequency (Dfr; average 7.0 
breaths.min-1); systolic blood pressure (SBP; mmHg), diastolic blood pressure (DBP; mmHg),  
pulse pressure (PP; mmHg), mean arterial blood pressure (MAP; mmHg); mean inspiration (i), 
mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr 
(*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
Peak-valley intra-breath phase responses 
 
Percentage change BP oscillations were calculated during inspiration, producing relative 
intra-breath phase peak-valley differences (Δi) as a percentage of average BP during 
inspiration (i). The equivalent analysis for variables during expiration were also 
calculated. There were significant increases in the amplitude of BP oscillations during all 




14.2 breaths .min-1 
8Ffr Dfr 
7.0 breaths .min-1 
6Ffr 4Ffr p value 
SBP 122.1 ± 12.5 117.1 ± 17.4 115.4 ± 13.9 117.1 ± 10.7 117.2 ± 15.8 0.347 
SBPi 119.8 ± 12.5 115.6 ± 18.1 114.9 ± 14.4 118.0 ± 11.5 118.7 ± 15.5 0.519 
SBPe 124.3 ± 12.5 118.5 ± 16.8 116.0 ± 13.8 116.3 ± 10.3 115.7 ± 16.3 0.062 
SBPΔ -4.5 ± 1.8¤†§ -2.9 ± 3.8†§ -1.1 ± 4.1*†§ 1.7 ± 4.7*¥¤ 3.0 ± 2.2*¥¤ 0.000 
 
DBP 74.5 ± 10.2 73.2 ± 12.8 69.7 ± 10.3 71.6 ± 7.3 71.3 ± 12.3 0.289 
DBPi 73.2 ± 9.9 72.4 ± 13.2 69.9 ± 10.7 72.9 ± 7.9 72.9 ± 12.0 0.561 
DBPe 75.8 ± 10.4¤† 74.1 ± 12.4 69.5 ± 10.0* 70.3 ± 7.0* 69.7 ± 7.0 0.021 
DBPΔ -2.5 ± 0.9¤†§ -1.7 ± 1.8¤†§ 0.3 ± 2.1*¥†§ 2.6 ± 2.5*¥¤ 3.2 ± 2.2*¥¤ <0.001 
 
PP 47.6 ± 6.0 43.8 ± 7.5 45.8 ± 6.9 45.6 ± 7.7 45.8 ± 6.1 0.232 
PPi 46.6 ± 6.2 43.2 ± 7.8 45.1 ± 6.7 45.1 ± 8.0 45.7 ± 6.3 0.255 
PPe 48.6 ± 6.0 44.5 ± 7.5 46.4 ± 7.4 46.0 ± 7.6 46.0 ± 6.1 0.187 
PPΔ -1.9 ± 1.5§ -1.2 ± 2.4 -1.4 ± 3.0 -0.9 ± 2.8 -0.2 ± 2.1* 0.015 
 
MAP 88.8 ± 10.6 86.4 ± 13.9 83.4 ± 11.1 85.2 ± 7.7 85.1 ± 13.2 0.322 
MAPi 87.2 ± 10.4 85.3 ± 14.4 83.4 ± 11.5 86.4 ± 8.4 86.7 ± 12.8 0.569 
MAPe 90.3 ± 10.7¤† 87.4 ± 13.4 83.5 ± 10.8* 84.1 ± 7.4* 83.5 ± 13.6 0.030 




Figure 6-4 Blood pressure oscillations: Relative change of ΔI and ΔE for systolic 
blood pressure (A) and diastolic blood pressure (B) 
Systolic blood pressure (SBP), diastolic blood pressure (DBP); within inspiration difference (∆i),  
within expiration difference (∆e); Fixed breathing frequency (Ffr), Spontaneous breathing (Sfr), 
optimisation algorithm dynamic breathing frequency (Df r). Variable calculated as SBP∆i as a 
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7.0 breaths .min-1 
6Ffr 4Ffr p 
value 
SBPΔi 3.4 ± 1.5¥¤†§ 9.1 ± 2.6*¤† 11.2 ± 3.7*¥ 11.7 ± 3.8*¥ 12.9 ± 4.9* <0.001 
SBPΔe 3.7 ± 1.6¥¤†§ 7.4 ± 2.5*¤† 9.0 ± 2.4*¥ 9.7 ± 3.0*¥ 11.7 ± 6.1* <0.001 
SBPΔPV -7.7 ± 2.6§ -8.5 ± 9.0§ -3.7 ± 13.1§ 0.8 ± 14.7§ 12.3 ± 9.8*¥¤† <0.001 
SBPΔPV_Ind 12.9 ± 4.7§ 13.9 ± 3.7 15.9 ± 3.1 15.9 ± 3.8 17.6 ± 6.0* 0.033 
 
DBPΔi 1.8 ± 0.8¥¤†§ 6.6 ± 2.2* 7.7 ± 2.7* 7.5 ± 3.5* 7.6 ± 3.1* <0.001 
DBPΔe 2.7 ± 1.3¥¤†§ 6.7 ± 2.2*† 7.6 ± 1.8* 8.3 ± 2.2*¥ 9.9 ± 4.0* <0.001 
DBPΔPV -4.6 ± 1.7†§ -6.1 ± 6.7†§ 0.7 ± 9.3§ 5.3 ± 9.1*¥ 11.4 ± 3.4*¥¤ <0.001 
DBPΔPV_Ind 7.9 ± 2.8†§ 9.7 ± 2.8 10.3 ± 2.4 10.4 ± 2.7* 12.8 ± 5.5* 0.005 
 
PPΔi 2.9 ± 1.1¤†§ 4.1 ± 1.5†§ 4.9 ± 1.6*§ 5.6 ± 1.8*¥§ 7.8 ± 3.0*¥¤† <0.001 
PPΔe 2.7 ± 1.2¥¤†§ 4.4 ± 1.8*§ 4.9 ± 1.5* 5.1 ± 1.4* 6.4 ± 1.9*¥ <0.001 
PPΔPV -3.9 ± 3.3 -2.3 ± 6.5 -2.6 ± 7.4 -2.2 ± 7.7 0.3 ± 9.1 0.111 
 
MAPΔi 2.0 ± 1.0¥¤†§ 7.2 ± 2.3*¤ 8.6 ± 2.9*¥ 8.6 ± 3.5* 8.8 ± 3.6* <0.001 
MAPΔe 2.8 ± 1.3¥¤†§ 6.6 ± 2.1*¤† 7.8 ± 1.9*¥ 8.5 ± 2.5*¥ 10.1 ± 4.6* <0.001 
MAPΔPV -5.3 ± 1.8†§ -6.7 ± 7.1†§ -1.6 ± 10.1§ 3.6 ± 10.8*¥ 11.9 ± 3.7*¥¤ <0.001 
Data represent mean ± SD (mmHg; n = 17). Spontaneous (Sfr; average 14.2 breaths.min-1), fixed 
breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr),  
optimisation algorithm dynamic breathing frequency (Df r; average 7.0 breaths.min-1); systolic 
blood pressure (SBP; mmHg), diastolic blood pressure (DBP; mmHg), pulse pressure (PP; 
mmHg), mean arterial blood pressure (MAP; mmHg); within inspiration difference (∆i), within 
expiration difference (∆e), inter-breath phase peak-valley difference (∆PV), breath phase 
independent peak-valley difference (∆PV_Ind); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤),  
6Ffr (†), 4Ffr (§); P<0.05. 
 
6.3.5 Heart rate and respiratory sinus arrythmia 
 
For fcΔ, all SDB conditions except 4Ffr were significantly higher than Sfr (p<0.001; Table 
6-5).  
 
Respiratory sinus arrythmia (peak-valley inter-breath phase) 
Respiratory sinus arrythmia (RSA) was significantly higher for all SDB conditions 
compared with Sfr (p<0.001; Figure 6-5). 
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Figure 6-5 Respiratory sinus arrythmia (RSA) response to slow and deep 
breathing 
Values are mean ± SD; Spontaneous breathing (blue ◼; Sfr), fixed breathing conditions (black ⚫; 
Ffr) Brythm algorithm (green ⧫; Dfr); respiratory sinus arrhythmia (RSA). 
 
Table 6-5 Mean values (±SD) and inter-breath phase differences (Δ) for heart rate 
(fc), stroke volume (SV) and cardiac output (Q̇) variables 
 
Sfr 
14.2 breaths .min-1 
8Ffr Dfr 
7.0 breaths .min-1 
6Ffr 4Ffr p value 
fc 80.7 ± 10.1 82.6 ± 9.8 80.3 ± 9.3 81.7 ± 8.6 79.9 ± 8.4 0.123 
fci 80.4 ± 10.5¥¤† 85.2 ± 10.0* 83.9 ± 8.8* 85.1 ± 7.5* 82.1 ± 7.3 <0.001 
fce 80.9 ± 9.8 79.7 ± 9.8 76.4 ± 10.1 78.1 ± 10.0 77.7 ± 9.9 0.009 
fcΔ -0.5 ± 2.4¥¤† 5.5 ± 3.3* 7.4 ± 4.7* 7.0 ± 5.0* 4.3 ± 5.1 <0.001 
 
SV 82.3 ± 9.8 81.4 ± 10.4 82.5 ± 10.0 82.7 ± 9.2 83.1 ± 10.2 0.920 
SVi 80.3 ± 9.5 80.9 ± 10.5 81.9 ± 9.9 82.3 ± 9.2 82.7 ± 10.0 0.640 
SVe 84.2 ± 10.3 81.8 ± 10.8 83.0 ± 10.8 83.1 ± 9.9 83.5 ± 10.7 0.854 
SVΔ -3.9 ± 3.0 -0.9 ± 4.2 -1.1 ± 5.7 -0.8 ± 4.9 -0.7 ± 4.2 0.027 
 
Q̇ 6596 ± 923 6652 ± 1075 6564 ± 981 6706 ± 1027 6573 ± 863 0.728 
Q̇i 6427 ± 953¥¤† 6858 ± 1090* 6855 ± 1034* 6995 ± 990* 6749 ± 884 0.001 
Q̇e 6765 ± 913¤§ 6447 ± 1077 6268 ± 958* 6427 ± 1079 6399 ± 864* 0.003 
Q̇Δ -339 ± 286¥¤†§ 411 ± 278*¤ 588 ± 351*¥ 568 ± 238*§ 350 ± 257*† <0.001 
Data represent mean ± SD (n = 17). Spontaneous breathing (Sfr; average 14.2 breaths.min-1),  
fixed breathing frequency of 4 breaths.minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 7.0 breaths.min-1); heart  
rate (fc; beats.min-1), stroke volume (SV; ml), cardiac output (Q̇; ml.min-1); mean inspiration (i), 
mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr 




















6.3.6 Stroke volume and cardiac output 
 
Stroke volume (SV) showed no significant differences between breathing conditions for 
any mean or intra-breath phase variables (p>0.05; Table 6-5). All SDB conditions were 
significantly different from Sfr for SVΔi and SVΔe (p<0.001; Table 6-6). All SDB 
conditions were significantly different from Sfr for all cardiac output peak-valley measures 
(Q̇Δi, Q̇Δe, Q̇ΔPV; p<0.001). 
 
Table 6-6 Peak-valley differences (±SD) for heart rate (fc), stroke volume (SV) and 
cardiac output (Q̇) variables 
 
Sfr 
14.2 breaths .min-1 
8Ffr Dfr 
7.0 breaths .min-1 
6Ffr 4Ffr p value 
fcΔi 4.5 ± 2.9¥¤†§ 8.4 ± 5.0* 9.3 ± 5.2* 9.6 ± 5.8* 11.3 ± 5.7* <0.001 
fcΔe 6.1 ± 4.4¥¤ 10.5 ± 5.2* 9.9 ± 4.6* 9.7 ± 4.0 11.0 ± 6.0 0.004 
fcΔPV -3.1 ± 7.4¥¤†§ 13.4 ± 6.8* 15.3 ± 7.8* 15.1 ± 6.8* 11.2 ± 12.7* <0.001 
RSA 0.07 ± 0.05¥¤†§ 0.13 ± 0.08* 0.15 ± 0.09* 0.15 ± 0.09* 0.15 ± 0.09* <0.001 
 
SVΔi 5.8 ± 2.0 ¥¤†§ 9.0 ± 2.8 *†§ 10.7 ± 3.7 *§ 11.0 ± 3.3 *¥§ 15.3 ± 5.0 *¥¤† <0.001 
SVΔe 5.2 ± 1.9 ¥¤†§ 7.9 ± 2.3 *§ 9.2 ± 2.3 *§ 9.6 ± 2.3 *§ 12.5 ± 3.7 *¥¤† <0.001 
SVΔPV -8.0 ± 6.5 -2.9 ± 12.1 -3.4 ± 15.1 -1.7 ± 14.8 -0.4 ± 17.7 0.119 
SVΔPV_Ind 13.0 ± 4.0§ 13.4 ± 4.1§ 15.5 ± 5.6 15.6 ± 4.6 18.0 ± 5.2*¥ 0.002 
 
Q̇Δi 586 ± 293¥¤†§ 1151 ± 348* 1340 ± 468* 1292 ± 422* 1453 ± 300* <0.001 
Q̇Δe 563 ± 265¥¤†§ 920 ± 243* 1012 ± 336* 1040 ± 355* 1164 ± 479* <0.001 
Q̇ΔPV -745 ± 663¥¤†§ 1181 ± 732* 1432 ± 870* 1431 ± 842* 1452 ± 901* <0.001 
Q̇ΔPV_Ind 1198 ± 341 1382 ± 302 1602 ± 553 1496 ± 373 1426 ± 282 0.006 
Data represent mean ± SD (n = 17). Spontaneous breathing (Sfr; average 14.2 breaths.min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Dfr; average 7.0 breaths.min-1); heart  
rate (fc; beats.min-1), respiratory sinus arrhythmia peak/valley amplitude (RSA; s), stroke volume 
(SV; ml), cardiac output (Q̇; ml.min-1); within inspiration difference (∆i), within expiration difference 
(∆e), inter-breath phase peak-valley difference (∆PV), breath phase independent peak-valley  
difference (∆PV_Ind); Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
6.3.7 Pulse wave velocity and total peripheral resistance 
 
Pulse wave velocity (PWV) and total peripheral resistance (TPR) were not significantly 
different for mean variables (Table 6-7). Peak-valley TPR (TPRΔ) was significantly 




Table 6-7 Mean values (±SD) and inter-breath phase differences (Δ) for pulse 





7.0 breaths .min-1 
6Ffr 4Ffr p value 
PWV 5.1 ± 0.5 5.1 ± 0.5 5.0 ± 0.4 5.0 ± 0.5 5.0 ± 0.5 0.081 
PWVi 5.0 ± 0.5 5.0 ± 0.6 4.9 ± 0.4 5.0 ± 0.5 5.0 ± 0.5 0.205 
PWVe 5.2 ± 0.5†§ 5.1 ± 0.5† 5.1 ± 0.5 5.0 ± 0.5*¥ 5.1 ± 0.5* 0.004 
PWVΔ  -0.14 ± 0.1† -0.10 ± 0.2†§ -0.11 ± 0.1† -0.02 ± 0.1*¥¤ -0.02 ± 0.1¥ <0.001 
 
TPR 13.8 ± 3.1 13.4 ± 3.1 13.1 ± 2.6 13.1 ± 2.4 13.2 ± 2.2 0.419 
TPRi 14.0 ± 3.0¤† 12.8 ± 2.9 12.5 ± 2.6* 12.7 ± 2.3* 13.1 ± 2.2 0.020 
TPRe 13.7 ± 3.2 14.0 ± 3.2 13.7 ± 2.7 13.5 ± 2.6 13.3 ± 2.3 0.600 
TPRΔ  0.2 ± 0.7¥¤† -1.2 ± 0.7*§ -1.2 ± 0.6*§ -0.8 ± 0.7*§ -0.2 ± 0.4¥¤† <0.001 
Data represent mean ± SD (n = 17). Spontaneous breathing (Sfr; average 14.2 breaths.min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 7.0 breaths.min-1); pulse 
wave velocity (PWV; m.s-1), total peripheral resistance (TPR; mmHg⋅min⋅L-1); mean inspiration (i), 
mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr 
(*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
PWV and TPR were significantly higher during inspiration for intra-breath phase peak-
valley analysis for all SDB conditions compared with Sfr.  
 
Table 6-8 Peak-valley differences (±SD) for pulse wave velocity (PWV) and total 
peripheral resistance (TPR) variables 
Data represent mean ± SD (n = 17). Spontaneous breathing (Sfr; average 14.2 breaths.min-1),  
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r; average 7.0 breaths.min-1); pulse 
wave velocity (PWV; m.s-1), total peripheral resistance (TPR; mmHg⋅min⋅L-1); within inspiration 
difference (∆i), within expiration difference (∆e), inter-breath phase peak-valley difference (∆PV); 
Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
6.3.8 Antenatal blood pressure measurements 
Blood pressure measurements recorded during antenatal appointments were submitted 
from 15/17 participants (Figure 6-6), and 58.8% of participants provided data up until  
either week 40 gestation or until they gave birth. From the submitted data no participants 
developed hypertension after participating in the data collection session. 
 
Sfr 
14.2 breaths .min-1 
8Ffr Dfr 
7.0 breaths.min-1 
6Ffr 4Ffr p value 
PWVΔi 0.2 ± 0.1¥¤†§ 0.6 ± 1.3*†§ 0.3 ± 0.1* 0.4 ± 0.2*¥ 0.5 ± 0.2*¥ <0.001 
PWVΔe 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.4 0.3 ± 0.1 0.5 ± 0.2 0.088 
PWVΔPV  -0.32 ± 0.2 -0.05 ± 1.4 -0.42 ± 0.5 -0.14 ± 0.5 -0.14 ± 0.6 0.158 
 
TPRΔi 1.1 ± 0.6¥¤†§ 1.8 ± 0.8* 2.0 ± 0.8* 2.0 ± 0.9* 2.2 ± 0.7* <0.001 
TPRΔe 1.1 ± 0.6¤†§ 1.7 ± 1.1† 2.0 ± 1.2* 2.2 ± 1.1*¥ 2.2 ± 1.0* <0.001 
TPRΔPV  0.4 ±1.7¥¤† -2.8 ± 1.3* -2.9 ± 1.2* -2.5 ± 1.7* -0.7 ± 2.7 <0.001 
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Figure 6-6 Average blood pressure measured during routine antenatal 
appointments 
Data represent mean; week 10 (n=15), week 16 (n=15), week 25 (n=15), week 28 (n=14), week 
31 (n=14), week 34 (n=13), week 36 (n=12), week 38 (n=11), week 40 (n=6), week 41 (n=1).  
Systolic blood pressure (SBP purple ⧫), diastolic blood pressure (DBP blue ◼). 
 
6.3.9 Preferred breathing condition 
 
The majority of participants (10/18) picked the 6Ffr condition as their preferred breathing 
condition to perform at home daily breathing (Figure 6-7) and another 4 participants 
chose 6Ffr as their second preferred breathing condition where they had no preference 
between 2 conditions as their favourite. All 18 participants have been included in the 
analysis of preferred breathing condition as the excluded participant’s noncompliance of 
the breathing condition does not exclude them from making a judgement on their 
preference. 
 
Figure 6-7 Preferred breathing condition 
The breathing condition participants (n=18) felt most comfortable breathing at, and would choose 
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There was no correlation between gestational age and preferred breathing frequency 
(R2=0.00; Figure 6-8). Where Dfr was chosen, the average breathing frequency during 
this condition was used in Figure 6-8. There was also no correlation between the 
preferred breathing frequency and the position of the preferred breathing frequency in 
the randomised order (R2=0.15), i.e. preferred breathing frequency was not always 
performed at the start or end of the protocol. 
 
 





This discussion will focus on the specific responses of healthy pregnant women to SDB, 
compared with those reported in existing literature, where breathing exercises have been 
implemented during pregnancy. On the whole, the principal variables of interest 
responded similarly to those of healthy non-pregnant women, but a detailed comparison 
of the data from pregnant (Chapter 6) and healthy non-pregnant women (Chapter 5) can 
be found in the integrated paper in Chapter 7. 
 
This study adds to the literature reporting normal cardiovascular data during healthy 
pregnancies. Although sample size is low, Table 6-1 provides a starting point on which 
to build to a data set of normal data during pregnancy. This does not yet exist in the 
literature and textbooks such as Anatomy and Physiology for Midwives (Coad et al. 2020) 
do not always use cited references associated with their normative values. The data set 
provided by this study show that, on average, women of 31.4 (± 5.2) weeks gestational 
age have a spontaneous breathing frequency of 14.2 ± 2.7 breaths.min-1, which is ~1 



































Although spontaneous breathing frequency was not correlated with gestational age, 
given the wide range of gestational ages (20-39 weeks), more data is required to confirm 
this. Evaluation of breathing frequency is important for monitoring health while on 
hospital wards, and the accuracy of it is important for calculation of early warning scores 
(Jones et al. 2020). However, if breathing frequency is different across gestational ages 
then this should be fed into early warning scores as a relative comparison for baseline 
datal. Consequently, more data is needed on ‘normal’ breathing frequencies across 
trimesters and gestational ages. 
 
As expected, heart rate, stroke volume and cardiac output were all significantly higher 
for pregnant women than non-pregnant women. All BP measures were similar between 
pregnant and non-pregnant women, and the traditional ‘dip’ in BP during the first and 
second trimester was not seen in the data from antenatal BP measures. Recent evidence 
suggests that the traditionally expected drop in BP may not occur in every pregnancy 
(Salles et al. 2015), with steady SBP and DBP values throughout pregnancy. However, 
there was a slight decrease in BP from ~31 weeks gestation, which is in accordance with 
meta-analysis data showing a slight increase in SBP and DBP from 30 weeks gestation 
onwards (Loerup et al. 2019). Accordingly, it can be concluded that the sample of 
pregnant women in the present study were typical of normotensive pregnancies. 
 
The RSA values observed in the present study are higher than were reported in a 
previous study where pregnant women performed relaxation for 18-minutes, both at 
baseline (Sfr) and during the SDB/relaxation interventions (DiPietro et al. 2008). 
However, the RSA response to SDB mirrored the pattern found during relaxation, with 
both SDB and relaxation eliciting an approximate doubling of RSA measured at 
baseline/spontaneous breathing. Depressed RSA has been associated with 
hypertensive disorders of pregnancy (Lakhno 2016) and although the depression of RSA 
is not the cause of hypertension, it reflects the functional state of the autonomic nervous 
system (Buchner 2018), and as there is an overactivity of the sympathetic arm during 
PIH, RSA depression may reflect a deterioration in the balance of the autonomic nervous 
system. Thus, if daily practice of SDB can convert the acute increase in RSA into a long-
term increase in RSA, this may be beneficial for pregnant women. 
 
There are a handful of studies examining the acute responses of pregnant women to 
breathing exercises. For example, one study showed that SBP increased significantly 
during 6 minutes of paced breathing. However, the increase in SBP was only around 2.6 
mmHg, whilst the increase for DBP was 1.5mmHg and no change in heart rate was seen 
(0.4 beats.min-1) (Monk et al. 2011). In the present study, there was no significant 
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increase in mean SBP or DBP; changes were only observed in the peak-valley BP 
variables. This discrepancy between studies is likely to be attributable to differences in 
design; in the study by Monk and colleagues (2011), the slow paced breathing alternated 
between periods of breathing at 30 breaths.min-1, 20 breaths.min-1 and 10 breaths.min-1, 
all of which were faster than the highest frequency tested in the present study.  
 
It is reasonable to suggest that gestational age might influence the ability to expand tidal 
volume during SDB and thus the preferred SDB frequency. No correlation between 
preferred breathing frequency chosen by participants and gestational age was observed, 
suggesting that women did not find SDB more difficult during the later stages of 
pregnancy. Indeed, the three women who preferred 4Ffr (the lowest breathing frequency) 
participated at a wide range of gestational ages of 20, 26 and 37 weeks gestation. 
However, this finding might be explained by the fact that these women had pregnancies 
that were either <28 weeks or >36 weeks. There is more pressure on the diaphragm 
after 28 weeks gestation in the second trimester (Hegewald and Crapo 2011) which may 
make SDB harder to achieve and therefore lower breathing frequencies are harder to 
achieve or less comfortable. Moreover, during first time pregnancies, from 37 weeks 
onwards there is a drop in the bump, known as lightening (Coad et al. 2020), which might 
make it easier to breathe at the lower frequencies following lightening. These 
physiological changes during different stages of  gestation may explain why these 
participants were most comfortable breathing at the lowest frequency (4Ffr). 
 
It is interesting, but unsurprising, that the only group from which a participant was 
recruited (from the 8 antenatal groups who shared the study information with pregnant 
women) was the group that the investigator (MF) was able to attend in person to discuss 
the project. Additionally, the only event (from 3), where information was provided to 
women, yielding participants, was the event the investigator attended in person. This 
demonstrates the importance of face to face contact with potential participants. The 
exception to this was the NCT classes, from which 3 participants were recruited; 
however, the NCT has been an ongoing collaborator with the project and the antenatal 
teachers were enthusiastic about the research and encouraged women to take part. 
Additionally, although Facebook yielded the most participants, less than half of those 
who made contact following a Facebook promotion participated in the study. This shows 
that although Facebook is a good method for sharing the research to a wider group of 
women this does not necessarily translate to participation in research (Arcia 2013). Most 
maternity Facebook groups also have a majority of users who already have children, as 
confirmed by a local parent and user of some of the groups utilised in this study. As these 
women would be excluded from participation in this study, promoting the research to 
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them is of no benefit to the project and therefore adds a limitation to using maternity 
Facebook groups as a recruitment source. Additionally, first time mothers often join these 
local groups after their baby is born and therefore finding a place where pregnant women 
group together is difficult, outside of clinical settings. The next study (Chapter 8) will 
recruit directly from the local NHS maternity ward, and therefore access to participants 
will be streamlined to one organisation. For specific groups of pregnant women, in future 
it may be easier to access participants through local NHS Trusts for other research 
studies. The importance of meeting potential participants in person should not be 
overlooked when planning recruitment strategies for pregnant women. 
 
Finally, the data from this chapter show a similar response to SDB as non-pregnant 
women in Chapter 6, and this will be statistically analysed in the next chapter. Now that 
the acute cardiovascular responses of both healthy non-pregnant and healthy pregnant 
women have been characterised research can move onto investigating the differences 
in cardiovascular responses in women who develop pregnancy-induced hypertension. 
Comparison values during healthy pregnancies are important to differentiate between 
normal physiological adaptations and responses during pregnancy to those associated 
with cardiovascular disease. Therefore, more normative maternal data should be 




In conclusion, RSA more than doubled during all SDB conditions compared with 
spontaneous breathing, which is reflective of the capacity of SDB to modulate vagal 
activity. The amplitude of BP oscillations also increased in pregnant women to a similar 
level as non-pregnant women. The potential for BP oscillations to activate the 
baroreceptors, and provide repeated stimulus during daily practice, is present in 
pregnant women and therefore the data reflects no reason why SDB could not produce 




The short-term cardiovascular responses to SDB have been characterised in healthy 
non-pregnant and healthy pregnant women. The next chapter will present a manuscript 
combining the results from Chapters 5 and 6, providing an in-depth comparison of the 
responses. Mechanistically, data from this study provides a better understanding of the 
within-breath changes that may create error signal(s), which provides a platform from 
which to examine responses to SDB of pregnant women who develop hypertension.  
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Chapter 7. Comparison of short-term cardiovascular 




The main section of this chapter (7.2) has been prepared as a manuscript as it is intended 
for publication and will be submitted to the European Journal of Applied Physiology. The 
manuscript will synthesise data presented in Chapters 5 & 6, necessitating a degree of 
overlap between those chapters and the current chapter. However, this is justified 
because the direct comparison of cardiovascular responses between healthy pregnant 
and healthy non-pregnant women is an important output of this thesis. There is a need 
to understand how women respond to slow and deep breathing (SDB) and whether the 
normal physiological adaptations caused by pregnancy change the cardiovascular 
response to SDB. Characterising these differences may lead to a better understanding 
of how SDB reduces long-term blood pressure (BP), supporting the development of an 
evidence-based SDB intervention, designed specifically to treat high BP during 
pregnancy. 
 
A full explanation of the methods for each study can be found in Chapter 3 and sections 
5.2 and 6.2. The research questions, objectives and hypothesis are outlined below: 
 
Research questions 
1. Do healthy pregnant women exhibit the same acute cardiovascular responses to 
SDB as healthy non-pregnant women? 
2. Is there a difference in the acute cardiovascular response of healthy pregnant 
women to different SDB frequencies as healthy non-pregnant women? 
 
Objectives 
1. Identify whether mechanism-related parameters (e.g. respiratory sinus arrythmia, 
stroke volume, cardiac output, blood pressures) respond similarly during SDB for 
healthy non-pregnant women and healthy pregnant women. 
2. Evaluate whether the acute cardiovascular responses to a range of SDB 








1. Healthy pregnant women will exhibit the same acute physiological responses to 
SDB across different breathing frequencies as healthy non-pregnant women. 
 
7.2 Integrated paper: Acute cardiovascular responses to slow and 





Slow and deep breathing (SDB) is recommended by the American Heart Association for 
use as an adjunctive treatment for hypertension (Brook et al. 2013). A recent meta-
analysis of studies of SDB in primary hypertension found that following daily practice of 
SDB reductions of up to 5.26 mmHg for systolic blood pressure (SBP) and 2.97 mmHg 
for diastolic blood pressure (DBP) were observed (Chaddha et al. 2019). However, there 
is limited understanding of the acute cardiovascular responses to SDB, which produce 
the error signal(s) to reduce blood pressure (BP) chronically, as well as a lack of research 
investigating the underlying mechanisms (Gerritsen and Band 2018). 
 
A recent study (Felton et al. 2021 – in preparation)4 revealed that SDB increased the 
amplitude of respiratory sinus arrythmia (RSA) and BP oscillations, with maximal 
amplitudes occurring at 6 breaths.min-1. However, 6 breaths.min-1 was the lowest 
breathing frequency assessed and it is unknown whether lower breathing frequencies 
could increase the amplitude of cardiovascular oscillations further. To date, previous 
studies that have compared cardiovascular responses to SDB at a range of frequencies 
have done so using a SDB protocol that reduced breathing frequency dynamically, with 
only short durations at each individual SDB frequency (Anderson et al. 2009; Zhang et 
al. 2009). A systematic characterisation of the acute cardiovascular responses to a range 
of steady-state SDB frequencies is therefore needed. This may also shed light on the 
potential error signal(s) responsible for the anti-hypertensive effect of SDB following daily 
practice. 
 
Felton et al. (2021)4 found that there was no difference between the acute cardiovascular 
responses of men and women to SDB. However, pregnancy induces a series of 
cardiovascular adaptations, which may change the acute response to SDB, compared 
with those of non-pregnant women. During pregnancy, baseline cardiovascular 
 
4 Integrated paper presented in Chapter 4 
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measures such as heart rate, stroke volume and cardiac output are increased above 
normal non-pregnant levels (Soma-Pillay et al. 2016). It is possible that these changes 
in baseline cardiovascular function may influence the acute cardiovascular response to 
SDB. Additionally, the health benefits and reductions in BP associated with SDB are 
suggested to be related to diaphragmatic breathing (Gerritsen and Band 2018), however 
during pregnancy the diaphragm is forced upwards by as much as 5 cm (Elkus and 
Popovich Jr 1992), which may limit its mobility and the ability to perform SDB and/or 
achieve any associated health benefits. 
 
The need to understand the acute responses to SDB during pregnancy is important due 
to a specific condition called pregnancy-induced hypertension (PIH). PIH is defined as 
high blood pressure, presenting after 20 weeks of pregnancy, which was not present 
prior pregnancy (NICE: National Institute for Health and Care Excellence 2019b). PIH 
occurs in up to 15% of pregnancies (James and Nelson-Piercy 2004) and there is an 
increased risk for obstetric complications for these women (Scantlebury et al. 2013). 
There is potential for SDB to offer an effective treatment for PIH (Felton et al. 2021)5, 
and women who develop PIH are a promising group in which to investigate SDB as a 
potential treatment method. Firstly, many pregnant women are highly motivated to 
adhere to and undertake non-pharmacological interventions (Adams et al. 2009) as 
many have an aversion to medication (Twigg et al. 2016). The aetiology of PIH has also 
been linked to high breathing frequencies (Fischer and Voss 2014) and dysfunctional 
breathing (Jerath et al. 2009). SDB may be an important component of behavioural 
interventions aimed at reducing BP (Sica 2011) and therefore pregnant women are an 
ideal group to investigate the use of SDB to treat hypertension. 
 
Prior to undertaking an intervention there is a need to characterise and understand the 
acute responses to SDB of pregnant women and whether these differ from non-pregnant 
women. This normative and baseline data is needed as a comparison before moving 
forward to use SDB with women who develop PIH. The characterisation of acute 
cardiovascular responses can also support the development of SDB interventions 
designed specifically for pregnant women, based on their measured acute 
cardiovascular responses, including recognition of any preferences for specific breathing 
frequencies. Consequently, the present study compared the acute cardiovascular 








All experiments conformed to the Declaration of Helsinki and the experimental protocol 
was approved by Bournemouth University’s Research Ethics Committee. Written 
informed consent was obtained from all participants prior to participating in the study.  
 
Participants 
Forty-one women participated in the study: 23 healthy non-pregnant women and 18 
healthy pregnant women. All non-pregnant participants were of reproductive age as 
defined by the World Health Organization (2006) and all pregnant women were over 20 
weeks gestation. Participants were recruited from the local student and staff population 
and using local antenatal and maternal groups including social media. All pregnant 
women were nulliparous and were carrying single pregnancies. Participants diagnosed 
with any cardiovascular or respiratory disease were excluded, as were smokers and 
women who vaped. All participants were normotensive at the time of data collection and 
the pregnant women submitted regular BP measurements until birth to confirm they did 
not subsequently develop high BP during their pregnancy.  
 
Participants attended one session at the Cardiorespiratory Research Laboratory at 
Bournemouth University. Prior to the data collection session participants refrained from 
eating for 2 hours and from caffeine, strenuous exercise and alcohol for 12 hours. 
Average lab conditions during data collection were 24.0 ± 3.2 oC, 992.6 ± 13.5 hPa, 42.6 
± 10.6%. 
 
Slow and Deep Breathing Protocol 
Participants completed five6 breathing conditions in a randomised order; spontaneous 
breathing (Sfr), 4 (4Ffr), 6 (6Ffr), and 8 (8Ffr) breaths.min-1, and a dynamic frequency 
using an optimisation algorithm (Dfr), which maximised respiratory sinus arrythmia 
(RSA). All breathing conditions were 5-minutes in duration with a 5-minute break of 
normal breathing between each measurement. All SDB conditions were delivered using 
Bournemouth University’s Brythm app, which delivers either fixed breathing frequencies 
(4Ffr, 6Ffr, 8Ffr) or uses a novel, bespoke algorithm to deliver a personalised dynamic 
frequency (Dfr). The bespoke algorithm maximises cardiovascular perturbation, using the 
amplitude of RSA as the controlled variable. Changes in RSA are measured from a finger 
 
6 The non-pregnant participant group completed 6 breathing cond itions with the addition of  an 
inspiratory resistance condition, where participants breathed at 6 breaths .min-1 with an inspiratory 
resistance. The results of  this condition are not presented in this chapter as there is no 
comparison data with pregnant women. 
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sensor (photoplethysmography), connected via the headphone socked of an iPad. The 
app displays visual feedback on an iPad screen to guide breathing; user’s inhale when 
the dome graphic rises and exhale when the dome falls (Figure 7-1). 
 
Figure 7-1 Screenshots of Brythm graphic 
N.B: Arrows do not appear on app but are shown here to display the direction of graphic  
movement. 
 
Breathing frequencies of 4 and 8 breaths.min-1 were chosen to bookend the widely 
reported ‘optimal’ breathing frequency of 6 breaths.min-1 (Cullins et al. 2013; Russo et al. 
2017), in order to explore cardiovascular responses at a wider range of SDB frequencies. 
Following completion of the protocol, the pregnant participants were asked which 
breathing condition they felt most comfortable breathing at and would choose to use if 
they were asked to continue undertaking the breathing exercise daily until birth.  
 
Data Acquisition 
During each breathing condition, respiratory airflow, ECG and arterial blood pressure 
(ABP) were monitored continuously. Participants were seated in an upright position, at 
an approximate angle of 60o. Respired flow rate was measured continuously using a 
heated pneumotachograph (Model 3700, Hans Rudolph Inc., Kansas, USA), connected 
to a flow measurement system (RSS 100-HR, Hans Rudolph Inc., Kansas, USA) while 
participants wore an oronasal mask (Oro Nasal 7450 V2 Mask, Hans Rudolph Inc., 
Kansas, USA). 
 
A 3-lead ECG measured heart rate continuously, whilst non-invasive beat-to-beat ABP 
was obtained using finger photoplethysmography (Finapres NOVA, Finapres Medical 
Systems, The Netherlands). Finapres derived ABP was calibrated using a brachial cuff 
prior to and halfway through data collection. Analogue outputs from the Finapres NOVA 
and the flow meter were sampled continuously at 250Hz via an analogue to digital 
converter (NI USB-6218 BNC, National Instruments Inc.) and captured using bespoke 
acquisition and analysis software (LabView 2015, National Instruments, Inc.). The 
LabView software corrected for the 4 second delay between the Finapres NOVA output 
and the respiratory output. Stroke volume (SV) was calculated using the Modelflow 
method by the Finometer. Total peripheral resistance (TPR) was calculated as mean 
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arterial pressure divided by cardiac output (Q̇). Pulse wave analysis (PWV) was 
calculated as the distance between sternal notch and Finometer finger cuff divided by 
pulse transit time (Hansen 2010). Pulse transit time was calculated as the time delay 
between the peak of the R wave of the ECG and the peak of the pressure pulse recorded 
at the finger.  
 
Data Analysis 
The LabView bespoke software calculated and analysed variables beat-by-beat and 
breath-by-breath, including the minimum, maximum and mean values for each inhalation 
and exhalation breath phase. Data were averaged across each 5-minute breathing 
condition.  
 
Values are expressed as means ± SD unless stated otherwise. Statistical analysis was 
undertaken using SPSS Statistics 26 (IBM Corp.). After normality was confirmed 
(Shapiro Wilk) repeated measures ANOVA with planned pairwise comparisons using 
Bonferroni corrections were used. Between group (pregnant and non-pregnant) 
comparisons used independent samples t-tests. Reported p values are those following 
adjustment for repeated comparisons. For all analyses, P was set at 0.05. 
 
Respiratory sinus arrhythmia (RSA) was calculated using two methods 1) the difference 
between the average heart rate (fc) during inhalation (fci) and exhalation (fce) (fcΔ); 2) the 
difference in maximum and minimum beat-to-beat intervals (RR) during inhalation and 
exhalation respectively (RSA). RSA is a variable calculated to determine the amplitude 
of heart rate rhythms using the ‘peak-valley’ method, which was also used to analyse all 
variables including BP in the present study.  
 
The following calculations of variables are displayed on an example sinewave in Figure 
7-2 (with corresponding calculation numbers). Inter-breath phase indices (Δ) were 
quantified as the difference between mean inspiration (i) and mean expiration (e) values 
for all variables (calculation 4). Peak-valley (PV) indices were calculated as maximum 
minus minimum values during inspiration (Δi: calculation 6) and expiration (Δe: 
calculation 5). Inter-breath phase PV indices (ΔPV) were calculated using maximum 
inspiration minus minimum expiration, or minimum inspiration minus maximum 
expiration, dependent on which calculation gave the largest difference. Calculation 7 
shows an example using the calculation maximum inspiration minus minimum expiration. 
PV indices irrespective of breath phase, known as peak-valley breath phase independent 
calculations (ΔPV_Ind), were calculated as the difference between the maximum and 



































Figure 7-2 Calculations for example cardiovascular variable plot 
1) Ave = average of whole breath. 2) i = Average inspiration. 3) e = Average expiration. 4) Δ = i – 
e (average inspiration – average expiration). 5) Δe = Max E – Min E. 6) Δi = Max I – Min I. 7) ΔPV 
= Max I – Min E (Note ΔPV calculation varies and can be Min I – Max E depending on which 




Data were collected from 41 participants. Six participants were excluded from the 
analysis; three due to technical errors in the measurement of respiratory airflow, two 
because the participant failed to adhere to the prescribed breathing condition and one 
due to failure of the acquisition system to save the signal data. Consequently, data 
analysis was performed on data from 18 non-pregnant women and 17 pregnant women 
(Table 7-1). There were no significant differences in age, stature, systolic blood pressure 
(SBP) or diastolic blood pressure (DBP) between non-pregnant and pregnant 
participants. Mass was significantly greater (28%) in pregnant women, accounted for by 







Table 7-1 Participant characteristics 
 Non-pregnant Pregnant P value 
 n = 18 n = 17  
Age (years) 30.1 ± 8.8 32.0 ± 5.4 0.455 
Stature (m) 1.66 ± 0.5 1.67 ± 0.8 0.706 
Mass (kg) 65.6 ± 10.3 84.1 ± 13.4 <0.001* 
Baseline SBP (mmHg) 113.9 ± 9.1 118.2 ± 7.7 0.141 
Baseline DBP (mmHg) 68.9 ± 8.0 71.9 ± 7.9 0.265 
Gestational age (weeks) N/A 31.4 ± 5.2 N/A 





Table 7-2 shows the respiratory parameters for both groups. Breathing frequency (fr) was 
not significantly different between pregnant and non-pregnant women for any breathing 
conditions, including spontaneous breathing. The dynamic breathing frequency (Dfr) was 
significantly different from 6 breaths.min-1 for pregnant women (p=0.02), but not for non-
pregnant women. All other breathing frequencies were significantly different from each 
other. Sfr was not correlated with gestational age (R2=0.14) and neither was the average 
optimal breathing frequency based on RSA maximisation during Dfr (R2=0.11). 
 
Tidal volume was significantly higher for pregnant women during spontaneous breathing 
(Sfr, p=0.015), but not during any SDB conditions. Duty cycle remained consistent 
throughout conditions and was not significantly different between groups or between 
breathing conditions. 
 
Table 7-2 Respiratory parameters 
  Sfr 8Ffr Dfr 6Ffr 4Ffr 
fr 
Non-pregnant 13.3 ± 2.1¥¤†§ 8.0 ± 0.0*¤†§ 6.3 ± 1.1*¥§ 6.0 ± 0.0*¥§ 4.0 ± 0.0*¥¤† 
Pregnant 14.2 ± 2.7¥¤†§ 8.0 ± 0.1*¤†§ 7.0 ± 1.1*¥†§ 6.0 ± 0.0*¥¤§ 4.0 ± 0.0*¥¤† 
VT 
Non-pregnant 0.4 ± 0.2¥¤†§ 0.9 ± 0.4*†§ 1.0 ± 0.4* 1.1 ± 0.4*¥ 1.3 ± 0.4*¥ 
Pregnant 0.8 ± 0.5¤†§ 1.1 ± 0.3§ 1.1 ± 0.3*§ 1.5 ± 0.7* 1.6 ± 0.6*¥¤ 
TI / 
TTOT 
Non-pregnant 0.42 ± 0.0¥¤†§ 0.48 ± 0.0* 0.48 ± 0.0* 0.50 ± 0.1* 0.48 ± 0.0* 
Pregnant 0.54 ± 0.4 0.52 ± 0.2 0.48 ± 0.1 0.47 ± 0.0 0.56 ± 0.3 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Spontaneous breathing (Sfr), 
fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 breaths.minute-1 (6Ffr), 8 breaths.minute-1 
(8Ffr), optimisation algorithm dynamic breathing frequency (Df r); breathing frequency (fr) in 
breaths.min-1, tidal volume (VT) in L, duty cycle (TI /TTOT); Significantly different from Sfr (*), 8Ffr 
(¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
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Arterial blood pressures 
 
There were no significant differences for mean SBP or DBP between breathing 
conditions or between groups (see supplementary data). SBP and DBP peak-valley 
amplitude during breath phase (maximum minus minimum values) were significantly 
greater during both inspiration (Δi) and expiration (Δe) for all SDB conditions compared 
with spontaneous breathing (Table 7-3). This was true for both pregnant and non-
pregnant women (p<0.001). The only significant difference in SBPΔPV between 
pregnant and non-pregnant groups was for the 6Ffr condition (p=0.001).  
 
Peak-valley breath phase independent values (ΔPV_Ind) were higher for both pregnant 
and non-pregnant women compared with peak-valley analysis linked to breath phase 
(ΔPV). 
 
Table 7-3 Peak-valley differences (±SD) for blood pressure variables (mmHg) 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); systolic blood pressure (SBP; mmHg), diastolic blood pressure (DBP; mmHg);  
within inspiration difference (∆i), within expiration difference (∆e), inter-breath phase peak-valley  
difference (∆PV), breath phase independent peak-valley difference (∆PV_Ind); Significantly 
different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
 









NP 3.6 ± 1.7¥¤†§ 8.2 ± 2.9*¤†§ 12.8 ± 5.4*¥ 13.5 ± 4.6*¥ 15.5 ± 6.1*¥ <0.001 
0.925 P 3.4 ± 1.5¥¤†§ 9.1 ± 2.6*¤† 11.2 ± 3.7*¥ 11.7 ± 3.8*¥ 12.9 ± 4.9* <0.001 
SBP 
Δe 
NP 4.5 ± 2.5¥¤†§ 6.9 ± 2.7*¤†§ 10.2 ± 4.6*¥ 10.5 ± 4.6*¥ 12.1 ± 6.6*¥ <0.001 
0.592 P 3.7 ± 1.6¥¤†§ 7.4 ± 2.5*¤† 9.0 ± 2.4*¥ 9.7 ± 3.0*¥ 11.7 ± 6.1* <0.001 
SBP 
ΔPV 
NP -8.6 ± 3.6 -13.1 ± 7.0§ -11.5 ± 13.6§ -15.3 ± 9.5§ 2.3 ± 18.4¥¤† 0.001 
0.005 P -7.7 ± 2.6§ -8.5 ± 9.0§ -3.7 ± 13.1§ 0.8 ± 14.7§ 12.3 ± 9.8*¥¤† <0.001 
SBP 
ΔPV_Ind 
NP 15.0 ± 6.1 17.5 ± 5.6 19.1 ± 6.3 19.0 ± 5.1 17.4 ± 6.9 0.014 
0.089 P 12.9 ± 4.7§ 13.9 ± 3.7 15.9 ± 3.1 15.9 ± 3.8 17.6 ± 6.0* 0.033 
DBP 
Δi 
NP 2.5 ± 1.2¥¤†§ 5.2 ± 1.8*¤†§ 8.8 ± 2.9*¥ 9.3 ± 3.1*¥ 10.0 ± 3.0*¥ <0.001 
0.118 P 1.8 ± 0.8¥¤†§ 6.6 ± 2.2* 7.7 ± 2.7* 7.5 ± 3.5* 7.6 ± 3.1* <0.001 
DBP 
Δe 
NP 3.2 ± 1.6¥¤†§ 5.6 ± 2.1*¤†§ 7.6 ± 3.1*¥ 8.2 ± 3.2*¥ 8.8 ± 3.1*¥ <0.001 
0.553 P 2.7 ± 1.3¥¤†§ 6.7 ± 2.2*† 7.6 ± 1.8* 8.3 ± 2.2*¥ 9.9 ± 4.0* <0.001 
DBP 
ΔPV 
NP -4.0 ± 2.2¥§ -7.6 ± 2.0*§ -1.9 ± 11.2§ -3.4 ± 11.1§ 11.6 ± 7.3*¥¤† <0.001 
0.097 P -4.6 ± 1.7†§ -6.1 ± 6.7†§ 0.7 ± 9.3§ 5.3 ± 9.1*¥ 11.4 ± 3.4*¥¤ <0.001 
DBP 
ΔPV_Ind 
NP 9.9 ± 4.4 10.6 ± 2.9 12.1 ± 3.3 12.1 ± 2.5 12.7 ± 3.3 0.014 
0.130 P 7.9 ± 2.8†§ 9.7 ± 2.8 10.3 ± 2.4 10.4 ± 2.7* 12.8 ± 5.5* 0.005 
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A high correlation (>0.8) was observed between SBPΔi and SBP and between SBPΔe 
and SBP, including DBP equivalents, across all breathing conditions. To reveal the 
change in the amplitude of BP oscillations relative to mean BP, percentage change BP 
oscillations were calculated during each breath phase (peak-valley difference (Δi or Δe) 
as a percentage of average BP during corresponding inspiration or expiration (Figure 
7-3). All SDB conditions were significantly different from Sfr for all percentage BP 
oscillations (%SBPΔi, %DBPΔi, %SBPΔe, %DBPΔe) for both non-pregnant and 
pregnant women. There were no significant differences between groups.
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Figure 7-3 Blood pressure oscillations: Relative change for systolic blood pressure of Δi (A), Δe (B) and diastolic blood pressure of Δi (C), Δi (D) 
Systolic blood pressure (SBP), diastolic blood pressure (DBP); within expiration difference (∆i); within expiration difference (∆e); Fixed breathing frequency (Ffr) 
Spontaneous breathing (Sfr), optimisation algorithm dynamic breathing frequency (Df r). Variable calculated as SBP∆i as a percentage of average SBP during 






















































































































Antenatal appointment recorded BP data (available for 58.8% of participants), revealed 
that no pregnant participants who submitted data developed hypertension following 
participating in the data collection session (defined as SBP <140 mmHg and/or DBP <90 
mmHg). 
 
Heart rate and respiratory sinus arrythmia 
 
Peak-valley amplitude changes in heart rate during inspiration were significantly different 
between pregnant and non-pregnant women for all SDB conditions, except Sfr (Table 
7-4). There was also a significant increase for mean heart rate between non-pregnant 
and pregnant women, and for mean heart rate during inspiration and expiration for all 
conditions (see supplementary data). Peak-valley amplitude during expiration (fcΔe) and 
inter-breath phase (fcΔPV) were significantly higher during all SDB conditions compared 
with Sfr for both pregnant and non-pregnant participants (Table 7-4). 
 
Table 7-4 Peak-valley differences (±SD) for heart rate (fc) and respiratory sinus 
arrythmia (RSA) 
 









NP 5.4 ± 2.2¥¤†§ 14.4 ± 6.9* 15.5 ± 6.2* 15.5 ± 5.9* 15.9 ± 7.1* <0.001 
0.002 P 4.5 ± 2.9¥¤†§ 8.4 ± 5.0* 9.3 ± 5.2* 9.6 ± 5.8* 11.3 ± 5.7* <0.001 
fc 
Δe 
NP 7.3 ± 3.2¥¤† 14.3 ± 6.0* 14.1 ± 8.4* 13.4 ± 6.7* 10.3 ± 8.3 <0.001 
0.145 P 6.1 ± 4.4¥¤ 10.5 ± 5.2* 9.9 ± 4.6* 9.7 ± 4.0 11.0 ± 6.0 0.004 
fc 
ΔPV 
NP -6.6 ± 5.1¥¤†§ 16.1 ± 8.9*¤† 20.7 ± 8.5*¥ 20.6 ± 7.5*¥ 21.1 ± 9.5* <0.001 
0.044 P -3.1 ± 7.4¥¤†§ 13.4 ± 6.8* 15.3 ± 7.8* 15.1 ± 6.8* 11.2 ± 12.7* <0.001 
RSA 
(s) 
NP 0.12 ± 0.1¥¤†§ 0.21 ± 0.1*¤† 0.25 ± 0.1*¥ 0.25 ± 0.1*¥ 0.25 ± 0.1* <0.001 
0.002 P 0.07 ± 0.1¥¤†§ 0.13 ± 0.1* 0.15 ± 0.1* 0.15 ± 0.1* 0.15 ± 0.1* <0.001 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); heart rate (fc; beats.min-1), respiratory sinus arrythmia (RSA; s); within inspiration 
difference (∆i), within expiration difference (∆e), inter-breath phase peak-valley difference (∆PV); 
Significantly different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
RSA was significantly lower for the pregnant women, compared with non-pregnant 
women for all breathing conditions (p<0.001). RSA during SDB for pregnant women 
increased to a level similar to that observed during spontaneous breathing (Sfr) for non-
pregnant women (Figure 7-4) and plateaued (saturated) at 6 breaths.min-1 (6Ffr) for both 
groups. The maximum amplitude of RSA during SDB (≤6 breaths.min-1) was 2.1 times 
higher than RSA during Sfr for both the non-pregnant and pregnant group, albeit lower 




Figure 7-4 Respiratory sinus arrythmia (RSA) response to slow and deep 
breathing 
Values are mean ± SD; Respiratory sinus arrhythmia (RSA); Fixed breathing frequency (Ffr) 
Spontaneous breathing (Sfr), optimisation algorithm dynamic breathing frequency (Df r). 
 
Stroke volume and cardiac output 
 
Mean stroke volume (SV) and cardiac output (Q̇) were significantly higher for pregnant 
participants than non-pregnant participants (supplementary data). Peak-valley amplitude 
for SV and Q̇ during inspiration and expiration (SVΔi, SVΔe, Q̇Δi, Q̇Δe) were significantly 
different during all SDB conditions compared with Sfr for non-pregnant and pregnant 
participants (Table 7-5). The only exception was SVΔi, which was not significantly 
different between 8Ffr and Sfr for non-pregnant women. Peak-valley SV was significantly 
different between pregnant and non-pregnant women during all SDB conditions but not 
during Sfr (p<0.005). Peak-valley breath phase independent values were higher for SV 
and Q̇, compared with peak-valley values linked with breath phases for both non-



























Non-pregnant FfR Pregnant FfR
Non-pregnant SfR Pregnant SfR
Non-pregnant DfR Pregnant DfR
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Table 7-5 Peak-valley differences (±SD) for stroke volume (SV) and cardiac 
output (Q̇) 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); stroke volume (SV; ml), cardiac output (Q̇; ml.min-1); within inspiration difference 
(∆i), within expiration difference (∆e), inter-breath phase peak-valley difference (∆PV); breath 
phase independent peak-valley difference (∆PV_Ind). Significantly different from Sfr (*), 8Ffr (¥),  
Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
Total peripheral resistance and pulse wave velocity 
 
Table 7-6 shows a significant increase in TPRΔi and TPRΔe during SDB compared with 




















NP 5.1 ± 2.0¤†§ 7.3 ± 3.9§ 7.1 ± 3.5*§ 7.7 ± 4.0*§ 11.8 ± 4.9*¥¤† <0.001 
0.014 P 5.8 ± 2.0¥¤†§ 9.0 ± 2.8*†§ 10.7 ± 3.7*§ 11.0 ± 3.3*¥§ 15.3 ± 5.0 *¥¤† <0.001 
SVΔe 
 
NP 5.6 ± 2.0¥¤†§ 8.2 ± 3.1*§ 8.9 ± 4.0*§ 9.2 ± 3.9* 13.5 ± 6.3*¥¤ <0.001 
0.827 P 5.2 ± 1.9¥¤†§ 7.9 ± 2.3*§ 9.2 ± 2.3*§ 9.6 ± 2.3*§ 12.5 ± 3.7 *¥¤† <0.001 
SV 
ΔPV 
NP -8.9 ± 5.5§ -13.1 ± 8.0§ -13.8 ± 8.5 -14.6 ± 7.6 -18.6 ± 6.9*¥ 0.001 
0.002 P -8.0 ± 6.5 -2.9 ± 12.1 -3.4 ± 15.1 -1.7 ± 14.8 -0.4 ± 17.7 0.119 
SVΔPV 
_Ind 
NP 11.9 ± 4.2§ 13.7 ± 5.9 13.6 ± 6.4 13.4 ± 6.4 16.2 ± 6.4* 0.027 
0.361 P 13.0 ± 4.0§ 13.4 ± 4.1§ 15.5 ± 5.6 15.6 ± 4.6 18.0 ± 5.2*¥ 0.002 
Q̇Δi NP 292 ± 119¥¤†§ 1092 ± 646* 1107 ± 561* 1129 ± 607* 1073 ± 474* <0.001 
0.063 P 586 ± 293¥¤†§ 1151 ± 348* 1340 ± 468* 1292 ± 422* 1453 ± 300* <0.001 
Q̇Δe NP 414 ± 184¥¤†§ 831 ± 359* 840 ± 469* 787 ± 424* 747 ± 413* <0.001 
0.018 P 563 ± 265¥¤†§ 920 ± 243* 1012 ± 336* 1040 ± 355* 1164 ± 479* <0.001 
Q̇ 
ΔPV 
NP -738 ± 203¥¤†§ -638 ± 1153¤†§ 402 ± 1268*¥ 493 ± 1208*¥ 903 ± 923*¥ <0.001 
<0.001 P -745 ± 663¥¤†§ 1181 ± 732* 1432 ± 870* 1431 ± 842* 1452 ± 901* <0.001 
Q̇ΔPV 
_Ind 
NP 1352 ± 1982 1302 ± 667 1366 ± 1038 1191 ± 565 1018 ± 540 0.489 
0.409 P 1198 ± 341 1382 ± 302 1602 ± 553 1496 ± 373 1426 ± 282 0.006 
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Table 7-6 Peak-valley differences (±SD) for total peripheral resistance (TPR) and 
pulse wave velocity (PWV) variables 
 









NP 1.8 ± 2.2¥†§ 4.0 ± 1.9* 3.0 ± 1.2 4.3 ± 2.4* 3.5 ± 1.7* <0.001 
0.001 P 1.1 ± 0.6¥¤†§ 1.8 ± 0.8* 2.0 ± 0.8* 2.0 ± 0.9* 2.2 ± 0.7* <0.001 
TPR 
Δe 
NP 2.1 ± 2.0† 3.1 ± 1.4 2.8 ± 1.5 3.7 ± 2.3* 3.2 ± 1.3 0.020 
0.006 P 1.1 ± 0.6¤†§ 1.7 ± 1.1† 2.0 ± 1.2* 2.2 ± 1.1*¥ 2.2 ± 1.0* <0.001 
TPR 
ΔPV 
NP 2.3 ± 3.8¤† 0.8 ± 4.7 -3.3 ± 2.7* -3.3 ± 5.1* 0.3 ± 4.8 <0.001 
0.115 P 0.4 ±1.7¥¤† -2.8 ± 1.3* -2.9 ± 1.2* -2.5 ± 1.7* -0.7 ± 2.7 <0.001 
TPRΔPV 
_Ind 
NP 6.0 ± 6.3 5.2 ± 2.1 4.4 ± 1.9 5.4 ± 2.7 4.1 ± 1.7 0.192 
0.002 P 2.5 ± 1.1 3.0 ± 1.4 2.9 ± 1.2 2.8 ± 1.4 2.6 ± 1.1 0.159 
PWVΔi NP 0.2 ± 0.1¥¤†§ 0.4 ± 0.2* 0.5 ± 0.2* 0.5 ± 0.2* 0.4 ± 0.1* <0.001 
0.194 P 0.2 ± 0.1¥¤†§ 0.6 ± 1.3*†§ 0.3 ± 0.1* 0.4 ± 0.2*¥ 0.5 ± 0.2*¥ <0.001 
PWVΔe NP 0.3 ± 0.1¥¤† 0.4 ± 0.2* 0.5 ± 0.2* 0.4 ± 0.2* 0.4 ± 0.2 0.001 
0.528 P 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.4 0.3 ± 0.1 0.5 ± 0.2 0.088 
PWV 
ΔPV 
NP 0.4 ± 0.1¥¤†§ -0.7 ± 0.5*† -0.6 ± 0.3*† 0.6 ± 0.3*¥†§ -0.3 ± 0.5*† <0.001 
0.002 P -0.32 ± 0.2 -0.05 ± 1.4 -0.42 ± 0.5 -0.14 ± 0.5 -0.14 ± 0.6 0.158 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); total peripheral resistance (TPR; mmHg.min.L-1), pulse wave velocity (PWV; m.s-
1); within inspiration difference (∆i), within expiration difference (∆e), inter-breath phase peak-
valley difference (∆PV), breath phase independent peak-valley difference (∆PV_Ind). Significantly 
different from Sfr (*), 8Ffr (¥), Dfr (¤), 6Ffr (†), 4Ffr (§); P<0.05. 
 
Preferred breathing condition 
 
Fifty five percent of pregnant participants preferred the 6Ffr condition. Additionally, 
another 4 participants chose 6Ffr as their second preferred condition, where they had 
little preference between 2 conditions as their favourite. There was no correlation 




The present study builds on work from Felton et al. (2021 – in preparation7) to 
characterise acute cardiovascular responses to SDB, including an analysis of the inter- 
and intra-breath phase perturbations created by breathing. The first set of analyses show 
that heart rate, stroke volume and cardiac output were significantly higher in pregnant 
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women during spontaneous breathing (Sfr), which is in agreement with the known 
adaptations caused by pregnancy (Sanghavi and Rutherford 2014). Pregnant women 
had higher cardiac output and stroke volume at equivalent breathing frequencies, 
compared with non-pregnant women, which is consistent with the higher cardiovascular 
response seen during aerobic exercise in pregnant women (Hegewald and Crapo 2011).  
 
Although heart rate was higher in the pregnant group, their RSA was significantly lower 
for all breathing conditions, being just 58% the value observed in non-pregnant women 
during spontaneous breathing. This observation is consistent with the 65% difference 
found by Miyazato and Matsukawa (2010). SDB caused a significant increase in RSA for 
both non-pregnant and pregnant women compared with spontaneous breathing (Sfr); 
relative RSA (maximum RSA compared with baseline RSA) increased by a maximum of 
48% and 47%, respectively. Therefore, although absolute maximum RSA was higher in 
the non-pregnant group (0.25 v. 0.15 s), the response to SDB created almost a 50% 
increase in the amplitude of RSA. This is consistent with the absolute RSA response to 
relaxation, which was also lower in pregnant women compared with no pregnant women 
(DiPietro et al. 2012). Thus, during SDB breathing, the present study found a similar 
relative (%) increase in RSA amplitude, despite a lower absolute RSA amplitude. 
 
SDB increased RSA in pregnant women to levels similar to the RSA observed during 
spontaneous breathing for non-pregnant participants, revealing the ability of SDB to 
return RSA to pre-pregnancy levels. As an attenuated RSA has been suggested as a 
biophysical marker of pre-eclampsia (Lakhno 2016), the ability of an intervention to 
increase RSA during pregnancy is promising. Attenuated RSA per se is not the cause of 
hypertension, but reflects the functional state of the autonomic nervous system (Buchner 
2018), and as there is an overactivity of the sympathetic arm during PIH, changes in RSA 
may reflect an improvement in the balance of the autonomic nervous system. Although 
it should be noted that RSA’s ability to reflect the autonomic nervous system is queried 
(see point: counterpoint series) (Eckberg 2009; Julien et al. 2009; Karemaker 2009b, 
2009a), and therefore any suggestions of relationships must be carefully interpreted. 
Whether SDB can increase long-term RSA in pregnant women after daily SDB practice 
is unknown but needs investigating.  
 
RSA is a well-established physiological parameter, which is calculated using the peak-
valley method to quantify acute changes in heart rate induced by the two phases of 
breathing. RSA is quantified irrespective of the breath phase in which the heart beat was 
recorded, but the kinetics of the heart rate response to breathing are such that the peak 
of heart rate almost always occurs during inspiration, whilst the trough occurs during 
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expiration. However, the kinetics of haemodynamic responses are slower than for heart 
rate, with the peaks and troughs induced by each breath phase often occurring in the 
next (opposite) breath phase. The present study sought to reveal this phenomenon, as 
well as overcoming it, but using two different peak-valley methods of analysis, 1) peak-
valley amplitude calculated with respect to breath phase; 2) breath phase independent 
peak-valley amplitude (akin to RSA). This approach reveals the true magnitude of 
perturbations created by SDB, as well as the influence of response kinetics upon this 
amplitude. When only mean values are examined, the results mask the complex 
response including the increase in the amplitude of oscillations that occur to maintain 
homeostasis during SDB. 
 
The amplitude of BP oscillations (both SBP and DBP) during inspiration and expiration 
increased as breathing frequency reduced, reaching a peak at 4 breaths.min-1 (4Ffr), 
which was up to 4 and a half times higher (14.3%, 10 mmHg) than during spontaneous 
breathing (Sfr; see Figure 7-3). This supports the data from Felton et al. (2021 – in 
preparation8), which suggested that the amplitude of BP oscillations may be further 
increased at breathing frequencies below 6 breaths.min-1. However, although the 
amplitude of BP oscillations was further increased below 6 breaths.min-1, there was no 
significant difference at 4Ffr from the response during 6Ffr suggesting minimal 
differences between SDB conditions. The difference was only an average 1.2 mmHg 
(±0.7 mmHg) between 4Ffr and 6Ffr, which is unlikely to produce a meaningful clinical 
difference between the two conditions if used as a long-term SDB condition. 
 
Total peripheral resistance was significantly lower in pregnant women compared with 
non-pregnant women in the present study, which is most likely attributable to vasodilation 
that occurs during pregnancy (Ngene and Moodley 2017). Levels of BP are reliant on 
the balance between total peripheral resistance and cardiac output. Therefore, to 
maintain BP during pregnancy, cardiac output is increased to counteract the decreased 
total peripheral resistance (Moser et al. 2012). In the present study there was no 
significant differences in BP between pregnant and non-pregnant women, despite the 
lower total peripheral resistance, due to a significantly higher cardiac output in the 
pregnant women group. 
 
Interestingly, although an increased tidal volume was expected in pregnant women  
(McAuliffe et al. 2002), this was only observed during spontaneous breathing (Sfr), where 
tidal volume was double that of non-pregnant women. There were no significant 
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differences in tidal volume between non-pregnant and pregnant women during any SDB 
conditions, suggesting an ability of the respiratory system of pregnant women to adapt 
comfortably to reduced breathing frequencies in a similar way to non-pregnant women. 
Tidal volume in the pregnant women group increased significantly as breathing 
frequency was reduced below 8 breaths.min-1. 
 
Finally, there were limited differences in the cardiovascular responses observed in the 
present study between the SDB conditions of 4Ffr, 6Ffr and Dfr, however for many 
variables (such as percentage amplitudes of BP oscillations) the 8Ffr condition did not 
deliver a significantly different cardiovascular response compared with spontaneous 
breathing (Sfr). This suggests that 8 breaths.min-1 may be too high a breathing frequency 
to elicit the full cardiovascular response of SDB. As a group, the eighteen pregnant 
women chose 6 breaths.min-1 (6Ffr) as their preferred breathing frequency if they were 
asked to continue with the SDB exercise daily until birth Additionally, there was no 
correlation between gestational age and preferred SDB frequency, or for optimal 
breathing frequency derived from the bespoke optimisation algorithm, suggesting that all 
SDB frequencies are manageable at all stages of gestation. Therefore, the present study 
suggests that future studies should utilise 6 breaths.min-1 (6Ffr) for SDB interventions 
with pregnant women, which provides a good compromise between the optimising 




The present study adds to growing evidence that the analysis of inter- and intra-breath 
phase haemodynamic oscillations are vital to reveal the true extent of the cardiovascular 
perturbations created by SDB. The cardiovascular responses to SDB are similar in 
healthy pregnant and healthy non-pregnant women, with no significant differences in 
relative amplitude of BP oscillations and a similar relative increase in RSA from baseline 
values (Sfr). RSA is attenuated during spontaneous breathing in pregnant women, but 
can be increased acutely to non-pregnant levels by SDB. The data support future studies 
investigating the long-term changes to RSA, BP and other cardiovascular variables 




7.3 Supplementary material 
 
The following results tables will be included as supplementary information for the 
publication in European Journal of Applied Physiology. 
 
Table 7-7 Mean values (±SD) and inter-breath phase differences (Δ) for blood 
pressure variables (mmHg) 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); systolic blood pressure (SBP), diastolic blood pressure (DBP); mean inspiration 
(i), mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly different from Sfr 





















NP 121.3 ± 17.6 118.0 ± 9.6 115.3 ± 19.9 119.8 ± 13.8 116.2 ± 10.5 0.481 
0.921 P 122.1 ± 12.5 117.1 ± 17.4 115.4 ± 13.9 117.1 ± 10.7 117.2 ± 15.8 0.347 
SBPi 
NP 118.9 ± 17.4 114.3 ± 9.8 112.3 ± 20.2 117.1 ± 14.7 116.5 ± 10.4 0.475 
0.681 P 119.8 ± 12.5 115.6 ± 18.1 114.9 ± 14.4 118.0 ± 11.5 118.7 ± 15.5 0.519 
SBPe 
NP 123.8 ± 17.8 121.8 ± 9.6 118.4 ± 20.0 122.7 ± 13.3 115.8 ± 11.1 0.200 
0.538 P 124.3 ± 12.5 118.5 ± 16.8 116.0 ± 13.8 116.3 ± 10.3 115.7 ± 16.3 0.062 
SBPΔ 
NP –4.9 ± 2.1§ –7.5 ± 3.4§ –6.0 ± 5.0§ –5.6 ± 5.2§ 0.7 ± 5.0*¥¤† <0.001 
0.001 P -4.5 ± 1.8¤†§ -2.9 ± 3.8†§ -1.1 ± 4.1*†§ 1.7 ± 4.7*¥¤ 3.0 ± 2.2*¥¤ 0.000 
DBP 
NP 74.7 ± 17.1 73.1 ± 7.3 67.5 ± 14.7 74.1 ± 11.4 69.8 ± 8.7 0.166 
0.942 P 74.5 ± 10.2 73.2 ± 12.8 69.7 ± 10.3 71.6 ± 7.3 71.3 ± 12.3 0.289 
DBPi 
NP 73.9 ± 17.3 71.8 ± 7.3 67.1 ± 15.4 73.6 ± 11.9 71.9 ± 9.0 0.286 
0.846 P 73.2 ± 9.9 72.4 ± 13.2 69.9 ± 10.7 72.9 ± 7.9 72.9 ± 12.0 0.561 
DBPe 
NP 75.5 ± 17.0 74.3 ± 7.3 68.0 ± 14.2 74.6 ± 11.1 67.7 ± 8.6 0.064 
0.961 P 75.8 ± 10.4¤† 74.1 ± 12.4 69.5 ± 10.0* 70.3 ± 7.0* 69.7 ± 7.0 0.021 
DBPΔ 
NP –1.5 ± 1.0§ –2.5 ± 1.5§ –0.9 ± 3.4§ –1.0 ± 3.4§ 4.2 ± 3.3*¥¤† <0.001 
0.134 P -2.5 ± 0.9¤†§ -1.7 ± 1.8¤†§ 0.3 ± 2.1*¥†§ 2.6 ± 2.5*¥¤ 3.2 ± 2.2*¥¤ <0.001 
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Table 7-8 Mean values (±SD) and inter-breath phase differences (Δ) for heart rate 
(fc), stroke volume (SV) and cardiac output (Q̇) variables 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); heart rate (fc; beats.min-1), stroke volume (SV; ml), cardiac output (Q̇; ml.min-1); 
mean inspiration (i), mean expiration (e), inter-breath phase difference (∆; i minus e); Significantly 

















NP 67.6 ± 10.9 70.7 ± 11.6 70.0 ± 11.0 70.0 ± 10.5 69.5 ± 10.3 0.091 
0.001 P 80.7 ± 10.1 82.6 ± 9.8 80.3 ± 9.3 81.7 ± 8.6 79.9 ± 8.4 0.123 
fc i 
NP 67.0 ± 11.3¤†§ 72.5 ± 12.1† 74.4 ± 12.5* 74.4 ± 12.0*¥ 74.5 ± 11.0* <0.001 
0.003 P 80.4 ± 10.5¥¤† 85.2 ± 10.0* 83.9 ± 8.8* 85.1 ± 7.5* 82.1 ± 7.3 <0.001 
fc e 
NP 68.3 ± 10.6§ 68.5 ± 10.8†§ 65.8 ± 10.3 65.6 ± 9.2¥ 64.6 ± 10.1*¥ 0.002 
0.001 P 80.9 ± 9.8 79.7 ± 9.8 76.4 ± 10.1 78.1 ± 10.0 77.7 ± 9.9 0.009 
fc Δ 
NP –1.4 ± 1.4¥¤†§ 4.0 ± 2.9*¤†§ 8.6 ± 5.4*¥ 8.9 ± 4.9*¥ 9.9 ± 4.8*¥ <0.001 
0.240 P -0.5 ± 2.4¥¤† 5.5 ± 3.3* 7.4 ± 4.7* 7.0 ± 5.0* 4.3 ± 5.1 <0.001 
SV 
NP 67.4 ± 19.8 66.7 ± 21.1 68.3 ± 21.3 66.2 ± 22.0 68.5 ± 18.4 0.539 
0.008 P 82.3 ± 9.8 81.4 ± 10.4 82.5 ± 10.0 82.7 ± 9.2 83.1 ± 10.2 0.920 
SVi 
NP 65.2 ± 19.7 63.5 ± 20.4 64.9 ± 20.4 63.1 ± 20.7 65.1 ± 18.1 0.366 
0.002 P 80.3 ± 9.5 80.9 ± 10.5 81.9 ± 9.9 82.3 ± 9.2 82.7 ± 10.0 0.640 
SVe 
NP 69.6 ± 20.0 69.9 ± 21.9 71.6 ± 22.4 69.3 ± 23.3 71.9 ± 18.9 0.490 
0.026 P 84.2 ± 10.3 81.8 ± 10.8 83.0 ± 10.8 83.1 ± 9.9 83.5 ± 10.7 0.854 
SVΔ 
NP –4.4 ± 2.9 –6.4 ± 3.6 –6.7 ± 4.6 –6.2 ± 4.4 –6.8 ± 3.5 0.188 
<0.001 P -3.9 ± 3.0 -0.9 ± 4.2 -1.1 ± 5.7 -0.8 ± 4.9 -0.7 ± 4.2 0.027 
Q̇ 
NP 4441 ± 1047 4564 ± 1144 4633 ± 1097 4482 ± 1220 4632 ± 1017 0.530 
<0.001 P 6596 ± 923 6652 ± 1075 6564 ± 981 6706 ± 1027 6573 ± 863 0.728 
Q̇i 
NP 4247 ± 1018¤ 4476 ± 1181 4707 ± 1184* 4562 ± 1266 4737 ± 1096 0.026 
<0.001 P 6427 ± 953¥¤† 6858 ± 1090* 6855 ± 1034* 6995 ± 990* 6749 ± 884 0.001 
Q̇e 
NP 4639 ± 1083 4639 ± 1117 4566 ± 1034 4406 ± 1197 4527 ± 952 0.435 
<0.001 P 6765 ± 913¤§ 6447 ± 1077 6268 ± 958* 6427 ± 1079 6399 ± 864* 0.003 
Q̇Δ 
NP –392 ± 155¥¤†§ –163 ± 250*¤†§ 141 ± 307*¥ 156 ± 278*¥ 210 ± 264*¥ <0.001 
<0.001 P -339 ± 286¥¤†§ 411 ± 278*¤ 588 ± 351*¥ 568 ± 238*§ 350 ± 257*† <0.001 
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Table 7-9 Mean values (±SD) and inter-breath phase differences (Δ) for total 
peripheral resistance (TPR) and pulse wave velocity (PWV) variables 
Data represent mean ± SD (non-pregnant n = 18, pregnant n = 17); Non-pregnant (NP), Pregnant  
(P); Spontaneous breathing (Sfr), fixed breathing frequency of 4 breaths .minute-1 (4Ffr), 6 
breaths.minute-1 (6Ffr), 8 breaths.minute-1 (8Ffr), optimisation algorithm dynamic breathing 
frequency (Dfr); total peripheral resistance (TPR) in mmHg⋅min⋅L-1, pulse wave velocity (PWV) in 
m.s-1; mean inspiration (i), mean expiration (e), inter-breath phase difference (∆; i minus e); 




A comprehensive characterisation of the cardiovascular responses to SDB in healthy 
non-pregnant and healthy pregnant women has been completed. The data reveal that, 
although there are baseline cardiovascular differences between pregnant and non-
pregnant women, including depression of RSA, the responses to SDB are similar. 
Specifically, RSA increases by a similar relative amount between non-pregnant and 
pregnant groups (2.1 times greater). Additionally, when the amplitude of BP oscillations 
is calculated relative to mean BP there are no significant differences between pregnant 
and non-pregnant groups across all breathing frequencies, reflected in similar absolute 
BP oscillation values. Overall, pregnancy does not appear to attenuate the response of 
key cardiovascular variables to SDB. 
 
 








NP 21.5 ± 8.3 20.0 ± 3.7 18.3 ± 3.5 20.9 ± 5.4 18.8 ± 3.5 0.171 
<0.001 P 13.8 ± 3.1 13.4 ± 3.1 13.1 ± 2.6 13.1 ± 2.4 13.2 ± 2.2 0.419 
TPRi 
NP 22.2 ± 8.6 20.0 ± 3.9 17.8 ± 3.6 20.2 ± 5.1 18.9 ± 3.8 0.084 
<0.001 P 14.0 ± 3.0¤† 12.8 ± 2.9 12.5 ± 2.6* 12.7 ± 2.3* 13.1 ± 2.2 0.020 
TPRe 
NP 20.8 ± 7.9 20.0 ± 3.5 18.8 ± 3.6 21.6 ± 5.7 18.8 ± 3.4 0.233 
<0.001 P 13.7 ± 3.2 14.0 ± 3.2 13.7 ± 2.7 13.5 ± 2.6 13.3 ± 2.3 0.600 
TPRΔ 
NP 1.3 ± 1.1¥¤† 0.0 ± 1.1*¤† -1.0 ± 0.9*¥ -1.4 ± 1.3*¥ 0.0 ± 1.6 <0.001 
0.015 P 0.2 ± 0.7¥¤† -1.2 ± 0.7*§ -1.2 ± 0.6*§ -0.8 ± 0.7*§ -0.2 ± 0.4¥¤† <0.001 
PWV 
NP 4.6 ± 0.4 4.6 ± 0.4 4.7 ± 0.4 4.7 ± 0.4 4.7 ± 0.4 0.143 
0.014 P 5.1 ± 0.5 5.1 ± 0.5 5.0 ± 0.4 5.0 ± 0.5 5.0 ± 0.5 0.081 
PWVi 
NP 4.6 ± 0.4 4.5 ± 0.4§ 4.6 ± 0.4 4.6 ± 0.4 4.7 ± 0.4¥ 0.002 
0.007 P 5.0 ± 0.5 5.0 ± 0.6 4.9 ± 0.4 5.0 ± 0.5 5.0 ± 0.5 0.205 
PWVe 
NP 4.7 ± 0.4 4.7 ± 0.4 4.8 ± 0.4 4.8 ± 0.4 4.8 ± 0.4 0.472 
0.029 P 5.2 ± 0.5†§ 5.1 ± 0.5† 5.1 ± 0.5 5.0 ± 0.5*¥ 5.1 ± 0.5* 0.004 
PWVΔ 
NP –0.2 ± 0.1 –0.2 ± 0.1 –0.1 ± 0.1 –0.2 ± 0.1 –0.1 ± 0.2 0.030 
0.006 P -0.14 ± 0.1† -0.10 ± 0.2†§ -0.11 ± 0.1† -0.02 ± 0.1*¥¤ -0.02 ± 0.1¥ <0.001 
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With the understanding that SDB produces similar responses in pregnant women as it 
does in non-pregnant women the next step is to replicate this study in women who 
develop high BP during pregnancy (pregnancy-induced hypertension; PIH). There are 
additional cardiovascular adaptations as a result of the underlying pathophysiology of 
PIH that may change the response to SDB from that of normotensive pregnant women. 
It is important to understand any differences in acute responses in pregnant women with 
PIH and how they may link to the error signals and mechanisms underpinning long-term 
reductions in BP.  
 
Finally, the feasibility of using SDB as a treatment method for PIH must be investigated 
to test whether pregnant women will accept and adhere to the intervention, in addition to 
whether it has health benefits, either prophylactically, or after a diagnosis of PIH. This 
chapter has revealed that the optimal breathing frequency is 6 breaths.min-1, and this 
should be used in future studies using SDB as an intervention in pregnant women. The 
next chapter will outline a proposed protocol to investigate the acute responses to SDB 
in pregnant women who develop PIH and trial the feasibility of using SDB as a daily 
intervention to reduce BP.  
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Chapter 8. Effects of slow and deep breathing on reducing 
obstetric intervention in women with pregnancy-induced 
hypertension: A feasibility study protocol 
8.1 Introduction 
 
The next step following the mechanistic understanding gained in the preceding chapters 
is to understand how pregnant women who develop pregnancy-induced hypertension 
respond to slow and deep breathing (SDB) and to test both the short- and long-term 
effects of SDB. Ethical approval for this study was received from the Hampshire B 
Research Ethics Committee alongside Health Research Authority (HRA) approval in Dec 
2019. However, in the first few months of 2020 the world was hit by a global pandemic 
when coronavirus spread across the world. This unprecedented situation coincided with 
the set up and recruitment phase of this study and consequently recruitment for this study 
was put on hold in March 2020. 
 
On 16th March pregnant women were classed as high risk by the UK government and on 
23rd March the country went into lockdown. With a subsequent extended lockdown period 
it was clear that the study could not be completed within the time restrictions of PhD 
research, with an unknown date when maternity research could restart. The local 
maternity unit had only 2/11 existing research studies open for recruitment during the 
coronavirus outbreak. It is hoped this research study will be conducted with future 
funding as part of a post-doc project. The protocol for this study has been published in 
Hypertension in Pregnancy (Felton et al. 2021) and the published version is presented 
overleaf. References for the published article are listed at the end of the article, and are 
not replicated in the thesis reference list, unless cited elsewhere in the thesis. 
 
The research questions and objectives for this chapter are outlined below: 
 
Research questions 
1. Is a daily SDB intervention accepted and adhered to by women with pregnancy-
induced hypertension? 
2. Does a daily programme of SDB reduce long-term blood pressure and/or 
obstetric intervention in women with pregnancy-induced hypertension? 
3. Do women with pregnancy-induced hypertension exhibit the same acute 




1. Design an evidence-based SDB intervention for women with pregnancy-induced 
hypertension. 
2. Evaluate the adherence and recruitment rates to a daily SDB intervention with 
pregnant women with pregnancy-induced hypertension. 
3. Assess blood pressure changes and obstetric intervention rates following 
completion of the SDB intervention. 
4. Assess if women accept SDB as a treatment method for pregnancy-induced 
hypertension. 
5. Identify whether mechanism-related parameters (e.g. respiratory sinus arrythmia, 
stroke volume, cardiac output) respond similarly to SDB for normotensive 
pregnant women and women with pregnancy-induced hypertension. 
6. Identify whether acute changes in blood pressure and amplitude of blood 
pressure oscillations during SDB are similar for normotensive pregnant women 
and women with pregnancy-induced hypertension. 
7. Evaluate whether the acute cardiovascular responses to a range of SDB 
frequencies are similar for normotensive pregnant women and women with 
pregnancy-induced hypertension. 
 
8.2 Integrated paper: Effects of slow and deep breathing on 
reducing obstetric intervention in women with pregnancy-
induced hypertension: A feasibility study protocol 
 




8.2     Integrated   paper:   Effects   of  slow   and   deep   breathing   on 
reducing obstetric intervention in women with pregnancy- 
induced hypertension:  A feasibility study protocol 
 
 
See: Felton, M., Hundley, V. A., Grigsby, S. and McConnell, A. K., 2021. Effects of slow 
and deep breathing on reducing obstetric intervention in women with pregnancy-induced 



































8.3 Additional protocol material  
 
Due to the nature of publishing research articles there were elements of this research 
study that were not published in the protocol (section 8.2). To provide all the relevant 
information for this thesis, additional material relating to this protocol are outlined below. 
 
8.3.1 Recruitment prior to COVID-19 shut down 
 
Although no-one had been recruited into the study at the date of pausing the study, the 
recruitment period was open, and 5 women had been approached. Unfortunately, the 
ANDA midwives were not able to record the reasons women declined to take part due to 
their busy schedules on the ward. However, initial feedback from the research midwife, 
following discussion with one woman, was that the pregnant women was already finding 
it hard to breath sometimes and she felt like the mask pictured in the PIS would be 
claustrophobic. It was the picture in the PIS that had put her off from taking part. 
Unfortunately, as the mask is essential for verifying the breathing frequency during the 
short-term protocol it is not possible to remove this from the research protocol. However, 
during future RCTs the protocol would not include the short-term lab-based session, 
instead focusing on the at-home SDB intervention, and therefore this woman may have 
been willing to take part. 
 
The inclusion and exclusion criteria for this study were originally set to match the criteria 
for the previous studies of pregnant women without high blood pressure (Chapter 6). 
However, due to slow recruitment for the study it was decided to make an amendment 
to the study and expand the criteria to allow multips to take part (women who have 
previously been pregnant). The justification for this was that blood pressure was not 
found to be significantly different between nulliparous and parous women across all 
stages of gestation (Loerup et al. 2019). An amendment was submitted via IRAS to the 
NHS Research Ethics Approval and was approved in March 2020 after the study had 
been paused. Consequently, recruitment rates with the new inclusion and exclusion 
criteria have not been tested. 
 
8.4 Patient and Public Involvement: Conducting maternal research 
during the coronavirus pandemic 
 
Patient and public involvement (PPI) has been an ongoing process integrated into the 
development stage of the SDB intervention. Prior to the PhD, (and undertaken 
independently from the author), PPI was undertaken with the National Childbirth Trust 
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(NCT) to consultant with pregnant women and practitioners about their views of using a 
SDB intervention to reduce BP during pregnancy. PPI was also undertaken during the 
development of the patient-facing documentation for the SDB intervention trial, to ensure 
paperwork was designed with the end-user in mind. Pregnant women were also involved 
in the decision of which SDB frequency to use for the long-term intervention protocol, 
where participant preference was noted during data collection in Chapter 6. 
 
In 2020, following the pausing of the majority of maternity research including the clinical 
protocol outlined in section 8.2, PPI was undertaken by the author with pregnant women 
and new mothers to explore their views of participating in research during the coronavirus 
pandemic. The aim of the PPI consultation was to discuss the proposed project with 
more women to explore their views on the general research topic, specific protocol 
(section 8.2), and most importantly to find out their views of taking part in research during 
the coronavirus pandemic. The latter discussions included what processes and 
reassurances researchers can put in place to make women feel more comfortable taking 
part in research, and our research project specifically.  
 
Women were recruited using the local network of maternity groups developed during the 
recruitment for Chapter 6, and through the local Dorset Maternity Matters Facebook page 
(www.facebook.com/DorsetMaternityVoices). Dorset Maternity Matters is run by the 
NHS Dorset Clinical Commissioning Group (CCG), which is responsible for the maternity 
services in Dorset. A promotional poster/leaflet was shared on social media and women 
contacted the investigator if they were interested in taking part. The only inclusion 
criterion was that women were currently pregnant or had given birth since April 2020, 
and therefore had experienced being pregnant during the coronavirus pandemic. 
 
Twelve women contacted the author expressing an interest in taking part in the PPI and 
five women participated in the consultation. One woman who was booked to attend was 
unable to join the consultation on the day. Two PPI consultations were set up, one with 
pregnant women (n=3) and one with new mothers (n=2) to ensure that all views were 
represented. Due to the ongoing restrictions related to COVID-19 the consultation was 
undertaken on Zoom. In the pregnant group, 1 woman was experiencing her first 
pregnancy, 1 woman had a previous miscarriage, and 1 woman already had a child. The 
mother with a child had experience of pre-eclampsia during her first pregnancy, but no 
other women in either group had experiences of high blood pressure previously. The 
pregnant women were an average of 24 weeks pregnant and 31.7 years old at the time 
of consultation. The women in the new mother’s group both had 1 child each who was 
an average of 5.5 months old, and the mothers were an average of 27 years old. 
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Following discussions of the clinical protocol outlined in section 8.2, all the women said 
they would be interested in taking part in the intervention study if approached to do so. 
However, this is not unsurprising given the opt-in nature of the consultation, with women 
choosing to take part and therefore already expressing an interest in this type of 
research. The new mothers were asked to consider the questions and frame their 
responses in the context that they would be currently pregnant if they took part in the 
project.  
 
“It’s just obviously a good idea if you can avoid taking extra drugs during 
pregnancy, then it’s a good study.”         Pregnant woman 
 
All pregnant women and half of the new mothers were more concerned about taking part 
in research during the coronavirus pandemic and would be more cautious about whether 
to take part in research, especially where it involved face-to-face interaction. 
 
“I know some friends of mine were absolutely terrified, and carry on being 
terrified. You know, now that they’ve got their babies. It’s just like a different kind 
of fear….you know with the government we have been told we were vulnerable.” 
         New mother 
 
As the current protocol includes an initial meeting at Bournemouth University, women 
discussed whether they would be comfortable attending a university campus. There was 
a split between the new mothers and pregnant women, with new mothers expressing 
that they would feel comfortable attending a university campus, whereas the pregnant 
women would not want to attend a university campus during coronavirus restrictions. The 
concerns around attending campus related mainly to the women having to mix in spaces 
with undergraduate students (such as main reception areas and toilets) and the 
possibility of contact tracing and having to isolate from ‘checking in’ using a QR code 
system in a university building used by potentially hundreds of students each day. 
Concerns were specifically related to being around too many people and having to use 
or walk through busy areas. 
 
“I think I’d rather if we have to attend campus, I don’t know, earlier in the morning 
or in the evening. Maybe when there’s not loads of students there because 
obviously we’re trying to protect ourselves from, you know, exposures to too 
many people.”               Pregnant woman 
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Some of the women had been unable to continue working during the coronavirus 
pandemic due to their pregnancy and underlying conditions. They felt conflicted that if 
they couldn’t attend their workplace then maybe they shouldn’t attend a university 
campus, which could put them at risk. The specific concern was what if they caught 
COVID-19 during the visit, and how their workplace would view this given the allowances 
made by their employer for shielding during the pandemic.  
 
“It’s really weird because normally I would have no worries about it whatsoever, 
but my work have gone out of the way to help me work from home. It would feel 
then irresponsible to then go oh yeah well I went to the uni and I caught it 
[coronavirus] there.”           Pregnant woman 
 
Women discussed that they would feel more comfortable attending campus if certain 
measures were in place. Firstly, to minimise potential contact and mixing with students 
the suggestion was made to have a separate less busy entrance to enter the room and 
also to have separate toilets that were not used by all students. This would be achievable 
in our current set-up as there is a private corridor and separate outside entrance for use 
by the clinical laboratory. There is also a dedicated toilet facilitates only used by staff and 
participants who have access to the corridor. Women stressed the importance of 
including all information regarding cleaning and wearing of personal protective 
equipment (PPE) in the participant information sheet, even if it seemed obvious that 
these processes would be followed. Adequate ventilation of the room was also raised as 
a comforting factor in attending the initial meeting, and extra precautions such as leaving 
equipment to rest for 48 hours between participants was welcomed as reassuring. 
 
“…and sharing what you’ve got in place [procedures]. Like, I know it sounds really 
really obvious, but just reminding people I think will add to feeling comfortable 
coming in [to campus]…the more information you can share the better” 
New mother 
 
The current protocol includes the short-term responses to SDB protocol, which requires 
access to equipment at the university campus. However, future studies may only include 
an induction session to receive instructions on accessing the SDB intervention and 
consenting to participate in the trial. Women were therefore asked where else they would 
feel comfortable to have the research induction session; 80% of women would be happy 
to have the induction inside their own home, 80% would be happy if it was outside in 
their own home (garden) and 100% of women would be happy to have the session 
virtually over Zoom or an equivalent online platform.  
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In conclusion, although pregnant women are more concerned and wary about taking part 
in research during the coronavirus pandemic there is still an appetite to participate in 
research if appropriate considerations and processes are put in place. Specifically, 
women would feel more comfortable when attending university campus if the time spent 
in communal areas shared with undergraduate students was minimised, such as a 
separate entrance rather than the main reception area and using dedicated and separate 
toilet facilities. Information regarding cleaning procedures and PPE should be made clear 
in the participant information sheet and should be updated and reviewed regularly in line 
with current guidelines. Future studies which do not require use of specialist equipment 




In summary, the clinical protocol outlined in this chapter was paused due to COVID-19, 
but the author has created a plan to re-start the study as a post-doc project following 
completion of this PhD. An application for an NIHR Advanced Fellowship has been 
submitting, to support funding of the project and development of the author as a health 
researcher. 
 
It is unfortunate that the coronavirus pandemic stopped the clinical study being 
completed as part of this PhD thesis. It would have provided the next step in the research, 
bridging the gap from the laboratory-based, mechanistic investigations characterising 
acute responses to SDB, to trialling SDB as intervention in pregnant women, with real-
world clinical implications. As a feasibility study it would have provided evidence for 
acceptance and adherence in a pregnant population, and initial clinical evidence on 
whether a SDB intervention was worth pursuing as a non-pharmacological treatment for 
PIH. As it stands, the protocol is designed, ethical approval remains in place and the 
clinical study is ready to be resumed when additional funding is secured.   
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Chapter 9. Discussion 
 
9.1 Introduction and overview 
 
This chapter will review the main findings of the thesis and evaluate them in the context 
of the existing state of knowledge. An interpretation of the findings in relation to their 
mechanistic potential for reducing chronic blood pressure (BP) is presented alongside 
the clinical implications of these findings. Finally, the directions for future research based 
on the new state of knowledge informed by this thesis are outlined. 
 
The unique nature of this thesis is that the research integrates two separate disciplines, 
applied human physiology and clinical health research in the maternity field. By using an 
interdisciplinary approach, this thesis provides the physiological evidence to support the 
development of a clinical health intervention designed specifically for pregnant women. 
 
The aim of this thesis was to characterise and compare the acute cardiovascular 
responses to slow and deep breathing (SDB) of pregnant women and design a specific 
SDB intervention for women who develop pregnancy-induced hypertension (PIH). The 
objectives set to meet the aim of the thesis are summarised below and can be viewed in 
full for each study in the relevant chapters. 
 
1. Identify the acute response in blood pressure and amplitude of blood pressure 
oscillations during SDB for healthy young men, healthy non-pregnant women and 
healthy pregnant women. 
2. Characterise and compare the response of mechanism-related parameters (e.g. 
respiratory sinus arrythmia, stroke volume, cardiac output) to SDB for healthy 
young men, healthy non-pregnant women and healthy pregnant women. 
3. Evaluate differences in acute cardiovascular responses to a range of SDB 
frequencies for healthy non-pregnant women and healthy pregnant women. 
4. Design an evidence based SDB intervention for women with PIH. 
 
9.2 Discussion of the key findings in relation to existing literature 
 
9.2.1 Novel analysis of cardiovascular responses 
 
This study is the first to use the peak-valley method of analysis across all cardiovascular 
variables to measure the range of complex responses to SDB. The data from all studies 
presented in this thesis revealed minimal cardiovascular responses to SDB when 
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examining simple averages of cardiovascular variables, either across the full breath or 
during individual breath phases (inspiration/expiration). However, using peak-valley 
analysis to evaluate differences between minimum and maximum values, reflecting the 
fluctuations caused by SDB, revealed significant increases during inspiration, expiration 
and between breath phases. SDB increased the amplitude of the respiratory sinus 
arrythmia (RSA), and of oscillations in stroke volume (SV), cardiac output, systolic blood 
pressure (SBP), diastolic blood pressure (DBP) and total peripheral resistance (TPR) in 
men, women and pregnant women. The novel analysis presented in this thesis highlights 
the importance of measuring more than the mean values for cardiovascular variables, 
since the mean overlooks the deeper and more complex cardiovascular responses. The 
true magnitude of perturbations created by SDB are only revealed when analysing peak-
valley (Δi, Δe, ΔPV) and breath phase independent peak-valley (ΔPV_Ind) at an inter- 
and intra-breath phase level. Figure 5-7 (page 116) demonstrates this hidden response  
for an example participant, by displaying mean heart rate (red series) during Sfr and 6Ffr 
plotted with beat-by-beat heart rate data. In this example, the true heart rate response is 
masked and averaged out of existence when only mean heart rate is considered. Due to 
the dynamic nature of blood pressure (BP), Parati et al. (1995) highlighted the 
importance of examining the fluctuations around the average BP as early as 1995, 
arguing that it is within these fluctuations that substantial insight is uncovered into the 
mechanisms of cardiovascular control. However, the peak-valley method used in this 
thesis has not previously been used. 
 
9.2.2 Amplitude of blood pressure oscillations and respiratory sinus arrythmia  
 
An important example of the perturbations revealed by the novel analysis employed in 
this thesis is the true amplitude of BP oscillations induced by SDB, which has not been 
reported previously. Previous studies have only examined average BP during or after 
SDB, for example Herakova et al. (2017) and Mori et al. (2005). For all participant groups, 
mean SBP or DBP were not significantly different during SDB compared with normal 
spontaneous breathing (Sfr). However, the amplitude of BP oscillations, calculated as 
the change in BP during breath phase (inspiration (Δi)/expiration (Δe)) relative to mean 
BP (corresponding mean BP during inspiration/expiration breath phase), was 
significantly higher during SDB. The range of SBP oscillations observed during SDB was 
between 8.0 - 13.4% (9.1 - 15.5mmHg) during inspiration (SBPΔi) and 5.7 - 10.4% (6.9 
- 12.1mmHg) during expiration (SBPΔe). In comparison, during spontaneous breathing 
(Sfr) oscillations were between just 2.9 - 3.0% (3.4 - 3.6mmHg) during inspiration and 3.0 
- 3.6% (3.7 - 4.5mmHg) during expiration. For DBP, amplitude of BP oscillations 
increased during SDB by between 7.3 - 14.3% (5.2 - 10.0mmHg) during inspiration 
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(DBPΔi) and 7.3 - 14.2% (5.1 - 9.9mmHg) during expiration (DBPΔe), compared with Sfr 
BP oscillations of between 2.1 - 3.5% (1.5 - 2.4mmHg) and 3.3 - 4.6% (2.4 - 3.2mmHg) 
respectively. Overall, SDB led to a roughly three-fold increase in the amplitude of BP 
oscillations, compared to spontaneous breathing.  
 
Variability within cardiovascular parameters and the body’s ability to react to different 
stressors is a sign of good health (Shaffer and Ginsberg 2017). Reductions in heart rate 
variability (HRV) are associated with numerous conditions related to autonomic 
dysfunction (Camm et al. 1996), whilst high HRV is associated with aerobic training (da 
Silva et al. 2015). As cardiovascular oscillations are attenuated or lost in many diseases, 
it is therefore reasonable to suggest that re-establishing fluctuations in people who have 
clinical conditions such as hypertension may provide health benefits (Elstad et al. 2018). 
The body uses variables such as heart rate to make adjustments to the cardiovascular 
system in order to maintain homeostasis, an equilibrium and steady state within the body. 
BP oscillations have been observed to have anti-hypertensive effects in dogs (Nafz et 
al. 2000), but not to date in humans. However, it follows that a similar effect could be 
seen in humans, although this has yet to be observed. It was suggested that BP 
oscillations may result in a change in renal haemodynamics through renal fluid and 
sodium excretion (Nafz et al. 2000).  As the kidneys play a major role in maintaining BP 
levels, then changes in renal BP management could be a pathway towards long-term BP 
change. Indeed, renal resistive index (RRI) has been shown to increase following 4-
weeks of SDB (Bazzini et al. 2011; Modesti et al. 2015), but no acute changes in RRI 
were observed in this thesis (Chapter 5).  
 
Fluctuations in BP are potentially linked to cardiorespiratory coupling of respiration, BP 
and heart rate (Chang et al. 2013; Russo et al. 2017). Fluctuations in BP are normally 
caused by an internal cardiovascular response to external perturbations. The body uses 
the autonomic nervous systems to oppose the response to external stimuli, in an attempt 
to maintain homeostasis. The aim of homeostasis is to adjust BP back to a reference 
“set point” (Parati et al. 2006) which it considers to be its normal state. Due to the 
variables that contribute to the production of BP, and therefore effect fluctuations in BP, 
heart rate and variations in heart rate can influence BP fluctuations directly. To take a 
step back, BP fluctuations will be caused by either variations in total peripheral resistance 
(TPR) or cardiac output (Q; see Figure 9-1). 
 
Changes in TPR need more time to develop due to the nature of their reaction time to 
external stimuli and therefore rapid fluctuations in BP are likely caused by cardiac output. 
As cardiac output is affected by variations in heart rate and/or stroke volume then either 
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could influence BP. It is heart rate that has been suggested to be the main driver of BP 
variability due to the respiration synchronous RSA (Elstad et al. 2001). Alternatively, SV 
is increased during SDB as a result of increased venous return, caused by the lower 
intrathoracic pressure during SDB (Harada et al. 2014; Russo et al. 2017). The increase 
in amplitude of RSA may act as a counteracting measure to oppose respiratory-induced 
SV changes, to maintain cardiac output. In support of this theory, BP oscillations increase 
as breathing frequency reduces, to peak at the lowest breathing frequency measured (4 
breaths.min-1). Our data show RSA becomes saturated ≤6 breaths.min-1 and therefore 
RSA is unable to act as a buffer for SV induced fluctuations, leading to peak amplitude 


















Figure 9-1 Cardiovascular variables contributing to arterial blood pressure 
during slow and deep breathing 
N.B. Figure updated from Figure 2-1 to reflect cardiovascular responses to slow and 
deep breathing  
 
The amplitude of RSA increased in all studies as breathing frequency declined, showing 
our population groups responded similarly to participants from previous studies 
(Anderson et al. 2009; Zhang et al. 2009). Although there was no significant change in 
mean heart rate, changes in heart rate during inspiration and expiration resulted in an 
increase in RSA amplitude. There were no significant differences between RSA during 
the 4Ffr and 6Ffr breathing conditions in any participant groups, showing a plateau at 6 
breaths.min-1 (6Ffr), and the amplitude of RSA reached saturation point at the lower 
breathing frequencies of 4 breaths.min-1 (4Ffr). Despite this, peak RSA for 35% of non-
pregnant and pregnant women occurred during 4Ffr, the most common condition for peak 
RSA to occur. 
 
The physiological function of RSA is still hotly debated, but Elstad et al. (2015) suggest 
that the main function of RSA is to stabilise arterial BP, by working as a central feed-
175 
forward mechanisms, whereby RSA reduces the mechanical effect respiration has on 
BP fluctuations. It is still unclear whether heart rate oscillations such as RSA contribute 
to BP oscillations by generating or by buffering the BP oscillations to produce Mayer 
waves (Castiglioni and Parati 2011). The results from this thesis suggest that SDB 
produces a physiological state where RSA is maximised and cannot further regulate BP 
at breathing frequencies of ~6 breaths.min-1. Central feed-forward mechanisms require 
a balance between the effect of respiration on venous return to the heart and the neural 
reflexes that stabilise arterial BP. Venous return increases during inspiration and RSA 
may act as a buffer against this (Elstad et al. 2015) by creating an inverse relationship 
during respiration between heart rate and stroke volume (Toska and Eriksen 1993). An 
inverse relationship also exists between cardiac output and TPR, with a counteracting 
effect produced to maintain homeostasis for BP, and for cardiac output in the former 
case. For example, heart rate increases to counteract the decrease in SV during 
inspiration to maintain cardiac output. However, variations in heart rate (specifically RSA) 
and subsequently cardiac output do not efficiently buffer BP oscillations (Elstad et al. 
2011). The main source of respiratory fluctuations in MAP are as a result of variations in 
SV, leading to changes in cardiac output (Toska and Eriksen 1993). Elstad et al. (2011) 
also observed that variations in cardiac output are not sufficient to alleviate MAP 
oscillations, which it is argued, are predominantly produced by variations in TPR. 
However, the data from this thesis suggest that, acutely, observed increases in amplitude 
in both TPR and cardiac output may contribute to the increase in amplitude of BP 
oscillations. RSA amplifies BP oscillations and through cardiac output is unable to buffer 
BP oscillations under physiological challenge such as tilt test (Elstad et al. 2011). SDB 
breathing could be sufficient to present a physiological challenge and therefore produce 
a state where RSA cannot buffer BP fluctuations.  
 
Overall, the relationship between RSA and BP oscillations may be influenced by the level 
of mechanical effects that respiration has on arterial BP. The relationship whereby RSA 
acts as a buffer, may only come into effect when external stimuli inputting into the 
cardiovascular system are greater than those in supine resting humans (Taylor and 
Eckberg 1996). The mechanical effects of respiration on stroke volume and cardiac 
output during SDB are greater than normal breathing in supine humans, and therefore 
could produce a sufficient stimulus to trigger RSA’s role as a buffer to maintain BP.  
 
It is interesting that the amplitude of BP oscillations increased as breathing frequency 
was reduced, to a maximum amplitude of BP oscillation at 4 breaths.min-1. BP oscillations 
are calculated as the difference between minimum and maximum values during breath 
phase (inspiration/expiration) and are therefore dependent on the change in BP during 
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the breath-phase. As breathing frequency reduces, breath phase duration increases, 
providing more time for BP to fluctuate within-breath phase and providing a possible 
explanation for the higher levels of amplitude of BP oscillations at lower breathing 
frequencies. This can be linked back to the observed RSA saturation point at 6 
breaths.min-1, resulting in a plateau of RSA but BP fluctuations increasing and peaking 
at 4 breaths.min-1. However, there was no significant difference between the SDB 
conditions <8 breaths.min-1 for amplitude of BP oscillations, suggesting minimal 
differences between cardiovascular responses and potentially no meaningful clinical 
difference between SDB frequencies when used as part of a long-term intervention, 
providing the frequency is less than 8 breaths.min-1. SDB frequencies in the literature are 
defined as <10 breaths.min-1, however these findings suggest that breathing frequencies 
may need to be lower than < 8 breaths.min-1 to elicit the full cardiovascular perturbations. 
This has implications for the RESPeRATE device specifically, as the average breathing 
frequency in Chapter 4 for the first 5 minutes was 8.1 breaths.min-1 , supporting 
previously observed average frequencies of 8.4 breaths.min-1 (Altena et al. 2009). 
Consequently, individuals using RESPeRATE may not gain the full benefits f rom SDB if 
their breathing frequency remains above 8 breaths.min-1.  
 
Acute responses to SDB immediately change cardiovascular variables and fluctuations 
during the SDB sessions such as the amplitude BP oscillations and RSA outlined above. 
The changes to these variables are easy to examine and measure during non-invasive 
data collection, however, long-term changes in BP caused by SDB are related to more 
complex factors that change the BP set point (Anderson et al. 2010). A resetting of the 
autonomic nervous system has been suggested to occur following pranayama breathing 
(a form of breath control used in yoga) (Keerthi et al. 2013), but the mechanism by which 
this is achieved has not been understood fully. The findings of this thesis suggest that 
the increase in amplitude of BP oscillations during SDB may be one of the error signals 
that contributes to the reset process and may thus offer an explanation for the 
effectiveness of yoga reducing hypertension. During the development of hypertension 
the body’s control circuits are adjusted to a higher set point (Wallbach and Koziolek 
2018), and therefore interventions that can restore this set point to a lower, healthy level 
could provide benefits and/or alleviation of the condition. BP fluctuations are caused by 
a cardiovascular response to an external perturbation, in this case the SDB condition 
which causes cardiorespiratory coupling. To oppose the fluctuations in BP, neural control 
mechanisms are activated to maintain homeostasis, adjusting BP back to a reference 
set point (Parati et al. 1995). The body’s various set points (e.g., BP, heart rate, blood 
glucose, arterial PCO2, etc.) which maintain homeostasis are internally set but can be 
changed over time.  A simple example of this is resting heart rate; following training of 
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the heart through exercise, the heart becomes more efficient at ejecting blood (stroke 
volume) and pumps out more blood with each beat. Thus, to maintain the required 
cardiac output, the heart can pump fewer times per minute to produce the same flow of 
blood around the body. Consequently, the body resets resting heart rate at a lower level, 
as the body aims to undertake the least amount of work possible to maintain 
homeostasis. Using this frame of thinking regarding the body’s adaptability, the body 
may also be able to re-set resting BP at lower levels, after it has experienced the training 
of daily SDB sessions. During each SDB session the body adapts to the SDB by 
increasing the amplitude of oscillations, which could lead to a resetting of BP to 
normotensive levels (see section 9.2.3 for full further discussion of this point). 
Consequently, the ability of SDB to increase the amplitude of BP oscillations, and 
therefore increase the fluctuations of acute BP, could be a potential mechanism for the 
chronic reduction in BP observed following daily practice. However, caution must be 
used when discussing the relationship of cardiovascular variabilities to measures of 
autonomic function. The relationship is complex and still relatively undiscovered, leading 
to much debate in the field and a cautious basis on which to build theories of chronic BP 
adaptations (Parati et al. 2006). 
 
The frequency of BP oscillations is clinically relevant as it is significantly related to end 
organ damage during hypertension (Parati et al. 1997), however the amplitude of BP 
oscillations is still an under-researched topic. BP oscillations are often calculated as 
standard deviations over 24-hour ambulatory measurements (Parati et al. 1994), not 
instantaneous BP fluctuations, as occurs during SDB and was measured in this thesis. 
Therefore, the data presented in the thesis should be carefully compared with previously 
collected BP variability data.  
 
9.2.3 Potential restoration of autonomic imbalance by slow and deep breathing 
 
Research into resistant hypertension, i.e., high BP that does not respond to traditional 
pharmacological intervention, has branched into bioelectronic medicine, by using 
approaches such as invasive vagus nerve stimulation and baroreflex activation therapy 
(Cracchiolo et al. 2021). Both approaches aim to modulate autonomic nervous system 
activity using electrical stimulation of different elements of the autonomic nervous system 
(Lauder et al. 2020). Hypertension is associated with overactivity of the sympathetic 
nervous system and therefore interventions that can reduce sympathetic activity and 
increase parasympathetic activity have the potential to reduce BP. When the baroreflex 
is activated by electronic stimulation (as part of baroreflex activation therapy) increased 
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vagal tone is observed (Gassler and Bisognano 2014), suggesting an increase in 
parasympathetic activity. 
 
Following 6 months of baroreceptor activation therapy, using an implanted stimulation 
device, SBP decreased by 26.0 ± 4.4 mmHg and DBP by 12.4 ± 2.5mmHg (Hoppe et al. 
2012). The device is implanted under the skin in the pectoral region and the lead system 
is tunnelled from there to wrap round the bilateral carotid bulbs in the neck (see Gassler 
and Bisognano (2014) for detailed description and diagram). After 2 years of use, 50% 
of patients had reached the target office SBP of <140mmHg, and 58% of participants 
had decreased the number of antihypertensive medications they were prescribed by at 
least one, due to confirmed BP levels at or below target levels (Wallbach et al. 2020). 
Mechanisms associated with baroreflex activation therapy are potentially its ability to 
reset the operating set-point of the system regulating BP (Gassler and Bisognano 2014). 
It has been suggested that by providing sustained activation of the baroreceptors, 
baroreflex activation therapy may reduce long-term BP by chronically suppressing 
central sympathetic outflow (Iliescu et al. 2014). Activation of the baroreceptors may also 
restore cardiac rhythmicity by shifting cardiac autonomic balance and improving 
spontaneous baroreflex sensitivity (Iliescu et al. 2014). 
 
During SDB, baroreflex sensitivity has been observed to increase acutely (Lewis et al. 
2018) and in hypertensive patients can return to levels found in normotensive patients 
(Joseph et al. 2005). The aforementioned oscillations in BP, which are increased during 
SDB, may provide a similar mechanistic pathway to reduce BP as baroreflex activation 
therapy. The baroreceptors are responsible for detecting changes in BP and 
subsequently signal the brain to activate homeostatic mechanisms to buffer beat-to-beat 
fluctuations in BP. This thesis revealed an increase in beat-to-beat fluctuations in BP 
during SDB, which would subsequently increase the activation of the baroreceptors due 
to the increased number and amplitude of BP changes. Consequently, it is plausible that 
increased amplitude of BP oscillations caused by SDB, which in turn increase activation 
of the baroreceptors, could provide the same error signal that leads to reduced BP 
following baroreflex activation therapy. 
 
Baroreflex activation is currently considered an investigational therapy, with a paucity of 
evidence and therefore is not yet recommended for routine treatment of hypertension 
(Bhatt et al. 2019; Lauder et al. 2020). Additionally, because of the unapproved nature 
of the intervention and its use only within limited clinical trials, the recruitment criteria to 
undertake the therapy excludes women who are pregnant (Wallbach et al. 2020). 
Consequently, although baroreflex activation therapy has not been tested on PIH, it has 
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been suggested that baroreflex activation therapy may provide the greatest clinical 
benefit where hypertension is associated with overactive sympathetic activity (Iliescu et 
al. 2014), such as in PIH. Therefore, the potential shared mechanisms for baroreflex 
activation therapy are likely to be applicable to the treatment of PIH, in addition to 
resistant hypertension. Electromechanical device-based therapies, although promising, 
are limited by the invasive nature of the intervention (Lauder et al. 2020), and safety 
concerns due to the surgery required to implant the devices and subsequent related 
complications. If SDB can produce similar activation of the baroreflex through non-
invasive intervention, then SDB has the potential to become a leading non-
pharmacological intervention in the treatment of hypertension.  
 
9.2.4 Differences between acute cardiovascular responses to slow and deep 
breathing in males and females, and pregnant and non-pregnant women 
 
There were no differences in the acute cardiovascular responses to SDB observed 
between males and females, or between non-pregnant and pregnant women. The data 
presented in Chapter 4 showed that despite physiological differences between men and 
women, women’s cardiovascular response to SDB was similar to the responses 
observed in men. Thereafter, an analysis of non-pregnant women showed that despite 
differences in baseline cardiovascular variables, the response to SDB was not altered 
fundamentally by pregnancy (Chapter 7). 
 
During pregnancy, RSA values were depressed under all conditions, as observed in 
Chapter 6. However, SDB was able to increase RSA to levels found during spontaneous 
breathing in non-pregnant women. During SDB in pregnant women, RSA doubled 
compared with spontaneous breathing, matching previous observations during 
relaxation (DiPietro et al. 2008). A reduced RSA is linked with hypertensive disorders of 
pregnancy (Lakhno 2016) and the future clinical study outlined in Chapter 8 will 
distinguish whether RSA is further reduced with women who have PIH, compared with 
healthy pregnancies (Felton et al. 2021). The short-term protocol study will also evaluate 
whether the RSA response to SDB is maintained in women with PIH and if the amplitude 
of RSA doubles because of reducing breathing frequency, independent of baseline RSA. 
The data observed in this thesis suggest no reason why RSA would not increase during 
SDB in women with PIH, even if baseline RSA is depressed. The response to SDB 
between non-pregnant and pregnant women was similar, despite reductions in baseline 
RSA in pregnant women. Therefore, the findings of this thesis support progressing this 
line of research, as the cardiovascular responses to SDB have been confirmed to be 
similar during pregnancy compared with responses in non-pregnant women. 
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Previous research studies investigating chronic effects of SDB on BP have focused on 
male participants or have not separated data by sex for analysis, such as the majority of 
studies included in the meta-analysis of SDB by Chaddha and colleagues (2019), who 
included participants who were predominately men. Although this thesis was not able to 
perform a long-term SDB intervention due to COVID-19, there is a suggestion from the 
acute cardiovascular responses studies that there are no differences between men and 
women. However, due to limited sample sizes between groups there is not enough 
evidence to provide a definite conclusion on this and larger trials would be needed. 
Consequently, it is plausible to suggest that long-term cardiovascular changes will be 
similar in women to those previously observed in men and that this research is worth 
continuing. Likewise, pregnant women respond in the same way to SDB as non-pregnant 
women and it is theorised that the chronic adaptations to continued practise of SDB will 
therefore be similar to the observed BP reductions in non-pregnant populations.  
 
9.2.5 Lack of normative cardiovascular pregnancy data  
 
During the literature review for this thesis a lack of normative cardiovascular and 
respiratory data during pregnancy was found. As recently as 2019, there was insufficient 
data on spontaneous breathing frequencies throughout pregnancy to produce normative 
values (Loerup et al. 2019). Importantly, despite acceptance that BP changes throughout 
pregnancy depend on gestational age and trimester, the normative values for BP during 
pregnancy are not categorised into different trimester ranges but use a ‘one size fits all’ 
approach across all gestational ages. The idea for normative BP guidelines to be related 
to gestational age is not new, but has not been widely accepted  (Higgins and de Swiet 
2001). Accordingly, the NICE Hypertension in Pregnancy guidelines (NICE: National 
Institute for Health and Care Excellence 2019b) for normal BP levels and ranges of BP 
to define hypertension are predominately based on non-pregnant adult guidance (NICE: 
National Institute for Health and Care Excellence 2019a). 
 
The preliminary normative data compiled during this thesis was collected from only 18 
participants, and therefore the dataset could not be considered a representative sample 
of all pregnancies on which to base the development of normative guidelines. However, 
the data presented in Chapter 6 could provide the start of a database of normative 
cardiovascular data and shows the ease in which physiologists can collect and analyse 
these data. Working with midwives, who routinely collect key cardiovascular data during 
antenatal appointments and on-ward monitoring, presents a unique opportunity to build 
on the current limited set of data. Currently, teaching textbooks for student midwives 
(Coad et al. 2020; Rankin 2020) do not cite peer-reviewed references for their normative 
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data or the source of the data is unclear. Producing a bank of normative data would 
support future research, especially when investigating maternal health conditions during 
pregnancy. A lack of comparative data for normal pregnancies is an issue when 
researchers want to investigate differences between healthy pregnancies and those 
affected by cardiovascular disease. Without a baseline comparison, researchers cannot 
be sure whether observed changes in the cardiovascular system are due to the 
pregnancy itself or the condition in question. 
 
Specifically for PIH research, women who develop PIH later in pregnancy exhibit higher 
than average BP (but not yet at hypertensive levels) early in their pregnancy compared 
with women who remain normotensive throughout pregnancy (Higgins and de Swiet 
2001). Only by knowing what ‘normal’ BP values should be, across trimesters and 
different gestational ages, can differences be discerned for hypertensive disorders of 
pregnancy. Observed differences during routine antenatal appointments could lead to 
further investigation with additional clinical screening to assess risk of PIH. If women can 
be identified earlier as high risk for developing hypertension during pregnancy, then extra 
measures could be put in place, including the potential to use SDB as a preventative 
measure, which will be discussed later in section 9.4. 
 
An example of the clinical implications of not having access to normative data is the 
obstetric early warning systems, which are widely used in the UK but with varied 
consistency across maternity units. Sub-optimal care and detection of physiological 
problems occur when there is a lack of uniformity across the early warning scales, and 
the important physiological parameters are not agreed upon (Isaacs et al. 2019). 
Obstetric early warning systems have been found to use a large range of normal vital 
signs with significant variations across different NHS Trusts and maternity units, which 
causes uncertainty regarding thresholds and escalation leading to a discrepancy of 
practice between units in the UK (Smith et al. 2017). The early warning systems are 
designed to reduce maternal morbidity and mortality, but without agreed upon normative 
values they cannot be effective. 
 
9.2.6 Implications of findings for optimal breathing frequency and methods of 
implementation of clinical SDB interventions 
 
RESPeRATE is the main device used to guide SDB in the literature and is recommended 
by the American Heart Association as an alternative treatment for high BP (Brook et al. 
2013). Chapter 4 compared RESPeRATE with a fixed breathing frequency of 6 
breaths.min-1 (6Ffr) and a novel, bespoke algorithm (Dfr) driven by RSA maximisation. 
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When comparing the final 5 minutes of each breathing condition, there was no significant 
difference in cardiovascular responses to SDB between any SDB conditions, but there 
was also no significant difference in breathing frequency. The studies reported in 
Chapters 5 and 6 revealed that the increase in cardiovascular perturbations 
predominately occurred at breathing frequencies less than 8 breaths.min-1, with the 8Ffr 
condition not producing a significantly different response from spontaneous normal 
breathing (Sfr). Consequently, it seems that the important element to produce maximum 
perturbation of the cardiovascular system is that the breathing frequency is < 8 
breaths.min-1, but that the method used to achieve the breathing frequency is 
unimportant (fixed or dynamic frequency). It is reasonable to suggest these alternative 
approaches to implementing SDB (4Ffr, 6Ffr, Dfr) may produce the same long-term health 
benefits as RESPeRATE, given that they all produce the same acute responses and 
therefore most likely the same error signal(s) that produce the chronic reduction in BP. 
As for subjective preference, pregnant women found 6Ffr the most comfortable condition 
to undertake and would choose this breathing frequency to use in a daily intervention if 
given the choice.  
 
Research on the dose-response relationship of SDB has not been undertaken 
systematically, either for acute or chronic SDB interventions, but it is important to 
understand if differences exist in cardiovascular responses to different doses of SDB 
(Sica 2011). The observed data (Chapter 7) for both amplitude of BP oscillations and 
RSA show differences only during breathing frequencies below 8 breaths.min-1, 
suggesting that not all SBD frequencies are equal in their effect. The literature defines 
SDB as a breathing at a rate less than 10 breaths.min-1 and indeed RESPeRATE’s 
therapeutic breathing zone is set at 10 breaths.min-1 to match this. However, this could 
be sub-optimal, given that the results from this thesis reveal that not all SDB conditions 
below 10 breaths.min-1 produce the same acute cardiovascular response. The data 
revealed that cardiovascular responses to SDB at 8 breaths.min-1 are on the whole not 
significantly different from spontaneous normal breathing (Sfr). In Chapter 4, during the 
first 5 minutes of data collection breathing frequency during RESPeRATE (Rfr) was 8.1 
breaths.min-1 and consequently the full impact of SDB could be lost during the first 5 
minutes of using RESPeRATE. This is reflected in the significantly lower amplitude of 
BP oscillations detected during the first 5-minutes of Rfr compared with the final 5-
minutes. 
 
Consequently, although the RESPeRATE device is currently recommended by the 
American Heart Associate as a treatment method for high BP, this thesis has outlined 
potential limitations to the individualised breathing frequency generated by 
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RESPeRATE. RESPeRATE recommends 10 minutes of SDB a day in the therapeutic 
breathing zone, however as the results from this thesis show it can take time for breathing 
frequency to be reduced to satisfactory levels. Sica (2011) recommends that 
RESPeRATE should be used for 15 minutes a day, which would allow the first 5 minutes 
to be above optimal breathing frequency, while still providing 10 minutes of SDB 
frequency <8 breaths.min-1. In previous studies using 15 minutes SDB duration, a 
breathing frequency of <10 breaths.min-1 was only achieved for an average 11.5 minutes 
(±1 minute) of the total session (Anderson et al. 2009). Although using a longer total 
duration solves the problem of optimal breathing frequency being met for a sufficient 
time, the duration of the full intervention is increased compared with an intervention 
where the SDB could be delivered fully within 10-minutes of SDB at a breathing 
frequency <8 breaths.min-1. Alternative delivery methods suggested in this thesis such 
as the fixed breathing frequency of 6 breaths.min-1 provide SDB from the very first breath 
and reduce additional burdens on participants by limiting the intervention time to 10-
minutes. While 5-minutes of time saved daily does not seem a lot, this adds up to 35 
minutes each week and 2 hours 35 minutes across a month, which could be saved by 
utilising a more effective SDB treatment method. Adherence to interventions is a problem 
for all research, and even over a period of just 1 week of SDB full adherence was not 
achieved with 9% of sessions not completed (Cheng et al. 2019). Using the example of 
cardiac rehab programs, which require behavioural change modifications to participate 
in the intervention, barriers to adherence include time limitations and needing to see 
benefits from the time participants do input (Daly et al. 2002). Consequently, by reducing 
duration of the SDB session and therefore required time input from participants, 
adherence could potentially be increased. Although fixed breathing frequencies of 6 
breaths.min-1 have not been trialled for long-term responses, the acute cardiovascular 
responses were similar to RESPeRATE and therefore it is logical the long-term 
responses would also be similar. 
 
The novel, bespoke algorithm used in the dynamic breathing frequency condition (Dfr) 
was designed to maximise cardiovascular perturbations using RSA as the controlled 
variable. However, average RSA for non-pregnant and pregnant women was the same 
for all SDB conditions <8 breaths.min-1. Additionally, when analysing the condition in 
which individual peak RSA occurred, Dfr accounted for only 28% of participants across 
the two studies (Chapters 5 and 6) in which a range of frequencies were used (35% = 
4Ffr. 28% = 6Ffr. 28% = Dfr. 10% = 8Ffr). This analysis shows that the dynamic algorithm 
could not maximise RSA beyond the increases in amplitude caused by other SDB 
conditions. An explanation may be that the average breathing frequency during Dfr (non-
pregnant women = 6.3 breaths.min-1 and pregnant women = 7.0 breaths.min-1) was not 
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significantly different from the breathing frequency during the 6Ffr condition and therefore 
RSA was saturated and unable to be maximised further. Therefore, this thesis found no 
added benefit of personalising breathing frequency during SDB and it is not 
recommended to continue with this condition for use in long-term SDB interventions. This 
will also reduce the cost of the intervention, as the finger sensor is only needed to 
dynamically change breathing frequency. The fixed breathing frequencies (such as 6Ffr) 
can be used without the finger sensor and associated cost (~£45). 
 
Additionally, the Dfr condition was not preferred more than other breathing conditions by 
pregnant women, so personalisation does not affect perceived effort or levels of comfort 
when undertaking SDB during pregnancy. In fact, breathing frequency during Dfr was 
higher in pregnant women than non-pregnant women and 2 pregnant participants had 
an average breathing frequency >8 breaths.min-1. As outlined above, this level of SDB 
may not produce the desired beneficial effect to its maximum potential and therefore if 
the Dfr condition had been used as the SDB intervention in the pregnant cohort of 
participants for long-term daily use, it may not have produced the desired outcomes in 
some participants who did not achieve a breathing frequency <8 breaths.min-1.  
 
There was no correlation between preferred breathing frequency and gestational age for 
pregnant women, and therefore it is suggested that SDB frequencies as low as 4 
breaths.min-1 are comfortable for pregnant women during all trimesters of pregnancy. 
Consequently, based on the cardiovascular responses observed in this thesis, the 
breathing frequencies suggested for use as part of SDB interventions in pregnant women 
should be either the 4Ffr or 6Ffr conditions. As preference from the majority of women 
was 6Ffr it is recommended that 6 breaths.min-1 is the optimal SDB intervention to be 
trialled in pregnant women. 
 
9.2.7 Designing an evidence-based slow and deep breathing intervention for 
pregnant women who develop pregnancy-induced hypertension 
 
The evidence produced by this thesis has provided a solid foundation on which to build 
a specifically designed SDB intervention for pregnant women who have developed 
pregnancy-induced hypertension (PIH). Importantly, the data from this thesis has 
explored a variety of breathing frequencies, which could be used as SDB interventions 
in pregnant women. All conditions used in Chapter 6 (4, 6 and 8 breaths.min-1 and the 
dynamic algorithm) were well tolerated in pregnant women across gestational ages and 
the full 5 minutes were completed for all conditions by every participant. A combination 
of both the cardiovascular responses to SDB and the subjective data from pregnant 
185 
women suggest that 6 breaths.min-1 is the optimal breathing frequency to trial in pregnant 
women. Although such an intervention has yet to be trialled in pregnant women, the PPI 
work conducted as part of this thesis suggest women would value such an intervention, 
and showed interest in the video graphic delivering SDB at 6 breaths.min-1.  
 
Unfortunately, due to COVID-19 the designed protocol for piloting SDB as a treatment 
method for PIH was paused. However, the protocol has been peer-reviewed and 
published in the Hypertension in Pregnancy journal in 2021. A National Institute for 
Health Research (NIHR) Advanced Fellowship application has been submitted, to 
support the re-starting of this study and continuation of the research project.  
 
9.3 Strengths and limitations of the research 
 
Strengths of the thesis 
 
The biggest strength of this research is that it bridges the gap between physiological and 
clinical maternal health research. The interdisciplinary approach links two disciplines, 
which are both similar but very independent and distinct. The research provides an 
opportunity to translate the physiological laboratory research, aimed at understanding 
the physiological mechanisms behind clinical changes, into an evidence-based clinical 
intervention. The author’s experiences of conducting the research presented in this 
thesis has further underpinned the need for interdisciplinary approaches in maternal 
health research. While applied physiology research publishes a wide range of normative 
data related to a varied range of sports and physical activities, including even those new 
and niche exercises such as stand up paddleboarding (Schram et al. 2016), there is a 
lack of normative cardiovascular data in maternal health. While there is no doubt that 
these data exist, they are currently not being collated, analysed or made accessible. 
Current midwifery textbooks and teachings to student midwives rely on observations and 
‘what is generally accepted’ rather than published data (Coad et al. 2020; Rankin 2020). 
Loerup et al. (2019) could not find enough data to perform a meta-analysis on normal 
breathing frequencies during pregnancy, and were therefore unable to conclude whether 
breathing frequencies differ from those of non-pregnant women. Using an 
interdisciplinary approach and building on the standard practice from the physiological 
research field of collecting and publishing normative data, the results from Chapter 6 
could form the start of a database of normative data. Sometimes developments such as 
this can only be made when looking at a discipline from a fresh perspective.  
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Using the novel peak-valley analysis outlined in section 9.2.1, has allowed the data 
collected as part of this thesis to be analysed at a deeper and more complex level. The 
starting point for the analytical approach was to take a hypothesis-driven, mechanistic 
approach to interrogating the data. In other words, based upon an understanding of how 
the cardiovascular system is regulated, the analyses sought to identify the ‘error signals’ 
for this regulation, which are generated by SDB. This has revealed acute cardiovascular 
responses previously not observed in the research published to date. Furthermore, 
combining the novel analysis methods and an interdisciplinary approach, permitted the 
research to take an evidence driven approach to the design of a SDB intervention for 
pregnant women. Additionally, the use of patient and public involvement (PPI) in the 
designing of the clinical study protocol supports a women-centred model of care, and 
ensures the research is tailored to the outcomes that matter to women. The evidence 
that will be produced from the trial, when completed, will add further evidence to the 
normative cardiovascular data of women who develop PIH, which would be unlikely to 
be produced and published without taking this approach. 
 
Limitations of the thesis 
 
Unfortunately, due to COVID-19 and the pausing of all non-COVID studies in the NHS 
(National Institute for Health Research (NIHR) 2020), an inevitable limitation of this thesis 
is that the planned clinical study (Felton et al. 2021), presented in Chapter 8, could not 
be undertaken. Consequently, it is unknown whether SDB can reduce BP in pregnant 
women who develop PIH, or whether it is an acceptable potential treatment method for 
pregnant women. The PPI undertaken indicated that pregnant women were more 
reluctant to take part in research during the coronavirus pandemic (section 8.4), including 
not wanting to visit a university campus for an induction meeting. This meant that the 
protocol was not feasible to re-start as part of the PhD. However, both initial and recent 
PPI work conducted during the thesis suggests there is an interest in non-
pharmacological methods to treat BP and that women would be interested in taking part 
in the SDB intervention, supporting the need and desire for a study such as this. The PPI 
has also provided guidance on the processes, support and reassurances needed to re-
start the project in a world where coronavirus will undoubtably cause additional worries 
and restrictions for at least the immediate future. This guidance on re-starting research, 
directly from pregnant women and new mothers, will support the re-starting of the trial in 
the future. 
 
Unsurprisingly recruitment for Chapter 6 was most successful when the researcher was 
able to attend face-to-face events and build a rapport with the pregnant women as 
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potential participants. Community recruitment was decided upon as a pragmatic 
approach, rather than recruiting through the local maternity unit, which would require 
NHS ethical approval. Although social media has been recommended as a means of 
recruiting women in pregnancy, and although it led to a wide reach of engagements with 
the research project, less than half of the women who made contact following a 
Facebook promotion went on to participate in the study. This mirrors previous studies 
with pregnant women, where only 18% of women who clicked through from a Facebook 
advertisement consented to participate (Arcia 2013). Therefore, although social media 
is a good way to promote information, the experiences from recruitment for this thesis 
suggest that for recruitment purposes face-to-face meetings are still preferable. This is 
in accordance with methods to increase recruitment for pregnancy trials including 
building trust by increasing the visibility of the research team (Strömmer et al. 2018).  If 
social media is to be used then Facebook and Instagram, as opposed to Twitter, are the 
platforms in which pregnant women and new mothers are most active (based on the 
authors experience of engagement with women and where local maternity groups can 
be found on social media). Local maternity groups are exclusively on Facebook and while 
larger organisations have a following on both Facebook and Twitter, engagement and 
activity is much higher on Facebook. Recruiting women during pregnancy is always a 
difficult task; up to 71% of women may decline to participate with 40% of those women 
not providing a reason (van Delft et al. 2013). 
 
An evaluation of the methods utilised in this thesis is required to objectively evaluate the 
protocols used. Cardiovascular variables by their nature are dynamic and fluctuate both 
within and between days. There are many external stressors and factors that can 
influence variables such as caffeine consumption causing an immediate and sustained 
increase in heart rate and BP. The data for this study were collected in a one-off session 
and consequently variability between days was not assessed. However, pre-session 
requirements such as avoiding exercise, caffeine and fasting were used to minimise 
external influences. Additionally, Elstad (2012) found no difference in heart rate, stroke 
volume or cardiac output variations between 2 experimental days during spontaneous 
breathing. As the participants in this study acted as their own controls due to the 
randomised crossover design, the study design reduces any potential problems with day-
to-day variability, as all comparisons are within-participants on the same day.  
 
Additionally, all equipment utilised in this thesis used indirect, non-invasive measures. 
Consequently, all cardiovascular variables are estimates and calculated values of 
haemodynamic responses. The Modelflow method used by the Finapres to estimate SV, 
produces measurements that show excellent agreement with SV measured by Doppler 
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ultrasound (Van Lieshout et al. 2003) and when blood is withdrawn by phlebotomy 
(Leonetti et al. 2004). Additionally, BP measures from the Finapres correlate highly with 
auscultatory BP measurements in normotensive participants (Carlson et al. 2019), but 
an acknowledgement of the use of indirect measurement in this thesis is required. 
Additionally, the Finapres has not been fully validated for use in pregnancy, and research 
shows it may overestimate SBP and underestimate DBP (Hehenkamp et al. 2002; 
Grindheim et al. 2012). Although individually within each chapter the participants act as 
their own controls, and therefore consistent over/under-estimations would not cause a 
problem, this thesis compares healthy non-pregnant women to healthy pregnant women. 
If the Finapres and associated calculations are not valid during pregnancy and create a 
bias and difference compared with non-pregnant women, then comparisons between 
groups should be made with caution. 
 
End-tidal CO2 was only measured in Chapter 4 and although no significant differences 
were found between SDB and spontaneous breathing conditions, this was measured in 
healthy male and non-pregnant female participants. However, during pregnancy PCO2 
increases as a result of an increase in ventilation (Weissgerber and Wolfe 2006), which 
may influence the response to SDB. Consequently, future studies exploring acute 
responses to SDB in pregnant women specifically should monitor end-tidal CO2 to 
evaluate whether baseline changes in PCO2 during pregnancy influence end-tidal CO2 
response to SDB. 
 
More as a word of caution, than a direct limitation, the relationships stated between the 
phenomena observed in this study and underlying physiology associated with the 
autonomic nervous system are hotly debated topics. Moreover, a point-counterpoint on 
whether cardiovascular variability is/is not an index of autonomic control of c irculation 
discussed this in detail (Parati et al. 2006). Within this series of articles Taylor and 
Studinger argued that the quantification of any variability is only truly a measurement of 
the resulting phenomenon, and not necessarily an analysis of the complex underlying 
interactions. Although the cardiovascular variability observed in this thesis suggests a 
degree of autonomic cardiovascular regulation, it does not suggest they can be 
substituted as a measure of that regulation. The variability measured in this study 
represents the end response to the complex interactions between sympathetic and 
parasympathetic activity and should be analysed with caution. However, there is a 
degree of physiological interpretation that can be applied to relate acute responses to 
potential clinical applications in the use of SDB to reduce BP, which has been conducted 
as part of this thesis. 
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Finally, as it has been argued that menstrual phase and use of oral contraception can 
influence cardiovascular responses (Minson et al. 2000b, 2000a) and as this was not 
controlled in any studies that form part of this thesis, this could be considered a limitation. 
Previous research has recommended that when examining cardiovascular function, data 
collection with women should be completed during the early follicular phase of the 
menstrual cycle, or placebo phase of oral contraception use (Minson et al. 2000a; Wallin 
et al. 2010). However, previous SDB research found no change in cardiovascular 
responses to SDB related to menstrual cycle or oral contraceptive use (Nili et al. 2017). 
Accordingly, Chapter 4 did not control for, or measure menstrual phase and/or 
contraceptive phase in the 6 female participants, and it must be acknowledged that it is 
unknown whether the cardiovascular responses of the women in this study (Chapter 4) 
were influenced by these female sex hormones. However, the menstrual phase and oral 
contraceptive use of the participants in the study reported in Chapter 5 were analysed. 
No significant difference was found between menstrual phase or contraceptive use and 
cardiovascular responses to SDB, or between cardiovascular variables at baseline. 
Therefore, it is reasonable to suggest that the responses of the female participants in the 
study reported in Chapter 4 were similarly unaffected by menstrual phase or 
contraceptive use. 
 
9.4 Conclusion and contribution to knowledge 
 
In conclusion, this thesis has contributed extensive new knowledge to the understanding 
of acute cardiovascular responses to slow and deep breathing, specifically in relation to 
the increase in amplitude of BP oscillations and their relationship to increased levels of 
RSA. The data presented in this thesis show the importance of using peak-valley 
methods of analysis to reveal the true magnitude of the cardiovascular perturbations 
caused by SDB, which are otherwise overlooked when only mean values of 
cardiovascular variables are analysed. The thesis also identified an important influence 
of differences in the kinetics of haemodynamic responses to SDB, which influence the 
timing of the breath phases, relative to the induced perturbations. 
 
The body’s internal monitoring systems, which aim to maintain homeostasis may be 
given a nudge by SDB to re-set BP at normal levels following daily practice of SDB, and 
daily exposure to the acute cardiovascular fluctuations. This could be linked to repeated 
stimulation of the baroreceptors, mirroring mechanisms observed following baroreflex 
activation therapy. The acute cardiovascular responses were present in all population 
group studies (men, healthy non-pregnant women, and healthy pregnant women) 
suggesting that the previous long-term reductions in BP observed in men and mixed-sex 
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participant groups following SDB, should also be observed in pregnant women. Based 
on the data analysed, 6 breaths.min-1 is recommended as the optimal breathing 
frequency to use for SDB interventions, as it matches the existing recommended device 
(RESPeRATE) in terms of acute cardiovascular responses, and may provide a longer 
exposure to the stimulus provided by cardiovascular perturbations, with a longer duration 
spent at the most perturbing SDB frequencies (<8 breaths.min-1). 
 
The results from the studies examining acute responses provides evidence to support 
continuation of this line of research and the development of a SDB intervention designed 
specifically for pregnant women who develop hypertension during pregnancy (PIH). The 
thesis shows the importance of undertaking interdisciplinary research to draw on the 
strengths of both fields. A clinical protocol for the intervention study has been developed, 
peer-reviewed and published. When completed, this research has the potential to 
provide an easy to use, inexpensive, intervention that could save lives, improve the 
health and experiences of women during pregnancy and have long-term consequences 









9.5 Directions for future research 
 
The first direction for future research is to undertake the clinical study outlined in Felton 
et al. (2021) (presented in Chapter 8). As part of the short-term responses protocol, there 
is a need to identify any differences in the acute cardiovascular responses to SDB for 
women with PIH, compared with normotensive pregnant women. Comparisons are 
important to identify responses that are not associated with the normal adaptations 
associated with pregnancy and which could be related to the underlying pathophysiology 
of the cardiovascular disease. This will provide further evidence of the mechanisms by 
which SDB may reduce long-term BP and allow interventions to be designed around the 
specific responses of women with PIH. By publishing and analysing cardiovascular 
variables, which may differ in women with PIH, the data may also reveal potential 
pathophysiological differences that underpin the development of PIH. 
 
The feasibility section of the clinical research study would be the first step in assessing 
whether SDB is accepted as a potential treatment method for PIH. Initial PPI supports 
women’s interest in participating in the trial, but recruitment and adherence rates from 
the completed trial will provide direct evidence of its acceptance. By providing women 
with a non-pharmacological treatment method, the intervention provides them with 
greater choice, and greater control over their own pregnancy and maternity care. If a 
SDB intervention is acceptable to women, then not only might the intervention improve 
their experiences of pregnancy and their present and future health status, it might reduce 
the burden on overworked maternity units. In present times during the global pandemic, 
both underlying health status and demand on healthcare settings are of the upmost 
importance. As the SDB intervention is managed independently by the women at home, 
and involves an element of self-monitoring of BP, it provides an easy to prescribe and 
undertake intervention that could result in less face-to-face contact and attendance at 
hospital by pregnant women. Furthermore, as the SDB intervention proposed in the 
protocol is a relatively inexpensive method of delivery it could easily be transferred for 
clinical use in low- and middle-income countries. 
 
There is much debate on the treatment of mild to moderate hypertension during 
pregnancy and how or if this should be treated at all (Moser et al. 2012). The decision to 
treat normally rests on the risk benefit ratio of hypertensive medication. However, as 
there are no known negative effects of SDB, the risk is low. Consequently, SDB could 
offer a non-pharmacological treatment method for women with mild levels of 
hypertension during pregnancy, at a time when clinicians are reluctant to prescribe 
medication and/or the women is reluctant to take it. Additionally, despite all hypertension 
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guidelines stating definitive boundaries which define hypertension, it has been 
suggested that BP should be seen as a continuum with no clear boundary between 
normal and the point where the health risk becomes unacceptably high (Haase et al. 
2019). NHS online guidance to the public (NHS 2019) also suggests that anyone with 
BP levels above normal, but lower than hypertensive levels (between 120/80 mmHg and 
140/90 mmHg), could benefit from lifestyle changes such as changes in diet and 
exercise. SDB would be classed as an adjunctive therapy, similar to exercise, and 
therefore this opens up the possibility that SDB could be beneficial at levels of BP lower 
than the currently accepted definitions of hypertension. 
 
The potential origins of the development of PIH specifically can be seen during the first 
trimester, prior to diagnosis, as sympathetic overactivity (Pal et al. 2011). Additionally, 
women classed as pre-hypertensive prior to 20 weeks gestation (120-139 mmHg SBP 
or 80-89 mmHg DBP) are associated with preterm and small-for-gestation age infants 
(Nagao et al. 2021), suggesting a health risk for pregnancies and adverse perinatal 
outcomes in pregnancies classified as being within normal BP ranges. If SDB can be 
prescribed to women at-risk of developing PIH or at prehypertensive levels, to maintain 
autonomic balance early in pregnancy, then there is potential that the sympathetic 
activity could be stopped before it develops into PIH and decrease adverse perinatal  
outcomes such as still births and neonatal deaths (Ananth and Basso 2010). 
 
Furthermore, although it is outside the scope of this thesis, it should be noted that the 
acceptable levels of BP that define hypertension have recently been reduced by the 
American College of Cardiology and American Heart Association (Whelton et al. 2018). 
The definition of hypertension has now changed from the long-standing threshold of 
140/90 mmHg to 130/80mmHg, which increased the prevalence of hypertension by 14% 
(from 32 to 46%) in the United States of America (Anaheim 2018). Other countries have 
since assessed whether they should also change their guidance on BP thresholds, and 
an article reviewing the guidelines in Canada calculated that using the thresholds 
recommended by the American Heart Association would nearly double the cases of 
hypertension in Canada and should be considered carefully as most of the individuals 
re-classified as hypertensive were young and at low to moderate cardiovascular risk 
(Garies et al. 2019). A recent review questioned whether the strength of evidence was 
sufficient to support the new BP thresholds and debated the problems with inconsistency 
of guidelines worldwide (Kaul 2020). 
 
Although the UK and NICE guidelines have not yet changed their hypertension threshold 
in the general population, or for pregnancy, the new threshold could be implemented in 
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the future if stronger evidence supports such a move. In fact, in 2017 NICE published an 
alert which shared the results of a systematic review reviewing BP targets in a total of 
55,163 patients (NICE: National Institute for Health Research 2017). They concluded 
that a target of <130mmHg for SBP was optimal, to have the best balance of efficacy 
and safety.  If BP is viewed as a continuum rather than a boundary for hypertension and 
healthy/unhealthy levels, then SDB could be beneficial for anyone at the higher end of 
this spectrum, including pregnant women who have not yet been diagnosed with 
hypertension but have BP higher than 130/80mmHg. The changing thresholds for 
diagnosis of hypertension add weight to the need for more normative data on BP during 
pregnancy. Normative BP data is needed specifically for gestational ages to allow 
accurate assessment of hypertensive risk in pregnant women. Whichever guidelines and 
thresholds are used, the importance of reinforcing lifestyle modification is agreed 
unanimously, as the preferred intervention, rather than simply writing prescriptions for 
more BP medications (Bakris et al. 2019). 
 
Additionally, women’s long term BP, measured postpartum, may be classed as ‘normal’ 
in women who have previously been diagnosed with PIH when in fact it is higher than it 
was prior to pregnancy and experiencing PIH (Davis et al. 2016). Therefore, the women’s 
BP would not be classed as normal for their individual level of  baseline BP pre-
pregnancy, although using BP thresholds in the current guidance they would not be 
monitored. Research is currently underway to generate data sets of normal values for 
BP post-partum in women who were normotensive during pregnancy, to compare against 
those who had PIH and pre-eclampsia (Davis et al. 2016). SDB could be a valuable 
intervention in these women. If cardiovascular abnormalities remain following a 
pregnancy affected by PIH, then SDB may be able to utilise the potential mechanisms 
outlined earlier in this chapter (9.2.2 and 9.2.3) to return the body’s set-point to normal 
levels, replicating their pre-pregnancy normal levels. 
 
Furthermore, women who have experienced PIH are also at a higher risk of subsequent 
diagnosis of high BP or pre-eclampsia during pregnancy (NICE: National Institute for 
Health and Care Excellence 2019b), developing primary hypertension (Stuart et al. 2018) 
and heart failure later in life (Chen et al. 2018). Women diagnosed with pre-eclampsia 
have an estimated doubling of risk odds for increased risk of future cardiovascular or 
cerebrovascular events (Brown et al. 2013). Therefore, as well as the potential for SDB 
to remove this future risk by minimising effects of hypertension during pregnancy, or 
stopping its development entirely, SDB could be also used postpartum. SDB may be able 
to help stop the development of subsequent episodes of hypertension or other 
cardiovascular disease, whether that is primary hypertension later in life, subsequent 
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PIH or pre-eclampsia in subsequent pregnancies. In this case, research could investigate 
whether daily use of SDB is beneficial for women who previously experienced a 
hypertensive pregnancy, and whether rates of future hypertensive pregnancies and 
cardiovascular disease are reduced in women who undertake SDB. 
 
As a starting point this thesis has focused on women with PIH as a population group to 
provide proof of concept for SDB reducing BP during pregnancy. If results from the 
clinical study (Felton et al. 2021) presented in Chapter 8) reveal beneficial effects, the 
intervention could be expanded to include pregnant women with chronic hypertension 
and pre-eclampsia. Although pre-eclampsia is a multi-system disease, SDB has the 
potential to reduce the hypertensive element of pre-eclampsia and due its potential re-
setting of the autonomic nervous system and/or normal BP level SDB has the potential 
to benefit other elements of the condition. 
 
Based on the findings presented in Chapter 4, regarding the acute cardiovascular 
responses to RESPeRATE, this thesis also provided generic recommendations for SDB 
research, i.e. not limited to hypertension during pregnancy. RESPeRATE may not 
produce low enough breathing frequencies in all individuals to maximise the 
cardiovascular perturbations caused by SDB. The duration RESPeRATE is used for, and 
specifically the average breathing frequency across this duration should be carefully 
considered when designing future interventions utilising SDB. 
 
When using the RESPeRATE device, Gavish (2010) calculated that for significant long-
term BP changes to occur a threshold of 180 minutes total SDB time was needed across 
the intervention period. With an average 8-week intervention in the previous studies, this 
equates to an average of only 22.5 minutes per week, showing that lower levels of 
engagement can potentially still produce health benefits compared with the 
recommended engagement with SDB. On the other hand, a comparison of SDB at 6 
breaths.min-1 found a similar heart rate variability response across different durations of 
SDB (5-, 7- and 9-min), but only a reduction in depression score following daily practice 
for 9-min (Cheng et al. 2019). The authors suggest that SDB duration may impact the 
shift in autonomic system activation and that longer durations are needed to produce a 
shift to parasympathetic activation. There is not currently enough evidence to suggest 
whether the same long-term benefits can be produced by different durations of SDB, but 
future research should examine this further. Future research should examine long-term 
BP changes in the context of the specific breathing frequencies experienced by the 
participants, and the total exposure time to the SDB frequencies that maximised 
cardiovascular perturbation. The present research suggests this should be examined at 
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both <10 breaths.min-1 and <8 breaths.min-1 to explore any differences in long-term BP 
reductions based on different breathing frequencies. 
 
Finally, maternal health research cannot neglect the impact of any intervention upon the 
fetus. It is not known whether the maternal cardiovascular response to SDB is mirrored 
by changes in fetal heart rate. However, fetal heart rate has been observed to increase 
alongside maternal heart rate increases during aerobic exercise (Hegewald and Crapo 
2011), suggesting a possibility of a fetal cardiovascular response to SDB. 
Synchronisation of maternal and fetal heart rate has not been shown, although 
occasional coupling does occur in normal breathing conditions (Van Leeuwen et al. 
2003), with increasing synchronisation at higher breathing frequencies (Van Leeuwen et 
al. 2009). SDB at a frequency of 7.5 breaths.min-1 has been shown to decrease fetal 
heart rate (Vasundhara et al. 2018), but feto-placental circulation and fetal cardiac 
function are not significantly affected by breathing conditions such as obstructive sleep 
apnoea (Robertson et al. 2020). Consequently, it is unknown whether fetal heart rate 
and/or placental flow would be influenced by breathing at the frequencies recommended 
in this thesis. Although the author did not set out to measure fetal movements, 
anecdotally there were multiple occasions during the data collection when participants 
indicated that the fetus had become noticeably more active during the episodes of SDB. 
Nonetheless, there is no empirical evidence to support that increased movement was 
linked to the SDB. Increased fetal movement could be due to maternal relaxation, the 
long period of sitting or simply coincidence, which was noticed by the author. Future 
studies should include fetal ECG or other monitoring devices to observe how the fetus 
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Appendix I: Research Outputs 
 
Appendix Ia: Bournemouth University Doctoral College Live Exhibition (2018) 
 
The Doctoral College Live Exhibition was an event at Bournemouth University (BU) to 
allow postgraduate researchers the opportunity to disseminate their research in new, 
creative and interactive ways to a wide audience. 
 
The abstract below was associated with a live demonstration of the Brythm app and 




Acute Cardiovascular Responses to Slow and Deep Breathing in Healthy Females 
using BU’s Brythm App 
 
A breathing technique known as slow and deep breathing (SDB) has been shown to 
reduce high blood pressure through daily practice. The mechanisms by which SDB 
reduces blood pressure are not fully understood and the acute cardiovascular responses 
to SDB require further exploration. Potential mechanisms for decreasing blood pressure 
may be the within-breath changes in cardiovascular variables such as stroke volume and 
heart rate. Using an external pacing device to guide SDB is the most robust method of 
delivery, and previous research suggests that the optimal breathing frequency for 
induction of cardiovascular perturbation may vary between individuals. BU’s Brythm App 
has a patent-pending algorithm that drives breathing frequency to a personalised 
optimum. 
 
In this study, female participants breathed at different breathing frequencies that have 
been found to span the optimal frequency in men. In addition to exploring any gender 
differences, the study compared the relative magnitudes of the cardiovascular responses 








Acute cardiovascular responses to slow and deep breathing in healthy women 
M.L. Felton1, V. Hundley1, A.K. McConnell1 
1. Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, United 
Kingdom. 
 
Background: Daily practice of device-guided slow breathing (DSB) has been shown to 
decrease blood pressure (Chaddha et al., 2019). However, there is still a lack of 
understanding of the mechanisms underpinning the improvements in blood pressure. 
Relatively few studies have characterised the acute cardiovascular responses to DSB, 
which hold the key to the mechanisms by which DSB might lower blood pressure. This 
study characterised the acute cardiovascular responses to different DSB protocols. 
Methods: Eighteen healthy, normotensive women completed five 5-minute protocols in 
randomised order: spontaneous breathing (SfR), fixed breathing frequencies of 4, 6 and 
8 breaths.min-1 (4fR, 6fR, 8fR) and a dynamic breathing frequency (DfR) determined by 
an algorithm designed to maximise respiratory sinus arrhythmia (RSA). Cardiovascular 
variables and respiratory airflow were monitored continuously and non-invasively. Data 
are mean±SD, compared by repeated measures ANOVA with planned pairwise 
comparisons. Results: Average breathing frequency for DfR was 6.3±1.1 breaths.min-
1. Mean heart rate was not significantly different between breathing protocols, but RSA 
increased significantly between SfR and all DSB protocols (SfR 0.12±0.05, 4fR 
0.25±0.10, 6fR 0.25±0.08, 8fR 0.21±0.07, DfR 0.25±0.09 sec; p<0.001). The ‘peak -
valley’ amplitude of intra-breath phase (inhalation vs exhalation) fluctuations of mean 
arterial pressure (MAP) were significantly different between 4fR and SfR, 6fR, 8fR and 
DfR (SfR 5.1±1.87, 4fR 7.8±11.81, 6fR 6.8±10.81, 8fR 9.1±2.38, DfR 4.8±11.30 mmHg; 
p<0.001). Peak MAP occurred during expiration for all protocols except 4fR. Intra-breath 
phase fluctuations also increased during DSB for stroke volume, cardiac output, systolic 
and diastolic blood pressure, and pulse wave velocity (p<0.001). Conclusions: DSB 
induces significant increases in intra-breath phase fluctuations of haemodynamic 
variables. It is conceivable that these acute haemodynamic perturbations generate error 
signal(s) for chronic regulation of blood pressure. Further research is required to 












Appendix Ic: Bournemouth University Doctoral College Conference (2019) 
 
The following abstract was presented as an oral presentation at Bournemouth 




Cardiovascular Responses to Slow and Deep Breathing in Healthy Pregnant and 
Non-pregnant Women  
 
Slow and deep breathing (SDB) causes immediate changes to cardiovascular variables 
(heart rate and blood pressure) but these are not fully understood. To understand how 
SDB can reduce blood pressure long-term through daily practice, we need to first 
understand the short-term responses. Pregnancy induces physiological changes that 
may affect how women respond to SDB and therefore it is important to include both 
pregnant and non-pregnant women.  
 
Continuous heart rate and blood pressure were measured while women conducted a 
series of breathing exercises. SDB causes greater within-breath cardiovascular changes 
than breathing at a normal frequency (spontaneous breathing), e.g. increasing 
respiratory sinus arrhythmia. Responses were similar in both groups, but respiratory 
sinus arrhythmia was lower in pregnant women, with SDB increasing respiratory sinus 
arrhythmia to non-pregnant spontaneous breathing levels. Understanding the within-
breath cardiovascular changes during SDB can be used to enhance clinical interventions 




Appendix Id: Bournemouth University Doctoral College Conference (2020) 
 
The following abstract was presented as an oral presentation at Bournemouth 
University’s 2020 Postgraduate Researcher Conference, which was presented virtually 




Adapting postgraduate research in the context of the coronavirus pandemic 
 
Undertaking a PhD is an independent journey and no two people will have the same 
experience, although everyone will face both ups and downs. However, in 2020 we all 
share a common struggle, completing our research during a global pandemic. While the 
exact barriers coronavirus caused will differ between projects, we have all adapted and 
changed how we work, and even what we are researching. This presentation will discuss 
how I coped with the changes to my PhD, including the stopping of all clinical studies in 
the NHS. I will discuss the skills and experience I gained, while sharing my coping 
strategies. Ultimately, I would not have got to this stage without sharing my highs and 
lows with my peers so I hope this presentation shows that although a PhD can feel like 




Appendix II: Participant information sheet 
Appendix IIa: Chapter 4 participant information sheet 
Participant Information Sheet 
 
 
‘Device guided slow breathing for the treatment of hypertension: 
Comparison of BU’s Brythm App with an NHS approved device’ 
 
We are inviting BU staff and students to take part in a research project and you have 
been selected for invitation because you are part of the HSS Faculty and may have an 
interest in health research. Before you decide, it is important for you to understand why 
the research is being conducted and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide 




Breathing exercises have long been used as part of yoga and meditation, claiming to aid 
relaxation. Research has more recently investigated the use of a breathing technique 
that employs a pacing device to guide slow and deep breathing (SDB) to test its effect 
on blood pressure. 
 
Based on their research into the short-term effects of slow and deep breathing, 
researchers from FHSS have developed an App (Brythm), which guides breathing 
frequency to produce a personalised optimum (typically around 6 breaths per minute). 
The Brythm App now needs to be validated against an existing device that is already 




The purpose of this study is to investigate the acute physiological response to slow 
breathing delivered using the BU Brythm App against that of an NHS/FDA approved 
device (RESPeRATE®). 
 
Key Requirements Summary 
 
The key requirements to the study are outlined overleaf. If you are eligible, and after 
reading the key requirements are interested in finding out more about participating, you 
can find a more detailed protocol description in the ‘Study Design’ section below and on 
pages 5-6. 










Pedro Vargas Research Project Manager 
 
--- pedrovargas@sapo.pt  
Malika Felton 
 





• You must be a non-smoker to participate in the study; 
• If you have a previous medical history of any the following conditions you will 
not be able to participate in the study; 
o Cardiovascular or respiratory disease (e.g. asthma, bronchitis, COPD 
(chronic obstructive pulmonary disease)); 
o An allergy or reaction to the conducting gel used for the ECG or for the 
ultrasound; 
• The entire experiment will require a single visit of approximately 1 ½ - 2 hours; 
• During the testing session we will collect some non-invasive cardiovascular and 
respiratory measurements, and you will learn how to control your breathing at a 
specific rhythm and depth, using a visual feedback device and an auditory 
feedback device; 
• You will be asked to refrain from eating for 2 hours and from caffeine, strenuous 




If you choose to participate in this study you will be required to attend the BU 
Cardiorespiratory Research Laboratory (Bournemouth House) on one occasion for 1 ½ 
to 2 hours. Approximately 1 hour and 20 minutes of the whole session will be used for 
the data collection and will involve using the Brythm App and RESPeRATE® to breathe 
at different frequencies, in addition to a spontaneous breathing condition. The 
spontaneous breathing condition will involve you breathing normally with no restrictions, 
while we collect data for 10 minutes. The App will be installed on an iPad and you will 
not be required to use your own device. See Figure 1 for an example equipment set up 
from a previous study involving pregnant women. 
 
Figure 1: Participant set up with equipment 
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Two of the slow and deep breathing conditions will be delivered using Brythm, the App 
developed at BU, and you will be asked to follow the visual feedback for 10 minutes for 
each condition. When using the App you will be instructed to inhale when the dome 
graphic rises and exhale when the dome falls (see Figure 2). You will be wearing a finger 
sensor throughout the testing that connects to the headphone socket of the tablet on 
which the App is installed (see Figure 3). You will be asked to follow a set breathing 
frequency of 6 breaths per minute, and a dynamic frequency determined by the App (this 








Figure 2: Screenshot of Brythm App Feedback Display.Figure 3: Brythm App Finger Sensor                                                
N.B. Arrows shown for illustrative purposes only and do not appear on App 
 
 
The final condition will be 10-minutes of controlled 
breathing using the NHS/FDA approved device, 
RESPeRATE®, which guides your breathing 
frequency using an auditory tone (Figure 4). You will 
be asked to wear a breathing sensor either across 
your chest, or your abdomen, depending on how you 
breathe (Figure 4 shows abdomen position). You will 
wear headphones and be asked to breathe in time 
with the auditory tones; a short high note is heard for 
start of inhalation and a short low note is heard for 
start of exhalation. RESPeRATE® aims to lower your 
breathing frequency to the ‘Therapeutic Breathing 
Zone’ of less than 10 breaths per minute.   
           Figure 4: RESPeRATE® device 
 
There will be a 10-minute break between each breathing condition, where you can 
breathe normally, and take off the mask if you wish. Your normal breathing frequency is 
around 12 breaths per minute, so you will be asked to breathe at around half the normal 
rate. This is not as difficult as you might think, because the reduction in breathing rate is 
compensated by increasing breathing depth, which your body will do automatically. You 
will be given an opportunity to practice this before the study begins. A visual overview of 




Figure 5: Schematic of breathing protocol 
Each block is 10-minutes in duration, including spontaneous baseline breathing (B) and all rest periods (R) 
of unrestricted breathing between each condition. 
You will be randomly assigned the order of breathing frequency conditions; Spontaneous Breathing, Brythm 
App Algorithm, Brythm App 6 breaths per minute and RESPeRATE®. 
 
Do I have to take part? Can I change my mind and withdraw from the study? 
 
Your participation in this research is entirely voluntary and it is up to you to decide 
whether or not to take part. You will be given this information sheet to keep and if you do 
decide to take part, you will be asked to sign a participant agreement form.  You can 
withdraw at any time, up to the point where the data are processed and become 
anonymous, so your identity cannot be determined, without it affecting any benefits that 
you are entitled to in any way.  You do not have to give a reason. Deciding to take part 
or not will not impact upon/adversely affect your employment or education/studies (or 
that of others). 
 
What are the possible disadvantages and risks of taking part? 
 
Since you will be breathing at a lower breathing frequency than your usual spontaneous 
breathing frequency, you may experience sensations of heat, sweating and ‘flushing’ and 
a strong urge to breath more. This is quite normal and does not present any known risk 
to your safety. In the unlikely event that you feel too uncomfortable, you are free to 
interrupt the procedure and remove the mask. The sensations subside quickly once 
spontaneous breathing is resumed. 
 
What will I get in return? 
 
You will get information about your current blood pressure. You will also be provided with 
a report of your test results at the end of the study and learn more about how breathing 
affects your blood pressure. No financial compensation will be given for participating in 







What will happen to me if I take part?  
 
As stated in the ‘Study Design’ section you will perform a total of 40 minutes of controlled 
breathing (including the 10 minutes of unrestricted spontaneous breathing, see Figure 
5), during which we will carry out a number of physiological measurements. These 




Upon arrival, you will first need to complete a health questionnaire and sign a consent 
form to confirm that you’re healthy and able to participate in the study. Your height and 
weight will also be measured at this stage; this will not require you to remove any clothes 




During the controlled breathing you will be asked to wear a mask to measure breathing 
patterns, which covers your mouth and nose but allows you to breathe normally through 
both (see Figure 1). We will measure your blood pressure and estimate the amount of 
blood that is pumped out of your heart using two cuffs; one placed on the upper arm and 
one on the middle finger (see Figure 6). The silver box is secured on the wrist, but does 
not take any measurements from your wrist. You will also have a finger sensor attached 




Figure 6 (left): The finger cuff used for 
the continuous measurement of 







Heart rate will be measured continuously using a 3-lead 
electrocardiogram (ECG). Sensors will be placed on your 
chest; 2 sensors just below each of your clavicles and 1 
sensor placed on the lower ribs (see Figure 7). These will be 
placed under your clothing and you will not need to remove 
any items of clothing for attach 
 
 
Will my taking part in this study be kept confidential and what will happen to the 
results of the research study? 
 
All the information we collect about you during the course of the research will be kept 
strictly in accordance with current Data Protection Regulations. The researchers hope to 
publish data collected from this study in scientific journal articles, and/or present the 
research findings at relevant scientific conferences. No personal information will be used 
Figure 7 (above): Placement sites 
for the 3-lead ECG electrodes 
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or referred to in the study and you will instead be issued with an identification number. 
All data will be kept for 5 years after publication on a BU password protected secure 
network and will not be released without written permission from yourself or unless 
required by law. The information collected about you may be used in an anonymous form 
to support other research projects in the future and access to it in this form will not be 
restricted.  It will not be possible for you to be identified from this data.  
 
What type of information will be sought from me and why is the collection of this 
information relevant for achieving the research project’s objectives? 
 
Prior to taking part in the study you will be required to fill in a health check questionnaire. 
This information is paramount to our research as your health status might show that you 
meet one of our exclusion criteria and cannot participate in this study. Also, a number of 
individual characteristics (age, ethnicity, current fitness level, medication, etc.), as well 
as some health conditions are known to impact several cardiovascular variables being 
measured in this study. 
 
Who is organising and funding the research? 
 
The research is being organised by the Faculty of Health and Social Sciences at 
Bournemouth University as part of pump-priming funding. 
 
What if something goes wrong? 
 
The procedures involved in this study are extremely low risk, requiring participants to do 
nothing more than to sit, and to breathe slowly and deeply, in a relaxed way. 
Nonetheless, an emergency name and contact telephone number must be provided by 
all participants in the health check questionnaire. You can find the researchers’ 
contact details at the beginning of this participant information sheet. 
 
In case of complaints you can contact the Deputy Dean of Research and Professional 
Practice, Professor Vanora Hundley, as an independent member of BU Staff, by email 
at researchgovernance@bournemouth.ac.uk.  
 
If you have any questions regarding this research project, please contact: 
Malika Felton 
Faculty of Health and Social Sciences 
Bournemouth University 
Room 305, Royal London House 
Christchurch Road 
Bournemouth, BH1 3LT 
Phone: 01202 961845 
Email: mfelton@bournemouth.ac.uk 
 
Thank you for considering taking part in this research project. 
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Appendix IIb: Chapter 5 participant information sheet 
Participant Information Sheet 
 
 
‘Acute effects of slow and deep breathing upon healthy young women’ 
 
We are inviting women of reproductive age (18-49 years) to take part in a research 
project and you have been selected for invitation because you are part of the HSS 
Faculty and may have an interest in health research. Before you decide, it is important 
for you to understand why the research is being conducted and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. The following people are 
involved in this study: 
 
Contact Position Phone Email 







































This research investigation has been reviewed in line with Bournemouth 




Breathing exercises have long been used as part of yoga and meditation, claiming to aid 
relaxation. Research has more recently investigated the use of a breathing technique 
that employs a pacing device to guide slow and deep breathing (SDB) to test its effect 
on blood pressure. SDB has an immediate impact on the cardiovascular system, such 
as blood pressure and heart rate. However, a complete understanding of the way in 
which SDB affects long term blood pressure has not been achieved and further research 
is needed. 
 
Using an external pacing device to guide SDB is the most robust method of delivery, and 
normally involves reducing your breathing to approximately 6 breaths per minute, which 
is around half normal breathing frequency. However, recent research found that the 
optimal breathing frequency to produce the maximum immediate changes in 
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cardiovascular variables is unique to each person. This research was undertaken with 
healthy young men, and the next stage of the research is to test the responses to SDB 




The ultimate aim of this programme of research is to assess the effects of daily SDB 
exercises upon long term blood pressure in pregnant women who have developed 
pregnancy-induced high blood pressure. The first step towards achieving this aim is to 
test the immediate effects of different SDB frequencies with healthy young women. This 
will allow us to identify the most effective breathing method(s), before moving on to test 
the effects in pregnant women. 
 
Key Requirements Summary 
 
The key requirements to the study are outlined below. If you are eligible, and after 
reading the key requirements are interested in finding out more about participating, you 
can find a more detailed protocol description in the ‘Study Design’ section below and on 
pages 5-6. 
 
• You must be a female non-smoker of reproductive age (18-49 years) and not 
currently pregnant to participate in the study; 
• If you have a previous medical history of any the following conditions you will 
not be able to participate in the study; 
o Cardiovascular or respiratory disease (e.g. asthma, bronchitis, COPD 
(chronic obstructive pulmonary disease)); 
o An allergy or reaction to the conducting gel used for the ECG or for the 
ultrasound; 
o Spontaneous collapsed lung (pneumothorax), or a recent traumatic 
pneumothorax; 
o Known or suspected eardrum rupture, or other middle ear conditions; 
o Current sinus infection (participation is allowed once this condition has 
been resolved). 
• The entire experiment will require a single visit of approximately 1 ½ hours; 
• During the testing session we will collect some non-invasive cardiovascular and 
respiratory measurements, and you will learn how to control your breathing at a 
specific rhythm and depth, using a visual feedback device; 
• You will be asked to refrain from eating for 2 hours and from caffeine, strenuous 
exercise and alcohol for 12 hours prior to testing; 
• We ask that you attend the session in appropriate clothing that allows access to 
the abdominal region for the ultrasound measurements (see Figure 8). You will 





If you choose to participate in this study you will be required to attend the BU 
Cardiorespiratory Research Laboratory (Bournemouth House) on one occasion. 
Approximately 1 hour of the whole 1 ½ session will be used for the data collection and 
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will involve using an App to breathe at different frequencies, in addition to a spontaneous 
breathing condition. The spontaneous breathing condition will involve you breathing 
normally with no restrictions, while we collect data. The App will be installed on an iPad 
and you will not be required to use your own device. See Figure 1 for an example 






















Figure 1: Participant set up with equipment 
 
The slow and deep breathing will be delivered using an App developed at BU and you 
will be asked to follow the visual feedback for 5 different conditions, for 5 minutes each. 
There will be a 5-minute break between each breathing condition, where you can breathe 
normally, and take off the mask if you wish. When using the App you will be instructed 
to inhale when the dome graphic rises and exhale when the dome falls (see Figure 2). 
You will be wearing a finger sensor throughout the testing that connects to the 








           
Figure 2: Screenshot of Brythm App Feedback Display.  Figure 3: Brythm App Finger 
Sensor                                                
N.B. Arrows shown for illustrative purposes only and do not appear on App 
 
You will be asked to follow breathing frequencies of 4, 6 and 8 breaths per minute and a 
dynamic frequency determined by the App (this will likely fall within the range of breathing 
frequencies above). The final condition will be 6 breaths per minute with a small 
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resistance during inhalation (roughly equivalent to breathing through one nostril). This 
resistance will be provided by a medical device (POWERbreathe Medic; see Figure 4).  
 
Figure 4: Inspiratory Resistance 





Your normal breathing frequency is around 12 breaths per minute, so you will be asked 
to breathe at around half the normal rate. This is not as difficult as you might think, 
because the reduction in breathing rate is compensated by increasing breathing depth, 
which your body will do automatically. You will be given an opportunity to practice this 
before the study begins. A visual overview of the protocol is provided in Figure 5.       
 
 
Figure 5: Visual overview of the protocol for breathing frequencies 
 
Each block is 5-minutes in duration, including spontaneous baseline breathing (B) and all rest periods (R) of 
unrestricted breathing between each condition. 
The order of breathing conditions will be assigned randomly at the start of the testing session; 
U – Uncontrolled spontaneous breathing; BA – App Algorithm; BF – Fixed Breathing Frequency; IL – 
Inspiratory Load 
 
Do I have to take part? Can I change my mind and withdraw from the study? 
 
Your participation in this research is entirely voluntary and it is up to you to decide 
whether or not to take part. You will be given this information sheet to keep and if you do 
decide to take part, you will be asked to sign a participant agreement form.  You can 
withdraw at any time, up to the point where the data are processed and become 
anonymous, so your identity cannot be determined, without it affecting any benefits that 
you are entitled to in any way.  You do not have to give a reason. Deciding to take part 
or not will not impact upon/adversely affect your employment or education/studies (or 
that of others). 
 
What are the possible disadvantages and risks of taking part? 
 
Since you will be breathing at a lower breathing frequency than your usual spontaneous 
breathing frequency, you may experience sensations of heat, sweating and ‘flushing’ and 
a strong urge to breath more. This is quite normal and does not present any known risk 
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to your safety. In the unlikely event that you feel too uncomfortable, you are free to 
interrupt the procedure and remove the mask. The sensations subside quickly once 
spontaneous breathing is resumed. 
 
What will I get in return? 
 
You will get information about your current blood pressure. You will also be provided with 
a report of your test results at the end of the study and learn more about how breathing 
affects your blood pressure. No financial compensation will be given for participating in 
this study.  
What will happen to me if I take part?  
 
As stated in the ‘Study Design’ section you will perform a total of 30 minutes of controlled 
breathing (including the 5 minutes of unrestricted spontaneous breathing, see Figure 5), 
during which we will carry out a number of physiological measurements. These 




Upon arrival, you will first need to complete a health questionnaire and sign a consent 
form to confirm that you’re healthy and able to participate in the study. Your height and 
weight will also be measured at this stage; this will not require you to remove any clothes 
except your shoes. Finally, you will be asked to tell us about your menstrual cycle stage 





During the controlled breathing you will be asked to wear a mask to measure breathing 
patterns, which covers your mouth and nose but allows you to breathe normally through 
both (see Figure 1). We will measure your blood pressure and estimate the amount of 
blood that is pumped out of your heart using two cuffs; one placed on the upper arm and 
one on the middle finger (see Figure 6). The silver box is secured on the wrist, but does 
not take any measurements from your wrist. You will also have a finger sensor attached 




Figure 6: The finger cuff used for the 





Heart rate will be measured continuously using a 3-lead 
electrocardiogram (ECG). Sensors will be placed on your 
chest; 2 sensors just below each of your clavicles and 1 
sensor placed on the lower ribs (see Figure 7). These will 
be placed under your clothing and you will not need to 
remove any items of clothing for attachment. 
 
 
Following the completion of each 5-minute breathing 
condition we will perform an ultrasound measurement of 
your kidney blood flow (see Figure 8), which will involve holding your breath for a few 





An additional measure of blood pressure will also be made using the arm cuff and 
additional cuffs placed on your upper leg and neck (see Figure 9). The neck cuff is placed 
loosely around the neck, with a 1 finger gap between the cuff and the neck, and therefore 
is not tight. The air bladder only inflates for the length shown in red in Figure 9, i.e. not 
around the whole neck. 
 
Will my taking part in this study be kept confidential and what will happen to the 
results of the research study? 
 
All the information we collect about you during the course of the research will be kept 
strictly in accordance with current Data Protection Regulations. The researchers hope to 
publish data collected from this study in scientific journal articles, and/or present the 
research findings at relevant scientific conferences. No personal information will be used 
or referred to in the study and you will instead be issued with an identification number. 
All data will be kept for 5 years either from the date of publication or after the award of 
the PhD, whichever is later, on a BU password protected secure network and will not be 
released without written permission from yourself or unless required by law. The 
information collected about you may be used in an anonymous form to support other 
research projects in the future and access to it in this form will not be restricted.  It will 




Figure 7: Placement sites for the 
3-lead ECG electrodes 
Figure 8 (right): 
Ultrasound probe 




Figure 9 (left): Neck 
cuff positioning and 
inflation bladder 
length (show in red) 
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What type of information will be sought from me and why is the collection of this 
information relevant for achieving the research project’s objectives? 
 
Prior to taking part in the study you will be required to fill in a health check questionnaire, 
and you will be asked to tell us about your menstrual cycle stage and whether you are 
taking oral contraceptives. This information is paramount to our research as your health 
status might show that you meet one of our exclusion criteria and cannot participate in 
this study. 
 
Also, a number of individual characteristics (age, menstrual cycle, ethnicity, current 
fitness level, medication, etc.), as well as some health conditions are known to impact 
several cardiovascular variables being measured in this study. 
 
Who is organising and funding the research? 
 
The research is being organised by the Faculty of Health and Social Sciences at 
Bournemouth University as part of the PhD doctoral studies of Malika Felton. 
 
What if something goes wrong? 
 
The procedures involved in this study are extremely low risk, requiring participants to do 
nothing more than to sit, and to breathe slowly and deeply, in a relaxed way. 
Nonetheless, an emergency name and contact telephone number must be provided by 
all participants in the health check questionnaire. You can find the researchers’ 
contact details at the beginning of this participant information sheet. 
 
In case of complaints you can contact the Acting Dean of the Faculty of Health & Social 
Sciences, Professor Elizabeth Rosser, as an independent member of BU Staff, by email 
at researchgovernance@bournemouth.ac.uk.  
 
If you have any questions regarding this research project, please contact: 
 
Malika Felton 
Faculty of Health and Social Sciences 
Bournemouth University 
Room 305, Royal London House 
Christchurch Road 
Bournemouth, BH1 3LT 








Appendix IIc: Chapter 6 participant information sheet 
Participant Information Sheet 
 
 
‘Acute effects of slow and deep breathing upon pregnant women’ 
 
We are inviting women who are over 20 weeks pregnant with their first pregnancy to take 
part in a research study. The study is part of a larger project to test the effect of slow and 
deep breathing upon blood pressure with pregnant women. Before you decide, it is 
important for you to understand why the research is being conducted and what it will 
involve. Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
This research investigation has been reviewed in line with Bournemouth 
University’s Research Ethics Code of Practice (Ethics ID 22930). 
 
Study Background & Purpose 
 
Breathing exercises have long been used as part of yoga and meditation, claiming to aid 
relaxation, and are often encouraged during pregnancy. Research has recently 
investigated the use of a breathing pacing device to test the effect of slow and deep 
breathing (SDB) upon blood pressure. SDB has an immediate impact on the 
cardiovascular system, such as blood pressure and heart rate, but the responses have 
not been studied with pregnant women.  
 
The ultimate aim of this programme of research is to assess the effects of daily SDB 
exercises upon long term blood pressure in pregnant women who have developed 
pregnancy-induced high blood pressure. The first step towards achieving this aim is to 
test the immediate effects of different SDB frequencies with pregnant women who do not 
have hypertension (high blood pressure). This will allow us to identify the most effective 
breathing method(s), before moving on to test the effects with women who have 
developed pregnancy-induced hypertension. 
 
Key Requirements Summary 
 
The key requirements to the study are outlined below. If you are eligible, and after 
reading the key requirements are interested in finding out more about participating, you 
can find a more detailed protocol description in the ‘Study Design’ section below. 
 
• You must be currently pregnant with your first pregnancy and be over 20 weeks 
gestation; 
• You must be carrying a singleton pregnancy (not twins, triplets, etc.); 
• You must be aged 18 or over and a non-smoker; 
• If you have a current medical diagnosis of any of the following conditions you 
will not be able to participate in the study; 
o Hypertension, pregnancy-induced hypertension or preeclampsia; 
o Cardiovascular or respiratory disease (e.g. asthma, bronchitis, COPD 
[chronic obstructive pulmonary disease]); 





• The project will require a single visit to Bournemouth University of 
approximately 1 ½ hours; 
• During the data collection session we will collect some non-invasive 
cardiovascular and respiratory measurements, and you will learn how to control 
your breathing at a specific rhythm and depth, using a visual feedback device; 
• After participation in the data collection session you will be asked to submit your 
blood pressure measurements taken at your antenatal sessions; 
• You will be asked to refrain from eating for 2 hours and from caffeine, strenuous 
exercise and alcohol for 12 hours prior to the data collection session. You are 
not required to refrain from drinking during this time; 
• We ask that you attend the session in appropriate clothing that allows access to 




If you choose to participate in this study you will be required to attend the Bournemouth 
University (BU) Cardiorespiratory Research Laboratory (Bournemouth House, 
Lansdowne Campus) on one occasion. Approximately 50 minutes of the whole 1 ½ hour 
session will be used for the data collection and will involve using an App to guide your 
breathing at different frequencies, as well as monitoring you during spontaneous 
breathing. You will be given a break at the mid-way point of the data collection to allow 
a bathroom break or for you to get up and move around. The spontaneous breathing 
protocol will involve you breathing normally with no pacing, while we collect data. The 
App will be installed on a laboratory iPad and you will not be required to use your own 























Figure 1: Participant set up with equipment 
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The slow and deep breathing will be delivered using an App developed at BU and you 
will be asked to follow the visual feedback for 4 different breathing protocols, for 5 
minutes each. There will be a 5-minute break between each breathing protocol, where 
you can breathe normally, and take off the mask if you wish. When using the App you 
will be instructed to inhale when the dome graphic rises and exhale when the dome falls 
(see Figure 2). You will be wearing a finger sensor throughout that connects to the 








           
Figure 2: Screenshot of Brythm App Feedback Display Figure 3: Brythm App Finger Sensor                                                
N.B. Arrows shown for illustrative purposes only and do not appear on App 
 
You will be asked to follow breathing frequencies of 4, 6 and 8 breaths per minute and a 
dynamic frequency determined by the App (this will likely fall within the range of breathing 
frequencies above and for non-pregnant females was on average 6.2 breaths per 
minute). Normal breathing frequency is around 12 breaths per minute, so you will be 
asked to breathe at around half the normal rate. This is not as difficult as you might think, 
because the reduction in breathing rate is compensated by increasing breathing depth, 
which your body will do automatically. You will be given an opportunity to practice this 
before the study begins. A visual overview of the protocol is provided in Figure 4. 
  
 
Figure 4: Visual overview of the protocol for breathing frequencies 
 
Each block is 5-minutes in duration, including spontaneous baseline breathing (B) and all rest periods (R) of 
unrestricted breathing between each protocol. 
The order of breathing protocols will be assigned randomly at the start of the data collection session and 
you will be informed of the order before you start. 




What will happen to me if I take part?  
 
You will perform a total of 25 minutes of breathing protocols (including the 5 minutes of 
unrestricted spontaneous breathing, see Figure 4), during which we will carry out a 
number of physiological measurements. These measurements are described below: 
 
Pre-data collection requirements 
 
Upon arrival, you will first need to complete a health questionnaire and sign a consent 
form to confirm that you’re healthy and able to participate in the study. You will complete 
a form with your contact details and contact preference to allow us to contact you after 
the data collection session (see post-data collection section below). Your height and 
weight will also be measured at this stage; this will not require you to remove any clothing 




During the breathing protocols you will be asked to wear a mask to measure breathing 
patterns, which covers your mouth and nose but allows you to breathe normally through 
both (see Figure 1). The mask can be taken off between breathing protocols in the 5-
minute rest periods. We will measure your blood pressure and estimate the amount of 
blood that is pumped out of your heart using two cuffs; one placed on the upper arm and 
one on the middle finger (see Figure 5). The silver box is secured on the wrist, but does 
not take any measurements from your wrist. You will also have a finger sensor attached 




Figure 5: The finger cuff used for the 







Heart rate will be measured continuously using a 3-lead 
electrocardiogram (ECG). Sensors will be placed on your 
chest; 2 sensors just below each of your clavicles and 1 
sensor placed on the lower ribs (see Figure 6). These will be 
placed under your clothing and you will not need to remove 
any items of clothing for attachment. ECG monitoring is safe 
to have while pregnant, with no known risks. 
 
 
Post Data Collection 
 
After participating in the data collection session, you will be asked to submit your blood 
pressure measurements that are taken during your antenatal appointments, as recorded 
in your maternity record notes. You will be provided with a link to a secure online form to 
Figure 6: Placement sites for the 
3-lead ECG electrodes 
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submit these measures. Alternatively, you can request to be sent a paper template and 
send this back to us in the stamped envelope provided.  You will be contacted at 29 and 
36 weeks and after your due date to remind you to complete the form. You will have a 
choice on how to be contacted, either by phone, text, e-mail or post and can indicate 
your preference on the contact form before participating in the study. We ask for this 
blood pressure information so we can monitor your blood pressure throughout your 
pregnancy.  
 
Do I have to take part? Can I change my mind and withdraw from the study? 
 
Your participation in this research is entirely voluntary and it is up to you to decide 
whether or not to take part. You will be given this information sheet to keep and if you do 
decide to take part, you will be asked to sign a participant agreement form.  You can 
withdraw from participation during the data collection session at any time and without 
giving a reason., If you decided to withdraw we will usually remove any data collected 
about you from the study. Once the data collection session has finished you may still be 
able to withdraw your data up to the point where the data is analysed and incorporated 
into the research findings or outputs. At this point your data will usually become 
anonymous, so your identity cannot be determined, and it may not be possible to identify 
your data within the anonymous dataset. Withdrawing your data at this point may also 
adversely affect the validity and integrity of the research. You can withdraw from being 
contacted regarding your ongoing blood pressure measurements by contacting an 
investigator. Deciding to take part or not will not impact upon/adversely affect your 
treatment, care or access to other services. 
 
What are the possible disadvantages and risks of taking part? 
 
Since you will be breathing at a lower breathing frequency than your usual spontaneous 
breathing frequency, you may experience sensations of heat, sweating and ‘flushing’ and 
a strong urge to breath more. This is uncommon but a normal response to slow and deep 
breathing, and does not present any known risk to your safety or the pregnancy. In the 
unlikely event that you feel uncomfortable, you are free to interrupt the protocol and 
remove the mask. The sensations subside quickly once spontaneous breathing is 
resumed. 
 
What will I get in return? 
 
You will get information about your current blood pressure, in the form of graphical 
representation of your antenatal blood pressure measurements. You will be assisting in 
a research project which is looking for a potential alternative treatment method for high 
blood pressure during pregnancy. No financial compensation will be given for 
participating in this study.  
 
How will my information be kept? 
 
All the information we collect about you during the course of the research will be kept 
strictly in accordance with current data protection legislation. Research is a task that 
we perform in the public interest, as part of our core function as a university.  
Bournemouth University (BU) is a Data Controller of your information which means that 
we are responsible for looking after your information and using it appropriately.  BU’s 
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Research Participant Privacy Notice sets out more information about how we fulfil our 
responsibilities as a data controller and about your rights as an individual under the 
data protection legislation.  We ask you to read this Notice so that you can fully 





You will not be able to be identified in any external reports or publications about the 
research without your specific consent. Otherwise your information will only be included 
in these materials in an anonymous form, i.e. you will not be identifiable.   
 
Security and access controls 
BU will hold the information we collect about you in hard copy in a secure location and 
on a BU password protected secure network where held electronically. Except where it 
has been anonymised your personal information will be accessed and used only by 
appropriate, authorised individuals and when this is necessary for the purposes of the 
research or another purpose identified in the Privacy Notice. This may include giving 
access to BU staff or others responsible for monitoring and/or audit of the study, who 
need to ensure that the research is complying with applicable regulations. 
 
Sharing and further use of your personal information 
The information collected about you may be used in an anonymous form to support other 
research projects in the future and access to it in this form will not be restricted.  It will 
not be possible for you to be identified from this data. Anonymised data will be added to 
BU’s Data Repository (a central location where data is stored) and which will be publicly 
available. 
 
Retention of your data 
All personal data collected for the purposes of this study will be held for 5 years either 
from the date of publication of the research or after the award of the PhD, whichever is 
later. Although published research outputs are anonymised, we need to retain underlying 
data collected for the study in a non-anonymised form for a certain period to enable the 
research to be audited and/or to enable the research findings to be verified. 
 
What type of information will be sought from me and why is the collection of this 
information relevant for achieving the research project’s objectives? 
 
Prior to taking part in the study you will be required to fill in a health check questionnaire. 
This information is paramount to our research as your health status might show that you 
meet one of our exclusion criteria and cannot participate in this study. We ask for your 
due date so that we know when to contact you to remind you to submit your blood 
pressure measurements. We need to monitor your blood pressure to ensure that all 
participants in the study maintain normal blood pressure levels throughout their 
pregnancy. 
 
Physiological changes caused by pregnancy-induced hypertension (PIH) and 
preeclampsia could affect the study results, as we do not yet know if these conditions 
affect the responses to slow and deep breathing. If you are diagnosed with PIH or 
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preeclampsia then your results will be removed from the main analysis but your data may 
still be used as part of a small subsection data analysis.  
 
Who is organising and funding the research? 
 
The research is being organised by the Faculty of Health and Social Sciences at 
Bournemouth University as part of the PhD doctoral studies of Malika Felton. 
 
What if something goes wrong? 
 
The procedures involved in this study are extremely low risk, requiring participants to do 
nothing more than to sit, and to breathe slowly and deeply, in a relaxed way. 
Nonetheless, an emergency name and contact telephone number must be provided by 
all participants in the health check questionnaire. You can contact any of the research 
team regarding any queries using the contact details below. 
 
In case of complaints you can contact the Executive Dean of the Faculty of Health & 
Social Sciences, Professor Stephen Tee, as an independent member of BU Staff, by 
email at researchgovernance@bournemouth.ac.uk.  
 
If you have any questions or would like further information regarding this research 
project, please contact the main investigator: 
 
Malika Felton 
Bournemouth University, Room 305, Royal London House, Christchurch Road, 
Bournemouth, BH1 3LT 




Thank you for considering taking part in this research project. 
  













Deputy Dean of 
Research And 
Professional Practice, 







Appendix IId: Chapter 8 participant information sheet 
 
Participant Information Sheet (PIS) 
 
Effects of slow and deep breathing (SDB) on reducing obstetric 





We are inviting pregnant women with high blood pressure (pregnancy-induced 
hypertension; PIH) to take part in our research study. Before you decide, it is important 
you understand why the research is being completed and what it will involve. Please 
read this information carefully and discuss it with others. Ask us if there is anything that 
is unclear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
Study Background & Purpose 
 
Breathing exercises have long been used as part of yoga and meditation to aid relaxation 
during pregnancy. Slow and deep breathing immediately changes blood pressure and 
heart rate. It can also reduce blood pressure in the long-term when practiced daily. Using 
a video graphic is the easiest way to guide breathing to a slower rate, but to date this 
hasn’t been used with pregnant women. 
 
Many women do not want to take medications during pregnancy. This means there is an 
urgent need for new and alternative ways of treating PIH (high blood pressure during 
pregnancy). Slow and deep breathing has produced promising but mixed results in other 
groups with high blood pressure.  However, we believe that slow and deep breathing 
may be more effective on PIH than other types of high blood pressure. This is because 
pregnancy affects women’s breathing, which may be a reason for PIH. 
 
This study is the first stage of a project using slow and deep breathing with pregnant 
women. We will be looking at how the study processes work in practice. We will assess 
whether we could use them in a future larger trial. We will look at the number of women 
taking part in the study and how often they complete the breathing exercises. The 
purpose of this study is to look at whether using slow and deep breathing with pregnant 
women with PIH is successful. The study will also look at the short term responses to 





• You must have been diagnosed with high blood pressure that has developed 
after 20 weeks gestation, which you did not have before the pregnancy. OR 
diagnosed during pregnancy with one-off new high blood pressure but at risk of 
developing PIH; 
• You must be carrying a single pregnancy (not twins, triplets, etc.); 
• You must be aged 18 or over and a non-smoker; 
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• You must be under the care of a midwife for your pregnancy rather than being 
placed under the care of a doctor/obstetrician; 
• If you have a current medical diagnosis of asthma, bronchitis or COPD (chronic 
obstructive pulmonary disease) you will not be able to take part. An older (not 
current) diagnosis would not exclude you from taking part i.e. childhood asthma; 
• We will conduct an ECG (see page 6 for more details). If you have an allergy or 
previous reaction to the conducting gel used for the ECG you will not be able to 
take part. 
 
Key details to know  
 
The list below provides a summary of the key details for the study. If you are interested 
in taking part, then you can find more details in the ‘what would taking part involve’ 
section below: 
 
• You will be asked to complete a 10-min slow and deep breathing exercise every 
day until birth; 
• You will receive guidance on the breathing exercise and be given a blood 
pressure monitor to take home if you do not already have one; 
• We will ask you to measure your blood pressure daily using an automated 
blood pressure monitor. You will be asked to record the blood pressure results 
and how often you complete the breathing exercise on a daily record sheet; 
• You will attend 1 session at Bournemouth University (BU) lasting approximately 
1 ½ hours. We will collect some non-invasive measurements such as heart rate 
and blood pressure while you complete different breathing exercises; 
• You will be asked to refrain from eating for 2 hours before the session and for 
12 hours before, have no caffeine or alcohol and no strenuous exercise. You 
can drink water or other liquids during this time; 
• At 36 weeks gestation you will be asked to complete an online survey on your 
experiences of taking part in the study. 
 
What would taking part involve? 
 
You will come to Bournemouth University (BU) once at the start of the study. You can 
bring a partner, friend or family member with you if you wish. Children under 16 are not 
permitted to attend the sessions. The session will be arranged at a time convenient to 
you. Free visitor parking will be available. 
 
During this session you will be given the instructions and equipment needed to complete 
your daily breathing exercise and blood pressure measurements. We will also look at 
your responses to the slow and deep breathing exercises during a short protocol. At 36 
weeks gestation, you will be invited to complete an online survey. You can find more 
information about each of the 3 study sections in the next 3 pages. 
 
At BU, we will talk through what will be involved in taking part in the study. You will have 
the opportunity to ask any questions before consenting to take part in the study. You will 
also complete a health survey and a contact details form so we can get in touch with you 
during the study. The health survey will ask for your age, estimated date of delivery, 
gestational age, and other medical conditions. 
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1. Daily breathing exercise overview  
 
For the main study you will be asked to perform a 10-minute breathing exercise every 
day until you give birth. You can complete the breathing exercise at any time of day. The 
breathing exercise will be guided by a video. You will be asked to follow the visual graphic 
displayed; breathing in when the dome graphic rises and breathing out when the dome 




Figure 1: Screenshots of video 
graphic  
Note: Arrows do not appear on video. 





When you breathe in time with the video graphic your breathing rate will be lowered to 6 
breaths per minute. Your normal breathing rate is around 14 breaths per minute. So you 
will be asked to breathe at around half the normal rate. This is not as difficult as you 
might think. The body automatically increases how deeply you breathe. This means that 
you still receive enough oxygen for both you and your baby. You will be given the chance 
to practice breathing with the video during the BU session. Potential feelings of light-
headedness are rare. Most people report feeling relaxed during the breathing exercise. 
The video is hosted on the Panopto website and will be accessed via a link e-mailed to 
you. More details about how you will view the video are provided in Appendix A at the 
end of the document. 
 
In addition to the breathing exercise you will be asked to measure your blood pressure 
daily. You may already have been given an automated blood pressure monitor from 
Poole Hospital. If you have, then you can submit these readings. You do not have to take 
extra readings. If you haven’t been given a monitor, we will provide one for you to take 
home. You will be shown how to use it during the BU session. 
 
We will ask you to keep a record of your blood pressure results and how often you 
complete the breathing exercise on a daily record. You will complete the time of the 
breathing exercise session, duration and your blood pressure readings. You can do this 
online, via an e-mail link, or using a paper template that we provide. If you are placed 
under obstetric-led care (consultant/ doctor) during the study you may continue with the 
breathing exercise. You will be asked to make a note of this, including the date and 
medication type (if applicable) in your daily record. Finally, you will be asked to record 
your delivery date and mode of delivery after you have given birth. 
 
If you have any problems viewing the video or using the blood pressure monitor please 
contact Malika Felton for help (contact details at end of document). The blood pressure 
monitor we supply can be returned at the end of the study to Poole Hospital labelled c/o 
Steph Grigsby, Lead Research Midwife, or to Studland House reception desk at 
Bournemouth University c/o of Malika Felton.  
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This study does not replace standard care. You should continue to attend your 
appointments and take any regular or new medication as directed by your 
obstetrician or midwife. 
 
2. Breathing responses protocol overview 
 
The short-term responses section of the research study will last approximately 45 
minutes of the BU session. This section will include the video used in the daily breathing 
exercise (6 breaths per minute), as well as 2 other videos. The 2 other videos will guide 
your breathing rate to 4 and 8 breaths per minute. We will also measure your responses 
during your normal breathing. The reason we ask you to breathe at 4 and 8 breaths per 
minute is to ensure we are using the best rate for women with PIH.  
 
We will monitor your blood pressure, heart rate and breathing rate using the equipment 
shown in Figure 2. More details are provided on the next page. You can have a break 
halfway through the data collection if you want to get up and move around or for a 
bathroom break. Before we start we will measure your height and weight. This will not 




















Figure 2: Equipment set up 
 
The slow and deep breathing videos will be viewed on a BU iPad. You will not need to 
use your own device for this part of the study. The only difference between the 3 
breathing exercises (4, 6 and 8 breaths per minute) will be the speed of the video graphic. 
For the ‘normal’ breathing you will breathe normally with no pacing or guidance. 
 
Each breathing exercise will be performed for 5 minutes. There will be a 5-minute break 
between each exercise. During the break you can breathe normally and take off the mask 
if you wish.  
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You will complete 15 minutes of fixed breathing (following the video graphic), 5 minutes 
of normal breathing and 20 minutes of normal breathing while data is not collected 
(during the breaks). An overview of the protocol is shown below (Figure 3). 
Figure 3: Overview of the protocol for short-term responses to slow and deep 
breathing  
 
Each block is 5-minutes long. The order of breathing exercises will be randomly selected before the session.  
You will be told the order before you start. 
 
Measurements of respiration, blood pressure and heart rate 
 
During the breathing exercises you will be 
asked to wear a mask to measure your 
breathing. The mask covers your mouth and 
nose but allows you to breathe normally 
through both (see Figure 2). The mask can be 
taken off between breathing exercises in the 5-
minute rest periods. 
 
We will measure your blood pressure and 
estimate the amount of blood that is pumped 
out of your heart using two cuffs. One cuff 
placed on the upper arm and one on the middle 
finger (see Figure 4). The silver box is just 
secured at the wrist. It does not take any 
measurements. You will also have a finger 
sensor attached on the same hand (green sensor in Figure 4). 
 
Heart rate will be measured continuously using a 3-lead 
electrocardiogram (ECG). Sensors will be placed on your 
chest. 2 sensors just below your collarbone on each side 
and 1 sensor placed on the lower ribs just above your baby 
bump (see Figure 5 for example). These will be placed 
under your clothing but you will not need to remove any 
items. ECG monitoring is safe to have while pregnant, with 




3. Survey overview 
 
At 36 weeks gestation we will invite you to complete an online survey. If you give birth 
before 36 weeks you will be invited to complete the survey as soon as appropriate within 
3 weeks. The survey will ask about your experiences of completing the daily breathing 
Figure 4: The finger cuff used for the 
continuous measurement of blood 
pressure 
Figure 5: Placement sites for the 3-lead ECG electrodes 
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exercise and blood pressure measurements. This could be any problems you had or 
anything that stopped you completing the sessions. These data will help shape the 
design of future research studies.  
 
What are the possible benefits of taking part? 
 
You will have the opportunity to monitor your blood pressure every day. You will receive 
a graph to show your blood pressure changes over your pregnancy. This study is looking 
at the impact of slow and deep breathing so we cannot say whether it will have a 
beneficial effect on your blood pressure.  
 
You will continue to receive standard care. This will not be affected by taking part in the 
study. This research is not intended to replace any clinical treatments. Taking part in the 
short term responses section may add to the understanding of PIH and the potential 
benefits that slow and deep breathing could have as an alternative treatment method. 
No financial compensation will be given for taking part in this study but visitor parking will 
be provided during your BU session. 
 
What are the possible disadvantages and risks of taking part? 
 
There are no known risks to pregnancy, but as you will be breathing at a lower breathing 
rate than normal, you may have feelings of sweating, heat, ‘flushing’ and a strong urge 
to breath more. This is uncommon but a normal response to slow and deep breathing. 
It does not present any known risk to your safety or the pregnancy. In the unlikely event 
that you feel uncomfortable, you can stop the breathing exercise and return to breathing 
normally. The feelings decrease quickly once normal breathing is resumed. In a past 
research study with pregnant women breathing at these rates, none of the women felt 
uncomfortable during the short-term responses protocol. In the unlikely event that this 
occurs at home, this should be reported to Malika Felton using the contact details 
provided at the end of the document.  
 
Only Malika Felton and Steph Grigsby, Lead Research Midwife, within the research team 
will have access to information that could identify you, including your contact details. All 




Do I have to take part? Can I change my mind and withdraw from the study? 
 
Taking part in this research is voluntary. It is up to you to decide whether or not to take 
part. This study is outside of standard care but it will not affect the standard care you 
receive for your pregnancy or any other health matters. Deciding to take part or not won’t 
affect your treatment, quality of care or access to other services.  
 
You will be given this information sheet to keep. If you decide to take part, you will be 
asked to sign a consent form. You can withdraw from taking part at any time and without 
giving a reason. If you wish we can remove any previously collected data from you up 
until the point that data are analysed and included in research findings. At this point your 
data will become anonymous, so your identity cannot be determined. It may not be 
possible to identify your data within the anonymous dataset.  
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Informing Healthcare Staff 
 
We will include this participant information sheet in your maternity records so that your 
obstetrician and midwife are aware you are taking part. We will also write to your GP to 
inform them. 
 
How will my information be kept confidential? 
 
In this research study we will use information from you. We will only use information that 
we need for the research study. We will let very few people know your name or contact 
details, and only if they really need it for this study. Everyone involved in this study will 
keep your data safe and secure. We will also follow all privacy rules. At the end of the 
study we will save some of the data in case we need to check it and for future research. 
This does not include identifiable data. We will make sure no-one can work out who you 
are from the reports we write. The ‘GDPR information’ pack tells you more about this. 
 
Who is organising and funding the research? 
 
The research is being organised by the Faculty of Health and Social Sciences at 
Bournemouth University as part of the PhD doctoral studies of Malika Felton. 
 
What will happen to the results of this study? 
 
The results of this study will be used as part of Malika Felton’s doctoral thesis. It is 
expected that the results will be published in peer-reviewed scientific journals and 
presented at conferences. All data will be anonymised at publication. You will not be 
identifiable in any way. The results could also be used to support future funding bids for 




How have patients and the public been involved in this study? 
 
Pregnant women/ mothers and antenatal class teachers were involved in reviewing the 
Participant Information Sheet. In designing this study, we have considered pregnant 
women’s opinions on the breathing rate they would feel most comfortable completing 
daily.  
 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed and 
given favourable opinion by Hampshire B Research Ethics Committee. 
 
What if something goes wrong? 
 
The procedures involved in this study are extremely low risk, with women having to do 
nothing more than to sit, and to breathe slowly and deeply, in a relaxed way. In case of 
an adverse event during the BU session, an emergency name and contact telephone 
number must be provided by all women in the health survey. Bournemouth University 
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holds Public Liability and Professional Indemnity insurance to cover the legal liability of 
the University involved in research and for its employees in the case of harm to a 
research participant arising from the management, design or conduct of the research by 
the University. 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact details below). If 
you remain unhappy and wish to complain formally, you can do this by contacting the 
Executive Dean of the Faculty of Health & Social Sciences, Professor Stephen Tee, as 
an independent member of BU Staff, by email at 
researchgovernance@bournemouth.ac.uk. You can also contact Poole Hospital PALS 
(Patient Advice and Liaison Service) on 01202 448499 or 
patientexperienceteam@poole.nhs.uk for confidential support.  
 




If you have any questions or would like further information regarding this research 
project, please contact the principal investigator: 
Malika Felton 
Bournemouth University, Room R305, Royal London House, Christchurch Road, 
Bournemouth, BH1 3LT 
 
Phone: 01202 961845 
Email: mfelton@bournemouth.ac.uk  
 
 
Appendix 1: Accessing the breathing aid video 
 
The video will be viewed on a webpage hosted by Panopto, an online video platform site. 
You will be shown how to access this in your BU session. The video can be accessed 
on any computer, tablet or phone with an internet connection. You will be e-mailed a link 
to access the video. We recommend watching the video while connected to a Wi-Fi 
internet connection. Watching the full 10-minute video could use approx. 200MB each 
time. Please note we cannot guarantee exact data usage. If you do not have access to 
Wi-Fi then you can request to download the file directly to your device. Please speak to 
Malika Felton. 
 
The video does not have to be watched on the same device for each session. We 
recommend bookmarking the webpage for easy access. We can show you how to do 
this during your BU session. Panopto records the following when you watch the video; 
number of views, time of day of each view, and duration of each view. This is linked only 
to the e-mail address to which the link is sent. No other personal data is collected from 
you or the device you use to access the video. BU will be able to access this information. 
Panopto’s privacy notice can be viewed at www.panopto.com/privacy/. 
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Appendix III: Consent form 
Appendix IIIa: Chapter 4 consent form 
Participant Agreement Form 
 
 
‘Device guided slow breathing for the treatment of hypertension: 
Comparison of BU’s Brythm App with an NHS approved device’ 
 
 





















I have read and understood the participant information sheet for the above 
research project.  
 
 
I confirm that I have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary. 
 
 
I understand that I am free to withdraw up to the point where the data are 
processed and become anonymous, so my identity cannot be determined.  
 
 
During the task or experiment, I am free to withdraw without giving reason 
and without there being any negative consequences. 
 
 
Should I not wish to answer any particular question(s) or complete a test, 
I am free to decline. 
 
 
I give permission for members of the research team to have access to my 
anonymised information for the purposes of this research project. I 
understand that my name will not be linked with the research materials, 
and I will not be identified or identifiable in the outputs that result from the 
research.   
 
 
I agree to take part in the above research project.  
I understand that the anonymised data I provide may be used by the 
research team to support other research projects in the future, including 
future publications, reports or presentations. 
 
 
________________________      _______________      ________________________ 
Name of Participant                      Date                             Signature 
 
________________________      _______________      ________________________ 
Name of Researcher                     Date                             Signature 
 
This form should be signed and dated by all parties after the participant receives a copy of the participant 
information sheet and any other written information provided to the participants. A copy of the signed and 
dated participant agreement form should be kept with the project’s main documents which must be kept in 
a secure location. 






Appendix IIIb: Chapter 5 consent form 
 
Participant Agreement Form 
 
‘Acute effects of slow and deep breathing upon healthy young 
women’ 
 
Contact Position Phone Email 
Malika Felton 
 














I have read and understood the participant information sheet for the above 
research project.  
 
 
I confirm that I have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary. 
 
 
I understand that I am free to withdraw up to the point where the data are 
processed and become anonymous, so my identity cannot be determined.  
 
 
During the task or experiment, I am free to withdraw without giving reason and 
without there being any negative consequences. 
 
 
Should I not wish to answer any particular question(s) or complete a test, I am 
free to decline. 
 
 
I give permission for members of the research team to have access to my 
anonymised information for the purposes of this research project. I understand 
that my name will not be linked with the research materials, and I will not be 
identified or identifiable in the outputs that result from the research.   
 
 
I agree to take part in the above research project.  
Use of the information I provide beyond this project: --- 
I agree for the anonymised data I provide to be archived at BU’s Online 
Research Data Repository. 
 
I understand that the anonymised data I provide may be used by the research 
team to support other research projects in the future, including future 




________________________      _______________      ________________________ 
Name of Participant                      Date                             Signature 
 
________________________      _______________      ________________________ 
Name of Researcher                     Date                             Signature 
 
This form should be signed and dated by all parties after the participant receives a copy of the participant 
information sheet and any other written information provided to the participants. A copy of the signed and 
dated participant agreement form should be kept with the project’s main documents which must be kept in 






Appendix IIIc: Chapter 6 consent form 
Participant Agreement Form 
 
‘Acute effects of slow and deep breathing upon 
pregnant women’ 
 
Contact Position Phone Email 
Malika Felton 
 












In this Form we ask you to confirm whether you agree to take part in the Project.  
You should only agree to take part in the Project if you understand what this will mean 
for you.  If you complete the rest of this Form, you will be confirming to us that:  
• You have read and understood the Project Participant Information Sheet [V1] 
and have been given access the BU Research Participant Privacy Notice which 




•  You have had the opportunity to ask questions;  
 
• You understand that: 
o Taking part in the research will include a data collection session where we 
will collect non-invasive cardiovascular and respiratory measurements, 
while you breathe at a specific rhythm and depth, using a visual feedback 
device. 
o Taking part in the research will include submitting your blood pressure 
measurements taking during your antenatal appointments either via an 
online or paper form. 
o Your participation is voluntary.  You can stop participating in research 
activities at any time without giving a reason, and you are free to decline to 
answer any particular question(s). 
o If you withdraw from participating in the Project, you may not always be 
able to withdraw all of your data from further use within the Project, 
particularly once we have anonymised your data and we can no longer 
identify you. 
o Data you provide may be included in an anonymised form within a dataset 
to be archived at BU’s Online Research Data Repository. 
o Data you provide may be used in an anonymised form by the research 
team to support other research projects in the future, including future 
publications, reports or presentations. 
Consent to take part in the Project  Yes No 
I agree to take part in the Project on the basis set out above   
 
_______________________      _______________      ________________________ 
Name of Participant                      Date                             Signature 
 
________________________      _______________      ________________________ 












Title of Project: Effects of slow and deep breathing (SDB) on reducing obstetric 
intervention in women with pregnancy-induced hypertension (PIH): A feasibility study 
Name of Researcher: Malika Felton 
 
 
1. I confirm that I have read the participant information sheet dated 
10/03/2020 (version 3) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected. If I withdraw from participating in the project, I understand I may not 
always be able to withdraw all of my data from further use within the project, 
particularly once my data has been anonymised and I can no longer be identified. 
 
3. I understand that relevant sections of my medical notes, may be looked at by 
individuals from Bournemouth University (the Sponsor), regulatory authorities or 
from Poole Hospital NHS Foundation Trust, where it is relevant to my taking part 
in this research. I give permission for these individuals to have access to my 
records.  
 
4. I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other 
researchers. 
 
5. I agree to my General Practitioner being informed of my participation in the study. 
 
6. I understand that the information held and maintained by Bournemouth University 
and Poole Hospital NHS Foundation Trust may be used to help contact me or 
provide information about my health status. Your medical notes will not be 
accessed for this project. 
 
7. I agree to take part in the above study. 
 
 
            
Name of Participant  Date    Signature 
 
            
Name of Person  Date    Signature 
taking consent    
 
  
Official Researcher Use Only 
IRAS ID 
Participant Identification 
Number for this trial 
251062  









Appendix IV: Health questionnaire 
Appendix IVa: Chapter 4 health questionnaire 
PRE-PARTICIPATION HEALTH CHECK QUESTIONNAIRE 
 
‘Device guided slow breathing for the treatment of hypertension: 
Comparison of BU’s Brythm App with an NHS approved device’ 
 
Health and safety within this investigation is of  paramount importance.  For this reason it is  
essential that we are aware of  your current health status before you begin any testing procedures.  
Additionally, the following questions are designed to establish whether you are suited to take part 
in this study. 
 
Participant name:                                                              Date of birth:    ____/____/_______ 
 
Emergency Contact Name:                                      Emergency Contact Tel:  _____________        
 
Please answer the following questions:     
                    
1. Has your doctor ever diagnosed a heart condition or recommended only  
medically supervised exercise? 
2. Do you suf fer f rom chest pains, heart palpitations, arrhythmia or tightness  
of  the chest? 
3. Do you have known high blood pressure? If  yes, please give details b elow (i.e. 
medication). 
4. Do you suf fer f rom any lung/chest problem? 
e.g., asthma, bronchitis, emphysema? If  yes, please give details below.  
5. Do you suf fer f rom epilepsy? If  yes, when was the last episode? 
6. Are you a smoker? If  yes, please give number of  cigarettes per week. 
7. Do you have any known allergy to conductive gel? (i.e. the gel used with ECG) 
 
Please give details if you answered yes to any of the above questions (number each 




Please document your current weekly exercise routine; 






   
 
If you feel at all unwell as a result of a temporary illness (cold or fever) please inform the 
investigator. Please note that if your health status changes and in any way affects the 
answers you provided to the questions above, it is paramount that you notify the 
investigator immediately. 
 
I have read and fully understand this questionnaire. I confirm that to the best of 
my knowledge the answers provided are correct and accurate. I am aware of no 
reasons why I should not participate in this study and I am fit and fully able to 
volunteer for this investigation.  I understand I will be taking part at my own risk. 
 
Participant’s name & signature:     Date: __________                                                 
Witness name & signature:      Date: __________          















Appendix IVb: Chapter 5 health questionnaire 
PRE-PARTICIPATION HEALTH CHECK QUESTIONNAIRE  
  
‘Acute effects of slow and deep breathing upon healthy young women’ 
 
Health and safety within this investigation is of  paramount importance.  For this reason it is 
essential that we are aware of  your current health status before you begin any testing procedures.  
Additionally, the following questions are designed to establish whether you are suited to t ake part 
in this study. 
 
Participant name:                                                              Date of birth:    ____/____/_______ 
 
Emergency Contact Name:                                      Emergency Contact Tel:  _____________        
 
Please answer the following questions:     
             
1. Has your doctor ever diagnosed a heart condition or recommended only  
medically supervised exercise? 
2. Do you suf fer f rom chest pains, heart palpitations, arrhythmia or tightness of  
the chest? 
3. Do you have known high blood pressure? If  yes, please give details below (i.e. 
medication). 
4. Do you suf fer f rom any lung/chest problem? 
e.g., asthma, bronchitis, emphysema? If  yes, please give details below. 
5. Do you suf fer f rom epilepsy? If  yes, when was the last episode? 
6. Are you a smoker? If  yes, please give number of  cigarettes per week.  
7. Do you have any known allergy to conductive gel? (i.e. the gel used with ECG, 
ultrasounds, etc.) 
8. Have you ever been diagnosed with a spontaneous pneumothorax (collapsed lung) 
or a recent traumatic pneumothorax? If  yes, please give details below.  
9. Do you suf fer f rom an eardrum rupture, or other middle ear condition? 
10.  Are you currently (or have you ever) been prescribed the oral contraceptive pill? 
If  yes, please give details (i.e. pill type, years of  use) 
11.  Are you currently pregnant? 
12.  How many days are you into your current menstrual cycle?           
First day of  bleeding is Day 1.     Day __________ 
 
Please give details if you answered yes to any of the above questions (number each 
answer in relation to the question above): 
_________________________________________________________________________ 
 
Please document your current weekly exercise routine; 









If you feel at all unwell as a result of a temporary illness (cold or fever) please inform the 
investigator. 
 
I have read and fully understand this questionnaire. I confirm that to the best of my 
knowledge the answers provided are correct and accurate. I am aware of no reasons why 
I should not participate in this study and I am fi t and fully able to volunteer for this 
investigation.  I understand I will be taking part at my own risk.  
 
Participant’s name & signature:     Date: __________                                                 
Witness name & signature:      Date: __________ 













Appendix IVc: Chapter 6 health questionnaire 
 
PRE-PARTICIPATION HEALTH CHECK QUESTIONNAIRE  
 
‘Acute effects of slow and deep breathing upon pregnant women’ 
 
Health and safety within this investigation is of  paramount importance.  For this reason it is 
essential that we are aware of  your current health status before you begin any testing procedures.  
Additionally, the following questions are designed to establish whether you are suited to take part 
in this study. 
 
Participant name:                                                              Age:    _______________ 
 
Emergency Contact Name:                                      Emergency Contact Tel:  _____________ 
 
Please answer the following questions:     
                
 
1. Has your doctor ever diagnosed a heart condition or recommended only 
medically supervised exercise? 
2. Do you suf fer f rom chest pains, heart palpitations, arrhythmia or tightness of  the chest? 
3. Do you have known high blood pressure? If  yes, please give details below (i.e. 
medication). 
4. Do you suf fer f rom any lung/chest problem? 
e.g., asthma, bronchitis, emphysema? If  yes, please give details below. 
5. Do you suf fer f rom epilepsy? If  yes, when was the last episode? 
6. Are you a smoker? If  yes, please give number of  cigarettes per week.  
7. Do you have any known allergy to conductive gel? (i.e. the gel used with ECG, 
ultrasounds, etc.) 
8. How many weeks pregnant are you?              Week_________ 
9. Are you carrying a multiple pregnancy? (i.e. twins, triplets, etc.)  
10.  Have you previously been pregnant? 
 
Please give details if you answered yes to any of the above questions (number each 




If you feel at all unwell as a result of a temporary illness (cold or fever) please inform the 
investigator. 
 
I have read and fully understand this questionnaire. I confirm that to the best of 
my knowledge the answers provided are correct and accurate. I am aware of no 
reasons why I should not participate in this study and I am fit and fully able to 
volunteer for this investigation.  I understand I will be taking part at my own risk. 
 
 
_______________________      _______________      ________________________ 
Name of Participant                     Date                            Signature 
 
________________________      _______________      ________________________ 
Name of Witness                          Date                             Signature



















PRE-PARTICIPATION HEALTH QUESTIONNAIRE  
 
Effects of slow and deep breathing (SDB) on reducing obstetric intervention in 
women with pregnancy-induced hypertension (PIH): A feasibility study 
 
Health and safety within this investigation is of  paramount importance.  For this reason it is 
essential that we are aware of  your current health status before you begin any research 
procedures.  Additionally, the following questions are designed to check that you are suited to 
take part in this study. Your responses to one or more of  the questions may mean that you are 
ineligible to participate in this study. 
 
Participant name:                                                          Date of birth:    ___________________ 
 
Emergency Contact Name:                                           Emergency Contact Tel:  __________         
 
Please answer the following questions:     
                           
1. Do you have high blood pressure that has developed during pregnancy? 
2. Were you told that you had one-off high blood pressure       or pregnancy-induced 
hypertension?  
3. How many weeks pregnant were you when you were diagnosed with high blood 
pressure? 
4. Are you on any medication for your high blood pressure? Please provide details 
_________________________________________________________________ 
5. Are you carrying a multiple pregnancy? (i.e. twins, triplets, etc.)  
6. Have you previously been pregnant and given birth? If  yes, how many times (including 
this pregnancy)? _____________ 
7. Did you experience pre-eclampsia or pregnancy-induced hypertension during any of your 
previous pregnancies? Please provide details 
__________________________________________________________________ 
8. Do you suffer from chest pains, heart palpitations, arrhythmia or tightness of the chest? 
9. Do you currently suffer f rom any lung/chest problem? 
e.g., asthma, bronchitis, emphysema, COPD? If yes, please provide details 
_________________________________________________________________ 
10.  Are you a smoker? (either cigarettes, electronic cigarettes or vaping) 
11.  Do you have any known allergy to conductive gel? (i.e. the gel used with ECG) 
12.  How many weeks pregnant are you?       Week_________ 
13.  When is your estimated date of delivery?            ___/____/20__ 
 
I have read and fully understand this questionnaire. I confirm that to the best of 
my knowledge the answers provided are correct and accurate. I am aware of no 
reasons why I should not participate in this study and I am fit and fully able to 
volunteer.  I understand the implications and procedures involved in this research 
project. 
_______________________      _______________      ________________________ 
Name of Participant                     Date                            Signature 
 
________________________      _______________      ________________________ 
Name of Witness                          Date                             Signature  
Official Researcher Use Only 
IRAS ID Participant Identification 
Number for this trial 
251062  







Appendix V: Post-intervention questionnaire (copy of OnlineSurveys) 
 
Intro page: Welcome to the slow and deep breathing feasibility questionnaire 
 
You have been invited to take part in this questionnaire as part of your participation in 
the slow and deep breathing research study (Full Title: Effects of slow and deep 
breathing on reducing obstetric intervention in women with pregnancy-induced 
hypertension: A feasibility study). 
 
The questionnaire will ask about your experiences of taking part in the intervention and 
completing the daily breathing exercises. Your feedback will have a direct influence on 
future studies looking to use this intervention in a larger group of women.  
 
If you have any questions regarding the study you can contact the principal investigator 
Malika on mfelton@bournemouth.ac.uk or 01202 961845. 
 
The questionnaire should take approximately 10 minutes to complete. If viewing on a 
phone, for questions requiring statements of how strongly you agree you can zoom out 
to see all the answers together on the screen.  
 
By clicking next you are consenting to take part in the questionnaire. If you do want to 
take part or change your mind part way through the questionnaire please close the 
browser and the answers will not be sent to us. 
 
Thank you again for your continued participation in this research project. 
 
New page (pg.2): Research motivations and initial meeting 
 
1. What initially motivated you to take part in the research study? Please tick all 
which apply. 
  I am keen to participate in research      
  I am interested in alternative treatment methods (drug-free)  
  I wanted to feel in control of treating my high blood pressure  
  I hoped to gain health benefits      
I wanted to help develop a new way of reducing blood pressure  
  I thought it sounded interesting      
  I wanted to help the heath of future pregnant women   
  Other          
If you selected Other, please specify: 
 
2. What motivated you to continue with the research study and breathing exercise 
intervention once you had started? Please tick all which apply. 
  I was committed to complete the research              
  I found it relaxing              
  I enjoyed taking time out of my day to complete the breathing exercise
  I thought it was helping my blood pressure           
  I liked helping develop a better treatment for high blood pressure        
  Other                
If you selected Other, please specify: 
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3. Please indicate your agreement with the following statements regarding the 
initial meeting at Bournemouth University: 
(Table with Likert scale; strongly agree, agree, uncertain, disagree, strongly disagree) 
 
The meeting contained enough detail to understand the study 
It was clear how to access the video aid for breathing exercise 
It was clear how to use the blood pressure monitor 
 
New page (pg.3): Experiences of completing the breathing exercise 
 
4. How many weeks pregnant were you when you started the intervention 
(breathing exercise)?  ____ weeks 
 
5. Please indicate your agreement with the following statements regarding the 
breathing video aid: 
(Table with Likert scale; strongly agree, agree, uncertain, disagree, strongly disagree) 
 
The video graphic’s appearance encouraged me to complete the breathing exercise 
It was easy to breathe in time with the breathing graphic 
The breathing graphic felt too slow to breathe in time with 
The breathing graphic felt too fast to breathe in time with 
 
6. Did you experience any issues with accessing the video aid? (feeder question) 
 Yes    No  
 
6a. Please provide details of any issues that you experienced while accessing the video 
aid, even if these were resolved. 
(Only asked if ‘yes’ to Q6) 
 
Please provide details:   
 
6b. Which of the following did you use to resolve the issues? Please tick all which apply. 
(Only asked if ‘yes’ to Q6) 
  Referred to the invitation email     
Contacted the study team       
Spoke with my midwife/GP       
Searched the Internet (i.e. Google)     
Other         












7. Please tell us of any other issues which may have prevented you from 
completing the breathing exercise during the course of the study. You should 
answer this specifically about the breathing exercise, and not the blood 
pressure measurements. We will ask about this later. Please tick all which 
apply. 
I struggled to remember each day     
I was too busy to find time each day     
I went away/on holiday      
It was inconvenient       
It took too much time       
Having to access Wi-Fi made completing the breathing 
exercises more difficult to complete     
Other         
If you selected Other, please specify: 
 
New page (pg.4): Experiences of using the blood pressure monitor 
 
8. Did you use a Bournemouth University or Poole Hospital NHS Foundation Trust 
blood pressure monitor for this research study?  
 
Bournemouth University    Poole Hospital   Both   
Neither (own monitor)   
 
9. Please indicate your agreement with the following statements regarding the 
blood pressure monitor: 
(Table with Likert scale; strongly agree, agree, uncertain, disagree, strongly 
disagree) 
 
It was straightforward to use 
It was easy to put the cuff on 
I had time to complete the blood pressure measurements as directed 
It was easy to add the blood pressure readings to the website 
 
10. Did you experience any issues with using the blood pressure monitor? (feeder 
question) 
 Yes    No  
 
10a. Please tell us of any issues you experienced while using the blood pressure 
monitor, even if these were resolved. Please tick all which apply. (Only asked if ‘yes’ to 
Q10) 
Four columns and tick in appropriate column; problem with Bournemouth University 
monitor, problem with Poole Hospital, problem with both monitors and no problem 
Putting the cuff on         
Getting a valid reading       
Other          
 
If you selected Other, please specify (and include whether this was a problem with a 




10b. If yes, which of the following did you use to resolve the issues? Please tick 
all which apply. 
(Only asked if ‘yes’ to Q10) 
Referred to the product blood pressure monitor user instructions  
Referred to the BU blood pressure monitor user guide   
Contacted the study team        
Spoke with my midwife/GP        
Searched the Internet (i.e. Google)      
Other          
If you selected Other, please specify: 
 
11. Please tell us of any other issues which may have prevented you from regularly 
measuring and recording your blood pressure during the course of the study. 
Please tick all which apply. 
I struggled to remember each day      
 I was too busy to find time each day      
 I went away/on holiday       
 It was inconvenient        
 It took too much time        
 I could not remember how to record blood pressure on the website  
  Other          
If you selected Other, please specify: 
 
New page (pg.5): Please tell us a bit about how the study fitted into your day 
 
12. Where did you mainly undertake the breathing exercise? (feeder question) 
  At home       
  At work       
During my morning commute     
During my afternoon commute     
It varied depending on circumstances each day   
  Other        
If you selected Other, please specify: 
 
12b. If it varied depending on circumstances each day please tick all places 
where you undertook the breathing exercise.  
(Only asked if ‘if varied depending…’ selected in Q12) 
  At home       
  At work       
During my morning commute     
During my afternoon commute     
It varied depending on circumstances each day   
  Other        
If you selected Other, please specify: 
 
13. What device did you mainly used to watch the breathing video? 
Phone         
Tablet         
Laptop         
Desktop computer       
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Other       
If you selected Other, please specify: 
 
14. Please indicate your agreement with the following statements regarding the 
research study: 
(Table with Likert scale; strongly agree, agree, uncertain, disagree, strongly 
disagree) 
 
The daily breathing exercise was easy to incorporate into my daily life 
The blood pressure measurement was easy to incorporate into my daily life 
It was easy to complete the breathing exercise daily for the full duration of the study 
I would recommend the breathing exercise to other pregnant women with high blood 
pressure 
 
15. Did you experience any additional barriers to incorporating the breathing 
exercise into your day that you haven’t already mentioned? You should answer 
this specifically about the breathing exercise, and not the blood pressure 
measurements. We will ask about this in the next question. (feeder question) 
 Yes    No  
 
   15a. Please describe the additional barriers you experienced: 
(Only asked if ‘yes’ to Q15) 
 
16. Did you experience any additional barriers to incorporating the blood pressure 
measurement into your day that you haven’t already mentioned? (feeder 
question) 
 Yes    No  
 
   16a. Please describe the additional barriers you experienced: 
(Only asked if ‘yes’ to Q16) 
 
New page (pg. 6): Future studies 
 
17. As you know this research study is a feasibility study being used to help plan for 
future larger-scale trials. To help us understand women’s views about a future 
study we would be grateful if you would answer the following questions as if you 
were considering taking part in this future study. Please tick all that apply. 
 
I would be willing to be randomised i.e. you would be randomised (like flipping a coin) 
into an intervention group (slow and deep breathing) or a placebo group (another 
breathing rate)             
I would prefer to access the video aid as a file that is available to download onto my 
device, rather than accessing online           
I would prefer to submit my blood pressure measurements online      
I would prefer to submit my blood pressure measurements on a paper daily record  
I would prefer to submit my blood pressure readings using an app      
I would be willing to downloading and use an app to deliver the slow and deep breathing 
               
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Note: To improve our future research studies we welcome your feedback so please 
comment freely in the following questions, including any information you haven’t been 
able to convey above, so that we can improve for future studies. 
 
18. From a participant’s point of view, is there anything that could be improved in 
the process of undertaking the study? (i.e. the initial meeting, information 
provided) 
 
19. Is there anything that could be improved for the breathing graphic or video? 
Please describe what you would change. 
 
20. Is there anything you particularly like about completing the breathing exercise? 
 
21. Is there anything you particularly dislike about completing the breathing 
exercise? 
 
22. Finally, if you were asked to provide helpful top tips of best practice for 
completing the breathing exercise for future participants what would they be? 
 
Final page (pg. 7) 
Thank you for taking part in this questionnaire. 
 
Your answers will be used to help design future larger trials involving slow and deep 
breathing to lower blood pressure in pregnant women. 
 
If you have any questions please contact Malika Felton (mfelton@bournemouth.ac.uk) 




Appendix VI: Ethical approval 
Appendix VIa: Chapter 4 BU ethical approval 
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Appendix VId: Chapter 8 HRA & REC ethical approval 
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